{
  "patients": [
    {
      "type": "Adult",
      "cancers": [
        {
          "id": 5,
          "title": "Breast Cancer",
          "regimenList": [
            {
              "id": 509,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 398,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 501,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 502,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 503,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 504,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 505,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 506,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 507,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 508,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 522,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 511,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 510,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 512,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 513,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 514,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 515,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 516,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 517,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 519,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 518,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 520,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 521,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            }
          ],
          "subCancers": []
        },
        {
          "id": 1,
          "title": "CNS Tumors",
          "regimenList": [
            {
              "id": 1,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 2,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 3,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 4,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 5,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 670,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            }
          ],
          "subCancers": []
        },
        {
          "id": 3,
          "title": "Gastrointestinal",
          "regimenList": [],
          "subCancers": []
        },
        {
          "id": 6,
          "title": "Gynecologic Malignancy",
          "regimenList": [],
          "subCancers": []
        },
        {
          "id": 2,
          "title": "Head & Neck Malignancies",
          "regimenList": [
            {
              "id": 7,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 8,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 9,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 10,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 11,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 12,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 13,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            }
          ],
          "subCancers": []
        },
        {
          "id": 27,
          "title": "Kaposi's Sarcoma- AIDS Related",
          "regimenList": [
            {
              "id": 210,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 211,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 212,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 213,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            }
          ],
          "subCancers": []
        },
        {
          "id": 12,
          "title": "Leukemia",
          "regimenList": [
            {
              "id": 80,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 81,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 82,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 83,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 84,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 85,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 86,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 87,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 88,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 89,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 90,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 91,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 92,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 93,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 94,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 95,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 96,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            }
          ],
          "subCancers": []
        },
        {
          "id": 11,
          "title": "Lymphoma",
          "regimenList": [
            {
              "id": 48,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 49,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 50,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 51,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 52,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            }
          ],
          "subCancers": []
        },
        {
          "id": 37,
          "title": "Myeloma",
          "regimenList": [
            {
              "id": 281,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 282,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 283,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 284,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 285,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 286,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 287,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 288,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 289,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 290,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 291,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 292,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 293,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 294,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 295,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 296,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            }
          ],
          "subCancers": []
        },
        {
          "id": 26,
          "title": "Sarcoma",
          "regimenList": [
            {
              "id": 204,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 205,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 206,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 207,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 208,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 209,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            }
          ],
          "subCancers": []
        },
        {
          "id": 108,
          "title": "Skin",
          "regimenList": [],
          "subCancers": []
        },
        {
          "id": 4,
          "title": "Thoracic",
          "regimenList": [
            {
              "id": 53,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 54,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 55,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 56,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 57,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 58,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 59,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 60,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 61,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 62,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 63,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 66,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 67,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 68,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 69,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 70,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 71,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 72,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            }
          ],
          "subCancers": [
            {
              "id": 97,
              "title": "Non-Small Cell Lung Cancer",
              "regimenList": [],
              "subCancers": []
            },
            {
              "id": 13,
              "title": "Small Cell Lung Cancer",
              "regimenList": [
                {
                  "id": 98,
                  "name": null,
                  "schedule": null,
                  "emetogenicPotential": null,
                  "dosageModifications": null,
                  "references": null,
                  "drugs": [],
                  "regimenLevels": []
                },
                {
                  "id": 99,
                  "name": null,
                  "schedule": null,
                  "emetogenicPotential": null,
                  "dosageModifications": null,
                  "references": null,
                  "drugs": [],
                  "regimenLevels": []
                },
                {
                  "id": 100,
                  "name": null,
                  "schedule": null,
                  "emetogenicPotential": null,
                  "dosageModifications": null,
                  "references": null,
                  "drugs": [],
                  "regimenLevels": []
                },
                {
                  "id": 101,
                  "name": null,
                  "schedule": null,
                  "emetogenicPotential": null,
                  "dosageModifications": null,
                  "references": null,
                  "drugs": [],
                  "regimenLevels": []
                },
                {
                  "id": 102,
                  "name": null,
                  "schedule": null,
                  "emetogenicPotential": null,
                  "dosageModifications": null,
                  "references": null,
                  "drugs": [],
                  "regimenLevels": []
                },
                {
                  "id": 103,
                  "name": null,
                  "schedule": null,
                  "emetogenicPotential": null,
                  "dosageModifications": null,
                  "references": null,
                  "drugs": [],
                  "regimenLevels": []
                },
                {
                  "id": 104,
                  "name": null,
                  "schedule": null,
                  "emetogenicPotential": null,
                  "dosageModifications": null,
                  "references": null,
                  "drugs": [],
                  "regimenLevels": []
                }
              ],
              "subCancers": []
            }
          ]
        },
        {
          "id": 28,
          "title": "Unknown Primary",
          "regimenList": [
            {
              "id": 214,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 215,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 216,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 217,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 218,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 219,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 220,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            }
          ],
          "subCancers": []
        },
        {
          "id": 7,
          "title": "Urinary Tract",
          "regimenList": [],
          "subCancers": []
        }
      ]
    },
    {
      "type": "Pediatric",
      "cancers": [
        {
          "id": 38,
          "title": "CNS Tumors",
          "regimenList": [
            {
              "id": 297,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 298,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 299,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 300,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 301,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 302,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            }
          ],
          "subCancers": []
        },
        {
          "id": 41,
          "title": "Hepatoblastoma",
          "regimenList": [
            {
              "id": 308,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            }
          ],
          "subCancers": []
        },
        {
          "id": 21,
          "title": "Leukemias",
          "regimenList": [
            {
              "id": 180,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 181,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 182,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            }
          ],
          "subCancers": []
        },
        {
          "id": 20,
          "title": "Lymphoma",
          "regimenList": [
            {
              "id": 153,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 154,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 155,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 156,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 157,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 158,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 159,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 160,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 161,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 162,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 163,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 164,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            }
          ],
          "subCancers": []
        },
        {
          "id": 39,
          "title": "Neuroblastoma",
          "regimenList": [
            {
              "id": 303,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 304,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 305,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 306,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            }
          ],
          "subCancers": []
        },
        {
          "id": 40,
          "title": "Retinoblastoma",
          "regimenList": [
            {
              "id": 307,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            }
          ],
          "subCancers": []
        },
        {
          "id": 19,
          "title": "Sarcoma",
          "regimenList": [
            {
              "id": 165,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 166,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 167,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            },
            {
              "id": 168,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            }
          ],
          "subCancers": []
        },
        {
          "id": 42,
          "title": "Wilms' Tumor",
          "regimenList": [
            {
              "id": 309,
              "name": null,
              "schedule": null,
              "emetogenicPotential": null,
              "dosageModifications": null,
              "references": null,
              "drugs": [],
              "regimenLevels": []
            }
          ],
          "subCancers": []
        }
      ]
    }
  ],
  "regimen": [
    {
      "id": 1,
      "name": "<b>Bevacizumab/Irinotecan</b>",
      "schedule": "<b>Bevacizumab</b> 15 mg/kg IV<br> Repeat Every 21 Days<br> <b>Irinotecan</b> 350 mg/m<sup>2</sup> with enzyme-inducing antiepileptic drugs, days 1, 8, 22, 29<br> <b>OR</b><br> <b>Irinotecan</b> 125 mg/m<sup>2</sup> with non-enzyme-including antiepileptic drugs, IV, days 1, 8, 22, 29<br> Repeat every 6 weeks",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Irinotecan:<br>If bilirubin 1-2 mg/dL, may need to reduce the dose<br>                               If bilurubin > 2 mg/dL, may not use  </li></ul><b>Renal Impairment</b><ul><li>Irinotecan:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 5,
          "referenceValue": "Vredenburgh JJ, Desjardins A, Herndon JE, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme."
        },
        {
          "id": 6,
          "referenceValue": "J Clin Oncol. 2007;25(30):4722-4279."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 2,
      "name": "<b>PCV</b>",
      "schedule": "<b>Procarbazine</b> 60 mg/m<sup>2</sup>/d PO, days 8-21<br> <b>Lomustine</b> 110 mg/m<sup>2</sup> PO, day 1<br> <b>Vincristine</b> 1.4 mg/m<sup>2</sup> IV, days 8, 29<br> Repeat every 6 weeks upto 7 cycles ",
      "emetogenicPotential": "Moderate-High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Lomustine:<br>No dose reduction</li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Lomustine:<br>If CrCl < 60 mL/min, do not use</li><li>Procarbazine:<br>If CrCl < 30 mL/min, do not use</li><li>Vincristine:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 7,
          "referenceValue": "Levin VA, Uhm JH, Jaeckle KA, et al. Phase III randomized study of postradiotherapy chemotherapy with alpha-difluromethylornithine- procarbazine, N-(2-chloroethyl)-N' -cyclohexyl- N-nitrosuera, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme."
        },
        {
          "id": 8,
          "referenceValue": "Clin Cancer Res.2000;6(10):3878-3884."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 3,
      "name": "<b>Temozolomide+RT</b>",
      "schedule": "<b>Temozolomide</b> 75 mg/m<sup>2</sup> daily along with radiation<br> <b>FOLLOWED 28 DAYS LATER BY</b><br><b>Temozolomide<sup>e</sup></b> 150 mg/m<sup>2</sup> daily for 5 days<br>Repeat every 28 days.",
      "emetogenicPotential": "Moderate for IV<br> <=75 mg/m<sup>2</sup> PO is minimal-low;<br> >75 mg/m<sup>2</sup> PO is moderate-high   ",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Temozolomide:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul></ul>",
      "references": [
        {
          "id": 9,
          "referenceValue": "Stupp R, et al.  Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma."
        },
        {
          "id": 10,
          "referenceValue": "N Engl J Med 2005; 352:987-996"
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 4,
      "name": "<b>BCNU (Carmustine)</b>",
      "schedule": "<b>Carmustine</b> 200 mg/m<sup>2</sup> IV over 30-60 minutes<br> Repeat every 8 weeks ",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Carmustine:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Carmustine:<br>If CrCl < 60 mL/min, do not use</li></ul>",
      "references": [
        {
          "id": 11,
          "referenceValue": "Selker RG, Sharipo WR, Burger p, et al. The Brain tumor cooperative group NIH Trial 87-01: a randomized comparision of surgery, external radiotherapy, and carmustine versus surgery, interstital radiotherapy, and carmustine."
        },
        {
          "id": 12,
          "referenceValue": "Neurosurgery.2002;51(2):343-355; discussion 355-357."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 5,
      "name": "<b>Bevacizumab</b>",
      "schedule": "<b>Bevacizumab</b> 10 mg/kg IV<br> Repeat every 14 days on a 28-day cycle<br><b>OR</b><br><b>Bevacizumab</b> 15 mg/kg IV<br> Repeat every 21 days ",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>",
      "references": [
        {
          "id": 13,
          "referenceValue": "Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab plus irinotecan at tumor progression in recuurent glioblastoma."
        },
        {
          "id": 14,
          "referenceValue": "J Clin Oncol. 2009;27(5):740-745."
        },
        {
          "id": 15,
          "referenceValue": "Raizer JJ, Grimm S, et al. Aphase 2 trial of single-agent bevacizumab plus irinotecan at tumor progression in recurrent high- grade schedule for patients with recurrent high- grade gliomas."
        },
        {
          "id": 16,
          "referenceValue": "Cancer.2010;116(22):597-5305."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 6,
      "name": "<b>Temozolomide</b>",
      "schedule": "<b>Temozolomide</b> 150 mg/m<sup>2</sup> every day for 5 days per 28-day cycle<br> ",
      "emetogenicPotential": "Moderate for IV<br> >75 mg/m<sup>2</sup> PO is moderate-high   ",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Temozolomide:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul></ul>",
      "references": [
        {
          "id": 17,
          "referenceValue": "Gállego Pérez-Larraya J, et al.Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial."
        },
        {
          "id": 18,
          "referenceValue": "J Clin Oncol. 2011 Aug 1;29(22):3050-5. doi: 10.1200/JCO.2011.34.8086. Epub 2011 Jun 27"
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 7,
      "name": "<b>Carboplatin/Fluorouracil/Cetuximab</b>",
      "schedule": "<b>Carboplatin</b> AUC of 5, day 1<br> <b>Fluorouracil</b> 1,000 mg/m<sup>2</sup>/d CIVI, days 1-4<br> Repeat every 21 days for a maximum of 6 cycles<br> <b>Cetuximab</b> 400 mg/m<sup>2</sup> IV load over 4 hours, day 1, cycle 1 <b>THEN</b> 250 mg/m<sup>2</sup> IV over 1 hour, every week.",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Fluorouracil:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 19,
          "referenceValue": "Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer."
        },
        {
          "id": 20,
          "referenceValue": "N Engl J Med. 2008;359(11):1116-1127."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 8,
      "name": "<b>CF</b>",
      "schedule": "<b>Cisplatin</b> 100 mg/m<sup>2</sup> IV, day 1<br> <b>5-Fluorouracil</b> 1000 mg/m<sup>2</sup>/day CIVI, days 1-4<br> Repeat every 21 days",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li></ul>",
      "references": [
        {
          "id": 21,
          "referenceValue": "Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group."
        },
        {
          "id": 22,
          "referenceValue": "J Clin Oncol. 2005;23(15):3562-3567."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 9,
      "name": "<b>Cisplatin/Fluorouracil/Cetuximab</b>",
      "schedule": "<b>Cisplatin</b> 100 mg/m<sup>2</sup> IV, day 1<br> <b>Fluorouracil</b> 1,000 mg/m<sup>2</sup>/d CIVI, days 1-4<br> Repeat every 21 days for a maximuum of 6 cycles<br> <b>Cetuximab</b> 400 mg/m<sup>2</sup> IV load over 4 hours, day 1, cycle 1. <b>THEN</b> 250 mg/m<sup>2</sup> IV over 1 hour, every week",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Fluorouracil:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 23,
          "referenceValue": "Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer."
        },
        {
          "id": 24,
          "referenceValue": "N Engl J Med. 2008;359(11):1116-1127."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 138,
      "name": "<b>Anastrozole</b>",
      "schedule": "<b>Anastrozole</b> 1 mg PO  once daily",
      "emetogenicPotential": "N/A",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Anastrozole:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Anastrozole:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 25,
          "referenceValue": "Arimidex [package insert]."
        },
        {
          "id": 26,
          "referenceValue": "Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2011."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 10,
      "name": "<b>Cisplatin + radiation</b>",
      "schedule": "<b>Cisplatin</b> 75 mg/m<sup>2</sup>  IV, days 1,22, 43 concomitantly with radiation",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li></ul>",
      "references": [
        {
          "id": 27,
          "referenceValue": "Franchin G, Minatel E, Politi D, et al. Postoperative reduced dose of cisplatin concomitant with radiatoin therapy in high-risk head and neck squamous cell carcinoma."
        },
        {
          "id": 28,
          "referenceValue": "Cancer. 2009;115(11):2464-2471."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 11,
      "name": "<b>CP</b>",
      "schedule": "<b>Cisplatin</b> 75 mg/m<sup>2</sup>, day 1 and<br> <b>Paclitaxel</b> 175 mg/m<sup>2</sup> over 3 hours on day 1<br> Repeat cycle every 21 days",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Paclitaxel:<br>No dose reduction</li></ul>",
      "references": [
        {
          "id": 29,
          "referenceValue": "Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group."
        },
        {
          "id": 30,
          "referenceValue": "J Clin Oncol. 2005;23(15):3562-3567."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 12,
      "name": "<b>TPF</b>",
      "schedule": "<b>Docetaxel<sup>b</sup></b> 75mg/m<sup>2</sup> IV over 1 hour, day1<br> <b>Cisplatin</b> 75mg/m<sup>2</sup> IV over 1 hour, day 1<br> <b>Fluorouraacil</b> 750 mg/m<sup>2</sup>/d, days 1-5<br> Repeat every 21 days<br> <b>OR</b><br> <b>Docetaxel<sup>b</sup></b> 75 mg/m<sup>2</sup> IV, day 1<br> <b>Cisplatin</b> 100 mg/m<sup>2</sup> IV, day 1<br> <b>Fluorouracil</b> 1,000 mg/m<sup>2</sup>/d CIVI, days 1-4<br> Repeat every 21 days for 3 cycles",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Docetaxel:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 31,
          "referenceValue": "Vermorken JB, Remenar E, Van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer."
        },
        {
          "id": 32,
          "referenceValue": "N Engl J Med. 2007;357(17):1695-1704."
        },
        {
          "id": 33,
          "referenceValue": "<br> Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer."
        },
        {
          "id": 34,
          "referenceValue": "N Engl J Med. 2007;357(17):1705-1715."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 13,
      "name": "<b>Cetuximab</b>",
      "schedule": "<b>Cetuximab</b> 400 mg/m<sup>2</sup> loading dose over 120 minutes, <b>THEN</b> 250 mg/m<sup>2</sup> over 60 minutes, every 7 days",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>",
      "references": [
        {
          "id": 35,
          "referenceValue": "Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival datat from a phase 3 randomised trial, and relation between cetuximab-induced rash and surival."
        },
        {
          "id": 36,
          "referenceValue": "Lancet Oncol.2010;11(1):21-28."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 14,
      "name": "<b>5-Fluorouracil + Cisplatin</b>",
      "schedule": "<b>5-Fluorouracil</b>1,000 mg/m<sup>2</sup>/day IV continuous infusion on days 1-5<br><b>Cisplatin</b>100 mg/m<sup>2</sup> IV on day 1<br>Repeat cycle on weeks 1, 5, 8, and 11.",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Fluorouracil:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 37,
          "referenceValue": "Kies MS, et al. Cancer 1987;60:2156-2160."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 15,
      "name": "<b>Irinotecan + Cisplatin</b>",
      "schedule": "<b>Irinotecan</b>65 mg/m<sup>2</sup> IV weekly for 4 weeks<br><b>Cisplatin</b>30 mg/m<sup>2</sup> IV weekly for 4 weeks<br>Repeat cycle every 6 weeks.",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Irinotecan:<br>If bilirubin 1-2 mg/dL, may need to reduce the dose<br>                               If bilurubin > 2 mg/dL, may not use  </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Irinotecan:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 38,
          "referenceValue": "Ilson DH, et al. J Clin Oncol 1999;17:3270-3275."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 16,
      "name": "<b>Paclitaxel + Cisplatin</b>",
      "schedule": "<b>Paclitaxel</b>200 mg/m<sup>2</sup> IV over 24 hours on day 1<br><b>Cisplatin</b>75 mg/m<sup>2</sup> IV on day 2<br>Repeat cycle every 21 days. G-CSF support is recommended.",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Paclitaxel:<br>No dose reduction</li></ul>",
      "references": [
        {
          "id": 39,
          "referenceValue": "Ilson DH, et al. J Clin Oncol 1998;16:1826-1834."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 17,
      "name": "<b>Capecitabine + Oxaliplatin</b>",
      "schedule": "<b>Capecitabine</b>1,000 mg/m<sup>2</sup> PO bid on days 1-14<br><b>Oxaliplatin</b>130 mg/m<sup>2</sup> IV on day 1<br>Repeat cycle every 21 days.",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>",
      "references": [
        {
          "id": 40,
          "referenceValue": "Van Meerten E, et al. Br J Cancer 2007;96:1348-1352."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 18,
      "name": "<b>ECF</b>",
      "schedule": "<b>Epirubicin</b>50 mg/m<sup>2</sup> IV on day 1<br><b>Cisplatin</b>60 mg/m<sup>2</sup> IV on day 1<br><b>5-Fluorouracil</b>200 mg/m<sup>2</sup>/day IV continuous infusion for 24 weeks.<br>Repeat cycle every 21 days.",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li></ul>",
      "references": [
        {
          "id": 41,
          "referenceValue": "Cunningham D, et al. N Engl J Med 2008;358:36-46."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 714,
      "name": "",
      "schedule": "<p><strong>Olaparib:&nbsp;</strong>300 mg PO twice daily</p>\n\n<p>Continue therapy until evidence of disease progression. Patients must have germline <em>BRCA1/2&nbsp;</em>mutation and have received at least 16 weeks of platinum-based chemotherapy.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 19,
      "name": "<b>EOF</b>",
      "schedule": "<b>Epirubicin</b>50 mg/m<sup>2</sup> IV on day 1<br><b>Oxaliplatin</b>130 mg/m<sup>2</sup> IV on day 1<br><b>5-Fluorouracil</b>200 mg/m<sup>2</sup>/day IV continuous infusion for 24 weeks<br>Repeat cycle every 21 days.",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>",
      "references": [
        {
          "id": 42,
          "referenceValue": "Cunningham D, et al. N Engl J Med 2008;358:36-46."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 20,
      "name": "<b>ECX</b>",
      "schedule": "<b>Epirubicin</b>50 mg/m<sup>2</sup> IV on day 1<br><b>Cisplatin</b>60 mg/m<sup>2</sup> IV on day 1<br><b>Capecitabine</b>625 mg/m<sup>2</sup> PO bid continuously<br>Repeat cycle every 21 days.",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li><li>Cisplatin:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li></ul>",
      "references": [
        {
          "id": 43,
          "referenceValue": "Cunningham D, et al. N Engl J Med 2008;358:36-46."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 21,
      "name": "<b>EOX</b>",
      "schedule": "<b>Epirubicin</b>50 mg/m<sup>2</sup> IV on day 1<br><b>Oxaliplatin</b>130 mg/m<sup>2</sup> IV on day 1<br><b>Capecitabine</b>625 mg/m<sup>2</sup> PO bid times 21 days<br>Repeat cycle every 21 days.",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>",
      "references": [
        {
          "id": 44,
          "referenceValue": "Cunningham D, et al. N Engl J Med 2008;358:36-46."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 22,
      "name": "<b>Paclitaxel</b>",
      "schedule": "<b>Paclitaxel</b>250 mg/m<sup>2</sup> IV over 24 hours on day 1<br>Repeat cycle every 21 days. G-CSF support is recommended.",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Paclitaxel:<br>No dose reduction</li></ul>",
      "references": [
        {
          "id": 45,
          "referenceValue": "Ajani JA, et al. Semin Oncol 1995;22 (Suppl 6):35-40."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 23,
      "name": "<b>DCF</b>",
      "schedule": "<b>Docetaxel</b> 75mg/m<sup>2</sup> IV over 1 hour, day 1<br> <b>Cisplatin</b> 75 mg/m<sup>2</sup> IV over 1-3 hours, day 1<br> <b>Fluorouracil</b> 750 mg/m<sup>2</sup>/d CIVI, days 1-5<br> Repeat every 21 days",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Docetaxel:<br>No dose reduction </li><li>Fluorouracil:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 49,
          "referenceValue": "Van Custem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus florouracil compared with cisplatin and flouorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group."
        },
        {
          "id": 50,
          "referenceValue": "J Clin Oncol. 2006;24(31):4991-4997"
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 24,
      "name": "<b>Docetaxel/Cisplatin</b>",
      "schedule": "<b>Docetaxel</b> 85 mg/m<sup>2</sup> IV over 1 hour, day 1,<br> <b>FOLLOWED BY</b><br> <b>Cisplatin</b> 75 mg/m<sup>2</sup> IV over 1 hour, day 1<br> Repeat every 21 days for a maximum of 8 cycles",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Docetaxel:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 51,
          "referenceValue": "Roth AD, Maibach R, Martinelli G, et al. Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma."
        },
        {
          "id": 52,
          "referenceValue": "Ann Oncol. 2000;11(3):301-306"
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 25,
      "name": "<b>ECF</b>",
      "schedule": "<b>Epirubicin</b> 50 mg/m<sup>2</sup> IV, day 1<br> <b>Cisplatin</b> 60 mg/m<sup>2</sup> IV, day 1<br> <b>Fluorouracil</b> 200 mg/m<sup>2</sup>/d CIVI, for up to 6 months<br> Repeat every 21 days for a maximum of 8 cycles",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li></ul>",
      "references": [
        {
          "id": 53,
          "referenceValue": "Waters JS, Norman A, Cunningham D, et al. Long-term survival afer epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial."
        },
        {
          "id": 54,
          "referenceValue": "Br J Cancer. 1999;80(1-2):269-272."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 720,
      "name": "",
      "schedule": "<p><strong>Capecitabine:&nbsp;</strong>1,250 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-14</p>\n\n<p><strong>Cisplatin:&nbsp;</strong>60 mg/m<sup>2</sup>&nbsp;IV on day 2</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 26,
      "name": "<b>ELF</b>",
      "schedule": "<b>Leucovorin calcium</b> 300 mg/m<sup>2</sup>/d IV over 10 minutes, <b>FOLLOWED BY</b><br> <b>Etoposide</b> 120 mg/m<sup>2</sup>/d IV over 50 minutes,<br> <b>THEN</b><br> <b>Fluorouracil</b> 500 mg/m<sup>2</sup>/d IV  bolus<br> Give all agents on days 1-3; repeat every 22 days",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li><li>Fluorouracil:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 55,
          "referenceValue": "Vanhoefer U, Rougier P, Wilke H, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional flurorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gasttrointestinal Tract Cancer Cooperative Group."
        },
        {
          "id": 56,
          "referenceValue": "J Clin Oncol. 2000;18(41):2648-2657"
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 27,
      "name": "<b>5-FU/LV and Radiation</b>",
      "schedule": "<b>Fluorouracil</b> 425 mg/m<sup>2</sup>/d for 5 days<br> <b>Leucovorin calcium</b> 20 mg/m<sup>2</sup>/d for 5 days,<br> <b>FOLLOWED BY</b><br> <b>RT</b> 4,500 cGy (180cGy/d), 5 days a week for 5 weeks<br> <b>Fluorouracil</b> 400 mg/m<sup>2</sup>/d IV, on the first 4 and last 3 days of RT<br> <b>Leucovorin calcium</b> 20 mg/m<sup>2</sup>/d, on the first 4 and last 3 days of RT,<br> <b>FOLLOWED BY</b><br> <b>Fluorouracil</b> 425 mg/m<sup>2</sup>/d for 5 days<br> <b>Leucovorin calcium</b> 20 mg/m<sup>2</sup>/d for 5 days<br>repeat 28 days X 2 cycles",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 57,
          "referenceValue": "Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy afer surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction."
        },
        {
          "id": 58,
          "referenceValue": "N Engl J Med. 2001;345(10):725-730."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 28,
      "name": "<b>Trastuzumab + Cisplatin + Capecitabine or Fluorouracil</b>",
      "schedule": "<b>Trastuzumab</b> 8 mg/kg IV, day 1 of the first cycle <b>THEN</b>  6 mg/kg IV, day 1<br><br> <b>Cisplatin</b> 80 mg/m<sup>2</sup> IV, day 1. <b>Capecitabine</b> 1,000 mg/m<sup>2</sup> PO bid, days 1-14 <br> Repeat  every 21 days<br> <b>OR</b><br> <b>Fluorouracil</b> 800 mg/m<sup>2</sup>/d CIVI for 5 days of each 3-week cycle<br> Repeat for 6 cycles",
      "emetogenicPotential": "High day 1, low for the remaining treatment days",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li><li>Cisplatin:<br>No dose reduction</li><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Fluorouracil:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 59,
          "referenceValue": "Bang YJ, Van Cutsem E, Feyereislava A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3 open-label, randomised controlled trial."
        },
        {
          "id": 60,
          "referenceValue": "Lancet. 2010;376(99742):687-697."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 31,
      "name": "<b>GEMOX</b>",
      "schedule": "<b>Gemcitabine</b>1,000 mg/m<sup>2</sup> IV on day 1<br><b>Oxaliplatin</b>100 mg/m<sup>2</sup> IV on day 2<br>Repeat cycle every 2 weeks.",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>",
      "references": [
        {
          "id": 46,
          "referenceValue": "Taieb J, et al. Cancer 2003;98:2664-2670."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 32,
      "name": "<b>FOLFOX4",
      "schedule": "<b>Oxaliplatin</b>85 mg/m<sup>2</sup> IV on day 1<br><b>5-Fluorouracil</b>400 mg/m<sup>2</sup> IV bolus, followed by 600 mg/m<sup>2</sup> IV continuous infusio for 22 hours on days 1 and 2<br><b>Leucovorin</b>200 mg/m<sup>2</sup> IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil<br>Repeat cycle every 2 weeks.",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Leucovorin:<br>No dose reduction</li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Leucovorin:<br>No dose reduction</li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>",
      "references": [
        {
          "id": 61,
          "referenceValue": "Qin S, et al. J Clin Oncol 2010;28:303S (abstract 408)."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 33,
      "name": "<b>Bevacizumab + Erlotinib</b>",
      "schedule": "<b>Bevacizumab</b>10 mg/kg IV on days 1 and 14<br><b>Erlotinib</b>150 mg PO daily<br>Repeat cycle every 28 days.",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Erlotinib:<br>If AST > 3 upper normal limit, 50 mg  <br>                                                        If direct bilirubin 1-7 mg/dL, 75 mg </li></ul><b>Renal Impairment</b><ul><li>Erlotinib:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 62,
          "referenceValue": "Thomas MB, et al. J Clin Oncol 2009;27:843-850."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 34,
      "name": "<b>Sorafenib</b>",
      "schedule": "<b>Sorafenib</b>400 mg PO bid.",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Sorafenib:<br>If Child-Pugh A or B, no dose reduction     <br>                                                 If Child-Pugh C, reduce dose by 50% </li></ul><b>Renal Impairment</b><ul><li>Sorafenib:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 63,
          "referenceValue": "Llovet J, et al. N Engl J Med 2008;359:378-390."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 35,
      "name": "<b>Doxorubicin</b>",
      "schedule": "<b>Doxorubicin</b>20-30 mg/m<sup>2</sup> IV weekly<br>Repeat cycle every week.",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Doxorubicin:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 64,
          "referenceValue": "Venook AP. J Clin Oncol 1994;12:1323-1334."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 36,
      "name": "<b>Cisplatin</b>",
      "schedule": "<b>Cisplatin</b>80 mg/m<sup>2</sup> IV on day 1<br>Repeat cycle every week.",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li></ul>",
      "references": [
        {
          "id": 65,
          "referenceValue": "Okada S, et al. Oncology 1993;50:22-26."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 37,
      "name": "<b>Capecitabine</b>",
      "schedule": "<b>Capecitabine</b>1,000 mg/m<sup>2</sup> PO bid on days 1-14<br>Repeat cycle every 21 days. PO bid on days 1-14.",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li></ul>",
      "references": [
        {
          "id": 66,
          "referenceValue": "Patt YZ, et al. Cancer 2004;101:578-586."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 38,
      "name": "<b>Bevacizumab</b>",
      "schedule": "<b>Bevacizumab</b>10 mg/kg IV on day 1<br>Repeat cycle every 14 days.",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>",
      "references": [
        {
          "id": 67,
          "referenceValue": "Siegel AB, et al. J Clin Oncol 2008;26:2992-2998."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 39,
      "name": "<b>Gemcitabine + Cisplatin</b>",
      "schedule": "<b>Gemcitabine</b> 1,250 mg/m<sup>2</sup> IV on Day 1, 8<br> <b>Cisplatin</b> 75 mg/m<sup>2</sup> IV on Day 1<br> Repeat cycle every 21 days",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Gemcitabine:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 68,
          "referenceValue": "Thongprasert S, et al. Ann Oncol 2005;16:279-281"
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 40,
      "name": "<b>Gemcitabine + Capecitabine</b>",
      "schedule": "<b>Gemcitabine</b> 1,000 mg/m<sup>2</sup> IV on Day 1, 8<br> <b>Capecitabine</b> 650 mg/m<sup>2</sup> PO BID on Days 1-14<br> Repeat cycle every 21 days",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li><li>Gemcitabine:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 69,
          "referenceValue": "Knox JJ, et al. J Clin Oncol 2005;23:2332-2338."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 41,
      "name": "<b>Gemcitabine + Oxaliplatin</b>",
      "schedule": "<b>Gemcitabine</b> 1,000 mg/m<sup>2</sup> IV on Day 1<br> <b>Oxaliplatin</b> 100 mg/m<sup>2</sup> on Day 2<br> Repeat cycle every 14 days",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>",
      "references": [
        {
          "id": 70,
          "referenceValue": "Andre T, et al. Ann Oncol 2004;15:1339-1343."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 42,
      "name": "<b>5-Fluorouracil + Cisplatin</b>",
      "schedule": "<b>5-FU</b> 400 mg/m<sup>2</sup> on Day 1<br> <b>FOLLOWED BY</b> 600 mg/m<sup>2</sup> continuous infusion over 22 hours on days 1 and 2<br> <b>Cisplatin</b> 50 mg /m<sup>2</sup> IV on day 2<br> Repeat cycle every 21 days",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li></ul>",
      "references": [
        {
          "id": 71,
          "referenceValue": "Taieb J, et al. Ann Oncol 2002;13:1192-1196."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 43,
      "name": "<b>Capecitabine + Cisplatin</b>",
      "schedule": "<b>Capecitabine</b> 1,250 mg/m<sup>2</sup> PO bid on days 1-14<br> <b>Cisplatin</b> 60 mg/m<sup>2</sup> IV on day 2<br> Repeat cycle every 21 days",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li><li>Cisplatin:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li></ul>",
      "references": [
        {
          "id": 72,
          "referenceValue": "Hong YS, et al. Cancer Chemother Pharmacol 2007;60:321-328."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 44,
      "name": "<b>Capecitabine + Oxaliplatin</b>",
      "schedule": "<b>Capecitabine</b> 1,000 mg/m<sup>2</sup> PO bid on days 1-14<br> <b>Oxaliplatin</b> 130 mg/m<sup>2</sup> IV on day 1<br> Repeat cycle every 21 days",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>",
      "references": [
        {
          "id": 75,
          "referenceValue": "Nehis O, et al. Br J Cancer 2008;98:309-315."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 45,
      "name": "<b>Capecitabine</b>",
      "schedule": "<b>Capecitabine</b> 1,000 mg/m<sup>2</sup> PO bid on days 1-14<br> Repeat cycle every 21 days",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li></ul>",
      "references": [
        {
          "id": 76,
          "referenceValue": "Patt YZ, et al. Cancer 2004;101:578-586."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 46,
      "name": "<b>Docetaxel</b>",
      "schedule": "<b>Docetaxel</b> 100 mg/m<sup>2</sup> IV on day 1<br> Repeat cycle every 21 days",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li></ul><b>Renal Impairment</b><ul><li>Docetaxel:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 77,
          "referenceValue": "Papakostas P, et al. Eur J Cancer 2001;37:1833-1838."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 47,
      "name": "<b>Gemcitabine</b>",
      "schedule": "<b>Gemcitabine</b> 1,000 mg/m<sup>2</sup> IV on days 1 and 8<br> Repeat cycle every 21 days",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 78,
          "referenceValue": "Park JS, et al. Jpn J Clin Oncol 2005;35:68-73."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 139,
      "name": "<b>Capecitabine</b>",
      "schedule": "<b>Capecitabine</b> 1,250 mg/m<sup>2</sup> PO bid, days 1-14, <br>Repeat every 21 days ",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li></ul>",
      "references": [
        {
          "id": 79,
          "referenceValue": "Xeloda [package insert]."
        },
        {
          "id": 80,
          "referenceValue": "San Francisco, CA: Genentech; 2011."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 244,
      "name": "<b>Temsirolimus</b>",
      "schedule": "<b>Temsirolimus</b> 175 mg IV per week for 3 weeks<br> <b>FOLLOWED BY</b><br> <b>Temsirolimus</b> 75 mg IV weekly  ",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Temsirolimus:<br>Unknown </li></ul><b>Renal Impairment</b><ul><li>Temsirolimus:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 81,
          "referenceValue": "Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evalute temsirolimus compared with investigator's choice therapy for the treatment or relapsed or refractory mantle cell lymphoma."
        },
        {
          "id": 82,
          "referenceValue": "J Clin Oncol.2009; 27(23):3822-3829."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 48,
      "name": "<b>FOLFIRINOX</b>",
      "schedule": "<b>Oxaliplatin</b> 85 mg/m<sup>2</sup> IV over 2 hours <b>FOLLOWED BY Leucovorin calcium</b> 400 mg/m<sup>2</sup> IV over 2 hours with the addition, after 30 minutes <b>Irinotecan</b> 180 mg/m<sup>2</sup> IV over 90 minutes; <b>IMMEDIATELY FOLLOWED BY</b><br> <b>Fluorouracil</b> 400 mg/m<sup>2</sup> IV bolus, <b>THEN</b><br> <b>Fluorouracil</b> 2,400 mg/m<sup>2</sup> IV over 46 hours<br> Repeat cycle every 2 weeks",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li><li>Irinotecan:<br>If bilirubin 1-2 mg/dL, may need to reduce the dose<br>                               If bilurubin > 2 mg/dL, may not use  </li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li><li>Irinotecan:<br>No dose reduction </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>",
      "references": [
        {
          "id": 83,
          "referenceValue": "Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer."
        },
        {
          "id": 84,
          "referenceValue": "N Engl J Med. 2011;364(19):1817-1825."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 49,
      "name": "<b>Gemcitabine/Capecitabine</b>",
      "schedule": "<b>Gemcitabine</b> 1,000 mg/m<sup>2</sup> IV over 30 minutes, days 1, 8<br> <b>Capecitabine</b> 650 mg/m<sup>2</sup> PO bid, days 1-14<br> Repeat every 21 days.",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li><li>Gemcitabine:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 85,
          "referenceValue": "Herrmann R, Bodoky G, Ruhstaller T, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group."
        },
        {
          "id": 86,
          "referenceValue": "J Clin Oncol. 2007;25(16):221-2217."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 50,
      "name": "<b>Gemcitabine/Erlotinib</b>",
      "schedule": "<b>Gemcitabine</b> 1,000 mg/m<sup>2</sup> IV over 30 minutes once weekly for 7 weeks,<br> <b>FOLLOWED BY</b> 1 week of rest<br> <b>Erlotinib</b> 100 <b>OR</b> 150 mg/d PO<br> Repeat subsequent cycles once weekly for 3 consecutive weeks out of every 4 weeks",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Erlotinib:<br>If AST > 3 upper normal limit, 50 mg  <br>                                                        If direct bilirubin 1-7 mg/dL, 75 mg </li><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Erlotinib:<br>No dose reduction </li><li>Gemcitabine:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 87,
          "referenceValue": "Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer institute of Canada Clinical Trials Group."
        },
        {
          "id": 88,
          "referenceValue": "J Clin Oncol. 2007;25(15):1960-1966."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 51,
      "name": "<b>GEMOX</b>",
      "schedule": "<b>Gemcitabine</b> 1,000 mg/m<sup>2</sup>, day 1 as 100-minute infusion<br> <b>Oxaliplatin</b> 100 mg/m<sup>2</sup>, day 2 as 2-hour infusion<br> Repeat every 14 days",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>",
      "references": [
        {
          "id": 89,
          "referenceValue": "Louvet C, Labianca R, Hammel P, at al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial."
        },
        {
          "id": 90,
          "referenceValue": "J Clin Oncol. 2005;23(15):3509-3516."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 52,
      "name": "<b>Gemcitabine</b>",
      "schedule": "<b>Gemcitabine 1,000 mg/m<sup>2</sup> IV over 30 minutes once weekly for 7 weeks,<br> <b>FOLLOWED BY</b> 1 week of rest<br> Repeat subsequent cycles once weekly for 3 consecutive weeks out of every 4 weeks",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 91,
          "referenceValue": "Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survivial and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial."
        },
        {
          "id": 92,
          "referenceValue": "J Clin Oncol. 1997;15(6):2403-2413."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 53,
      "name": "<b>Cetuximab/Irinotecan</b>",
      "schedule": "<b>Cetuximab</b> 400 mg/m<sup>2</sup> IV initial dose,<b>THEN</b> 250 mg/m<sup>2</sup> IV every 7 days<br> <b>Irinotecan</b> 350 mg/m<sup>2</sup> IV every 21 days<br> <b>OR</b> 180 mg/m<sup>2</sup> IV every 14 days",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Irinotecan:<br>If bilirubin 1-2 mg/dL, may need to reduce the dose<br>                               If bilurubin > 2 mg/dL, may not use  </li></ul><b>Renal Impairment</b><ul><li>Irinotecan:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 93,
          "referenceValue": "Cunningham D, Humblet Z, Siena S,et al. Cetuximab monothherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer."
        },
        {
          "id": 94,
          "referenceValue": "N Engl J Med. 2004;351(4):337-345."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 54,
      "name": "<b>5-FU/LV (Mayo regimen)</b>",
      "schedule": "<b>Fluorouracil</b> 370mg/m<sup>2</sup>/d IV bolus 1 hour after start of leucovorin, days 1-5<br> <b>FOLLOWING Leucovorin calcium</b> 200 mg/m<sup>2</sup>/d IV bolus, days 1-5<br> Repeat at 4 and 8 weeks, and every 5 weeks thereafter",
      "emetogenicPotential": "Low ",
      "dosageModifications": "<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>",
      "references": [
        {
          "id": 95,
          "referenceValue": "Poon MA, O'Connell MJ, Moertel CG. Biochemical modulation of fluorouracil: evidence of significant improvement of surival and quality of life in patients with advanced colorectal carcinoma."
        },
        {
          "id": 96,
          "referenceValue": "J Clin Oncol. 1989;7(10):1407-1418"
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 55,
      "name": "<b>5-FU/LV (Roswell Park regimen)</b>",
      "schedule": "<b>Fluorouracil</b> 600 mg/m<sup>2</sup>/d IV bolus 1 hour after start of leucovorin, days 1,8, 15, 22, 29, 35<br> <b>Leucovorin calcium</b> 500 mg/m<sup>2</sup>/d IV over 2 hours, days 1, 8, 15, 22, 29, 35<br> Repeat every 8 weeks",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 97,
          "referenceValue": "Petreli N, Douglass HO Jr, Herrera L, et al. The modulation of fluroouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial."
        },
        {
          "id": 98,
          "referenceValue": "J Clin Oncol. 1989;7(10):1419-1426"
        },
        {
          "id": 99,
          "referenceValue": "<br> Petrelli N, Herrera L, Rustum Y, et al. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previoulsy untreated patients with advanced colorectal carcinoma."
        },
        {
          "id": 100,
          "referenceValue": "J Clin Oncol. 1987;5(10):1559-1565."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 721,
      "name": "",
      "schedule": "<p><strong>Capecitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-14</p>\n\n<p><strong>Oxaliplatin:&nbsp;</strong>130 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 56,
      "name": "<b>5-FU/LV + Bevacizumab</b>",
      "schedule": "<b>Fluorouracil</b> 600 mg/m<sup>2</sup>/d IV bolus 1 hour after start of leucovorin, days 1,8, 15, 22, 29, 35<br> <b>Leucovorin calcium</b> 500 mg/m<sup>2</sup>/d IV over 2 hours, days 1, 8, 15, 22, 29, 35<br> Repeat every 8 weeks<br> <b>Bevacizumab</b> 5mg/kg IV<br> Repeat every 14 days",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 101,
          "referenceValue": "Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergland E, Sarkar S. Combined analysis of efficacy: the addition of bevacizumb to flurouracil/leucovorin improves survival for patients with metastatic colorectal cancer."
        },
        {
          "id": 102,
          "referenceValue": "J Clin Oncol. 2005;23(16):3706-3712."
        },
        {
          "id": 103,
          "referenceValue": "<br> Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin; an active regimen for firstline metastatic colorectal cancer."
        },
        {
          "id": 104,
          "referenceValue": "J Clin Oncol. 2005;23(15):3502-3508"
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 57,
      "name": "<b>FLOX</b>",
      "schedule": "<b>Oxaliplatin</b> 85 mg/m<sup>2</sup> IV over 2 hours, days 1, 15, 29<br> <b>Leucovorin calcium</b> 500 mg/m<sup>2</sup> IV over 2 hours, days 1, 8, 15, 22, 29, 36<br> <b>Fluorouracil</b> 500 mg/m<sup>2</sup> IV bolus 1 hour after the infusion begins, days 1, 8, 15, 22,    29, 36<br> Repeat every 8 weeks for 3 cycles",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>",
      "references": [
        {
          "id": 105,
          "referenceValue": "Kuebler JP, Wieand HS, O'Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07."
        },
        {
          "id": 106,
          "referenceValue": "J Clin Oncol. 2007;25(16):2198-2204."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 58,
      "name": "<b>FOLFIRI</b>",
      "schedule": "<b>Irinotecan</b> 180 mg/m<sup>2</sup> IV over 90 minutes, day 1<br> <b>Leucovorin calcium</b> 400 mg/m<sup>2</sup> IV over 2 hours during irinotecan infusion,<br> <b>FOLLOWED BY</b><br> <b>Fluorouracil</b> 400 mg/m<sup>2</sup> IV bolus,<br> <b>Fluorouracil</b> 2,400 mg/m<sup>2</sup> CIVI over 46 hours<br> Repeat every 14 days",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li><li>Irinotecan:<br>If bilirubin 1-2 mg/dL, may need to reduce the dose<br>                               If bilurubin > 2 mg/dL, may not use  </li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li><li>Irinotecan:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 107,
          "referenceValue": "Tournigand C, Andre T, Achille E, et al. FOLFIRI  followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study."
        },
        {
          "id": 108,
          "referenceValue": "J Clin Oncol. 2004;22(2):229-237"
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 59,
      "name": "<b>FOLFIRI + Bevacizumab</b>",
      "schedule": "<b>Irinotecan</b> 180 mg/m<sup>2</sup> IV over 90 minutes, day 1<br> <b>Leucovorin calcium</b> 400 mg/m<sup>2</sup> IV over 2 hours, day 1<br> <b>Fluorouracil</b> 400 mg/m<sup>2</sup> IV bolus, day 1<br> <b>Fluorouracil</b> 2,400 mg/m<sup>2</sup> CIVI over 46 hours, day 1<br> <b>Bevacizumab</b> 5 mg/kg IV, day 1<br> Repeat every 14 days",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li><li>Irinotecan:<br>If bilirubin 1-2 mg/dL, may need to reduce the dose<br>                               If bilurubin > 2 mg/dL, may not use  </li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li><li>Irinotecan:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 113,
          "referenceValue": "Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study."
        },
        {
          "id": 114,
          "referenceValue": "J Clin Oncol. 2007;25(30):4779-4786."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 60,
      "name": "<b>FOLFIRI + Cetuximab</b>",
      "schedule": "<b>Irinotecan</b> 180 mg/m<sup>2</sup> IV over 90 minutes, day 1<br> <b>Leucovorin calcium</b> 400 mg/m<sup>2</sup> IV over 2 hours during irinotecan infusion,<br> <b>FOLLOWED BY</b><br> <b>Fluorouracil</b> 400 mg/m<sup>2</sup> IV bolus,<br> <b>Fluorouracil</b> 2,400 mg/m<sup>2</sup> CIVI over 46 hours<br> Repeat every 14 days<br> <b>Cetuximab</b> 400 mg/m<sup>2</sup> IV initial dose, <b>THERE AFTER</b> 250mg/m<sup>2</sup> IV weekly",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li><li>Irinotecan:<br>If bilirubin 1-2 mg/dL, may need to reduce the dose<br>                               If bilurubin > 2 mg/dL, may not use  </li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li><li>Irinotecan:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 115,
          "referenceValue": "Van Cutsem E, Nowacki M, Lang I, et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial."
        },
        {
          "id": 116,
          "referenceValue": "J Clin Oncol. 2007;25:4000 (abstract)."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 61,
      "name": "<b>FOLFOX4</b>",
      "schedule": "<b>Day 1</b><br><b>Oxaliplatin</b> 85 mg/m<sup>2</sup> IV AND <br> <b>Leucovorin calcium</b> 200 mg/m<sup>2</sup> over 120 minutes, <b>FOLLOWED BY</b><br> <b>Fluorouracil</b> 400 mg/m<sup>2</sup> IV bolus over 2-4 minutes, <b>FOLLOWED BY</b><br> <b>Fluorouracil</b> 600mg/m<sup>2</sup> CIVI over 22 hours,<br><b>Day 2</b><br><b>Leucovorin calcium</b> 200 mg/m<sup>2</sup> IV over 120 minutes, <b>FOLLOWED BY</b><br> <b>Fluorouracil</b> 400mg/m<sup>2</sup> IV bolus over 2-4 minutes, <b>FOLLOWED BY</b><br> <b>Fluorouracil</b> 600mg/m<sup>2</sup> CIVI over 22 hours,<br> Repeat  every 14 days",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>",
      "references": [
        {
          "id": 117,
          "referenceValue": "Richard M. Goldberg, et al.Pooled Analysis of Safety and Efficacy of Oxaliplatin Plus Fluorouracil/Leucovorin Administered Bimonthly in Elderly Patients With Colorectal Cancer."
        },
        {
          "id": 118,
          "referenceValue": "http://jco.ascopubs.org/content/24/25/4085.abstract"
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 62,
      "name": "<b>FOLFOX4 + Bevacizumab</b>",
      "schedule": "<b>Day 1</b><br><b>Oxaliplatin</b> 85 mg/m<sup>2</sup> IV <b>AND</b><br> <b>Leucovorin calcium</b> 200 mg/m<sup>2</sup> over 120 minutes, <b>FOLLOWED BY</b><br> <b>Fluorouracil</b> 400 mg/m<sup>2</sup> IV bolus over 2-4 minutes, <b>FOLLOWED BY</b><br> <b>Fluorouracil</b> 600mg/m<sup>2</sup> CIVI over 22 hours, <br><b>Bevacizumab</b> 5 mg/kg IV.<br><b>Day 2</b><br> <b>Leucovorin calcium</b> 200 mg/m<sup>2</sup> IV over 120 minutes, day 2, <b>FOLLOWED BY</b><br> <b>Fluorouracil</b> 400mg/m<sup>2</sup> IV bolus over 2-4 minutes, <b>FOLLOWED BY</b><br> <b>Fluorouracil</b> 600mg/m<sup>2</sup> CIVI over 22 hours,<br> Repeat  every 14 days <br> Repeat every 14 days",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>",
      "references": [
        {
          "id": 119,
          "referenceValue": "Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study."
        },
        {
          "id": 120,
          "referenceValue": "J Clin Oncol. 2008;26(18)2013-2019."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 63,
      "name": "<b>FOLFOX4 + panitumumab</b> ",
      "schedule": "<b>Panitumumab</b> 6 mg/kg IV over 60 minutes <br> <b>Oxaliplatin</b> 85 mg/m<sup>2</sup> IV, day 1<br> <b>Leucovorin calcium</b> 200 mg/m<sup>2</sup> IV on day 1<br> <b>FOLLOWED BY Fluorouracil</b> 400 mg/m<sup>2</sup> IV bolus, <b>FOLLOWED BY Fluorouracil</b> 600mg/m<sup>2</sup> IV infusion over 22 hours on days 1 and 2<br> Repeat cycle every 14 days",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>",
      "references": [
        {
          "id": 121,
          "referenceValue": "Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study."
        },
        {
          "id": 122,
          "referenceValue": "J Clin Oncol. 2010;28(31):4697-4705."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 66,
      "name": "<b>XELIRI</b>",
      "schedule": "<b>Irinotecan</b> 250 mg/m<sup>2</sup> IV over 30-90 minutes, day 1<br> <b>Cappecitabine 1,000 mg/m<sup>2</sup> PO bid, days 1-14<br> Repeat cycle every 21 days",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Irinotecan:<br>If bilirubin 1-2 mg/dL, may need to reduce the dose<br>                               If bilurubin > 2 mg/dL, may not use  </li></ul><b>Renal Impairment</b><ul><li>Irinotecan:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 123,
          "referenceValue": "Patt YZ, Lee F, Liebman JE, et al. Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer."
        },
        {
          "id": 124,
          "referenceValue": "Am J Clin Oncol. 2007;30(4):350-357"
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 67,
      "name": "<b>XELOX</b>",
      "schedule": "<b>Oxaliplatin</b> 130 mg/m<sup>2</sup> IV, day 1<br> <b>Capecitabine</b> 1,000 mg/m<sup>2</sup> PO bid from evening day 1 to 14<br> Repeat every 21 days",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>",
      "references": [
        {
          "id": 109,
          "referenceValue": "Cassidy J, Tabernero J, Twelves C, et al. XELOX (capecitabine plus oxaliplatin); active first-line therapy for patients with metastatic colorectal cancer."
        },
        {
          "id": 110,
          "referenceValue": "J Clin Oncol. 2004;22(11):2084-2091"
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 68,
      "name": "<b>XELOX + Bevacizumab</b>",
      "schedule": " <b>Oxaliplatin</b> 130 mg/m<sup>2</sup> IV, day 1<br><b>Bevacizumab</b> 7.5 mg/kg IV, day 1<br> <b>Capecitabine</b> 1,000 mg/m<sup>2</sup> PO bid from evening day 1 to 14<br> Repeat every 21 days<br> Repeat every 21 days",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>",
      "references": [
        {
          "id": 125,
          "referenceValue": "Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study."
        },
        {
          "id": 126,
          "referenceValue": "J Clin Oncol. 2008;26(18)2013-2019."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 69,
      "name": "<b>Capecitabine</b>",
      "schedule": "<b>Capecitabine</b> 1,000- 1,250 mg/m<sup>2</sup>/d PO bid, days 1-14, <b>FOLLOWED BY</b> 7 days rest<br> Repeat every 21 days",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li></ul>",
      "references": [
        {
          "id": 127,
          "referenceValue": "Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large Phase III Study."
        },
        {
          "id": 128,
          "referenceValue": "J Clin Oncol. 2001;19(21):4097-4106"
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 70,
      "name": "<b>Cetuximab</b>",
      "schedule": "<b>Cetuximab</b> 400 mg/m<sup>2</sup> IV initial dose over 120 minutes, <b>FOLLOWED BY</b> 250 mg/m<sup>2</sup> IV over 60 minutes<br> Repeat every 7 days",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>",
      "references": [
        {
          "id": 129,
          "referenceValue": "Erbitux [package insert]."
        },
        {
          "id": 130,
          "referenceValue": "Branchburg, NJ, and Princeton, NJ: ImClone Systems/ Bristol-Myers Squibb; 2011."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 71,
      "name": "<b>5-FU</b>",
      "schedule": "<b>Fluorouracil</b> 1,000 mg/m<sup>2</sup>/d CIVI, days 1-5<br> Repeat every 28 days",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Fluorouracil:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 131,
          "referenceValue": "Kemeny N, Israel K, Niedzwieki D, et al. Randomized study of continuous-infusion fluorouracil versus fluorouracil plus cisplatin in patients with metastatic colorectal cancer."
        },
        {
          "id": 132,
          "referenceValue": "J Clin Oncol. 1990;8(2):313-318."
        },
        {
          "id": 133,
          "referenceValue": "<br> Schmoll HJ. Development of treatment for advanced colorectal cancer: infusional 5-FU and the role of new agents."
        },
        {
          "id": 134,
          "referenceValue": "lEur J Cancer. 1996;32A(suppl 5):S18-S22."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 151,
      "name": "<b>Trastuzumab q3wk</b>",
      "schedule": "<b>Trastuzumab</b> 8 mg/kg IV over 90 minutes, day 1, then 6 mg/kg IV over 90 minutes<br> Repeat every 21 days for 1 year(adjuvant).",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>",
      "references": [
        {
          "id": 135,
          "referenceValue": "Piccart-Gebhart MJ, Proctor M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer."
        },
        {
          "id": 136,
          "referenceValue": "N Engl J Med. 2005;353(16):1659-1672."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 72,
      "name": "<b>Irinotecan</b>",
      "schedule": "<b>Irinotecan</b> 125 mg/m<sup>2</sup>/d IV over 90 minutes, days 1,8, 15,22 <b>FOLLOWED BY</b> 2 weeks rest<br> Repeat every 6 weeks<br> <b>OR</b><br> <b>Irinotecan</b> 350 mg/m<sup>2</sup> IV over 90 minutes<br> Repeat every 21 days",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Irinotecan:<br>If bilirubin 1-2 mg/dL, may need to reduce the dose<br>                               If bilurubin > 2 mg/dL, may not use  </li></ul><b>Renal Impairment</b><ul><li>Irinotecan:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 137,
          "referenceValue": "Rougier P, Bugat R, Douillard JY, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naïve patients and patients pretreated with fluorouracil-based chemotherapy."
        },
        {
          "id": 138,
          "referenceValue": "J Clin Oncol. 1997;15(1):251-260"
        },
        {
          "id": 139,
          "referenceValue": "<br> Camptosar [package insert]. New York, NY: Pfizer; 2010.<br> Conti JA, Kemeny NE, jSaltz LB, et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer."
        },
        {
          "id": 140,
          "referenceValue": "J Clin Oncol. 1996;14(3):709-715."
        },
        {
          "id": 141,
          "referenceValue": "<br> Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer."
        },
        {
          "id": 142,
          "referenceValue": "Lancet. 1998;352(9138):1413-1418."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 77,
      "name": "<b>Imatinib</b>",
      "schedule": "<b>Imatinib mesylate</b> 400-800 mg PO, daily",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Imatinib:<br>If bilirubin < 3 upper normal limit, no dose reduction <br>                            If bilirubin > 3 upper normal limit, use with caution </li></ul><b>Renal Impairment</b><ul><li>Imatinib:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 143,
          "referenceValue": "Blanke CD, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the Kit receptor tyrosine kinase: S0033."
        },
        {
          "id": 144,
          "referenceValue": "J Clin Oncol. 2008;26(4):626-632"
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 78,
      "name": "<b>Nilotinib</b>",
      "schedule": "<b>Nilotinib</b> 400 mg PO bid",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Nilotinib:<br>Unknown </li></ul><b>Renal Impairment</b><ul><li>Nilotinib:<br>Not tested. Not renally excreted </li></ul>",
      "references": [
        {
          "id": 145,
          "referenceValue": "Montemurro M, Schoffski P, Reichardt P, et al. Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib."
        },
        {
          "id": 146,
          "referenceValue": "Eur J Cancer. 2009;45:2293-2297."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 79,
      "name": "<b>Sunitinib</b>",
      "schedule": "<b>Sunitinib malate</b> 50 mg/d for 28 days, 14 days rest then repeat cycle",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Sunitinib:<br>If Child-Pugh A or B, no dose reduction  <br>                                                    If Child-Pugh C, reduce dose by 50% </li></ul><b>Renal Impairment</b><ul><li>Sunitinib:<br>If CrCl > 42 mL/min, no dose reduction </li></ul>",
      "references": [
        {
          "id": 147,
          "referenceValue": "Demetri GD, van Oossterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour afer failure of imatinib: a randomised controlled trial."
        },
        {
          "id": 148,
          "referenceValue": "Lancet. 2006;368(9544):1329-1338."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 80,
      "name": "<b>Carbo-Tax</b>",
      "schedule": "<b>Paclitaxel</b> 225mg/m<sup>2</sup> IV over 3 hours, day 1<br> <b>Carboplatin</b> dose targeted by AUC of 6 mg/mL/min, day 1<br> Repeat every 21 days",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Paclitaxel:<br>No dose reduction</li></ul>",
      "references": [
        {
          "id": 149,
          "referenceValue": "Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer."
        },
        {
          "id": 150,
          "referenceValue": "N Engl J Med. 2002;346(2):92-98."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 81,
      "name": "<b>Cisplatin/Pemetrexed</b>",
      "schedule": "<b>Cisplatin</b> 75 mg/m<sup>2</sup> IV, day 1<br> <b>Pemetrexed</b> 500 mg/m<sup>2</sup> IV, day 1<br> Repeat every 21 days for up to 6 cycles",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Pemetrexed:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Pemetrexed:<br>If CrCl > 45 mL/min, no dose reduction    <br>                                                                        If CrCl < 45 mL/min, do not use </li></ul>",
      "references": [
        {
          "id": 152,
          "referenceValue": "Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer."
        },
        {
          "id": 153,
          "referenceValue": "J Clin Oncol. 2008;26(21):3543-3551."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 82,
      "name": "<b>Cisplatin/Vinorelbine/Cetuximab</b>",
      "schedule": "<b>Cetuximab</b> 400 mg/m<sup>2</sup> IV initial dose, <b>THEN</b><br> 250 mg/m<sup>2</sup>/wk<br> <b>Cisplatin</b> 80 mg/m<sup>2</sup> IV, day 1<br> <b>Vinorelbine</b> 25 mg/m<sup>2</sup> IV, days 1, 8<br> Repeat every 21 days",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Vinorelbine:<br>If bilirubin 2-3 mg/dL, reduce dose by 50%    <br>                                           If bilirubin 3.1-5 mg/dL, reduce dose by 75%      <br>                                      If bilirubin > 5 mg/dL, do not use</li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Vinorelbine:<br>No dose reduction</li></ul>",
      "references": [
        {
          "id": 154,
          "referenceValue": "Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial."
        },
        {
          "id": 155,
          "referenceValue": "Lancet. 2009;373(9674):1525-1531."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 83,
      "name": "<b>Docetaxel/Cisplatin</b>",
      "schedule": "<b>Docetaxel</b> 75 mg/m<sup>2</sup> IV, day 1<br> <b>Cisplatin</b> 75 mg/m<sup>2</sup> IV, day 1<br> Repeat every 21 days",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Docetaxel:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 156,
          "referenceValue": "Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer."
        },
        {
          "id": 157,
          "referenceValue": "N Engl J Med. 2002;346(2):92-98."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 152,
      "name": "<b>Vinorelbine</b>",
      "schedule": "<b>Vinorelbine</b> 30 mg/m<sup>2</sup> IV<br> Repeat every 7 days",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Vinorelbine:<br>If bilirubin 2-3 mg/dL, reduce dose by 50%    <br>                                           If bilirubin 3.1-5 mg/dL, reduce dose by 75%      <br>                                      If bilirubin > 5 mg/dL, do not use</li></ul><b>Renal Impairment</b><ul><li>Vinorelbine:<br>No dose reduction</li></ul>",
      "references": [
        {
          "id": 158,
          "referenceValue": "Weber BL, Vogel C, Jones S, et al. Intravenous vinorelbine as first-line and second-line therapy in advanced breast  cancer."
        },
        {
          "id": 159,
          "referenceValue": "J Clin Oncol. 1995;13(11):2722-2730."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 84,
      "name": "<b>Gemcitabine/Cisplatin</b>",
      "schedule": "<b>Gemcitabine</b> 1,000mg/m<sup>2</sup> /d IV,days 1,8,15<br> <b>Cisplatin</b> 100 mg/m<sup>2</sup> IV, day 1<br> Repeat every 28 days<br> <b>OR</b><br> <b>Gemcitabine</b> 1,250 mg/m<sup>2</sup>/d IV over 30 minutes, days 1, 8<br> <b>Cisplatin</b> 100 mg/m<sup>2</sup> IV over 60 minutes, day 1<br> Repeat every 21 days                                         ",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Gemcitabine:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 160,
          "referenceValue": "Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer."
        },
        {
          "id": 161,
          "referenceValue": "N Engl J Med. 2002;346(2):92-98."
        },
        {
          "id": 162,
          "referenceValue": "<b> Cardenal F, Lopez-Cabrerizo MP, Anton A, et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer."
        },
        {
          "id": 163,
          "referenceValue": "J Clin Oncol. 1999;17(1):12-18."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 85,
      "name": "<b>Gemcitabine/Docetaxel</b>",
      "schedule": "<b>Gemcitabine</b> 1,100 mg/m<sup>2</sup>/d IV over 30 minutes, days 1, 8<br> <b>Docetaxel</b> 100 mg/m<sup>2</sup> IV over 1 hour, day 8<br>  Repeat every 21 days.",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Docetaxel:<br>No dose reduction </li><li>Gemcitabine:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 164,
          "referenceValue": "Georgoulias V, Papadakis E, Alexopoulos A, et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomized multicentre trial."
        },
        {
          "id": 165,
          "referenceValue": "Lancet. 2001;357(9267):1478-1484."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 86,
      "name": "<b>Gemcitabine/Paclitaxel</b>",
      "schedule": "<b>Gemcitabine</b> 1,000 mg/m<sup>2</sup>/d IV over 30 minutes, days 1, 8<br> <b>Paclitaxel</b> 200 mg/m<sup>2</sup> IV over 3 hours, day 1<br> Repeat every 21 days",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li><li>Paclitaxel:<br>No dose reduction</li></ul>",
      "references": [
        {
          "id": 166,
          "referenceValue": "Kosmidis P, Mylonakis N, Nicolaides C, et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial."
        },
        {
          "id": 167,
          "referenceValue": "J Clin Oncol. 2002;20(17):3578-3585."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 87,
      "name": "<b>Gemcitabine/Vinorelbine</b>",
      "schedule": "<b>Gemcitabine</b> 1,200 mg/m<sup>2</sup>/d IV, days 1, 8<br> <b>Vinorelbine</b> 30 mg/m<sup>2</sup>/d IV, days 1, 8<br> Repeat every 21 days<br> <b>OR</b><br> <b>Gemcitabine</b> 800-1,000 mg/m<sup>2</sup>/d IV over 30 minutes, days 1, 8, 15<br> <b>Vinorelbine</b> 20 mg/m<sup>2</sup>/d IV over 10-30 minutes, days 1, 8, 15<br> Repeat every 28 days",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li><li>Vinorelbine:<br>If bilirubin 2-3 mg/dL, reduce dose by 50%    <br>                                           If bilirubin 3.1-5 mg/dL, reduce dose by 75%      <br>                                      If bilirubin > 5 mg/dL, do not use</li></ul><b>Renal Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li><li>Vinorelbine:<br>No dose reduction</li></ul>",
      "references": [
        {
          "id": 172,
          "referenceValue": "Frasci G, Lorusso V, Panza N, et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer."
        },
        {
          "id": 173,
          "referenceValue": "J Clin Oncol. 2000;18(13):2529-2536."
        },
        {
          "id": 174,
          "referenceValue": "<br> Chen YM, Perng, RP, Yang KY, et al. A multi-gemcitabine in previously untreated inoperable (stageIIIB/IV) non-small-cell lung cancer."
        },
        {
          "id": 175,
          "referenceValue": "Chest. 2000;117(6):1583-1589."
        },
        {
          "id": 176,
          "referenceValue": "<br> Hainsworth JD, Burris HA 3rd, Litchy S, et al. Gemcitabine and vinorelbine in the second-line treatment of non-small-celll lung carcinoma patients: a Minnie Pearl Cancer Research Network phase II trial."
        },
        {
          "id": 177,
          "referenceValue": "Cancer. 2000;88(6):1353-1358."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 88,
      "name": "<b>PC</b>",
      "schedule": "<b>Paclitaxel</b> 135mg/m<sup>2</sup> over 24hours, day 1<br> <b>Cisplatin</b> 75mg/m<sup>2</sup> IV, day 2<br> Repeat every 21 days<br> <b>OR</b><br> <b>Paclitaxel</b> 175 mg/m<sup>2</sup> over 3 hours,day 1<br> <b>Cisplatin</b> 80 mg/m<sup>2</sup> IV, day 1<br> Repeat every 21 days   ",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Paclitaxel:<br>No dose reduction</li></ul>",
      "references": [
        {
          "id": 178,
          "referenceValue": "Schiller JH, Hamington D, Belani CP, et al. Comparison of four chemotherapy regiments for advanced non-small-cell lung cancer."
        },
        {
          "id": 179,
          "referenceValue": "N Eng/J Med.2002;346(2);92-98."
        },
        {
          "id": 180,
          "referenceValue": "<br> Smit EF., van Meerbeeck JP,lianes P,et al.Three-arm randomaized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advance m=non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of cancer Lung Group-EORTC 08975."
        },
        {
          "id": 181,
          "referenceValue": "J Clin Oncol.2003;21(21):3909-3917."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 89,
      "name": "<b>PCB</b>",
      "schedule": "<b>Paclitaxel</b> 200 mg/m<sup>2</sup> IV, day 1<br> <b>Carboplatin</b> AUC of IV ,day 1<br> <b>Bevacizumab</b> 15 mg/kg IV, day 1<br> Repeat every 21 days",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Paclitaxel:<br>No dose reduction</li></ul>",
      "references": [
        {
          "id": 182,
          "referenceValue": "Sandler A, Gray R, Perry MC,et al. Paclitaxel-carboplatin alone or with bevacizumab for non small-cell lung cancer."
        },
        {
          "id": 183,
          "referenceValue": "N Engl J Med. 2006;355(24):2542-2550."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 189,
      "name": "<b>Docetaxel/Prednisone</b>",
      "schedule": "<b>Docetaxel</b> 75 mg/m<sup>2</sup> IV over 1 hour, day 1<br> <b>Prednisone</b> 5 mg PO bid, days 1-21<br> Repeat every 21 days",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li></ul><b>Renal Impairment</b><ul><li>Docetaxel:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 184,
          "referenceValue": "Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer."
        },
        {
          "id": 185,
          "referenceValue": "N Engl J Med. 2004;351(15):1502-1512."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 90,
      "name": "<b>Vinorelbine/Cisplatin</b>",
      "schedule": "<b>Vinorelbine</b> 30 mg/m<sup>2</sup> IV over 20 minutes, day 1,8,15,22.<br> <b>Cisplatin</b> 100mg/m<sup>2</sup> IV over 1 hour day 1.<br>Repeat cycle every 28 days.",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Vinorelbine:<br>If bilirubin 2-3 mg/dL, reduce dose by 50%    <br>                                           If bilirubin 3.1-5 mg/dL, reduce dose by 75%      <br>                                      If bilirubin > 5 mg/dL, do not use</li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Vinorelbine:<br>No dose reduction</li></ul>",
      "references": [
        {
          "id": 186,
          "referenceValue": "Douillard JY, Rosell R, De Lena M,et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-III A non small-cell lung cancer  (Adjuvant Naverlbine International Trialist Association [ANITA): a randomised controlled trial."
        },
        {
          "id": 187,
          "referenceValue": "Lancet Oncol.2006:7(9):719-727."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 91,
      "name": "<b>Crizotinib</b>",
      "schedule": "<b>Crizotinib</b> 250 mg PO bid in 28-day cycles",
      "emetogenicPotential": "Moderate-High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>",
      "references": [
        {
          "id": 188,
          "referenceValue": "Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic Lymphoma Kinase inhabitation in non-small-cell lung cancer."
        },
        {
          "id": 189,
          "referenceValue": "N engl J Med.2010;363(18):1693-1703."
        },
        {
          "id": 190,
          "referenceValue": "<br> Xalkori [packages insert]."
        },
        {
          "id": 191,
          "referenceValue": "New York, NY: Pfizer labs;2011."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 92,
      "name": "<b>Docetaxel</b>",
      "schedule": "<b>Docetaxel</b> 75mg/m<sup>2</sup> IV over 1hour.<br> Repeat every 21 days",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li></ul><b>Renal Impairment</b><ul><li>Docetaxel:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 192,
          "referenceValue": "Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy."
        },
        {
          "id": 193,
          "referenceValue": "J Clin Oncol. 2000;18(10):2095-2103."
        },
        {
          "id": 194,
          "referenceValue": "<br> Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-lung cancer previously treated with platinum-containing chemotherapy regimens."
        },
        {
          "id": 195,
          "referenceValue": "J Clin Oncol. 2000;18(12):2354-2362."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 93,
      "name": "<b>Erlotinib</b>",
      "schedule": "<b>Erlotinib</b> 150mg PO daily at least 1hour before <b>OR</b> 2 Hours after eating",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Erlotinib:<br>If AST > 3 upper normal limit, 50 mg  <br>                                                        If direct bilirubin 1-7 mg/dL, 75 mg </li></ul><b>Renal Impairment</b><ul><li>Erlotinib:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 168,
          "referenceValue": "Wheatley-Price P, Ding K, Seymour L, et al. Erlotinib for advanced non small cell  lung cancer Institute of Canada Clinical trials group study BR 21."
        },
        {
          "id": 169,
          "referenceValue": "J Clin Oncol. 2008;26(14):2350-2357."
        },
        {
          "id": 170,
          "referenceValue": "<br> Tarceva [packaga insert]."
        },
        {
          "id": 171,
          "referenceValue": "Melville, NY south San Fransisco, CA:OSI Pharmaceuticals Inc & Genentich Inc;2010."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 94,
      "name": "<b>Gemcitabine</b>",
      "schedule": "<b>Gemcitabine</b> 1000 mg/m<sup>2</sup>/d IV over 30 minutes, day 1,8,15<br> <br>  Repeat every 28 days.",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 198,
          "referenceValue": "Crino L, Mosconi AM, Scaglotti G, et al.              Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: a phase II trial."
        },
        {
          "id": 199,
          "referenceValue": "J Clin Oncol. 1999;17(7):2081-2085."
        },
        {
          "id": 200,
          "referenceValue": "<br> Ricci S, Anonuzzo A, Galli L, et al. Gemcitabine monotherapy in elderly paients with advanced non-smell-cell lung cancer: a multicenter phase II study."
        },
        {
          "id": 201,
          "referenceValue": "Lung Cancer.2000;27(2):75-80."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 95,
      "name": "<b>Pemetrexed</b>",
      "schedule": "<b>Pemetrexed</b> 500mg/m<sup>2</sup> IV over 10 minutes<br> Repeat every 21 days ",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Pemetrexed:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Pemetrexed:<br>If CrCl > 45 mL/min, no dose reduction    <br>                                                                        If CrCl < 45 mL/min, do not use </li></ul>",
      "references": [
        {
          "id": 202,
          "referenceValue": "Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III study of premtrexed versus docetaxel in patients with non-smell-cell lung cancer previously treated with chemotherapy."
        },
        {
          "id": 203,
          "referenceValue": "J Clin Oncol. 2004;22(9):1589-1597."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 96,
      "name": "<b>Vinorelbine</b>",
      "schedule": "<b>Vinorelbine</b> 30 mg/m<sup>2</sup> IV over 20 minutes, day 1,8,15,22.<br> Repeat every 7 days .",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Vinorelbine:<br>If bilirubin 2-3 mg/dL, reduce dose by 50%    <br>                                           If bilirubin 3.1-5 mg/dL, reduce dose by 75%      <br>                                      If bilirubin > 5 mg/dL, do not use</li></ul><b>Renal Impairment</b><ul><li>Vinorelbine:<br>No dose reduction</li></ul>",
      "references": [
        {
          "id": 204,
          "referenceValue": "Le Chevalier T, Brisgand D, Douillard JY, et al. Randomized study of vinorelbine and cisplatin versus vindesin and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients."
        },
        {
          "id": 205,
          "referenceValue": "J Clin Oncol.1994;12(2):360-367."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 97,
      "name": "<b>Carboplatin/Irinotecan</b>",
      "schedule": "<b>Carboplatin</b> AUC of 5 IV, day 1<br> <b>Irinotecan</b> 175mg/m<sup>2</sup> IV, day 1<br> Repeat every 21days",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Irinotecan:<br>If bilirubin 1-2 mg/dL, may need to reduce the dose<br>                               If bilurubin > 2 mg/dL, may not use  </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Irinotecan:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 206,
          "referenceValue": "Hermes A, Bergman B, Bremnes R, et al           Irinotecan plus carboplatin in extensive versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial."
        },
        {
          "id": 207,
          "referenceValue": "J Clin Oncol. 2008:26(26):4261-4267."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 98,
      "name": "<b>Cisplatin + CPT-11</b>",
      "schedule": "<b>Cisplatin</b> 60mg/m<sup>2</sup>, day 1<br> <b>Irinotecan</b> 60mg/m<sup>2</sup>/d, days 1, 8, 15<br> Repeat every 28days",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Irinotecan:<br>If bilirubin 1-2 mg/dL, may need to reduce the dose<br>                               If bilurubin > 2 mg/dL, may not use  </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Irinotecan:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 208,
          "referenceValue": "Noda K, Nishiwaki Y, Kawahara M, et al.                     Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer."
        },
        {
          "id": 209,
          "referenceValue": "N Engl J Med. 2002;346(2):85-91."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 190,
      "name": "<b>FL</b>",
      "schedule": "<b>Flutamide</b> 250 mg PO tid <b>WITH</b><br> <b>Leuprolide acetate depot</b> 7.5 mg IM<br> Repeat every 28 days",
      "emetogenicPotential": "N/A",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Leuprolide:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul></ul>",
      "references": [
        {
          "id": 210,
          "referenceValue": "Sarosdy MF, Schellhammer PF, Johnson R, Carroll K, Kolvenbag GJCM. Does prolonged combined androgen blockade have survival benefits over short-term combined androgen blockade therapy?"
        },
        {
          "id": 211,
          "referenceValue": "Urology. 2000;55(3):391-396."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 99,
      "name": "<b>CAV</b>",
      "schedule": "<b>Cyclophosphamide</b>  1,000 mg/m<sup>2</sup>IV on day 1.  <br>                                              <b>Doxorubicin</b> 40 mg/m<sup>2</sup>IV on day 1.<br>                                                                <b>Vincristine</b> 1 mg/m<sup>2</sup>IV on day 1. (maximum, 2 mg) <br>Repeat cycle every 21 days.",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Vincristine:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 212,
          "referenceValue": "Roth  BJ, et al. J Clin Oncol 1992;10:282-291."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 100,
      "name": "<b>Carboplatin + Paclitaxel</b>",
      "schedule": "<b>Carboplatin</b>AUC of 2, IV on days1,8, and 15.<br><b>Paclitaxel</b> 80 mg/m<sup>2</sup> IV on days 1,8, and 15. Repeat cycle every 28 days.",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Paclitaxel:<br>No dose reduction</li></ul>",
      "references": [
        {
          "id": 213,
          "referenceValue": "Neubauer M, et al. J Clin Oncol2004;22:1872-1877"
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 101,
      "name": "<b>EC</b>",
      "schedule": "<b>Etoposide</b> 100mg/m<sup>2</sup>/d IV, days 1-3<br><b>Carboplatin</b> 450mg/m<sup>2</sup> IV, day 1<br> Repeat every 28 days for 6 cycles",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>",
      "references": [
        {
          "id": 214,
          "referenceValue": "Viren M, Liippo K, Ojala a, et al. Carboplatin and etoposide in extensive small-cell lung cancer."
        },
        {
          "id": 215,
          "referenceValue": "Acta Oncal. 1994;33(8):921-924."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 102,
      "name": "<b>EP</b>",
      "schedule": "<b>Etoposide</b> 80mg/m<sup>2</sup>/d IV, days 1-3<br> <b>Cisplatin</b> 80mg/m<sup>2</sup> IV, day 1 (Standard dose)<br> Repeat every 21 days <b>OR</b><br> <b>Etoposide</b> 80mg/m<sup>2</sup>/d IV, days 1-5<br> <b>Cisplatin</b> 27mg/m<sup>2</sup> IV, days 1-5(high dose)<br> Repeat every 21 days",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>",
      "references": [
        {
          "id": 216,
          "referenceValue": "Ihde DC, Mulshine JL, Kramer BS, et al.  Prospective randomized comparision of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer."
        },
        {
          "id": 217,
          "referenceValue": "J Clin Oncol.1994; 12(10):2022-2034."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 103,
      "name": "<b>Etoposide</b>",
      "schedule": "<b>Etoposide</b> 160 mg/m<sup>2</sup>/d PO, days 1-5<br> Repeat every 28 days<br> <b>OR</b><br> <b>Etoposide</b> 50 mg PO bid for 14 days<br> Repeat every 21 days",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>",
      "references": [
        {
          "id": 218,
          "referenceValue": "Johnson DH. Recent developments in chemotherapy treatment of small-cell lung cancer."
        },
        {
          "id": 219,
          "referenceValue": "Semin Oncol. 1993;20(4):315-325."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 104,
      "name": "<b>Paclitaxel</b>",
      "schedule": "<b>Paclitaxel</b> 250 mg/m<sup>2</sup> IV over 24 hours<br> Repeat every 21 days",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Paclitaxel:<br>No dose reduction</li></ul>",
      "references": [
        {
          "id": 220,
          "referenceValue": "Ettinger DS, Finkelstein DM, Sarma RP, Johnson DH. Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study."
        },
        {
          "id": 221,
          "referenceValue": "J Clin Oncol. 1995;13(6):1430-1435."
        },
        {
          "id": 222,
          "referenceValue": "<br> Kirschling RJ, Grill JP, Marks RS, et al. Paclitaxel and G-CSF in previously untreated patients with extensive-stage small-cell lung cancer: a phase II study of the North Central Cancer Treatment Group."
        },
        {
          "id": 223,
          "referenceValue": "Am J Clin Oncol. 1999;22(5):517-522"
        },
        {
          "id": 224,
          "referenceValue": "<br>"
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 105,
      "name": "<b>Topotecan IV</b>",
      "schedule": "<b>Topotecan</b> 1.5 mg/m<sup>2</sup>/d IV over 30 minutes, days 1-5<br> Repeat every 21 days",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Topotecan:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Topotecan:<br>If CrCl > 40 mL/min, no dose reduction   <br>                                                                          If CrCl 20-39 mL/min, reduce to 0.75 mg/m2 </li></ul>",
      "references": [
        {
          "id": 225,
          "referenceValue": "Ardizzoni A, Hansen H, Dombernowsky P, et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease."
        },
        {
          "id": 226,
          "referenceValue": "J Clin Oncol.1997;15(5):2090-2096."
        },
        {
          "id": 227,
          "referenceValue": "<br> von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer."
        },
        {
          "id": 228,
          "referenceValue": "J Clin Oncol. 1999;17(2):658-667."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 106,
      "name": "<b>Topotecan PO</b>",
      "schedule": "<b>Topotecan</b> 2.3 mg/m<sup>2</sup>/d PO, days 1-5<br> Repeat every 21 days",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Topotecan:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Topotecan:<br>If CrCl > 40 mL/min, no dose reduction   <br>                                                                          If CrCl 20-39 mL/min, reduce to 0.75 mg/m2 </li></ul>",
      "references": [
        {
          "id": 229,
          "referenceValue": "Eckardt JR, von Pawel J, Pujol JL, et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer."
        },
        {
          "id": 230,
          "referenceValue": "J Clin Oncol. 2007;25(15):2086-2092."
        },
        {
          "id": 231,
          "referenceValue": "Erratum in: J Clin Oncol. 2007;25(22):3387."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 509,
      "name": "",
      "schedule": "<p><strong>Ado-trastuzumab</strong>: 3.6mg/kg IV on day 1</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "Minimal",
      "dosageModifications": "",
      "references": [
        {
          "id": 851,
          "referenceValue": "Verma S, Miles D, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783-91."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 107,
      "name": "<b>CAP</b>",
      "schedule": "<b>Cyclophosphamide</b> 500 mg/m<sub>2</sub> IV on day 1<br><b>Doxorubicin</b> 500 mg/m<sub>2</sub> IV on day 1<br><b>Cisplatin</b> 500 mg/m<sub>2</sub> IV on day 1<br>Repeat cycle every 21 days.",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 232,
          "referenceValue": "Loehrer PJ, et al."
        },
        {
          "id": 233,
          "referenceValue": "J Clin Oncol 1994;12:1164-1168."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 108,
      "name": "<b>Cisplatin + Etoposide</b>",
      "schedule": "<b>Cisplatin</b> 60 mg/m<sub>2</sub> IV on day 1<br><b>Etoposide</b> 120 mg/m<sub>2</sub> IV on day 1 - 3<br>Repeat cycle every 21 days.",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>",
      "references": [
        {
          "id": 234,
          "referenceValue": "Giaccone G, et al."
        },
        {
          "id": 235,
          "referenceValue": "J Clin Oncol 1996;14:814-820."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 109,
      "name": "<b>ADOC</b>",
      "schedule": "<b>Cisplatin</b> 50 mg/m<sub>2</sub> IV on day 1<br><b>Doxorubicin</b> 40 mg/m<sub>2</sub> IV on day 1<br><b>Vincristine</b> 0.6 mg/m<sub>2</sub> IV on day 3<br><b>Cyclophosphamide</b> 700 mg/m<sub>2</sub> IV on day 4<br>Repeat cycle every 28 days.",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Vincristine:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 242,
          "referenceValue": "Fornasiero A, et al."
        },
        {
          "id": 243,
          "referenceValue": "Cancer 1991;68:30-33."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 110,
      "name": "<b>VIP</b>",
      "schedule": "<b>Etoposide(VP-I6)</b> 75 mg/m<sub>2</sub> IV on days 1-4<br><b>Ifosfamide</b> 1200 mg/m<sub>2</sub> IV on days 1-4<br><b>Cisplatin</b> 20 mg/m<sub>2</sub> IV on days 1-4<br><b>Mesna</b> 240 mg/m<sub>2</sub> IV before first ifosfamide dose, then 4 and 8 hours later on days 1-4<br>Repeat cycle every 21 days for a total of 4 cycles.G-CSF support at 5 micro grams/kg/day on days 5-15",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Ifosfamide:<br>No dose reduction</li><li>Mesna:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>",
      "references": [
        {
          "id": 244,
          "referenceValue": "Loehrer PJ, et al."
        },
        {
          "id": 245,
          "referenceValue": "Cancer 2001;91:2010-2015."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 111,
      "name": "<b>Gemcitabine + Topotecan</b>",
      "schedule": "<b>Gemcitabine</b>1000 mg/m<sub>2</sub> IV on days 1,8, and 15.<br><b>Topotecan</b>0.75-1.5 mg/m<sub>2</sub> IV on days 1,8, and 15.<br> Repeat cycle every 21 days",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li><li>Topotecan:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li><li>Topotecan:<br>If CrCl > 40 mL/min, no dose reduction   <br>                                                                          If CrCl 20-39 mL/min, reduce to 0.75 mg/m2 </li></ul>",
      "references": [
        {
          "id": 246,
          "referenceValue": "William WN, et al."
        },
        {
          "id": 247,
          "referenceValue": "Am J Clin Oncol 2009;32:15-19."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 112,
      "name": "<b>Carboplatin + Paclitaxel</b>",
      "schedule": "<b>Carboplatin</b> AUC of 6, IV on day 1 <br><b>Paclitaxel</b>225 mg/m<sub>2</sub> IV on day 1<br> Repeat cycle every 21 days",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Paclitaxel:<br>No dose reduction</li></ul>",
      "references": [
        {
          "id": 248,
          "referenceValue": "Lemma GL, et al."
        },
        {
          "id": 249,
          "referenceValue": "J Clin Oncol 2011;29:2060-2065."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 722,
      "name": "",
      "schedule": "<p><strong>Gemcitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;IV on days 1, 8, and 15</p>\n\n<p><strong>Nab-Paclitaxel:&nbsp;</strong>125 mg/m<sup>2</sup>&nbsp;IV on days 1, 8, and 15</p>\n\n<p>Repeat cycle every 28 days.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 113,
      "name": "<b>AC</b>",
      "schedule": "<b>Doxorubicin</b> 60mg/m<sup>2</sup> IV,day 1<br> <b>Cyclophosphamide</b> 600mg/m<sup>2</sup>  IV,day 1<br> Repeat every 21 days for 4 cycles",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 250,
          "referenceValue": "Fisher B,Brown AM,Dimitor NV,et al.Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide,methotrexade,and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors:results from the National Surgical Adjuvant Breast and Bowel Project B-15."
        },
        {
          "id": 251,
          "referenceValue": "J Clin Oncol. 1990;8(9):1483-1496"
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 115,
      "name": "<b>AC  Paclitaxel/Trastuzumab</b>",
      "schedule": "<b>Doxorubicin</b> 60mg/m<sup>2</sup> IV,day 1<br> <b>Cyclophosphamide</b> 600mg/m<sup>2</sup>  IV,day 1<br> Repeat every 21 days for 4 cycles<br> <b>FOLLOWED BY</b><br> <b>Paclitaxel</b> 175 mg/m<sup>2</sup> IV over 3 hours, day 1<br> Repeat every 21 days for 4 cycles<br> <b>OR</b><br> <b>Paclitaxel</b> 80 mg/m<sup>2</sup> IV over 1 hour, weekly X 12 <br> <b>Trastuzumab</b> (concurrently with paclitaxel) 4 mg/kg IV over 90 minutes, day 1<br> <b>FOLLOWED BY</b><br> 2 mg/kg IV weekly for 51 additional weeks     ",
      "emetogenicPotential": "High for AC,low for paclitaxel and/or tratuzumab",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Paclitaxel:<br>No dose reduction</li></ul>",
      "references": [
        {
          "id": 254,
          "referenceValue": "Romond EH,perez EA,Bryant J.et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer."
        },
        {
          "id": 255,
          "referenceValue": "N Engl J Med. 2005;353(16):1673-1684."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 116,
      "name": "<b>AC  T (dose-dense)</b>               ",
      "schedule": "<b>Doxorubicin</b> 60mg/m<sup>2</sup> IV,day 1<br> <b>Cyclophosphamide</b> 600mg/m<sup>2</sup>  IV,day 1<br> Repeat every 21 days for 4 cycles<br> <b>Filgrastim</b> (prophylactic) given on days 3-10 of   each cycle<br><b>OR</b> <b>PEG-Filgastrim</b> 6 mg SQ on day 2<b>FOLLOWED BY</b><br> <b>Paclitaxel</b> 175 mg/m<sup>2</sup> IV over 3 hours every 14 days for 4 cycles<br> <b>Filgrastim</b> (prophylactic) given on days 3-10 of each cycle<b>OR</b> <b>PEG-Filgastrim</b> 6 mg SQ on day 2.                                                                               ",
      "emetogenicPotential": "High for AC, low for paclitaxel  ",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Paclitaxel:<br>No dose reduction</li></ul>",
      "references": [
        {
          "id": 256,
          "referenceValue": "Citron ML, berry DA, Cirrincione C,et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combinational chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer : first report of intergroup trial C9741/cancer and leukemia Group B trial 9741."
        },
        {
          "id": 257,
          "referenceValue": "J Clin Oncol. 2003;21(8): 1431-1439"
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 122,
      "name": "<b>CAF(oral)</b>",
      "schedule": "<b>Cyclophosphamide</b> 100mg/m<sup>2</sup> PO, days 1-14<br> <b>Doxorubicin</b> 30 mg/m<sup>2</sup> IV ,days 1,8<br> <b>Fluorouracil</b> 500 mg/m<sup>2</sup> IV, days 1,8<br> Repeat every 28 days for 6 cycles      ",
      "emetogenicPotential": "Moderate-High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Fluorouracil:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 258,
          "referenceValue": "Hutchins LF, Green SJ, Favolin PM, et al. Randomized controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high risk, node-negative breast cancer:treatment results of Intergroup Protocol INT-0102."
        },
        {
          "id": 259,
          "referenceValue": "J Clin Oncol. 2005;23(33):8313-8321."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 123,
      "name": "<b>FEC</b>",
      "schedule": "<b>Cyclophosphamide</b> 75 mg/m<sup>2</sup>/d PO, days 1-14<br> <b> Epirubicin</b> 60 mg/m<sup>2</sup>/d IV, days 1,8<br> <b>Fluorouracil</b> 500 mg/m<sup>2</sup>/d IV, days 1,8<br> Repeat every 28 days for 6 cycles<br> <b>OR</b><br> <b>Cyclophosphamide</b> 500 mg/m<sup>2</sup> IV, day 1<br> <b>Epirubicin</b> 100 mg/m<sup>2</sup> IV, day 1<br> <b>Fluorouracil</b> 500 mg/m<sup>2</sup> IV, day 1<br> Repeat every 21 days for 4 cycles",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Fluorouracil:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 276,
          "referenceValue": "Levine MN, Bramwell VH, Pritchard KI, et al. Randomized tiral of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer."
        },
        {
          "id": 277,
          "referenceValue": "J Clin Oncol. 1998;16(8):2651:2658."
        },
        {
          "id": 278,
          "referenceValue": "<br> French Epirubicin Study Group. Epirubicin-based chemotherapy in metastatic breast cancer patients: role of dose intensity and duration of treatment."
        },
        {
          "id": 279,
          "referenceValue": "J Clin Oncol. 2000;18(7):3115-3124."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 117,
      "name": "<b>AC  TH</b>                                                  ",
      "schedule": "<b>Doxorubicin</b> 60mg/m<sup>2</sup> IV,day 1<br> <b>Cyclophosphamide</b> 600mg/m<sup>2</sup>  IV,day 1<br> Repeat every 21 days for 4 cycles<br> <b>FOLLOWED BY</b><br> <b>Docetaxel</b> 100 mg/m<sup>2</sup> IV, day1<br> Repeat every 21 days for 4 cycles<br> <b>Trastuzumab</b> 4 mg/kg IV, day 1,<br> <b>FOLLOWED BY</b><br> 2 mg/kg IV weekly during docetaxel,<br> <b>FOLLOWED BY</b><br> 6 mg/kg IV every 21 days for 1 year                                                      ",
      "emetogenicPotential": "High for AC, low for docetaxel and/or trastuzumab",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Docetaxel:<br>No dose reduction </li><li>Doxorubicin:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 260,
          "referenceValue": "Neyt M, Albrecht J, Cocquyt V.An economic evaluation of herceptinR  in adjuvant setting: the Breast Cancer International Research Group 006 trial."
        },
        {
          "id": 261,
          "referenceValue": "Ann Oncol. 2006; 17(3):381-390"
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 118,
      "name": "<b>AT - Docetaxel</b>",
      "schedule": "<b>Doxorubicin</b> 50 mg/m<sup>2</sup> IV over 15 minutes, day 1<br> <b>FOLLOWED 1 HOUR LATER BY</b><br> <b>Docetaxel</b> 75 mg/m<sup>2</sup> day 1<br> Repeat every 21 days.",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Docetaxel:<br>No dose reduction </li><li>Doxorubicin:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 266,
          "referenceValue": "Nabholz,JM,Falkson C,Campos D, et al. Docetaxel and doxorubicin comparewd with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer:results of a randomized , multicenter, phase III trial."
        },
        {
          "id": 267,
          "referenceValue": "J Clin Oncol. 2003;21(6):968-975."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 119,
      "name": "<b>AT - Paclitaxel</b>",
      "schedule": "<b>Doxorubicin</b> 50 mg/m<sup>2</sup> IV over, day 1<br> <b>FOLLOWED 24 HOUR LATER BY</b><br> <b>Paclitaxel</b>  220 mg/m<sup>2</sup>,IV over 3 hours ,day 2<br> Repeat every 21 days for up to 8 cycles",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Doxorubicin:<br>No dose reduction </li><li>Paclitaxel:<br>No dose reduction</li></ul>",
      "references": [
        {
          "id": 268,
          "referenceValue": "Jassem J, Pienkowski T, Pluzanska A.et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial."
        },
        {
          "id": 269,
          "referenceValue": "J Clin Oncol. 2001;19(6):1707-1715"
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 120,
      "name": "<b>A - T - C (dose-dense)</b>",
      "schedule": "<b>Doxorubicin</b> 60 mg/m<sup>2</sup> IV ,every 14 days for 4 cycles, <b>FOLLOWED BY</b><br> <b>Paclitaxel</b> 175 mg/m<sup>2</sup> IV, every 14 days for 4 cycles, <b>FOLLOWED BY</b><br> <b>Cyclophosphamide</b> 600 mg/m<sup>2</sup> IV, every 14 days for 4 cycles<br> <b>Filgrastim</b> (prophylactic) given on days 3-10 of each cycle<b>OR</b> <b>PEG-Filgastrim</b> 6 mg SQ on day 2.                                                  ",
      "emetogenicPotential": "Moderate, low for paclitaxel",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Paclitaxel:<br>No dose reduction</li></ul>",
      "references": [
        {
          "id": 270,
          "referenceValue": "Citron ML, Berry DA, Cirrincione C,et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer : first report of intergroup trial C9741/cancer and leukemia Groüp B Trial 9741."
        },
        {
          "id": 271,
          "referenceValue": "J Clin Oncol. 2003;21(8):1431-1439"
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 121,
      "name": "<b>Bevacizumab/Paclitaxel</b>",
      "schedule": "<b>Bevacizumab</b> 10 mg/kg IV, days 1, 15<br> <b>Paclitaxel</b> 90 mg/m<sup>2</sup> IV over 1 hour, days 1, 8, 15<br> Repeat every 28 days",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Paclitaxel:<br>No dose reduction</li></ul>",
      "references": [
        {
          "id": 272,
          "referenceValue": "Miller KD. E2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer."
        },
        {
          "id": 273,
          "referenceValue": "J Clin Oncol. 2003;3(6):421-422"
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 130,
      "name": "<b>Sequential AC --> T</b>",
      "schedule": "<b>Doxorubicin</b> 60 mg/m<sup>2</sup> over 5-15 minutes, day 1<br> <b>Cyclophosphamide</b> 600 mg/m<sup>2</sup> IV 30-60 minutes, day 1<br> Repeat every 21 days for 4 cycles<br> <b>FOLLOWED BY</b><br> <b>Paclitaxel</b> 80 mg/m<sup>2</sup> IV over 1 hour<br> Repeat every 7 days for 12 cycles",
      "emetogenicPotential": "High for AC, low for paclitaxel  ",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Paclitaxel:<br>No dose reduction</li></ul>",
      "references": [
        {
          "id": 274,
          "referenceValue": "Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer."
        },
        {
          "id": 275,
          "referenceValue": "N Engl J Med. 2008;238(16):1663-1671."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 124,
      "name": "<b>CMF</b>",
      "schedule": "<b>Cyclophosphamide </b>100 mg/m<sup>2</sup>/d PO, days 1-14<br> <b>Methotrexate</b> 40 mg/m<sup>2</sup>/d IV, days 1,8<br> <b>Fluorouracil</b> 600 mg/m<sup>2</sup>/d IV, days 1, 8<br> Repeat every 28 days for up to 6 cycles<br> <b>OR</b><br> <b>Cyclophosphamide</b> 600 mg/m<sup>2</sup> IV, day 1<br> <b>Methotrexate</b> 40 mg/m<sup>2</sup> IV, day 1<br> <b>Fluorouracil</b> 600 mg/m<sup>2</sup> IV, day 1<br> Repeat every 21 days for up to 12 courses",
      "emetogenicPotential": "Moderate for IV, Moderate-High for PO",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Fluorouracil:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 282,
          "referenceValue": "Amadori D, Nanni O, Marangolo M, et al. Disease-free survival advantage of adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with node-negative, rapdly proliferating breast cancer: a randomized multicenter study."
        },
        {
          "id": 283,
          "referenceValue": "J Clin Oncol. 2000:18(17):3125-3134."
        },
        {
          "id": 284,
          "referenceValue": "<br> Bonadonna G, Zambetti M, Valagussa P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes: ten-year results."
        },
        {
          "id": 285,
          "referenceValue": "JAMA. 1995:273(7):542-547."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 125,
      "name": "<b>Gemcitabine/Paclitaxel</b>",
      "schedule": "<b>Gemcitabine 1,250 mg/m<sup>2</sup> IV over 30-60 minutes, days 1, 8<br> <b>Paclitaxel</b> 175 mg/m<sup>2</sup> IV over 3 hours before gemcitabine, day 1<br> Repeat every 21 days",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li><li>Paclitaxel:<br>No dose reduction</li></ul>",
      "references": [
        {
          "id": 286,
          "referenceValue": "Albain KS, Nag SM, Calderillo-Ruiz G, et al. Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment."
        },
        {
          "id": 287,
          "referenceValue": "J Clin Oncol. 2008;26(24):3950-3957."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 126,
      "name": "<b>EC</b>",
      "schedule": "<b>Epirubicin</b> 100 mg/m<sup>2</sup> IV, day 1<br> <b>Cyclophosphamide</b> 830 mg/m<sup>2</sup> IV, day 1<br> Repeat every 21 days for up to 8 cycles",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li></ul>",
      "references": [
        {
          "id": 288,
          "referenceValue": "Piccart MJ, Di Leo A, Beauduin M, et al. Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer."
        },
        {
          "id": 289,
          "referenceValue": "J Clin Oncol. 2001;19(12):3103-3110."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 127,
      "name": "<b>Ixabepilone/Capecitabine</b>",
      "schedule": "<b>Ixabepilone</b> 40 mg/m<sup>2</sup> IV over 3 hours, day 1<br> <b>Capecitabine</b> 1,000 mg/m<sup>2</sup> PO bid, days 1-14<br> Repeat every 21 days for up to 8 cycles",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li><li>Ixabepilone:<br>Monotherapy:  <br>                                                                                                 If AST and ALT < 2.5 upper normal limit, and bilirubin < 1 upper normal limit, use 40 mg/m2<br>                                                                         If AST or ALT < 10 upper normal limit, and bilirubin < 1 upper normal limit, use 32 mg/m2  <br>                                                                                     If AST and ALT < 10 upper normal limit, and bilirubin 1.5-3 upper normal limit, use 20-30 mg/m2 <br>                                                                  If AST or ALT > 10 upper normal limit, or bilirubin > 3 upper normal limit, do not use <br>                                                                                                                                                                                   In combination with capecitabine:  <br>                                                             If AST and ALT < 2.5 upper normal limit, and bilirubin < 1 upper normal limit, use 40 mg/m2 <br>                                                                        If AST or ALT > 2.5 upper normal limit, or bilirubin > 1 upper normal limit, do not use </li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li><li>Ixabepilone:<br>If CrCl > 30 mL/min, no dose reduction</li></ul>",
      "references": [
        {
          "id": 290,
          "referenceValue": "Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment."
        },
        {
          "id": 291,
          "referenceValue": "J Clin Oncol. 2007;25(33):5210-5217."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 128,
      "name": "<b>Lapatinib/Capecitabine</b>",
      "schedule": "<b>Lapatinib</b> 1,250 mg PO 1 hour before breakfast, daily<br> <b>Capecitabine</b> 1,000 mg/m<sup>2</sup> PO bid, days 1-14<br> Repeat every 21 days",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li><li>Lapatinib:<br>If Child-Pugh C, reduce dose to 750 mg/d </li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li><li>Lapatinib:<br>Not studied. Only 2% eliminated by kidneys </li></ul>",
      "references": [
        {
          "id": 292,
          "referenceValue": "Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer."
        },
        {
          "id": 293,
          "referenceValue": "N Engl J Med. 2006;355(26):2733-2743."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 129,
      "name": "<b>Lapatinib/Letrozole</b>",
      "schedule": "<b>Lapatinib</b> 1,500 mg PO, daily<br> <b>Letrozole</b> 2.5 mg PO, daily",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Lapatinib:<br>If Child-Pugh C, reduce dose to 750 mg/d </li><li>Letrozole:<br>If Child-Pugh A or B, no dose reduction <br>                                                     If Child-Pugh C, reduce dose by 50% </li></ul><b>Renal Impairment</b><ul><li>Lapatinib:<br>Not studied. Only 2% eliminated by kidneys </li><li>Letrozole:<br>If CrCl > 10 mL/min, no dose reduction </li></ul>",
      "references": [
        {
          "id": 294,
          "referenceValue": "Johnston S, Pippen J Jr, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer."
        },
        {
          "id": 295,
          "referenceValue": "J Clin Oncol. 200927(33):5538-5546."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 131,
      "name": "<b>TAC</b>",
      "schedule": "<b>Doxorubicin</b> 50 mg/m<sup>2</sup> as a 15-minute IV bolus, <b>FOLLOWED BY</b><br> <b>Cyclophosphamide</b> 500 mg/m<sup>2</sup> as a 1- to 5-minute IV bolus,<br> <b>Docetaxel</b> 75 mg/m<sup>2</sup> IV over 1 hour",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Docetaxel:<br>No dose reduction </li><li>Doxorubicin:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 296,
          "referenceValue": "Martin M, Pienkowshi T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer."
        },
        {
          "id": 297,
          "referenceValue": "N Engl J Med. 2005;352(22):2303-2313."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 723,
      "name": "",
      "schedule": "<p><strong>Capecitabine:</strong>&nbsp;1,000 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-14</p>\n\n<p>Repeat cycle every 21 days. Dose may be reduced to 825-900 mg/m<sup>2</sup> PO twice daily on days 1-14.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 132,
      "name": "<b>TC</b>",
      "schedule": "<b>Docetaxel</b> 75 mg/m<sup>2</sup> IV over 30-60 minutes, day 1<br> <b>Cyclophosphamide</b> 600 mg/m<sup>2</sup> IV over 30-60 minutes, day 1<br> Repeat every 21 days for 4 cycles",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Docetaxel:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 298,
          "referenceValue": "Jones SE, Savin MA, Holmes FA, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer."
        },
        {
          "id": 299,
          "referenceValue": "J Clin Oncol. 2006:24(34):5381-5387."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 133,
      "name": "<b>X+T</b>",
      "schedule": "<b>Capecitabine</b> 1,250 mg/m<sup>2</sup> PO bid, days 1-14<br> <b>Docetaxel</b> 75 mg/m<sup>2</sup> as a 1-hour IV infusion, day 1<br> Repeat every 21 days",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li><li>Docetaxel:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 300,
          "referenceValue": "O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthraccline-pretreated patients with advanced breast cancer: phase III trial results."
        },
        {
          "id": 301,
          "referenceValue": "J Clin Oncol. 2002;20(12):2812-2823."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 134,
      "name": "<b>TCH</b>",
      "schedule": "<b>Docetaxel</b> 75 mg/m<sup>2</sup> IV, day 1<br> <b>Carboplatin</b> AUC of 6 day 1 <br> Repeat every 21 days for 8 cycles<br> <b>Trastuzumab</b> 4 mg/kg IV,<br> <b>FOLLOWED BY</b><br> <b>Trastuzumab</b> 2 mg/kg IV weekly during chemotherapy, <b>THEN</b> 6 mg/kg IV<br> Repeat every 21 days for 1 year",
      "emetogenicPotential": "Moderate for combination therapy, low for trastuzumab monotherapy",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Docetaxel:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 302,
          "referenceValue": "Pegram M, Forbes J, Pienkowski T, et al. BCIRG 007: first overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC)."
        },
        {
          "id": 303,
          "referenceValue": "J Clin Oncol. 2007;25:LBA 1008 (abstract)."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 135,
      "name": "<b>TP</b>",
      "schedule": "<b>Trastuzumab</b> 4 mg/kg IV loading dose, day 1 <b>THEN</b> 2 mg/kg IV weekly, days 8, 15<br> <b>Paclitaxel</b> 175 mg/m<sup>2</sup> IV, day 2<br> Repeat every 21 days",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Paclitaxel:<br>No dose reduction</li></ul>",
      "references": [
        {
          "id": 304,
          "referenceValue": "Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer."
        },
        {
          "id": 305,
          "referenceValue": "J Clin Oncol. 2006;24(18):2786-2792."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 136,
      "name": "<b>Trastuzumab/Paclitaxel/Carboplatin</b>",
      "schedule": "<b>Trastuzumab</b> 4 mg/kg loading dose, day 1 of cycle 1, <b>THEN</b> 2 mg/kg weekly thereafter<br> <b>Paclitaxel</b> 175 mg/m<sup>2</sup> IV, day 2<br> <b>Carboplatin</b> AUC of 6, day 2<br> Repeat every 21 days for at least 6 cycles<br> <b>FOLLOWED BY Trastuzumab</b> 2 mg/kg weekly until disease progression.",
      "emetogenicPotential": "Moderate (low for single-agent trastuzumab)",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Paclitaxel:<br>No dose reduction</li></ul>",
      "references": [
        {
          "id": 306,
          "referenceValue": "Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer."
        },
        {
          "id": 307,
          "referenceValue": "J Clin Oncol. 2006;24(18):2786-2792."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 137,
      "name": "<b>Abraxane</b>",
      "schedule": "260 mg/m<sup>2</sup> IV over 30 minutes<br> Repeat every 21 days",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>",
      "references": [
        {
          "id": 308,
          "referenceValue": "Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer."
        },
        {
          "id": 309,
          "referenceValue": "J Clin Oncol. 2005;23(31):7794-7803."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 140,
      "name": "<b>Docetaxel</b>",
      "schedule": "<b>Docetaxel</b> 100 mg/m<sup>2</sup> IV over 1 hour<br> Repeat every 21 days <b>OR</b><br><b>Docetaxel</b>40 mg/m <sup>2</sup>",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li></ul><b>Renal Impairment</b><ul><li>Docetaxel:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 310,
          "referenceValue": "Chan S, Friedrichs K, Noel D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer."
        },
        {
          "id": 311,
          "referenceValue": "J Clin Oncol. 1999;17(8):2341-2354."
        },
        {
          "id": 312,
          "referenceValue": "<br> Nabholtz JM, Senn Hj, Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy."
        },
        {
          "id": 313,
          "referenceValue": "J Clin Oncol. 1999;17(5):1413-1424."
        },
        {
          "id": 314,
          "referenceValue": "<br> Taxotere [package insert]."
        },
        {
          "id": 315,
          "referenceValue": "New York, NY: Sanofi-Aventis; 2010."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 141,
      "name": "<b>Eribulin</b>",
      "schedule": "<b>Eribulin</b> 1.4 mg/m<sup>2</sup> IV over 2-5 minutes, days 1 and 8<br> Repeat cycle every 21 days",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>",
      "references": [
        {
          "id": 316,
          "referenceValue": "Cortes J, O'Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study."
        },
        {
          "id": 317,
          "referenceValue": "Lancet. 2011;377(9769):914-923."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 142,
      "name": "<b>Exemestane</b>",
      "schedule": "<b>Exemestane</b> 25 mg PO once daily",
      "emetogenicPotential": "NA",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Exemestane:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Exemestane:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 236,
          "referenceValue": "Lonning PE, Bajetta E, Murray R, et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase in hibitors: a phase II trial."
        },
        {
          "id": 237,
          "referenceValue": "J Clin Oncol. 2000;18(11):2234-2244."
        },
        {
          "id": 238,
          "referenceValue": "<br> Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group."
        },
        {
          "id": 239,
          "referenceValue": "J Clin Oncol. 2000;18(7):1399-1411."
        },
        {
          "id": 240,
          "referenceValue": "<br> Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer."
        },
        {
          "id": 241,
          "referenceValue": "N Engl J Med. 2004;350(11):1081-1092."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 143,
      "name": "<b>Fulvestrant</b>",
      "schedule": "<b>Fulvestrant</b> 500 mg IM loading dose on day 1,15, and 29 and then every 28 days. ",
      "emetogenicPotential": "N/A",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Fulvestrant:<br>If SGOT, SGPT, bilirubin and alkaline phosphatase < 2 upper normal limit, no dose reduction<br>                                                                                If SGOT, SGPT, bilirubin and alkaline phosphatase > 2 upper normal limit, unknown </li></ul><b>Renal Impairment</b><ul><li>Fulvestrant:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 252,
          "referenceValue": "Di Leo A, et al.Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer."
        },
        {
          "id": 253,
          "referenceValue": "J Clin Oncol. 2010 Oct 20;28(30):4594-600"
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 144,
      "name": "<b>Gemcitabine</b>",
      "schedule": "<b>Gemcitabine</b> 800 mg/m<sup>2</sup>/d IV over 30 minutes, days 1, 8, 15<br> Repeat every 28 days",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 262,
          "referenceValue": "Carmichael J, Possinger K, Phillip P, et al. Advanced breast cancer: a phase II trial with gemcitabine."
        },
        {
          "id": 263,
          "referenceValue": "J Clin Oncol. 1995;13(11):2731-2736."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 145,
      "name": "<b>Letrozole</b>",
      "schedule": "<b>Letrozole</b> 2.5 mg PO once daily",
      "emetogenicPotential": "NA",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Letrozole:<br>If Child-Pugh A or B, no dose reduction <br>                                                     If Child-Pugh C, reduce dose by 50% </li></ul><b>Renal Impairment</b><ul><li>Letrozole:<br>If CrCl > 10 mL/min, no dose reduction </li></ul>",
      "references": [
        {
          "id": 318,
          "referenceValue": "Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol aectate."
        },
        {
          "id": 319,
          "referenceValue": "J Clin Oncol. 1998;16(2):453-461."
        },
        {
          "id": 320,
          "referenceValue": "<br> Ingle JN, et al. A randomized phase II trial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinoma."
        },
        {
          "id": 321,
          "referenceValue": "Cancer. 1997;80(2):218-224."
        },
        {
          "id": 322,
          "referenceValue": "<br> Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer."
        },
        {
          "id": 323,
          "referenceValue": "N Engl J Med. 2003;349(19): 1793-1802."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 146,
      "name": "<b>Megestrol</b>",
      "schedule": "<b>Megestrol</b> 40 mg PO, every 6 hours",
      "emetogenicPotential": "N/A",
      "dosageModifications": "<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>",
      "references": [
        {
          "id": 324,
          "referenceValue": "Buzdar A, Douma J, et al. Phase III, multicenter, double-blind, randomized study of letrozole, and aromatiase inhibitor, for advanced breast cancer versus megestrol acetate."
        },
        {
          "id": 325,
          "referenceValue": "J Clin Oncol. 2001;19(14):3357-3366."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 147,
      "name": "<b>Paclitaxel</b>",
      "schedule": "<b>Paclitaxel</b> 175 mg/m<sup>2</sup> IV over 3 hours<br> Repeat every 21 days",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Paclitaxel:<br>No dose reduction</li></ul>",
      "references": [
        {
          "id": 326,
          "referenceValue": "Seidman AD, Tiersten A, Hudis C, et al. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer."
        },
        {
          "id": 327,
          "referenceValue": "J Clin Oncol. 1995;13(10):2575-2581."
        },
        {
          "id": 328,
          "referenceValue": "<br> Smith RE, Brown AM, Mamounas EP, et al. Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26."
        },
        {
          "id": 329,
          "referenceValue": "J Clin Oncol. 1999;17(11):3403-3411."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 148,
      "name": "<b>Tamoxifen</b>",
      "schedule": "<b>Tamoxifen</b> 20-40 mg PO once daily",
      "emetogenicPotential": "N/A",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Tamoxifen:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Tamoxifen:<br>No dose reduction</li></ul>",
      "references": [
        {
          "id": 330,
          "referenceValue": "Hackshaw A, Roughton M, et al. Long-term benefits of 5 years of tamoxifen: 10-year follow-up of a large randomized trial in women at least 50 years of age with early breast cancer."
        },
        {
          "id": 331,
          "referenceValue": "J Clin Oncol. 2011;29(13):1657-1663."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 149,
      "name": "<b>Toremifene</b>",
      "schedule": "<b>Toremefene</b> 60 mg/d PO",
      "emetogenicPotential": "N/A",
      "dosageModifications": "<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>",
      "references": [
        {
          "id": 332,
          "referenceValue": "Hayes DF, Van Zyl JA, Hacking A, et al. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer."
        },
        {
          "id": 333,
          "referenceValue": "J Clin Oncol. 1995;13(10):2556-2566."
        },
        {
          "id": 334,
          "referenceValue": "<br> Fareston [package insert]."
        },
        {
          "id": 335,
          "referenceValue": "Memphis, TN: GTx, Inc,:2011."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 150,
      "name": "<b>Trastuzumab qwk</b>",
      "schedule": "<b> Trastuzumab</b> 4 mg/kg IV loading dose over 90 minutes, <b>FOLLOWED BY</b> 2 mg/kg IV over 30 minutes, weekly",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>",
      "references": [
        {
          "id": 336,
          "referenceValue": "Herception [package insert]."
        },
        {
          "id": 337,
          "referenceValue": "South San Francisco, CA: Genentech, Inc: 2010."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 153,
      "name": "<b>Carbo-Docetaxel</b>",
      "schedule": "<b>Docetaxel</b> 75 mg/m<sup>2</sup> IV over 1 hour, day 1,<br> <b>FOLLOWED BY</b><br> <b>Carboplatin</b> dose AUC of 5 IV over 1 hour day 1<br> Repeat every 21 days for 6 cycles",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Docetaxel:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 338,
          "referenceValue": "Vasey PA, Jayson GC, Gordon A, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma."
        },
        {
          "id": 339,
          "referenceValue": "J Natl Cancer Inst. 2004;96(22):1682-1691."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 154,
      "name": "<b>Carbo-Tax</b>",
      "schedule": "<b>Paclitaxel</b> 175 mg/m<sup>2</sup> IV over 3 hours, day 1<br> <b>Carboplatin</b> dose AUC of 5 IV  day 1<br> Repeat every 21 days",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Paclitaxel:<br>No dose reduction</li></ul>",
      "references": [
        {
          "id": 340,
          "referenceValue": "Neijt JP, Engelholm SA, Tuxen MK, et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer."
        },
        {
          "id": 341,
          "referenceValue": "J Clin Oncol. 2000;18(17):3084-3092."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 155,
      "name": "<b>CD (Doxil/Carboplatin)</b>",
      "schedule": "<b>Liposomal doxorubicin</b> 30 mg/m<sup>2</sup> IV, day 1 <b>Carboplatin</b>AUC of 5 IV day 1<br> Repeat every 28 days",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li></ul>",
      "references": [
        {
          "id": 342,
          "referenceValue": "Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relppase."
        },
        {
          "id": 343,
          "referenceValue": "J Clin Oncol. 2010;28:3323-3329."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 156,
      "name": "<b>CT</b>",
      "schedule": "<b>Paclitaxel</b> 135 mg/m<sup>2</sup> CIVI over 24 hours, day 1<br> <b>Cisplatin</b> 75 mg/m<sup>2</sup> IV, day 1<br> Repeat every 21 days for 6 cycles<br> <b>OR</b><br> <b>Paclitaxel</b> 175 mg/m<sup>2</sup> IV over 3 hours, day 1<br> <b>Cisplatin</b> 75 mg/m<sup>2</sup> IV, day 1<br> Repeat every 21 days",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Paclitaxel:<br>No dose reduction</li></ul>",
      "references": [
        {
          "id": 344,
          "referenceValue": "McGuire WP, Hoskins WJ, Brady MF, et al. Cyclo-phosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer."
        },
        {
          "id": 345,
          "referenceValue": "N Engl J Med. 1996;334(1):1-6."
        },
        {
          "id": 346,
          "referenceValue": "<br> Neijt JP, Engelholm SA, Tuxen MK, et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer."
        },
        {
          "id": 347,
          "referenceValue": "J Clin Oncol. 2000;18(17):3084-3092."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 157,
      "name": "<b>GC</b>",
      "schedule": "<b>Gemcitabine</b> 1,000 mg/m<sup>2</sup> IV, days 1, 8<br> <b>Carboplatin</b> AUC of 4, IV, day 1<br> Repeat every 21 days for 6 cycles",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Gemcitabine:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 350,
          "referenceValue": "Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG."
        },
        {
          "id": 351,
          "referenceValue": "J Clin Oncol. 2006;24(29):4699-4707."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 158,
      "name": "<b>Intraperitoneal CT</b>",
      "schedule": "<b>Paclitaxel</b> 135 mg/m<sup>2</sup> CIVI over 24 hours, day 1<br> <b>Cisplatin</b> 100 mg/m<sup>2</sup> IP, day 2<br> <b>Paclitaxel</b> 60 mg/m<sup>2</sup> IP, day 8<br> Repeat every 21 days for 6 cycles",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Paclitaxel:<br>No dose reduction</li></ul>",
      "references": [
        {
          "id": 352,
          "referenceValue": "Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer."
        },
        {
          "id": 353,
          "referenceValue": "N Engl J Med. 2006;354(1):34-43."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 159,
      "name": "<b>Altretamine</b>",
      "schedule": "<b>Altretamine</b> 260 mg/m<sup>2</sup>/d PO in 4 divided doses for 14 days<br> Repeat every 28 days",
      "emetogenicPotential": "Moderate-High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Altretamine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul></ul>",
      "references": [
        {
          "id": 354,
          "referenceValue": "Markman M, Blessing JA, Moore D, Ball H, Lentz SS. Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial."
        },
        {
          "id": 355,
          "referenceValue": "Gynecol Oncol. 1998;69(3):226-229."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 160,
      "name": "<b>Bevacizumab</b>",
      "schedule": "<b>Bevacizumab</b> 15 mg/kg IV, day 1<br> Repeat every 21 days until disease progression ",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>",
      "references": [
        {
          "id": 356,
          "referenceValue": "Burger RA, Sill MW, Monk BJ, et al. Phase II trial of bevacizumab in persistant or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study."
        },
        {
          "id": 357,
          "referenceValue": "J Clin Oncol. 2007;25(33):5165-5171."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 161,
      "name": "<b>Gemcitabine</b>",
      "schedule": "<b>Gemcitabine</b> 800 mg/m<sup>2</sup>/d, days 1, 8, 15<br> Repeat every 28 days",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Gemcitabine:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 358,
          "referenceValue": "Lund B, Hansen OP, Theilade K, Hansen M, Neijt JP. Phase II study of gemcitabine (2', 2' difluorodeoxycytidine) in previously treated ovarian cancer patients."
        },
        {
          "id": 359,
          "referenceValue": "J Natl Cancer Inst. 1994;86(20):1530-1533."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 191,
      "name": "<b>FZ</b>",
      "schedule": "<b>Flutamide</b> 250 mg PO tid <b>WITH</b><br> <b>Goserelin acetate implant</b> 3.6 mg SQ<br> Repeat every 28 days, beginning 8 weeks prior to Radiation theraupy for 4 cycles<br> <b>OR</b><br> <b>Goserelin acetate implant</b> 3.6 mg SQ 8 weeks prior to Radiation theraupy <b>AND</b><br> <b>Goserelin acetate implant</b> 10.8 mg SQ 4 weeks prior to Radiation theraupy",
      "emetogenicPotential": "N/A",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Goserelin:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Goserelin:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 360,
          "referenceValue": "Zoladex 3.6 mg, Zoladex 10.8 mg [package inserts]. Wilmington, DE: AstraZeneca; 2010. Roach M, Bae K, Speight J, et al. Short-term androgen deprivation therapy and external beam radiotherapy for locally advanced prostate cancer: Long-term results of RJOG 8610."
        },
        {
          "id": 361,
          "referenceValue": "J Clin Oncol. 2009;26(4):585-591."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 162,
      "name": "<b>Paclitaxel</b>",
      "schedule": "<b>Paclitaxel</b> 175 mg/m<sup>2</sup> IV over 3 hours<br> Repeat every 21 days",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Paclitaxel:<br>No dose reduction</li></ul>",
      "references": [
        {
          "id": 362,
          "referenceValue": "ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer."
        },
        {
          "id": 363,
          "referenceValue": "J Clin Oncol. 1997;15(6):2183-2193."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 163,
      "name": "<b>Pegylated liposomal doxorubicin</b>",
      "schedule": "<b>Pegylated liposomal doxorubicin</b> 50 mg/m<sup>2</sup> IV every 28 days",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>",
      "references": [
        {
          "id": 364,
          "referenceValue": "Gordon AN, Granai CO, Rose CG, et al. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer."
        },
        {
          "id": 365,
          "referenceValue": "J Clin Oncol. 2000;18(17):3093-3100."
        },
        {
          "id": 366,
          "referenceValue": "<br> Doxil [package insert]."
        },
        {
          "id": 367,
          "referenceValue": "Raritan, NJ: Centocor Ortho Biotech Products, LP;2010."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 164,
      "name": "<b>Topotecan</b>",
      "schedule": "<b>Topotecan</b> 1.5 mg/m<sup>2</sup>/d IV over 30 minutes, days 1-5<br> Repeat every 21 days",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Topotecan:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Topotecan:<br>If CrCl > 40 mL/min, no dose reduction   <br>                                                                          If CrCl 20-39 mL/min, reduce to 0.75 mg/m2 </li></ul>",
      "references": [
        {
          "id": 368,
          "referenceValue": "ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer."
        },
        {
          "id": 369,
          "referenceValue": "J Clin Oncol. 1997;15(6):2183-2193."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 165,
      "name": "<b>Cisplatin/Doxorubicin</b>",
      "schedule": "<b>Doxorubicin</b> 60 mg/m<sup>2</sup> IV day 1<br> <b>Cisplatin</b> 50 mg/m<sup>2</sup> IV, day 1, cycles 1-7<br> Repeat every 21 days upto 8 cycles",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Doxorubicin:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 374,
          "referenceValue": "Randall ME, Filiaci VL, Muss H, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study."
        },
        {
          "id": 375,
          "referenceValue": "J Clin Oncol. 2006;24(1):36-44."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 166,
      "name": "<b>TAP</b>",
      "schedule": "<b>Doxorubicin</b> 45 mg/m<sup>2</sup>, day 1<br> <b>FOLLOWED BY</b><br> <b>Cisplatin</b> 50 mg/m<sup>2</sup>, day 1<br> <b>Paclitaxel</b> 160 mg/m<sup>2</sup> over 3 hours, day 2<br> <b>Filgrastim</b> 5 mcg/kg d SQ, days 3-12<br> <b>OR</b><br>Repeat every 21 days for a maximum of 7 cycles<br><b>PEG-Filgastrim</b>6 mg SQ on day 3.",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Doxorubicin:<br>No dose reduction </li><li>Paclitaxel:<br>No dose reduction</li></ul>",
      "references": [
        {
          "id": 376,
          "referenceValue": "Fleming GF, Brunetto VL, Cella D, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastimin advanced endometrial carcinoma: a Gynecologic Oncology Group Study."
        },
        {
          "id": 377,
          "referenceValue": "J Clin Oncol. 2004;22(11):2159-2166."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 167,
      "name": "<b>Doxorubicin</b>",
      "schedule": "<b>Doxorubicin</b> 60 mg/m<sup>2</sup> IV every 21 days (maximum cumulative dose, 500 mg/m<sup>2</sup>)<br> Repeat every 21 days",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Doxorubicin:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 378,
          "referenceValue": "Thigpen JT, Brady MF, Homesly HD, et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: A Gynecologic Oncology Group Study."
        },
        {
          "id": 379,
          "referenceValue": "J Clin Oncol. 2004;22(19):3902-3908."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 168,
      "name": "<b>Medroxy-progesterone</b>",
      "schedule": "<b>Medroxyprogesterone acetate</b> 200 mg/d PO",
      "emetogenicPotential": "N/A",
      "dosageModifications": "<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>",
      "references": [
        {
          "id": 380,
          "referenceValue": "Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecological Oncology Group."
        },
        {
          "id": 381,
          "referenceValue": "J Clin Oncol. 1999;17(6):1736-1744."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 188,
      "name": "<b>Docetaxel/Estramustine</b>",
      "schedule": "<b>Docetaxel</b> 60 mg/m<sup>2</sup> IV, day 2<br><b>Estramustine</b> 280 mg PO tid, days 1-5<br> Repeat every 21 days until progression or to a maximum of 12 cycles ",
      "emetogenicPotential": "Moderate-High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li><li>Estramustine:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Docetaxel:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 382,
          "referenceValue": "Petrylak DP, Tangen CM, Hussain MA, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer."
        },
        {
          "id": 383,
          "referenceValue": "N Engl J Med. 2004;351(15):1513-1520."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 260,
      "name": "<b>ATRA</b>",
      "schedule": "<b>All-trans-retinoic acid</b> (ATRA, tretinoin) 45 mg/m<sup>2</sup>/d PO",
      "emetogenicPotential": "N/A",
      "dosageModifications": "<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>",
      "references": [
        {
          "id": 384,
          "referenceValue": "Degos L, Dombret H, Chomienne C, et al. All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia."
        },
        {
          "id": 385,
          "referenceValue": "Blood. 1995;85(10):2643-2653."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 169,
      "name": "<b>Cisplatin/Fluorouracil</b>",
      "schedule": "<b>Cisplatin</b> 75 mg/m<sup>2</sup> IV over 4 hours, day 1, given within 16 hours of the first dose of RT<br> <b>Fluorouracil</b> 4,000 mg/m<sup>2</sup> CIVI over 96 hours, days 2-5<br> Repeat every 21 days for 3 cycles<br> <b>OR</b><br> <b>Cisplatin</b> 50 mg/m<sup>2</sup>/d IV, days 1, 29, given 4 hours before the first dose of RT<br> <b>Fluorouracil</b> 1,000 mg/m<sup>2</sup>/d IV, days 2-5, 30-33",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Fluorouracil:<br>If bilirubin < 5 mg/dL, no dose reduction  <br>                                                   If bilirubin > 5 mg/dL, do not use  <br>                       No dose reduction for infusional administration </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Fluorouracil:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 386,
          "referenceValue": "Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemoterapy compared with pelvic and para-aortic radiation for high-risk cervical cancer."
        },
        {
          "id": 387,
          "referenceValue": "N Engl J Med. 1999;340(15):1137-1143."
        },
        {
          "id": 388,
          "referenceValue": "<br> Whitney CW, Sausse W, Bundy BN, et al. Randomized commparison of fluorouuracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group Study."
        },
        {
          "id": 389,
          "referenceValue": "J Clin Oncol. 1999;17(5):1339-1348."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 724,
      "name": "",
      "schedule": "<p><strong>Pembrolizumab:&nbsp;</strong>200 mg IV on day 1</p>\n\n<p>Repeat cycle every 3 weeks. Used only in the setting of MSI/dMMR tumors.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 170,
      "name": "<b>C-P</b>",
      "schedule": "<b>Cisplatin</b> 50 mg/m2 IV, day 1<br> <b>Paclitaxel</b> 135 mg/m<sup>2</sup> CIVI over 24 hours<br> Repeat every 21 days for 6 cycles",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Paclitaxel:<br>No dose reduction</li></ul>",
      "references": [
        {
          "id": 390,
          "referenceValue": "Monk BJ, Sill MW, McMeekin DS, et al. Phase III trial of four cisplatin-containing doublet commbinations in stage IVB recurrent or persistent cervical carcinoma: A Gynecologic Group Study."
        },
        {
          "id": 391,
          "referenceValue": "J Clin Oncol. 2009;27(28):4649-4655."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 171,
      "name": "<b>Cisplatin/Topotecan</b>",
      "schedule": "<b>Cisplatin</b> 50 mg/m<sup>2</sup> IV, day 1<br> <b>Topotecan</b> 0.75 mg/m<sup>2</sup>/d IV, days 1-3<br> Repeat every 21 days",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Topotecan:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Topotecan:<br>If CrCl > 40 mL/min, no dose reduction   <br>                                                                          If CrCl 20-39 mL/min, reduce to 0.75 mg/m2 </li></ul>",
      "references": [
        {
          "id": 394,
          "referenceValue": "Long HJ, Bundy BN, Grendys EC, et al. Randomized Phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study."
        },
        {
          "id": 395,
          "referenceValue": "J Clin Oncol. 2005;23(21):4626-4633."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 172,
      "name": "<b>Cisplatin</b>",
      "schedule": "<b>Cisplatin</b> 40 mg/m<sup>2</sup> IV once per week during RT for up to 6",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li></ul>",
      "references": [
        {
          "id": 396,
          "referenceValue": "Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma."
        },
        {
          "id": 397,
          "referenceValue": "N Engl J Med. 1999;340(15):1154-1161."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 177,
      "name": "<b>Sorafenib</b>",
      "schedule": "<b>Sorafenib</b> 400 mg PO bid",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Sorafenib:<br>If Child-Pugh A or B, no dose reduction     <br>                                                 If Child-Pugh C, reduce dose by 50% </li></ul><b>Renal Impairment</b><ul><li>Sorafenib:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 398,
          "referenceValue": "Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma."
        },
        {
          "id": 399,
          "referenceValue": "N Engl J Med. 2007;356(2):125-134."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 178,
      "name": "<b>Sunitinib</b>",
      "schedule": "<b>Sunitinib malate</b> 50 mg PO daily for 28 days on<br> <b>FOLLOWED BY</b> 14 days off",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Sunitinib:<br>If Child-Pugh A or B, no dose reduction  <br>                                                    If Child-Pugh C, reduce dose by 50% </li></ul><b>Renal Impairment</b><ul><li>Sunitinib:<br>If CrCl > 42 mL/min, no dose reduction </li></ul>",
      "references": [
        {
          "id": 400,
          "referenceValue": "Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma."
        },
        {
          "id": 401,
          "referenceValue": "N Engl J Med. 2007;356(2):115-124"
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 179,
      "name": "<b>Temsirolimus</b>",
      "schedule": "<b>Temsirolimus</b> 25 mg IV over 30 minutes weekly",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Temsirolimus:<br>Unknown </li></ul><b>Renal Impairment</b><ul><li>Temsirolimus:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 402,
          "referenceValue": "Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alpha, or both for advanced renal-cell carcinoma."
        },
        {
          "id": 403,
          "referenceValue": "N Engl J Med. 2007;356(22):2271-2281."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 180,
      "name": "<b>Gemcitabine/Carboplatin</b>",
      "schedule": "<b>Gemcitabine</b> 1,000 mg/m<sup>2</sup> IV over 30 minutes, days 1 and 8<br> <b>Carboplatin</b> AUC of 5 IV over 1 hour, day 1<br> Repeat cycle every 21 days upto 6 cycles",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Gemcitabine:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 404,
          "referenceValue": "Bamias A, Moulopoulos LA, Koutras A, et al. The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma."
        },
        {
          "id": 405,
          "referenceValue": "Cancer. 2006;106(2):297-303."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 181,
      "name": "<b>Gemcitabine/Cisplatin</b>",
      "schedule": "<b>Gemcitabine</b> 1,000 mg/m<sup>2</sup>/d IV over 30-60 minutes, days 1,8,15<br> <b>Cisplatin</b> 70mg/m<sup>2</sup> IV, day 2<br> Repeat every 28 days",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Gemcitabine:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 406,
          "referenceValue": "von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and ciplatin in advanced or metastatic bladder cancer: results of a large, randomized, mulinational, multicenter, phase III study."
        },
        {
          "id": 407,
          "referenceValue": "J Clin Oncol. 2000;18(17):3068-3077."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 261,
      "name": "<b>Arsenic</b>",
      "schedule": "<b>Arsenic trioxide</b> 0.15 mg/kg/d IV for 25 doses up to 5 weeks",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>",
      "references": [
        {
          "id": 408,
          "referenceValue": "Trisenox [package insert]."
        },
        {
          "id": 409,
          "referenceValue": "Frazer, PA: Cephalon; 2010."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 182,
      "name": "<b>MVAC</b>",
      "schedule": "<b>Methotrexate</b> 30 mg/m<sup>2</sup>/d IV, days 1, 15, 22<br> <b>Vinblastine</b> 3 mg/m<sup>2</sup>/d IV, days 2, 15,22<br> <b>Doxorubicin</b> 30 mg/m<sup>2</sup> IV, day 2<br> <b>Cisplatin</b> 70 mg/m<sup>2</sup> IV, day 2<br> Repeat every 28 days",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Vinblastine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Doxorubicin:<br>No dose reduction </li><li>Vinblastine:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 410,
          "referenceValue": "von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and ciplatin in advanced or metastatic bladder cancer: results of a large, randomized, mulinational, multicenter, phase III study."
        },
        {
          "id": 411,
          "referenceValue": "J Clin Oncol. 2000;18(17):3068-3077."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 347,
      "name": "<b>Belinostat</b>",
      "schedule": "<b>Belinostat</b> 1000 mg/m<sup>2</sup>  days 1-5, <br> Repeat every 21 days",
      "emetogenicPotential": "Minimal",
      "dosageModifications": "",
      "references": [
        {
          "id": 2,
          "referenceValue": "Foss F, Advani R, Duvic M, et al. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma."
        },
        {
          "id": 3,
          "referenceValue": "Br J Haematol. 2015 Mar;168(6):811-9."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 183,
      "name": "<b>BEP</b>",
      "schedule": "<b>Bleomycin</b> 30 units IV bolus, weekly for 12 weeks<br> <b>Etoposide</b> 100 mg/m<sup>2</sup>/d IV over 30-60 minutes,days 1-5<br> <b>Cisplatin</b> 20 mg/m<sup>2</sup>/d IV over 30-60 minutes, days 1-5<br> Repeat every 21 days for 4 courses",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Bleomycin:<br>No dose reduction</li><li>Cisplatin:<br>No dose reduction</li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Bleomycin:<br>If CrCl 10-50 mL/min, reduce dose by 25% <br>                                                                     If CrCl < 10 mL/min, reduce dose by 50% </li><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>",
      "references": [
        {
          "id": 416,
          "referenceValue": "Nichols CR, Catalano PJ, Crawford ED, et al. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, jSouthwest Oncology Group, and Cancer and Leukemia Group B Study."
        },
        {
          "id": 417,
          "referenceValue": "J Clin Oncol. 1998;16(4):1287-1293."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 184,
      "name": "<b>EP</b>",
      "schedule": "<b>Etoposide</b> 100 mg/m<sup>2</sup>/d CIVI, days 1-5<br> <b>Cisplatin</b> 20 mg/m<sup>2</sup>/d IV, days 1-5<br> Repeat after 21 days",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>",
      "references": [
        {
          "id": 418,
          "referenceValue": "Motzer RJ, Sheinfeld J, Mazumdar M, et al. Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumors."
        },
        {
          "id": 419,
          "referenceValue": "J Clin Oncol. 1995;13(11):2700-2704."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 185,
      "name": "<b>TIP</b>",
      "schedule": "<b>Paclitaxel</b> 250 mg/m<sup>2</sup>/d CIVI over 24 hours, day 1<br> <b>Ifosfamide</b> 1,500 mg/m<sup>2</sup>/d IV over 1 hour, days 2-5<br> <b>Cisplatin</b> 25 mg/m<sup>2</sup>/d IV over 30 minutes, days 2-5<br> <b>Mesna</b> 500 mg/m<sup>2</sup> IV before ifosfamide, and at 4 and 8 hours after ifosfamide daily, days 2-5<br> <b>Peg-Filgrastim</b> 6 mcg SQ, days 6<br> Repeat every 21 days for 4 cycles",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Ifosfamide:<br>No dose reduction</li><li>Mesna:<br>No dose reduction</li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Paclitaxel:<br>No dose reduction</li></ul>",
      "references": [
        {
          "id": 420,
          "referenceValue": "Kondagunta GV, Bacik J, Donadio A, et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors."
        },
        {
          "id": 421,
          "referenceValue": "J Oncol. 2005;23(27):6549-6555."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 186,
      "name": "<b>VIP</b>",
      "schedule": "<b>Vinblastine</b> 0.11 mg/kg/d IV, days 1, 2<br> <b>OR</b><br> <b>Etoposide</b> 75 mg/m<sup>2</sup>/d IV, days 1-5<br> <b>AND</b><br> <b>Infosfamide</b> 1,2000 mg/m<sup>2</sup>/d IV, days 1-5<br> <b>Cisplatin</b> 20mg/m<sup>2</sup>/d IV, days 1-5<br> <b>Mesna</b> 400 mg IV 15 minutes prior to ifosfamide, <b>THEN</b> 1,200 mg/d CIVI, days 1-5<br> Repeat every 21 days for 4 cycles",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Mesna:<br>No dose reduction</li><li>Vinblastine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li><li>Vinblastine:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 422,
          "referenceValue": "Loehrer PJ, Lauer R, Roth BJ, et al. Salvage therapy in recurrent germ-cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide."
        },
        {
          "id": 423,
          "referenceValue": "Ann Intern Med. 1988;109(7):540-546."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 187,
      "name": "<b>Cabazitaxel</b>",
      "schedule": "<b>Cabazitaxel</b> 25 mg/m<sup>2</sup> IV over 1 hour, day 1<br> <b>Prednisone</b> 10 mg PO daily<br> Repeat every 21 days",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cabazitaxel:<br></li></ul><b>Renal Impairment</b><ul><li>Cabazitaxel:<br>Caution should be used in patients with severe renal impairment (creatinine clearence of <30 ml/hr)</li></ul>",
      "references": [
        {
          "id": 424,
          "referenceValue": "de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial."
        },
        {
          "id": 425,
          "referenceValue": "Lancet. 2010;376(9747):1147-1154."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 245,
      "name": "<b>Tositumomab</b>",
      "schedule": "Dosimetric step: <b>Tositumomab</b> 450 mg IV over 60 minuutes<br> <b>I-131 tositumomab</b> (35 mg tositumomab containing 5.0 mCi I-131) IV over 20 minutes<br> Therapeutic step: <b>Tositumomab</b> 450mg infused over 60minutes<br> <b>I-131 tositumomab</b> (dose individualized for each patient based on results of dosemetric step)",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>",
      "references": [
        {
          "id": 426,
          "referenceValue": "Bexxar [package insert]."
        },
        {
          "id": 427,
          "referenceValue": "Seattle, WA, and Philadelphia, PA: Corixa Corp and GlaxoSmithKline;2011."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 192,
      "name": "<b>Mitoxantrone/Prednisone</b>",
      "schedule": "<b>Mitoxantrone</b> 12 mg/m<sup>2</sup> IV, day 1<br> <b>Prednisone</b> 5 mg PO bid<br> Repeat every 21 days",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Mitoxantrone:<br>If bilirubin > 3 mg/dL, reduce dose by 25%</li></ul><b>Renal Impairment</b><ul><li>Mitoxantrone:<br>No dose reduction</li></ul>",
      "references": [
        {
          "id": 428,
          "referenceValue": "Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisonealone for symptptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative endpoints."
        },
        {
          "id": 429,
          "referenceValue": "J Clin Oncol. 1996;14(6)1756-1764."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 262,
      "name": "<b>HiDAC</b>",
      "schedule": "For patients <60 years of age:<br> <b>Cytarabine</b> 3,000 mg/m<sup>2</sup> CIVI over 3 hours, every 12 hours, days 1, 3, 5<br> Repeat every 28 days",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cytarabine:<br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>                                           If bilirubin > 3 mg/dL, reduce dose by 50%</li></ul><b>Renal Impairment</b><ul></ul>",
      "references": [
        {
          "id": 430,
          "referenceValue": "Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid deukemia. Cancer and Leukemia Group B."
        },
        {
          "id": 431,
          "referenceValue": "N Engl J Med. 1994;331(14):896-903."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 193,
      "name": "Bicalutamide/Leuprolide.  ",
      "schedule": "<b>Bicalutamide</b> 50 mg/d PO <b>WITH</b><br> <b>Leuprolide acetate depot</b> 7.5 mg IM<br> Repeat every 28 days",
      "emetogenicPotential": "N/A",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Bicalutamide:<br>No dose reduction</li><li>Goserelin:<br>No dose reduction </li><li>Leuprolide:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Bicalutamide:<br>No dose reduction </li><li>Goserelin:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 412,
          "referenceValue": "Schellhammer P, Sharifi R, Block N, et al. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer."
        },
        {
          "id": 413,
          "referenceValue": "Urology. 1995;45(5):745:752."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 194,
      "name": "<b>Degarelix</b>",
      "schedule": "<b>Degarelix</b> 240 mg SQ <br> <b>FOLLOWED BY</b><br> 80 mg SQ<br> Repeat every 28 days for 13 courses",
      "emetogenicPotential": "N/A",
      "dosageModifications": "<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>",
      "references": [
        {
          "id": 414,
          "referenceValue": "Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer."
        },
        {
          "id": 415,
          "referenceValue": "BJU Int. 2008;102(11):1531-1538."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 195,
      "name": "<b>Abaraterone</b>",
      "schedule": "<b>Abaraterone</b>1000 mg PO once daily on empty stomach<br> <b>Prednisone</b> 5 mg PO twice daily",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Abaraterone:<br>No dosage adjustment is necessary for patients with baseline mild hepatic impairment. <br>In patients with baseline moderate hepatic impairment (Child-Pugh Class B), reduce the recommended dose of ZYTIGA to 250 mg once daily. If elevations in ALT or AST >5X ULN or total bilirubin >3X ULN occur in patients with baseline moderate hepatic impairment, discontinue ZYTIGA treatment. <br> The safety of ZYTIGA in patients with baseline severe hepatic impairment has not been studied. These patients should not receive ZYTIGA. For patients who develop hepatotoxicity during treatment, interruption of treatment</li></ul><b>Renal Impairment</b><ul><li>Abaraterone:<br>No dose adjustment needed</li></ul>",
      "references": [
        {
          "id": 433,
          "referenceValue": "N. Engl. J. Med. 368 (2): 138–48."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 198,
      "name": "<b>Goserelin</b>",
      "schedule": "<b>Goserelin acetae implant</b> 3.6 mg SQ every 28 days or 10.8 mg SQ every 12 weeks.",
      "emetogenicPotential": "N/A",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Goserelin:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Goserelin:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 434,
          "referenceValue": "Zoladex 3.6 mg, Zoladex 10.8 mg [package inserts]."
        },
        {
          "id": 435,
          "referenceValue": "Wilmington, DE: AstraZeneca; 2010."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 199,
      "name": "<b>Leuprolide</b>",
      "schedule": "<b>Leuprolide acetate depot</b> 7.5 mg IM every 28 days <br>22.5 mg IM every 3 months, <br><b>OR</b> <br>30 mg IM every 4 months",
      "emetogenicPotential": "N/A",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Leuprolide:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul></ul>",
      "references": [
        {
          "id": 436,
          "referenceValue": "Lupron Depot 7.5 mg, 22.5 mg, 30 mg [package insers]."
        },
        {
          "id": 437,
          "referenceValue": "North Chicago, IL: Abbot Laboratories; 2011."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 200,
      "name": "<b>Nilutamide</b>",
      "schedule": "<b>Nilutamide</b> 300 mg/d PO, days 1-30, <b>THEN</b> 150 mg/d PO, in combination with surgical castration; begin on same day or day after castration",
      "emetogenicPotential": "N/A",
      "dosageModifications": "<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul><li>Nilutamide:<br>No dose reduction</li></ul>",
      "references": [
        {
          "id": 438,
          "referenceValue": "Dijkman GA, Janknegt RA, et al. Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate speific antigen normalization. International Anadron Study Group."
        },
        {
          "id": 439,
          "referenceValue": "J Urol. 1997;158(1):160-163."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 201,
      "name": "<b>Prednisone</b>",
      "schedule": "<b>Prednisone</b> 5 mg PO bid",
      "emetogenicPotential": "N/A",
      "dosageModifications": "<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>",
      "references": [
        {
          "id": 440,
          "referenceValue": "Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisonealone for symptptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative endpoints."
        },
        {
          "id": 441,
          "referenceValue": "J Clin Oncol. 1996;14(6)1756-1764."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 202,
      "name": "<b>Sipuleucel-T</b>",
      "schedule": "<b>Sipuleucel-T</b> Administer 3 doses at 14-day intervals",
      "emetogenicPotential": "N/A",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Sipuleucel-T:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Sipuleucel-T:<br>Unknown</li></ul>",
      "references": [
        {
          "id": 442,
          "referenceValue": "Provenge [package insert]."
        },
        {
          "id": 443,
          "referenceValue": "Parsippany, NJ: Watson Pharma, Inc.; 2011."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 203,
      "name": "<b>Triptorelin</b>",
      "schedule": "<b>Triptorelin pamoate depot</b> 3.75 mg IM<br> Repeat every 28 days",
      "emetogenicPotential": "N/A",
      "dosageModifications": "<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>",
      "references": [
        {
          "id": 444,
          "referenceValue": "Trelstar [package insert]."
        },
        {
          "id": 445,
          "referenceValue": "Parsippany, NJ: Watson Pharma, Inc.; 2011."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 204,
      "name": "<b>AD</b>",
      "schedule": "<b>Doxorubicin</b> 15 mg/m<sup>2</sup>/d CIVI, days 1-4<br> Dacarbazine 250 mg/m<sup>2</sup>/d CIVI, days 1-4<br> Repeat every 21 days",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Dacarbazine:<br>No dose reduction</li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Dacarbazine:<br>If CrCl 10-50 mL/min, reduce dose by 25%    <br>                                                                  If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 446,
          "referenceValue": "Antman K, Crowley J, Balcerzak SP, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas."
        },
        {
          "id": 447,
          "referenceValue": "J Clin Oncol. 1993;11(7):1276-1285."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 205,
      "name": "<b>DI</b>",
      "schedule": "<b>Doxorubicin</b> 50 mg/m<sup>2</sup> IV bolus, day 1,<br> <b>FOLLOWED BY</b><br> <b>Ifosfamide</b> 5,000 mg/m<sup>2</sup> CIVI, day 1<br> <b>Mesna</b> 600 mg/m<sup>2</sup> IV bolus, before ifosfamide, FOLLOWED BY 2,500 mg/m<sup>2</sup> CIVI with ifosfamide, and 1,250 mg/m<sup>2</sup> IV over 12 hours following ifosfamide<br> Repeat every 21 days ",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Ifosfamide:<br>No dose reduction</li><li>Mesna:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Doxorubicin:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 448,
          "referenceValue": "Santoro A, Tursz T, Mouridsen H, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group."
        },
        {
          "id": 449,
          "referenceValue": "J Clin Oncol. 1995;13(7):1537-1545."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 263,
      "name": "<b>Cytarabine</b>",
      "schedule": "For patients >=60 years of age:<br> <b>Cytarabine</b> 100 mg/m<sup>2</sup>/d CIVI, days 1-5<br> Repeat every 28 days for 4 courses",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cytarabine:<br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>                                           If bilirubin > 3 mg/dL, reduce dose by 50%</li></ul><b>Renal Impairment</b><ul></ul>",
      "references": [
        {
          "id": 487,
          "referenceValue": "Stone RM, Berg DT, George SL, et al. Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine."
        },
        {
          "id": 488,
          "referenceValue": "Blood. 2001;98(3):548-553."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 206,
      "name": "<b>VAC-IE</b>",
      "schedule": "<b>Cyclophosphamide</b> 1,200 mg/m<sup>2</sup> IV, day 1<br> <b>FOLLOWED BY</b>  mesna<br> <b>Vincristine<sup></b> 2 mg/m<sup>2</sup> IV, day 1<br> <b>Doxorubicin</b> 75 mg/m<sup>2</sup> IV bolus, day 1<br> <b>Dactinomycin</b> 1.25 mg/m<sup>2</sup> IV, day 1 substitued for doxorubicin when cumulative doxorubicin dose reaches 375 mg/m<sup>2</sup><br> Alternating with each cycle<br> <b>Ifosfamide</b> 1,800 mg/m<sup>2</sup>/d IV, days 1-6 (given with mesna)<br> <b>Etoposide</b> 100 mg/m<sup>2</sup>/d IV, days 1-5<br> Repeat cycle every 21 days for 17 total cycles",
      "emetogenicPotential": "VAC-High<br> IE-Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Dactinomycin:<br>If bilirubin > 3 mg/dL, reduce dose by 50%</li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Ifosfamide:<br>No dose reduction</li><li>Mesna:<br>No dose reduction</li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li><li>Vincristine:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 450,
          "referenceValue": "Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone."
        },
        {
          "id": 451,
          "referenceValue": "N Engl J Med. 2003;348(8):694-701."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 207,
      "name": "<b>MAID</b>",
      "schedule": "<b>Mesna</b> 2,500 mg/m<sup>2</sup>/d CIVI, days 1-4<br> <b>Doxorubicin</b> 15 mg/m<sup>2</sup>/d CIVI, days 1-4<br> <b>Ifosfamide</b> 2,500 mg/m<sup>2</sup>/d CIVI, days 1-3<br> <b>Dacarbazine</b> 250 mg/m<sup>2</sup>/d CIVI, days 1-4<br> Repeat every 21 days",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Dacarbazine:<br>No dose reduction</li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Ifosfamide:<br>No dose reduction</li><li>Mesna:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Dacarbazine:<br>If CrCl 10-50 mL/min, reduce dose by 25%    <br>                                                                  If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 454,
          "referenceValue": "Antman K, Crowley J, Balcerzak SP, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas."
        },
        {
          "id": 455,
          "referenceValue": "J Clin Oncol. 1993;11(7):1276-1285."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 208,
      "name": "<b>Methotrexate/Cisplatin/Doxorubicin Ifosfamide</b>",
      "schedule": "<b>Methotrexate</b> 12,000 mg/m<sup>2</sup> IV over 4 hours day 1<br> <b>WITH Leucovorin calcium</b> 8 mg/m<sup>2</sup> IV every 6 hours for 11 doses beginning 24 hours from the start of the Methotrexate infusion, days 1, 42 (preoperatively); days 133, 196, 238 (postoperatively)<br> <b>Cisplatin</b> 120 mg/m<sup>2</sup> CIVI over 48 hours, days 7-8, 49-50 (preoperatively); days 140-141, 203-204, 245-246 (postoperatively). <br> <b>Doxorubicin</b> 75 mg/m<sup>2</sup> CIVI over 24 hours, days 7, 49 (preoperatively); days 98, 161 (postoperatively). Doxorubicin was increased to 90 mg/m<sup>2</sup> IV over 24 hours for postoperative treatment courses<br> <b>Ifosfamide</b> 3,000 mg/m<sup>2</sup>/d CIVI for 5 days with equimolar doses of mesna, days 28-32, 70-74 (preooperatively); days 119-123, 182-186, 224-228 (postoperatively)",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Ifosfamide:<br>No dose reduction</li><li>Leucovorin:<br>No dose reduction</li><li>Methotrexate:<br>If bilirubin 3.1-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25% <br>  If bilirubin > 5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Doxorubicin:<br>No dose reduction </li><li>Leucovorin:<br>No dose reduction</li><li>Methotrexate:<br>If CrCl 30-60 mL/min, reduce dose by 50%    <br>                                                                  If CrCl < 30 mL/min, do not use</li></ul>",
      "references": [
        {
          "id": 456,
          "referenceValue": "Ferrrari S, Smeland S, Mercuri M, et al. Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups."
        },
        {
          "id": 457,
          "referenceValue": "J Clin Oncol. 2005;23(34):8845-8852."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 209,
      "name": "<b>Doxorubicin</b>",
      "schedule": "<b>Doxorubicin</b> 75 mg/m<sup>2</sup> IV<br> Repeat every 21 days",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Doxorubicin:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 458,
          "referenceValue": "Nielsen OS, Dombernowsky P, Mouridsen H, et al. High-dose epirubicin is not alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas: a study of the EORTC soft tissue and bone sarcoma group."
        },
        {
          "id": 459,
          "referenceValue": "Br J Cancer. 1998;78(12):1634-1639."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 210,
      "name": "<b>Interferon alfa-2b</b>",
      "schedule": "<b>Interferon alfa-2b</b>  30 million IU/m<sup>2</sup> IM <b>OR</b> SQ 3 times per week<br>Repeat until disease progression ",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>",
      "references": [
        {
          "id": 460,
          "referenceValue": "Groopman JE, et al. Recombinant alpha-2 interferon therapy for Kaposi's sarcoma associated with the acquired immunodeficiency syndrome."
        },
        {
          "id": 461,
          "referenceValue": "Ann Intern Med. 1984 May;100(5):671-6"
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 211,
      "name": "<b>Liposomal daunorubicin</b>",
      "schedule": "<b>Liposomal daunorubicin</b> 40 mg/m<sup>2</sup> IV over 60 minutes<br>  Repeat every 14 days",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>",
      "references": [
        {
          "id": 462,
          "referenceValue": "Rosenthal E, Poizot-Martin I, Saint Marc T, et al. Phase Ivstudy of liposomal daunorubicin (DaunoXome) in AIDS-related Kaposi sarcoma."
        },
        {
          "id": 463,
          "referenceValue": "AM J Clin Oncol.2002;25(1): 57-59"
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 212,
      "name": "<b>Paclitaxel</b>",
      "schedule": "<b>Paclitaxel</b>  135 mg/m<sup>2</sup> IV over 3 hours<br> Repeat every 21 days<br><b>OR</b><br> <b>Paclitaxel<sup>a</sup></b> 100 mg/m<sup>2</sup> IV over 3 hours<br>Repeat every 14 days   ",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Paclitaxel:<br>No dose reduction</li></ul>",
      "references": [
        {
          "id": 464,
          "referenceValue": "Parkash S. Gill, et al. Paclitaxel Is Safe and Effective in the Treatment of Advanced AIDS-Related Kaposi's Sarcoma."
        },
        {
          "id": 465,
          "referenceValue": "http://jco.ascopubs.org/content/17/6/1876.full"
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 213,
      "name": "<b>Pegylated liposomal doxorubicin</b>",
      "schedule": "<b>Pegylated liposomal doxorubicin</b> 20 mg/m<sup>2</sup> IV every 3 weeks as tolerated",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>",
      "references": [
        {
          "id": 466,
          "referenceValue": "Udhrain A, et al.Pegylated liposomal doxorubicin in the treatment of AIDS-related Kaposi’s sarcoma."
        },
        {
          "id": 467,
          "referenceValue": "Int J Nanomedicine. 2007 September; 2(3): 345–352."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 242,
      "name": "<b>Rituximab Maintenance</b>",
      "schedule": "<b>Rituximab</b> 375 mg/m<sup>2</sup>/d IV, day 1<br> Repeat every 90 days until relapse or maximum of 2 years",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Rituximab:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul></ul>",
      "references": [
        {
          "id": 468,
          "referenceValue": "van Oers NH, Van Glabbeke M, Glurgea L, et al. Rituximab maintenance treatment of relapsed/residual follicular Non Hodgikin's lymphoma: Long-term outcome or EROTC 20891 phase III randomized intergroup study."
        },
        {
          "id": 469,
          "referenceValue": "JClin Oncol. 2010;28(17):2853-2858."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 214,
      "name": "<b>Carbo-Tax</b>",
      "schedule": "<b>Carboplatin</b> AUC of 6 mg/ml/min IV over 30 minutes.<br><b>FOLLOWED  BY</b><br><b>Paclitaxel</b> 200mg/m<sup>2</sup>  IV over 3 hours, day 1<br><b> Filgrastim </b> 300 mcg/d SQ, days 5-12<br><b>OR</b> <br><b>PEG-Filgrastim</b>6 mg SQ on day 2.<br>Repeat every 21 days",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>paclitaxel:<br>No dose reduction</li></ul>",
      "references": [
        {
          "id": 470,
          "referenceValue": "Briasoulis E, Kalofonos H, Bafaloukos D, et al. Carboplatin plus paclitaxel in unknown primary Carcinoma: a Phase II Hellenic Cooperative Oncology Group Study."
        },
        {
          "id": 471,
          "referenceValue": "J Clin Oncol. 2000; 18(17):3101-3107."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 215,
      "name": "<b>Docetaxel/Carboplatin</b>",
      "schedule": "<b>Docetaxel</b> 75 mg/m<sup>2</sup> IV over 30 minutes, day1<br><b>Carboplatin</b> AUC of 5 mg/mL/min IV over 30 minutes, day 1<br>Repeat every 21 days",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Docetaxel:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 474,
          "referenceValue": "Pentheroudakis G, Briasoulis E, Kalofonos HP, et al. Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: a multicentre Hellenic Cooperative Oncology Group Phase II study."
        },
        {
          "id": 475,
          "referenceValue": "Acta Oncol. 2008;47(6): 1148-1155."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 216,
      "name": "<b>Gemcitabine/Carboplatin/paclitaxel</b>",
      "schedule": "<b>Gemcitabine</b> 1,000mg/m<sup>2</sup>  1V, days 1,8<br><b>Carboplatin</b> AUC of 5 IV, day 1<br><b>Paclitaxel</b> 200 mg/m2 IV over 1 hour, day 1<br>Repeat cycle every 21 days",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Gemcitabine:<br>No dose reduction </li><li>paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Gemcitabine:<br>No dose reduction </li><li>paclitaxel:<br>No dose reduction</li></ul>",
      "references": [
        {
          "id": 476,
          "referenceValue": "Greco FA, Burris HA III, Litchy S, et al. Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie pearl cancer center research Network study. J Clin Oncol.2002;20(6):1651-1656."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 217,
      "name": "<b>Gemcitabine/Cisplatin</b>",
      "schedule": "<b>Gemcitabine</b> 1,250 mg/m<sup>2</sup> IV, days 1 and 8<br><b>Cisplatin</b> 100mg/m<sup>2</sup> IV, day 1<br>Repeat every 21 days",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Gemcitabine:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 477,
          "referenceValue": "Culine S, Lortholary A, Voigt JJ, et al. Gemcitabine, carboplatin combintion with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study- trial for the French study Group on Carcinomas of Unknown Primary (GEFCAPI 01)."
        },
        {
          "id": 478,
          "referenceValue": "JClin Oncol. 2003;21(18):3479-3482."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 218,
      "name": "<b>Gemcitabine/Docetaxel</b>",
      "schedule": "<b>Gemcitabine</b> 1,000mg/m<sup>2</sup> IV over 30 minutes, days 1 and 8<br><b>Docetaxel</b> 75 mg/m<sup>2</sup>  IV over 1 hour, day 8<br>Repeat every 21 days",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Docetaxel:<br>If bilirubin > upper normal limit, do not use<br>                                              If  SGOT and/or SGPT > 1.5 upper normal limit plus alkaline                  Phosphatase >2.5 upper normal limit, do not use                                                  </li><li>Gemcitabine:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Docetaxel:<br>No dose reduction </li><li>Gemcitabine:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 479,
          "referenceValue": "Pouessel D, Culine S, Becht C, et al. Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site."
        },
        {
          "id": 480,
          "referenceValue": "Cancer. 2004; 100(6): 1257-1261."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 219,
      "name": "<b>Oxaliplatin Capecitabine</b>",
      "schedule": "<b>Oxaliplatin</b> 130 mg/m<sup>2</sup>  IV, day 1<br><b>Capecitabine</b> 1,000 mg/m<sup>2</sup> PO bid, days 1-14<br>Repeat cycle every 21 days upto 6 cycles                                                 ",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Capecitabine:<br>No dose reduction</li><li>Oxaliplatin:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Capecitabine:<br>If CrCl 30-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 30 mL/min, do not use </li><li>Oxaliplatin:<br>No dose reduction necessary in mild to moderate impairment <br> Reduce the dose to 65 mg/m<sup>2</sup> if there is severe renal impairment</li></ul>",
      "references": [
        {
          "id": 481,
          "referenceValue": "Hainsworth JD, Spigel DR, Burris HA, et al. Oxaliplatin and capecitabine inn the treatment of patients with recurrent or refractory carcinoma of unknown primary site: A phase 2 trial of the Sarah Cannon Oncology Research Consortium."
        },
        {
          "id": 482,
          "referenceValue": "Cancer. 2010; 116(10):2448-2454."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 220,
      "name": "<b>Paclitaxel/Carboplatin/Etoposide</b>",
      "schedule": "<b>Paclitaxel</b>  200mg/m<sup>2</sup> IV over 1 hour, day 1,<br><b>FOLLOWED BY</b><br> <b>Carboplatin</b> dose targeted by Calvert equation to AUC of 6 mg/mL/min IV, day 1<br><b>Etoposide</b> 50 mg/d PO alternated with 100mg/d PO, days 1-10<br> Repeat every 21 days",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Paclitaxel:<br>For 3-hour infusion:  <br>                                                                                      If transaminase < 10 upper normal limit and bilirubin < 1.25 upper normal limit, no dose reduction (175mg/m2)    <br>                                       If transaminase < 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2  <br>                                                           If transaminase < 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2  <br>                                                             If transaminase > 10 upper normal limit or bilirubin > 5 upper normal limit, do not use    <br>                                                                             For 24-hour infusion:    <br>                                                                                  If transaminase < 2 upper normal limit or bilirubin < 1.5 mg/mL, no dose reduction (135 mg/m2)   <br>                                                                     If transaminase 2-10 upper normal limit and bilirubin < 1.5 mg/dL, reduce to 100 mg/m2 <br>                                                                                    If transaminase < 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2    <br>                                                                                   If transaminase > 10 upper normal limit or bilirubin > 7.5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li><li>Paclitaxel:<br>No dose reduction</li></ul>",
      "references": [
        {
          "id": 483,
          "referenceValue": "Hainsworth JD, Spigel DR, Litchy S, Greco FA. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neutroendocrine carcinoma: a Minnie Pearl Cancer Network Study."
        },
        {
          "id": 484,
          "referenceValue": "J Clin Oncol. 2006;24(22):3548-3554."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 243,
      "name": "<b>Romidepsin</b>",
      "schedule": "<b>Romidepsin</b> 14mg\\m<sup>2</sup> IV on days 1,8,and 15.<br> Repeat every 28 days           ",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>",
      "references": [
        {
          "id": 485,
          "referenceValue": "Istodax [package insert]."
        },
        {
          "id": 486,
          "referenceValue": "Summit , NJ: Celgene Corporation; 2011."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 725,
      "name": "",
      "schedule": "<p><strong>Gemcitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;IV on days 1 and 8</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 221,
      "name": "<b>ABVD</b>",
      "schedule": "<b>Doxorubicin</b> 25 mg/m<sup>2</sup>/d IV, days 1, 15<br> <b>Bleomycin</b> 10 units/m<sup>2</sup>/d IV, days 1, 15<br> <b>Vinblastine</b> 6 mg/m<sup>2</sup>/d IV, days 1, 15<br> <b>Dacarbazine</b> 375 mg/m<sup>2</sup>/d IV, days 1, 15<br> Repeat every 28 days",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Bleomycin:<br>No dose reduction</li><li>Dacarbazine:<br>No dose reduction</li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Vinblastine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Bleomycin:<br>If CrCl 10-50 mL/min, reduce dose by 25% <br>                                                                     If CrCl < 10 mL/min, reduce dose by 50% </li><li>Dacarbazine:<br>If CrCl 10-50 mL/min, reduce dose by 25%    <br>                                                                  If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Vinblastine:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 491,
          "referenceValue": "Harker WG, Kushlan P, Rosenberg SA. Combination chemotherapy for advanced Hodgkin's disease after failure of MOPP: ABVD and B-CAVe."
        },
        {
          "id": 492,
          "referenceValue": "Ann Intern Med. 1984;  101(4):440-446"
        },
        {
          "id": 493,
          "referenceValue": ".<br> Longo DL, Glastein E, Duffey PL,et al. Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgikin's disease."
        },
        {
          "id": 494,
          "referenceValue": "J Clin Oncol. 1997; 15(11): 3338-3346"
        },
        {
          "id": 495,
          "referenceValue": "."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 222,
      "name": "<b>BEACOPP (Escalated)</b>",
      "schedule": "<b>Bleomycin</b> 10 mg/m<sup>2</sup> IV, day8<br> <b>Etoposide</b> 200 mg/m<sup>2</sup> IV, days 1-3<br> <b>Doxorubicin</b> 35 mg/m<sup>2</sup> IV, day 1<br> <b>Cyclophosphamide</b> 1,200 mg/m<sup>2</sup> IV, day 1<br> <b>Vincristine</b> 1.4 mg/m<sup>2</sup> IV, day 8<br> <b>Procarbazine</b> 100 mg/m<sup>2</sup> PO, days 1-7<br> <b>Prednisone</b> 40 mg/m<sup>2</sup> IV, days 1-14<br> Repeat on day 22 for 8 cycles",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Bleomycin:<br>No dose reduction</li><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Bleomycin:<br>If CrCl 10-50 mL/min, reduce dose by 25% <br>                                                                     If CrCl < 10 mL/min, reduce dose by 50% </li><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li><li>Procarbazine:<br>If CrCl < 30 mL/min, do not use</li><li>Vincristine:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 496,
          "referenceValue": "Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgikin's disease."
        },
        {
          "id": 497,
          "referenceValue": "N Engl J Med. 2003;348(24):2386-2395"
        },
        {
          "id": 498,
          "referenceValue": "."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 223,
      "name": "<b>Stanford V</b>",
      "schedule": "<b>Doxorubicin</b> 25 mg/m<sup>2</sup>/d IV, days 1, 15<br> <b>Vinblastine</b> 6 mg/m<sup>2</sup>/d IV, days 1, 15<br> <b>Mechlorethamine</b> 6 mg/m<sup>2</sup> IV,day1<br> <b>Vincristine</b> 1.4 mg/m<sup>2</sup>/d IV, days 8, 22<br> <b>Bleomycin</b> 5 units per m<sup>2</sup> per day  IV, days 8,22<br> <b>Etoposide</b> 60mg/m<sup>2</sup>/d IV, days 15,16<br> <b>Prednisone</b> 40 mg/m<sup>2</sup> PO every other day",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Bleomycin:<br>No dose reduction</li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Mechlorethamine:<br>No dose reduction</li><li>Vinblastine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Bleomycin:<br>If CrCl 10-50 mL/min, reduce dose by 25% <br>                                                                     If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li><li>Vinblastine:<br>No dose reduction </li><li>Vincristine:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 499,
          "referenceValue": "Bartlett NL, Rosenberg SA, Hoppe RT, Hancock SL, Horning SJ.Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgikin's disease: a Preliminary report."
        },
        {
          "id": 500,
          "referenceValue": "J Clin Oncol. 1995; 13(5):1080-1088"
        },
        {
          "id": 501,
          "referenceValue": "."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 224,
      "name": "<b>BR</b>",
      "schedule": "<b>Rituximab</b> 375mg/m<sup>2</sup> IV, day 1<br> <b>Bendamustine</b> 90 mg/m<sup>2</sup> IV, days 1, 2<br> Repeat every 28 days for 6 cycles",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Bendamustine:<br>If SGOT or SGPT 2.5-10 upper normal limit and bilirubin 1.5-3 upper normal limit, or bilirubin > 3 upper normal limit, do not use </li><li>Rituximab:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Bendamustine:<br>If CrCl < 40 mL/min, do not use </li></ul>",
      "references": [
        {
          "id": 502,
          "referenceValue": "Rummel MK, Niederle N, Mascmeyere G, et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared too CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and matle cell lymphomas: Final results of a randomized phase III study of StiL (Study Group of Indolent Lymphomas, Germany)."
        },
        {
          "id": 503,
          "referenceValue": "Presented at :51st American Society of Hematology Annual Meeting; December 5-8, 2009; New Orleans, LA. Abstract 405."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 225,
      "name": "<b>CHOP</b>",
      "schedule": "<b>Cyclophosphamide</b> 750 mg/m<sup>2</sup> IV, day 1<br> <b>Doxorubicin</b> 50 mg/m<sup>2</sup> IV, day 1<br> <b>Vincristine</b> 1.4 mg/m<sup>2</sup> IV, day 1<br> <b>Prednisolone</b> 50 mg/m<sup>2</sup>/d PO, days 1-5<br> Repeat every 21 days",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Vincristine:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 504,
          "referenceValue": "Bezwoda W, Ristogi RB, Erazo Valla A, et al. Long-term results of a multicentre randomised, comparitive phase III trial of CHOP versus CNOP regimens in patients with intermediate-and high-grade non-Hodgikin's lymphomas."
        },
        {
          "id": 505,
          "referenceValue": "Eur J Cancer. 1995;31A(6):903-911"
        },
        {
          "id": 506,
          "referenceValue": "."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 240,
      "name": "<b>Ibritumomab tiuxetan</b>",
      "schedule": "<b>Ibritumomab tiuxetan</b> is given in 2 steps:<br> Step 1: <b>Rituximab</b> 250 mg/m<sup>2</sup> infusion <b>FOLLOWED WITHIN 4 HOURS BY</b> 5.0 mCi (1.6 mg total antibody dose) of <b>In- 111 ibrituximomab tiuxetan</b> administered as a 10-minute IV push<br> Step 2: (7-9 days after step 1): <b>Rituximab</b> 250 mg/m<sup>2</sup> infusion <b>FOLLOWED WITHIN 4 HOURS BY</b><br> <b>Y-90 ibritumomab tiuxetan</b> 0.4 mCi/kg (maximum, 32 mCi) admistered as a 10-minute IV push               ",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>",
      "references": [
        {
          "id": 507,
          "referenceValue": "Zevalin [package insert]."
        },
        {
          "id": 508,
          "referenceValue": "San Deigo, CA: IDEC Pharmaceutical Coorporation; 2010."
        },
        {
          "id": 509,
          "referenceValue": "<br> Wiseman GA, White CA, Sparks RB, et al. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevali radiommunotherapy for low-grade, follicular, or transofrmed B-cell non-Hodgikin's lymphoma."
        },
        {
          "id": 510,
          "referenceValue": "Crit Rev Oncol Hematol. 2001;39(1-2):181-194."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 226,
      "name": "<b>R - CHOP</b>",
      "schedule": "<b>Cyclophosphamide</b> 750 mg/m<sup>2</sup> IV, day 1<br> <b>Doxorubicin</b> 50 mg/m<sup>2</sup> IV, day 1<br> <b>Vincristine</b> 1.4 mg/m<sup>2</sup> IV, day 1 upto a maximum dose of 2mg<br> <b>Prednisone</b> 40 mg/m<sup>2</sup>/d PO, days 1-5<br> <b>Rituximab</b> 375 mg/m<sup>2</sup> IV, day 1<br> Repeat every 21 days ",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Rituximab:<br>No dose reduction</li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Vincristine:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 511,
          "referenceValue": "Coiffier B, Leapage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma."
        },
        {
          "id": 512,
          "referenceValue": "N Engl J Med. 2002;346(4):235-242."
        },
        {
          "id": 513,
          "referenceValue": "<br> Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy."
        },
        {
          "id": 514,
          "referenceValue": "J Clin Oncol. 1999; 17(1):268-276"
        },
        {
          "id": 515,
          "referenceValue": "."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 227,
      "name": "<b>CODOX-M/IVAC</b>",
      "schedule": "<u>Cycles 1 AND 3 (CODOX-M)</u><br> <b>Cyclophosphamide</b> 800 mg/m<sup>2</sup> IV, day 1<br> <b>Cyclophosphamide</b> 600 mg/m<sup>2</sup>/d IV, days 2-5<br> <b>Doxorubicin</b> 40 mg/m<sup>2</sup> IV, day 1<br> <b>Vincristine</b> 1.5 mg/m<sup>2</sup> IV up to a maximum dose of 2 mg, days 1,8 for cycle 1, days 1,8, 15 for cycle 2<br> <b>Methotrexate</b> 1,200 mg/m<sup>2</sup> IV over 1 hour, day 10,          <b>THEN</b> 240 mg/m<sup>2</sup>/h CIVI for the next 23 hours<br> <b>Leucovorin calcium </b>192 mg/m<sup>2</sup> IV, starting at hour 36  <b>THEN</b> 12 mg/m<sup>2</sup> every 6 hours until Methotrexate level is <5*10<sup>-8</sup> M<br> <b>Filgrastim</b>5 mcg/kg/d SQ until ANC >1,000/mm<sup>3</sup><br> <b>Methotrexate</b> 12mg IT, day 15<br> <b>Leucovorin calcium</b> 15 mg PO 24 hours after Methotrexate, day 16<br>                                                              <u>CNS PROPHYLAXIS</u><br> <b>Cytarabine</b> 70 mg IT, days 1,3,5<br> <b>Methotrexate</b> 12 mg IT, day 12 Cycles 2 AND 4 (IVAC)<br> <b>Ifosfamide</b> 1,500mg/m<sup>2</sup> IV over 1 hour, days 1-5<br> <b>Mesna</b> 360 mg/m<sup>2</sup> IV over 1 hour <b>THEN</b> 360 mg/m<sup>2</sup> IV every 3 hours for a maximum of 7 doses  per 24 hour period, days 1-5<br> <b>Cytarabine</b>  2,000 mg/m<sup>2</sup> IV over 3 hours every 12 hours, days 1 and 2<br> <b>Methotrexate</b> 12 mg IT, day 5<br> <b>Leucovorin calcium</b> 15 mg PO 24 hours after Methotrexate, day 6<br> <b>Filgrastim</b> 5 mcg/kg/d SQ until ANC > 1,000/mm<sup>3</sup>                                                  ",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Cytarabine:<br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>                                           If bilirubin > 3 mg/dL, reduce dose by 50%</li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Ifosfamide:<br>No dose reduction</li><li>Leucovorin:<br>No dose reduction</li><li>Mesna:<br>No dose reduction</li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li><li>Leucovorin:<br>No dose reduction</li><li>Vincristine:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 516,
          "referenceValue": "Mead GM, Sydes MR, Walewski J, et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 Study."
        },
        {
          "id": 517,
          "referenceValue": "Ann Oncol. 2002, 13(8): 1254-1274."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 228,
      "name": "<b>R - CVP</b>",
      "schedule": "<b>Cyclophosphamide</b> 750 mg/m<sup>2</sup> IV, day 1<br> <b>Vincristine</b> 1.4 mg/m<sup>2</sup> up to a maximum dose of 2 mg IV, day 1<br> <b>Prednisone</b> 40 mg PO, days 1-5<br> <b>Rituximab</b> 375 mg/m<sup>2</sup> IV, day 1<br> Repeat every 21 days for a maximum off 8 cycles ",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Rituximab:<br>No dose reduction</li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Vincristine:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 518,
          "referenceValue": "Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma."
        },
        {
          "id": 519,
          "referenceValue": "Blood, 105(4): 1417-1423."
        },
        {
          "id": 520,
          "referenceValue": "<br> Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine and prednisone alone in patients with previously utreated advanced follicular lymphoma."
        },
        {
          "id": 521,
          "referenceValue": "J Clin Oncol. 2008;26(28):4578-4589."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 229,
      "name": "<b>DHAP</b>",
      "schedule": "<b>Dexamethasone</b> 40 mg/d PO or IV over 24 hours, days 1-4<br> <b>Cisplatin</b> 100 mg/m<sup>2</sup> CIVI, day 1<br> <b>Cytarabine</b> 2,000 mg/m<sup>2</sup> IV over 3 hours every 12 hours for 2 doses, day 2<br> Repeat every 21-28 days",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Cytarabine:<br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>                                           If bilirubin > 3 mg/dL, reduce dose by 50%</li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li></ul>",
      "references": [
        {
          "id": 523,
          "referenceValue": "Blood. 1988;71(1):117-122."
        },
        {
          "id": 522,
          "referenceValue": "Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP)."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 230,
      "name": "<b>ESHAP</b>",
      "schedule": "<b>Etoposide</b> 40 mg/m<sup>2</sup>/d IV, days 1-4<br> <b>Methylprednisolone</b> 500 mg/d IV, days 1-5<br> <b>Cytarabine</b> 2,000 mg/m<sup>2</sup> IV over 2-3 hours,             day 5<br> <b>Cisplatin</b> 25 mg/m<sup>2</sup>/d CIVI, days 1-4<br> <b>OR</b><br> <b>Etoposide</b> 60 mg/m<sup>2</sup>/d IV, days 1-4<br> <b>Methylprednisolone</b> 500 mg/d IV, days 1-4<br> <b>Cisplatin</b> 25 mg/m<sup>2</sup>/d CIVI, days 1-4<br> <b>Cytarabine</b> 2,000 mg/m<sup>2</sup> IV over 2 hours, day 5, immediately following completion of cisplatin<br> Repeat every 21-28 days        ",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Cytarabine:<br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>                                           If bilirubin > 3 mg/dL, reduce dose by 50%</li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>",
      "references": [
        {
          "id": 524,
          "referenceValue": "Velasquez WS, McLaughlin P, Tucker S, et al. ESHAP- an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study."
        },
        {
          "id": 525,
          "referenceValue": "J Clin Oncol. 1994; 12(6): 1169-1176."
        },
        {
          "id": 526,
          "referenceValue": "<br> Rodriguez MA, Cabanillas FC, Velasquez W, et al. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP."
        },
        {
          "id": 527,
          "referenceValue": "J Clin Oncol. 1995; 13(7): 1734-1741."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 241,
      "name": "<b>Pralatrexate</b>",
      "schedule": "<b>Pralatrexate</b> 30 mg/m<sup>2</sup> IV, weekly for 6 weeks<br> Repeat every 7 weeks",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>",
      "references": [
        {
          "id": 528,
          "referenceValue": "Folotyn [package insert]."
        },
        {
          "id": 529,
          "referenceValue": "Westminster, CO: Allos Therapeutics Inc.; 2012."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 246,
      "name": "<b>Vorinostat</b>",
      "schedule": "<b>Vorinostat</b> 400mg PO daily with food",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>",
      "references": [
        {
          "id": 530,
          "referenceValue": "Zolinza [package insert]."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 231,
      "name": "<b>Hyper-CVAD/MTX-Ara-C</b>",
      "schedule": "<u>COURSE 1</u><br> <b>Cyclophosphamide</b> 300 mg/m<sup>2</sup> over 3 hours every 12 hours  for 6 doses , days 1-3<br> <b>Doxorubicin</b> 50 mg/m<sup>2</sup> over 48 hours after cyclophosphamide, days 4-5<br> <b>Vincristine</b> 2 mg administered 12 hours  after last cyclophosphamide dose, repeated on day 11<br> <b>Dexamethasone</b> 40 mg/d IV or PO,days 1-4,11-14<br> <b>Filgrastim</b> 5 mcg/kg IV or SQ beginning 24 hours after doxorubicin is complete.<br> <u>COURSE 2 <br>(BEGIN AFTER CLINICAL AND HEMATOLOGIC RECOVERY FROM COURSE 1)</u><br> <b>Methotrexate</b> 200 mg/m<sup>2</sup> IV bolus, day 1<br> <b>FOLLOWED BY</b><br> <b>Methotrexate</b> 800mg/m<sup>2</sup>over 24 hours day1 <b>Followed by</b><br><b>Cytarabine</b>3000 mg/m<sup>2</sup> IV every 12 hours for 4 doses, days 2-3 (dose reduced to 1,000 mg/m<sup>2</sup> in patients >60 years or with serum creatinine >1.5 mg/dL)<br> <b>Leucovorin calcium</b> 50 mg PO 24 hours after end of Methotrexate infusion<br> <b>FOLLOWED 6 HOURS LATER BY</b><br> <b>Leucovorin calcium</b> 15 mg PO every 6 hours for 8 doses (dose adjusted for Methotrexate concentration at 24 and 48 hours after completion of Methotrexate infusion)<br> <b>Filgrastim</b> 5mcg/kg IV or SQ begining 24 hours after cytarabine.<br> Repeat courses every 21 days.            ",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Cytarabine:<br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>                                           If bilirubin > 3 mg/dL, reduce dose by 50%</li><li>Leucovorin:<br>No dose reduction</li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Leucovorin:<br>No dose reduction</li><li>Vincristine:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 531,
          "referenceValue": "Khouri IF, Romaguera J, Kantrajian H,et al. Hyper-CVAD and high -dose methotrexate/ cytarabine followed by stem-cell tans-plantation: an active regimen for aggressive mantle-cell lymphoma."
        },
        {
          "id": 532,
          "referenceValue": "J Clin Oncol. 1998; 16(12): 3803-3809"
        },
        {
          "id": 533,
          "referenceValue": "."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 232,
      "name": "<b>R-EPOCH</b>",
      "schedule": "<b>Rituximab</b> 375 mg/m<sup>2</sup> IV, day 1<br> <b>Etoposide</b> 65 mg/m<sup>2</sup>/d CIVI, days 2-4<br> <b>Doxorubicin</b> 15 mg/m<sup>2</sup>/d CIVI, days 2-4<br> <b>Vincristine</b> 0.5 mg/m<sup>2</sup>/d CIVI, days 2-4<br> <b>Cyclophosphamide</b> 750 mg/m<sup>2</sup> IV, day 5<br> <b>Prednisone</b> 60 mg/m<sup>2</sup>/d PO, days 1-14<br> Repeat every 21 days for 4 -6 cycles",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Rituximab:<br>No dose reduction</li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li><li>Vincristine:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 534,
          "referenceValue": "Jermann M, jost M, Taverna C, et al. Rituximab EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study."
        },
        {
          "id": 535,
          "referenceValue": "Ann Oncol. 2004; 15(3):511-516"
        },
        {
          "id": 536,
          "referenceValue": "."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 233,
      "name": "<b>RICE</b>",
      "schedule": "<b>Rituximab</b> 375 mg/m<sup>2</sup> IV, day 1 every 14 days<br> <b>Ifosfamide</b> 5,000 mg/m<sup>2</sup> with mesna 5,000 mg/m<sup>2</sup> CIVI over 24 hours, day 4<br> <b>Carboplatin</b> AUC of 5 (maximum 800 mg) IV, day 4<br> <b>Etoposide</b> 100 mg/m<sup>2</sup>/d CIVI, days 3-5<br> Repeat every 14 days",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Ifosfamide:<br>No dose reduction</li><li>Mesna:<br>No dose reduction</li><li>Rituximab:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>",
      "references": [
        {
          "id": 537,
          "referenceValue": "Kewalramani T, Zelenetz AD, Nimer SD, Nimer SD, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma."
        },
        {
          "id": 538,
          "referenceValue": "Blood. 2004; 103(10):3684-3688."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 234,
      "name": "<b>Bendamustine</b>",
      "schedule": "<b>Bendamustine</b> 120 mg/m<sup>2</sup> IV days 1 and 2<br> Repeat every 21 days",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Bendamustine:<br>If SGOT or SGPT 2.5-10 upper normal limit and bilirubin 1.5-3 upper normal limit, or bilirubin > 3 upper normal limit, do not use </li></ul><b>Renal Impairment</b><ul><li>Bendamustine:<br>If CrCl < 40 mL/min, do not use </li></ul>",
      "references": [
        {
          "id": 539,
          "referenceValue": "Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgikin lymphoma: results from a multicenter study."
        },
        {
          "id": 540,
          "referenceValue": "Cancer. 2010,116(1):106-114"
        },
        {
          "id": 541,
          "referenceValue": "."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 235,
      "name": "<b>Bexarotene</b>",
      "schedule": "<b>Bexarotene</b> 300 mg/m<sup>2</sup>/d PO with a meal",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>",
      "references": [
        {
          "id": 542,
          "referenceValue": "Targretin [package insert]."
        },
        {
          "id": 543,
          "referenceValue": "Woodcliff Lake, NJ: Eisai Inc.; 2011."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 236,
      "name": "<b>Bortezomib</b>",
      "schedule": "<b>Bortezomib</b> 1.3 mg/m<sup>2</sup>/d IV bolus, days 1,4, 8, 11<br> Repeat every 21 days for up to 17 cycles.",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul><li>Bortezomib:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 544,
          "referenceValue": "Goy A, Bernstein SH, Kahl BS, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time to event analyses of the multicenter Phase 2. PINNACLE study."
        },
        {
          "id": 545,
          "referenceValue": "Ann Oncol. 2009;20(3):520-525."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 237,
      "name": "<b>Brentuximab vedotin</b>",
      "schedule": "<b>Brentuximab</b> 1.8 mg/kg IV over 30 minutes,  day 1<br> Repeat every 21 days for upto 16 cycles",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>",
      "references": [
        {
          "id": 546,
          "referenceValue": "Advani RH, Shustov AR, Brice P, et al.                                     Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma: A Phase 2 study update."
        },
        {
          "id": 547,
          "referenceValue": "Blood (ASH Annula Meeting Abstracts). 2011; 118:443."
        },
        {
          "id": 548,
          "referenceValue": "<br> Adcetris [package insert]."
        },
        {
          "id": 549,
          "referenceValue": "Bothell, WA: Seattle Genetics; 2011."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 238,
      "name": "<b>Denileukin diftitox</b>",
      "schedule": "<b>Denileukin diftitox</b> 9 <b>OR</b> 18 mcg/kg/d/IV over 15-60 minutes, days 1-5<br> Repeat every 21 days",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>",
      "references": [
        {
          "id": 550,
          "referenceValue": "Olsen E, Duvic M Frankel A, et al. Pivotal Phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma."
        },
        {
          "id": 551,
          "referenceValue": "J Clin Oncol. 2001; 19(2):376-388."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 239,
      "name": "<b>Fludarabine</b>",
      "schedule": "<b>Fludarabine</b> 25 mg/m<sup>2</sup>/d IV over 10 minutes, days 1-5<br> Repeat every 28 days for up to 8 courses",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Fludarabine:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Fludarabine:<br>If CrCl 30-70 mL/min, reduce dose by 20%      <br>                                                                  If CrCl < 30 mL/min, do not use </li></ul>",
      "references": [
        {
          "id": 552,
          "referenceValue": "Klasa RJ,Meyer RM, Shustic C, et al. Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisione in patients with recurrent low-grade Non-Hodgikin's lymphoma previously treated with an alkylating agent or alkylatic containing regimen."
        },
        {
          "id": 553,
          "referenceValue": "J Clin Oncol. 2002;20(24):4649-4654."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 247,
      "name": "<b>CDE</b>",
      "schedule": "<b>Cyclophosphamide</b> 200mg/m<sup>2</sup>/d CIVI for 4 days<br><b>Doxorubicin</b> 12.5 mg/m<sup>2</sup>/d CIVI for 4 days<br> <b>Etoposide</b> 60 mg/m<sup>2</sup>/d CIVI for 4 days<br> Repeat every 28 days for a maximum of 8 cycles",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>",
      "references": [
        {
          "id": 554,
          "referenceValue": "Sparano JA,Lee S, Chen MG, et al. Phase II trial of   infusional, cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkins lymphoma: an Eastern Cooperative Oncology Group Trial (E1491)."
        },
        {
          "id": 555,
          "referenceValue": "J Clin Oncol. 2004; 22(8): 1491-1500."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 248,
      "name": "<b>CHOP</b>",
      "schedule": "<b>Cyclophosphamide</b> 750mg/m<sup>2</sup> IV, day 1<br> Doxorubicin 50 mg/m<sup>2</sup> IV, day 1<br><b>Vincristine</b> 1.4 mg/m<sup>2</sup> IV, day 1<br> <b>Prednisone</b> 100mg/m<sup>2</sup> PO, days 1-5<br> Repeat every 21 days.",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Vincristine:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 556,
          "referenceValue": "Weiss R, Mitrou P, Arasteh K, et.al. Acquired immunodeficiency syndrome-related lymphoma: Simultaneous treatment with combined cyclophosphamide, doxorubicin, Vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival--results of the German Multicenter Trial."
        },
        {
          "id": 557,
          "referenceValue": "Cancer. 2006; 106(7): 1560-1568."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 249,
      "name": "<b>CODOX-M/IVAC</b>",
      "schedule": "<u>CYCLES 1 and 3 (CODOX-M)</u><br>  <b>Cyclophosphamide</b> 800 mg/m<sup>2</sup> IV, day 1<br> <b>Cyclophosphamide</b> 200 mg/m<sup>2</sup>/d IV, days 2-5<br>  <b>Doxorubicin</b> 40 mg/m<sup>2</sup> IV, day 1<br> <b>Vincristine</b> 1.5 mg/m<sup>2</sup> IV, days 1, 8 for cycle 1,days 1, 8, 15 for cycle 2<br> <b>Methotrexate</b> 1,200 mg/m<sup>2</sup> IV over 1 h, day 10, <b>THEN</b> 240 mg/m2/h CIVI for the next 23 hours<br> <b>Leucovorin calcium</b> 50 mg IV q6h, begining 36 hours from the start of Methotrexate until Methotrexate level <0.05 mcM<br> <b>Filgrastim</b> beginning 24 h from the start of leucovorin until ANC>1,000<br> <u>CNS PROPHYLAXIS</u><br> <b>Cytarabine</b> 70 mg IT, days 1, 3<br> <b>Methotrexate<b> 12 mg IT, day 15<br> <u>CYCLES 2 AND 4 (IVAC)</u><br> <b>Ifosofamide</b> 1,500 mg/m<sup>2</sup> IV, days 1-5<br> <b>Mesna</b> 1,500 mg/m<sup>2</sup> IV, days 1-5<br> <b>Etoposide</b> 60 mg/m<sup>2</sup> IV, days 1-5<br> <b>Cytarabine</b> 2,000 mg/m<sup>2</sup> IV q 12h, days 1 and 2<br> <b>Filgrastim</b> beginning 24 h after completion of chemotherapy until ANC >1,000<br> <u>CNS PROPHYLAXIS</u><br> <b>Methotrexate</b> 12 mg IT, day 15<br> Additional IT Treatment for CNS disease- positive patients:<br> Cycle 1: cytarabine 70 mg IT, days 1,3,5, and Methotrexate 12 mg IT, days 15,17<br> Cycle 3: cytarabine 70 mg IT, days 1,3, and Methotrexate 12 mg IT, day 15                                                                                                                                                               ",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Cytarabine:<br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>                                           If bilirubin > 3 mg/dL, reduce dose by 50%</li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Ifosfamide:<br>No dose reduction</li><li>Leucovorin:<br>No dose reduction</li><li>Mesna:<br>No dose reduction</li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li><li>Leucovorin:<br>No dose reduction</li><li>Vincristine:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 558,
          "referenceValue": "Wang ES, Strauss DJ, Teruya-Feldstein J, et al. Intensive chemotherapy with cyclophosphosphamide, doxorucibicin, high-dose methotrecate/ ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC)for human immunodeficiency virus-associated Burkitt lymphoma."
        },
        {
          "id": 559,
          "referenceValue": "Cancer. 2003;98(6): 1196-1205."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 250,
      "name": "<b>EPOCH Dose-adjusted </b>",
      "schedule": "<b>Etoposide</b> 50 mg/m<sup>2</sup>/d CIVI, days 1-4 (96 hours)<br> <b>Doxorubicin</b> 10 mg/m<sup>2</sup>/d CIVI, days 1-4 (96 hours)<br> <b>Vincristine</b> 0.4 mg/m<sup>2</sup>/d /CIVI, days 1-4 (96 hours)<br> <b>Cyclophosphamide</b> <br>Cycle1: <br>375 mg/m<sup>2</sup> IV, day 5, if CD4+ cells >= 100/mm<sup>3</sup>; 187 mg/m<sup>2</sup> IV, day 5, if CD4+ cells<100/mm<sup>3</sup><br> After cycle 1: increase dose by 187 mg if nadir ANC > 500/mvL or platelets <25,000/mcL<br> <b>Prednisone</b> 60 mg/m<sup>2</sup>/d PO, days 1-5<br> <b>Filgrastim</b> 5 mcg/kg/d SQ, day 6, and until ANC >5,000/mcl<br> Repeat every 21 days",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li><li>Vincristine:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 560,
          "referenceValue": "Little RF, Pittaluga S, Grant N, et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology."
        },
        {
          "id": 561,
          "referenceValue": "BLOOD.2003;101(12):4653-4659."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 258,
      "name": "<b>7 + 3 with hi-dose daunorubicin <br>(<60 years)</b>",
      "schedule": "<b>Cytarabine</b> 100 mg/m<sup>2</sup>/d CIVI, days 1-7<br> <b>WITH</b><br> <b>Daunorubicin</b> 90 mg/m<sup>2</sup>/d IV, days 1-3",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cytarabine:<br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>                                           If bilirubin > 3 mg/dL, reduce dose by 50%</li><li>Daunorubicin:<br>If bilurubin 1.5-3 mg/dL, reduce dose by 25% <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 50%  <br>                                         If bilirubin >5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Daunorubicin:<br>If Cr > 3 mg/dL, reduce dose by 50%</li></ul>",
      "references": [
        {
          "id": 562,
          "referenceValue": "Fernandez HF, Sun Z, Pao X, et al. Anthracycline dose intensification in acute myeloid leukemia."
        },
        {
          "id": 563,
          "referenceValue": "N Engl J Med. 2009;361(13):1249-1259."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 259,
      "name": "<b>Arsenic</b>",
      "schedule": "<b>Arsenic trioxide</b> 0.15 mg/kg IV, daily until remission, not to exceed 60 doses",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>",
      "references": [
        {
          "id": 564,
          "referenceValue": "Trisenox [package insert]."
        },
        {
          "id": 565,
          "referenceValue": "Frazer, PA: Cephalon; 2010."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 251,
      "name": "<b>CALGB 8811</b>",
      "schedule": "<u>INDUCTION (COURSE 1:4 WEEKS)</u><br> <b>Cyclophosphamide</b> 1,200 mg/m<sup>2</sup> IV, day1 (800 mg/m<sup>2</sup> for patients >=60 years)<br> <b>Daunorubicin</b> 45 mg/m<sup>2</sup> IV, days 1-3 (30 mg/m<sup>2</sup> for patients>=60 years)<br> <b>Vincristine</b> 2 mg IV, days 1, 8, 15, 22<br> <b>Prednisone</b> 60 mg/m<sup>2</sup>/d PO, days 1-21 (days 1-7 for patients >=60 years)<br> <b>Asparaginase</b> 6,000 units/m<sup>2</sup> SQ, days 5, 8, 11, 15, 18, 22<br> <u>EARLY INTENSIFICATION (COURSE 2:4 WEEKS, REPEAT ONCE)</u><br> <b>Methotrexate</b> 15 mg IT, day 1<br> <b>Cyclophosphamide</b> 1,000 mg/m<sup>2</sup> IV, day 1<br> <b>Mercaptopurine</b> 60 mg/m<sup>2</sup>/d PO, days 1-14<br> <b>Cytarabine</b> 75 mg/m<sup>2</sup>/d SQ, days 1-4, 8-11<br> <b>Vincristine</b> 2 mg IV, days 15, 22<br> <b>Asparaginase</b> 6,000 units/m<sup>2</sup> SQ, days 15, 18, 22, 25<br> <u>CNS PROPHYLAXIS AND INTERIM MAINTENANCE (COURSE 3:12 WEEKS)</u><br> <b>Cranial RT</b> 2,400 cGy, days 1-12<br> <b>Methotrexate</b> 15 mg IT, days 1, 8, 15, 22, 29<br> <b>Mercaptopurine</b> 60 mg/m<sup>2</sup>/d PO, days 1-70<br> <b>Methotrexate</b> 20 mg/m<sup>2</sup> PO, days 36, 43, 50, 57, 64<br> <u>LATE INTENSIFICATION (COURSE 4:8 WEEKS)</u><br> <b>Doxorubicin</b> 30 mg/m<sup>2</sup> IV, days 1, 8, 15<br> <b>Vincristine</b> 2 mg IV, days 1, 8, 15<br> <b>Dexamethasone</b> 10 mg/m<sup>2</sup>/d PO, days 1-14<br> <b>Cyclophosphamide</b> 1,000 mg/m<sup>2</sup> IV, day 29<br> <b>Thioguanine</b> 60 mg/m<sup>2</sup>/d PO, days 29-42<br> <b>Cytarabine</b> 75 mg/m<sup>2</sup>/d SQ, days 29-32, 36-39<br> <u>MAINTENANCE (COURSE 5:4 WEEKS, FOR 2 YEARS FROM DIAGNOSIS)</u><br> <b>Vincristine</b> 2 mg IV, day 1 of every 4 weeks<br> <b>Prednisone</b> 60 mg/m<sup>2</sup>/d PO, days 1-5 of every 4 weeks<br> <b>Methotrexate</b> 20 mg/m<sup>2</sup> PO, days 1, 8, 15, 22<br> <b>Mercaptopurine</b> 60 mg/m<sup>2</sup>/d PO, days 1-28",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Cytarabine:<br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>                                           If bilirubin > 3 mg/dL, reduce dose by 50%</li><li>Daunorubicin:<br>If bilurubin 1.5-3 mg/dL, reduce dose by 25% <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 50%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Thioguanine:<br>If bilirubin > 5 mg/dL, do not use</li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Daunorubicin:<br>If Cr > 3 mg/dL, reduce dose by 50%</li><li>Doxorubicin:<br>No dose reduction </li><li>Vincristine:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 566,
          "referenceValue": "Larson RA, Dodge RK, Burns CP, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B study 8811."
        },
        {
          "id": 567,
          "referenceValue": "Blood. 1995;85(8):2025-2037."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 252,
      "name": "<b>Hyper-CVAD</b>",
      "schedule": "<u>ODD CYCLES (1, 3, 5, 7)</u><br>                            <b>Cyclophosphamide</b> 300 mg/m<sup>2</sup> IV over 3 hours every 12 hours, days 1-3<br> <b>Mesna</b> 600 mg/m<sup>2</sup>/d CIVI, days 1-3, ending 6 hours after cyclophosphamide completion<br> <b>Vincristine</b> 2 mg IV, days 4, 11<br> <b>Doxorubicin</b> 50 mg/m<sup>2</sup> IV, day 4<br> <b>Dexamethasone</b> 40 mg/d, days 1-4, 11-14<br> <b>Filgrastim</b> 5 mcg/kg bid SQ beginning 24 hours after doxorubicin completion <br> <b>OR</b><br><b>PEG-Filgrastim</b>6 mg SQ once 24 hours after doxorubicin completion<br> <u>EVEN CYCLES (2, 4, 6, 8)</u><br> <b>Methotrexate</b> 200 mg/m<sup>2</sup> IV over 2 hours, day 1,<br> <b>FOLLOWED BY</b>  800 mg/m<sup>2</sup> IV over 24 hours<br> <b>Leucovorin calcium</b> 15 mg IV every 6 hours for 8 doses, beginning 24 hours after Methotrexate completion; adjust per Methotrexate level<br> <b>Cytarabine</b> 3 g/m<sup>2</sup> IV over 2 hours every 12 hours for 4 doses, days 2, 3<br> <b>Methylprednisolone</b> 50 mg IV bid, days 1-3<br> <b>Filgrastim</b> 6 mg/kg SQ beginning 24 hours after cytarabine completion<br> <b>OR</b><br><b>PEG-Filgrastim</b>6 mg SQ once 24 hours after doxorubicin completion<br> <u>CNS PROPHYLAXIS</u><br> <b>Methotrexate</b> 12 mg IT, day 2 of each cycle<br> <b>Cytarabine</b> 100 mg IT, day 8 of each cycle<br>4-16 cycles based on risk profile",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Cytarabine:<br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>                                           If bilirubin > 3 mg/dL, reduce dose by 50%</li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Leucovorin:<br>No dose reduction</li><li>Mesna:<br>No dose reduction</li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Leucovorin:<br>No dose reduction</li><li>Vincristine:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 568,
          "referenceValue": "Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with Hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia."
        },
        {
          "id": 569,
          "referenceValue": "J Clin Oncol. 2000;18(3):547-561."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 253,
      "name": "<b>Nelarabine</b>",
      "schedule": "<b>Nelarabine</b> 1,500 mg/m<sup>2</sup>/d IV, days 1, 3 and 5",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>",
      "references": [
        {
          "id": 570,
          "referenceValue": "Arranon [package insert]."
        },
        {
          "id": 571,
          "referenceValue": "Research Triangle Park, NC: GlaxoSmithKline;2011."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 254,
      "name": "<b>ATRA/Arsenic</b>",
      "schedule": "<b>All-trans-retinoic acid (ATRA)</b> 45 mg/m<sup>2</sup> PO in 2 divided doses daily<br> <b>Arsenic trioxide</b> 0.15 mg/kg/d IV over 1 hour, daily beginning day 10 and continued until <5% blasts and absence of promyelocytes",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>",
      "references": [
        {
          "id": 572,
          "referenceValue": "Estey E, Garcia-Manero G, Ferrajoli A, et al. Use of all-trans-retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia."
        },
        {
          "id": 573,
          "referenceValue": "Blood. 2006;107(9):3469-3473."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 255,
      "name": "<b>ATRA/Idarubicin</b>",
      "schedule": "<b>All-trans-retinoic acid</b> (ATRA) 45 mg/m<sup>2</sup> PO, daily<br> <b>Idarubicin</b> 12 mg/m<sup>2</sup> IV, on days 2, 4, 6, 8",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Idarubicin:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 25%<br> If bilirubin 3.1-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 50% <br> If bilirubin > 5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Idarubicin:<br>If CrCl < 10 mL/min, reduce dose by 25% </li></ul>",
      "references": [
        {
          "id": 574,
          "referenceValue": "Sanz MA, Montesinos P, Vellenga E, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcomeon the LPA99 multicenter study by the PETHEMA Group."
        },
        {
          "id": 575,
          "referenceValue": "Blood. 2008;112(8):3130-3134."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 256,
      "name": "<b>Idarubicin/Cytarabine/Etoposide</b>",
      "schedule": "<b>Cytarabine</b> 25 mg/m<sup>2</sup> IV <b>FOLLOWED BY</b> 100 mg/m<sup>2</sup> CIVI, days 1-10<br> <b>Etoposide</b> 100 mg/m<sup>2</sup> IV, days 1-5<br> <b>Daunorubicin</b> 50 mg/m<sup>2</sup> IV, days 1, 3, 5<br> <b>OR</b><br> <b>Mitoxantrone</b> 12 mg/m<sup>2</sup> IV, days 1, 3, 5<br> <b>OR</b><br> <b>Idarubicin</b> 10 mg/m<sup>2</sup> IV, days 1, 3, 5",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cytarabine:<br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>                                           If bilirubin > 3 mg/dL, reduce dose by 50%</li><li>Daunorubicin:<br>If bilurubin 1.5-3 mg/dL, reduce dose by 25% <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 50%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Idarubicin:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 25%<br> If bilirubin 3.1-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 50% <br> If bilirubin > 5 mg/dL, do not use </li><li>Mitoxantrone:<br>If bilirubin > 3 mg/dL, reduce dose by 25%</li></ul><b>Renal Impairment</b><ul><li>Daunorubicin:<br>If Cr > 3 mg/dL, reduce dose by 50%</li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li><li>Idarubicin:<br>If CrCl < 10 mL/min, reduce dose by 25% </li><li>Mitoxantrone:<br>No dose reduction</li></ul>",
      "references": [
        {
          "id": 576,
          "referenceValue": "Mandelli F, Vignetti M, Suciu S, et al. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA group study AML-10."
        },
        {
          "id": 577,
          "referenceValue": "J Clin Oncol. 2009;32(10):5397-5403."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 257,
      "name": "<b>7 + 3</b>",
      "schedule": "<b>Cytarabine</b> 100 mg/m<sup>2</sup>/d CIVI, days 1-7<br> <b>WITH</b><br> <b>Daunorubicin</b> 45 mg/m<sup>2</sup>/d IV, days 1-3<br> <b>OR</b><br> <b>Idarubicin</b> 13 mg/m<sup>2</sup>/d IV, days 1-3<br> <b>OR</b><br> <b>Mitoxantrone</b> 12 mg/m<sup>2</sup>/d IV, days 1-3",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cytarabine:<br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>                                           If bilirubin > 3 mg/dL, reduce dose by 50%</li><li>Daunorubicin:<br>If bilurubin 1.5-3 mg/dL, reduce dose by 25% <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 50%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Idarubicin:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 25%<br> If bilirubin 3.1-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 50% <br> If bilirubin > 5 mg/dL, do not use </li><li>Mitoxantrone:<br>If bilirubin > 3 mg/dL, reduce dose by 25%</li></ul><b>Renal Impairment</b><ul><li>Daunorubicin:<br>If Cr > 3 mg/dL, reduce dose by 50%</li><li>Idarubicin:<br>If CrCl < 10 mL/min, reduce dose by 25% </li><li>Mitoxantrone:<br>No dose reduction</li></ul>",
      "references": [
        {
          "id": 578,
          "referenceValue": "Presler H, Davis RB, Kirshener J, et al. Comparison of three remission induction regimens and two post-induction strategies for the treatment of acute nonlymphocytic leukemia: a Cancer and Leukemia Group B study."
        },
        {
          "id": 579,
          "referenceValue": "Blood. 1987;69(5):1441-1449."
        },
        {
          "id": 580,
          "referenceValue": "<br> Wiernik PH, BAnks PL, Case DC Jr, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated patients with acute myeloid leukemia."
        },
        {
          "id": 581,
          "referenceValue": "Blood. 1992;79(2):313-319."
        },
        {
          "id": 582,
          "referenceValue": "<br> Wahlin A, Hornsten P, Hedenus M, Malm C. Mitoxantrone and cytarabine versus daunorubicin and cytarabine in previously untreated patients with acute myeloid leukemia."
        },
        {
          "id": 583,
          "referenceValue": "Cancer Chemother Pharmacol. 1991;28(6):480-483."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 264,
      "name": "<b>BR</b>",
      "schedule": "<b>Bendamustine</b> 90 mg/m<sup>2</sup> IV on days 1 and 2<br> <b>Rituximab</b> 375 mg/m<sup>2</sup> IV for the first cycle and 500 mg/m<sup>2</sup> for subsequent cycles<br> Repeat every 28 days for up to 6 cycles",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Bendamustine:<br>If SGOT or SGPT 2.5-10 upper normal limit and bilirubin 1.5-3 upper normal limit, or bilirubin > 3 upper normal limit, do not use </li><li>Rituximab:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Bendamustine:<br>If CrCl < 40 mL/min, do not use </li></ul>",
      "references": [
        {
          "id": 584,
          "referenceValue": "Fischer K, Cramer P, Stilgenbauer S, et al. Bendamustine combined with rituximab (BR) in first-line therapy of advanced CLL: A multicenter phase II trial of the German CLL Study Group (GCLLSG)."
        },
        {
          "id": 585,
          "referenceValue": "J Clin Oncol. 2011;29(26)3559-3566."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 265,
      "name": "<b>FC</b>",
      "schedule": "<b>Fludarabine</b> 25 mg/m<sup>2</sup>/d IV, days 1-3<br> <b>Cyclophosphamide</b> 250 mg/m<sup>2</sup>/d IV, days 1-3<br> Repeat every 28 days for 6 cycles",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Fludarabine:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Fludarabine:<br>If CrCl 30-70 mL/min, reduce dose by 20%      <br>                                                                  If CrCl < 30 mL/min, do not use </li></ul>",
      "references": [
        {
          "id": 586,
          "referenceValue": "Catovsky D, Richards S, Oscier D, et al. Assesmentof fludarabine plus cyclo-phosphamide for patients with chronic lymphocytic leukemia (the LRF CLL4 trial): a randomized ocntrolled trial."
        },
        {
          "id": 587,
          "referenceValue": "Lancet. 2007; 370(9583):230-239."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 266,
      "name": "<b>FCR</b>",
      "schedule": "<b>Fludarabine</b> 25 mg/m<sup>2</sup>/d IV, days 1-3<br> <b>Cyclophosphamide</b> 250 mg/m<sup>2</sup>/d IV, days 1-3<br> <b>Rituximab</b> 375 mg/m<sup>2</sup> IV, day 1 cycle 1<br> <b>FOLLOWED BY</b><br> <b>Rituximab</b> 500 mg/m<sup>2</sup> IV, day 1 cycles 2-6<br> Repeat every 28 days for 6 cycles",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Fludarabine:<br>No dose reduction</li><li>Rituximab:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Fludarabine:<br>If CrCl 30-70 mL/min, reduce dose by 20%      <br>                                                                  If CrCl < 30 mL/min, do not use </li></ul>",
      "references": [
        {
          "id": 588,
          "referenceValue": "Robak T, Dmoszynska A, Solal-Celigny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia."
        },
        {
          "id": 589,
          "referenceValue": "J Clin Oncol. 2010;28(10):1756-1765."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 267,
      "name": "<b>FR</b>",
      "schedule": "<b>Fludarabine</b> 25 mg/m<sup>2</sup>/d IV over 20-30 minutes, days 1-5<br> Repeat every 28 days for a total of 6 cycles<br> <b>Rituximab</b> 375 mg/m<sup>2</sup> IV<br> Repeat every 7 days for 4 doses",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Fludarabine:<br>No dose reduction</li><li>Rituximab:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Fludarabine:<br>If CrCl 30-70 mL/min, reduce dose by 20%      <br>                                                                  If CrCl < 30 mL/min, do not use </li></ul>",
      "references": [
        {
          "id": 590,
          "referenceValue": "Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lympocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)."
        },
        {
          "id": 591,
          "referenceValue": "Blood. 2003;101(1):6-14"
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 268,
      "name": "<b>PCR</b>",
      "schedule": "<b>Pentostatin</b> 2 mg/m<sup>2</sup> IV,day 1<br> <b>Cyclophosphamide</b> 600 mg/m<sup>2</sup> IV, day 1<br> <b>Rituximab</b> 375 mg/m<sup>2</sup> IV, day 1<br> Repeat every 21 days for 6 cycles",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Pentostatin:<br>No dose reduction</li><li>Rituximab:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li></ul>",
      "references": [
        {
          "id": 592,
          "referenceValue": "Kay NE, Geyer SM, Call TG, et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia."
        },
        {
          "id": 593,
          "referenceValue": "Blood. 2007;109(2):405-411."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 269,
      "name": "<b>Alemtuzumab</b>",
      "schedule": "<b>Alemtuzumab</b> 30 mg per day IV, 3 times per week, upto a maximum of 23 weeks",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Alemtuzumab:<br>Unknown</li></ul><b>Renal Impairment</b><ul><li>Alemtuzumab:<br>Unknown</li></ul>",
      "references": [
        {
          "id": 594,
          "referenceValue": "Campath [package insert]."
        },
        {
          "id": 595,
          "referenceValue": "Wayne, NJ: Bayer HealthCare Pharmaceuticals: 2009."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 270,
      "name": "<b>Bendamustine</b>",
      "schedule": "<b>Bendamustine</b> 100 mg/m<sup>2</sup> IV over 30 min, days 1, 2<br> Repeat every 28 days",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Bendamustine:<br>If SGOT or SGPT 2.5-10 upper normal limit and bilirubin 1.5-3 upper normal limit, or bilirubin > 3 upper normal limit, do not use </li></ul><b>Renal Impairment</b><ul><li>Bendamustine:<br>If CrCl < 40 mL/min, do not use </li></ul>",
      "references": [
        {
          "id": 596,
          "referenceValue": "Knauf WU, Lissichov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously treated patients with chronic lyphocytic leukemia."
        },
        {
          "id": 597,
          "referenceValue": "J Clin Oncol. 2009;27(26):4378-4348."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 271,
      "name": "<b>Chlorambucil</b>",
      "schedule": "<b>Chlorambucil</b> 0.4 mg/kg PO <br> Repeat therapy every 14 days, increase upto  0.8 mg/kg  if  tolerated",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Chlorambucil:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Chlorambucil:<br>No dose reduction</li></ul>",
      "references": [
        {
          "id": 598,
          "referenceValue": "Eichhorst BF, Busch R, Stilgenbauer S, et al. First line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia."
        },
        {
          "id": 599,
          "referenceValue": "Blood. 2009;114:3382-3391."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 272,
      "name": "<b>Fludarabine</b>",
      "schedule": "<b>Fludarabine</b> 25 mg/m<sup>2</sup>/d IV over 30 minutes , days 1-5<br> Repeat every 28 days",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Fludarabine:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Fludarabine:<br>If CrCl 30-70 mL/min, reduce dose by 20%      <br>                                                                  If CrCl < 30 mL/min, do not use </li></ul>",
      "references": [
        {
          "id": 600,
          "referenceValue": "Eichhorst BF, Busch R, Stilgenbauer S, et al. First line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia."
        },
        {
          "id": 601,
          "referenceValue": "Blood. 2009;114:3382-3391."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 273,
      "name": "<b>Ofatumumab</b>",
      "schedule": "<b>Previously untreated CLL:</b><br>300 mg IV on Day 1 followed by 1,000 mg IV on Day 8 (Cycle 1)<br>1,000 mg IV on Day 1 subsequent 28-day cycles for a minimum of 3 cycles until best response or maximum of 12 cycles.<br><b>Refractory CLL:</b><br><b>Ofatumumab</b> 300 mg IV, initial dose,<br> <b>FOLLOWED 1 week later BY</b><br> <b>Ofatumumab</b> 2,000 mg IV, weekly dose for 7 weeks<br> Repeat every 28 days for 4 doses",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>",
      "references": [
        {
          "id": 604,
          "referenceValue": "Arzerra [package insert]. <br> Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single agent CD20 immunotherapy in fluda-rabine-refractory chronic lymphocytic leukemia."
        },
        {
          "id": 605,
          "referenceValue": "J Clin Oncol. 2010;28:1749-1755."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 274,
      "name": "<b>Dasatinib</b>",
      "schedule": "<b>Dasatinib</b> 100 mg PO, daily (chronic phase)<br> <b>OR</b><br> <b>Dasatinib</b> 140 mg PO, daily (accelerated or blast phase)",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Dasatinib:<br>Unknown. Metabolism mainly hepatic </li></ul><b>Renal Impairment</b><ul><li>Dasatinib:<br>Unknown. < 4% excreted by kidney </li></ul>",
      "references": [
        {
          "id": 606,
          "referenceValue": "Kantarijan H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid deukemia."
        },
        {
          "id": 607,
          "referenceValue": "N Engl J Med. 2010;362(24):2260-2270."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 275,
      "name": "<b>Imatinib</b>",
      "schedule": "<b>Imatinib mesylate</b> 400 mg PO daily <b>OR</b> 600 mg PO daily(accelarated phase / blast crisis) ",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Imatinib:<br>If bilirubin < 3 upper normal limit, no dose reduction <br>                            If bilirubin > 3 upper normal limit, use with caution </li></ul><b>Renal Impairment</b><ul><li>Imatinib:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 608,
          "referenceValue": "Druker BJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia."
        },
        {
          "id": 609,
          "referenceValue": "N Engl J Med. 2001 Apr 5;344(14):1031-7."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 276,
      "name": "<b>Nilotinib</b>",
      "schedule": "<b>Nilotinib</b> 300 mg PO bid  (newly diagnosed)<br> <b>OR</b><br> <b>Nilotinib</b> 400 mg PO bid (resistant or intolerant chronic or accelerated phase)",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Nilotinib:<br>Unknown </li></ul><b>Renal Impairment</b><ul><li>Nilotinib:<br>Not tested. Not renally excreted </li></ul>",
      "references": [
        {
          "id": 610,
          "referenceValue": "Kantarjian HM, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial."
        },
        {
          "id": 611,
          "referenceValue": "Lancet Oncol. 2011 Sep;12(9):841-51. doi: 10.1016/S1470-2045(11)70201-7. Epub 2011 Aug 17"
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 277,
      "name": "<b>Cladribine</b>",
      "schedule": "<b>Cladribine:</b>0.09 mg/kg/day IV continuous infusion on days 1 to 7 <br>Administer one cycle",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cladribine:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul></ul>",
      "references": [
        {
          "id": 612,
          "referenceValue": "Saven A, et al."
        },
        {
          "id": 613,
          "referenceValue": "Blood 1992;79:1111-1120."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 278,
      "name": "<b>Pentostatin</b>",
      "schedule": "<b>Pentostatin:</b> 4 mg/m<sup>2</sup> IV on day 1 <br>Repeat cycle every 14 days for 6 cycles ",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Pentostatin:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul></ul>",
      "references": [
        {
          "id": 614,
          "referenceValue": "Cassileth PA, et al."
        },
        {
          "id": 615,
          "referenceValue": "J Clin Oncol. 1991;9:243-246."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 279,
      "name": "<b>Interferon alfa-2a</b>",
      "schedule": "<b>Interferon alfa-2a:</b> 3 million IU SC or IM, 3 times per week<br>Continue treatment for up to 1 to 1.5 years.",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>",
      "references": [
        {
          "id": 616,
          "referenceValue": "Ratain MJ, et al."
        },
        {
          "id": 617,
          "referenceValue": "Blood 1985;65:644-648."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 280,
      "name": "<b>Bortezomib/Doxil</b>",
      "schedule": "<b>Bortezomib</b> 1.3 mg/m<sup>2</sup> IV, bolus days 1, 4, 8, 11<br> <b>Pegylated liposomal doxorubicin</b> 30 mg/m<sup>2</sup> IV over 1 hour, day 4<br> Repeat every 21 days",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul><li>Bortezomib:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 618,
          "referenceValue": "Doxil [package insert]."
        },
        {
          "id": 619,
          "referenceValue": "Raritan, NJ: Centocor Ortho Biotech Products, LP; 2010."
        },
        {
          "id": 620,
          "referenceValue": "<br> Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression."
        },
        {
          "id": 621,
          "referenceValue": "J clin Oncol. 2007;25(25):3892."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 281,
      "name": "<b>Bortezomib/Doxorubicin/Dexamethasone</b>",
      "schedule": "<b>Bortezomib</b> 1.3 mg/m<sup>2</sup> IV, bolus days 1, 4, 8, 11<br> <b>Doxorubicin</b> 9 mg/m<sup>2</sup> IV, bolus days 1-4<br> <b>Dexamethasone</b> 40 mg PO days 1-4, 9-12, 17-20",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Bortezomib:<br>No dose reduction </li><li>Doxorubicin:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 622,
          "referenceValue": "Sonneveld P, van der Holt B, Schmidt-Wolf IGH, et al. First analysis of HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib, adriamycin, dexamethasone (PAD) vs VAD as induction treatment prior to high dose melphalan (HDM) in patients with newly diagnosed multiple myeloma (MM)."
        },
        {
          "id": 623,
          "referenceValue": "Blood. 2008;112(11):Abstract 653."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 282,
      "name": "<b>Bortezomib/Thalidomide/Dexamethasone (VTD)</b>",
      "schedule": "<b>Bortezomib</b> 1.3 mg/m<sup>2</sup> IV bolus, days 1, 4, 8, and 11<br> <b>Thalidomide</b> 100 mg PO daily for 14 days and 200 mg daily thereafter<br> <b>Dexamethasone</b> 40 mg PO daily on days 1, 2, 4, 5, 8, 9, 11, and 12; total of 320 mg per cycle",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul><li>Bortezomib:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 624,
          "referenceValue": "Cazo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study."
        },
        {
          "id": 625,
          "referenceValue": "Lancet. 2010;18;376(9758):2075-2085."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 283,
      "name": "<b>CyBorD</b>",
      "schedule": "<b>Cyclophosphamide</b> 300 mg/m<sup>2</sup> PO days 1, 8, 15, 22<br> <b>Bortezomib</b> 1.3 mg/m<sup>2</sup> IV on days 1, 4, 8, and 11<br> <b>Dexamethasone</b> 40 mg PO days 1-4, 9-12, and 17-20<br> Repeat every 28 days",
      "emetogenicPotential": "Moderate-High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Bortezomib:<br>No dose reduction </li><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li></ul>",
      "references": [
        {
          "id": 626,
          "referenceValue": "Khan ML, Reeder CB, Kumar SK, et al. A comparison af lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethansone in newly diagnosed multiple myeloma."
        },
        {
          "id": 627,
          "referenceValue": "Br J Haematol. 2011 [Epub ahead of print]."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 342,
      "name": "<b>Osimertinib</b>",
      "schedule": "<b>Osimertinib</b> 80 mg  PO daily<br> ",
      "emetogenicPotential": "Minimal",
      "dosageModifications": "",
      "references": [
        {
          "id": 628,
          "referenceValue": "Mitsudomi T, Tsai C, Shepherd F, et al. AZD9291 in pre-treated T790M positive advanced non-small cell lung carcinoma:AURA 2 phase II study. Presented at 16th world conference on lung cancer:September 6-9; Denverm CO. Abstract 1406."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 284,
      "name": "<b>DT-PACE</b>",
      "schedule": "<b>Dexamethasone</b> 40 mg PO, days 1-4<br> <b> Thalidomide</b> 400 mg/d PO<br> <b>Cisplatin</b> 10 mg/m<sup>2</sup>/d CIVI, days 1-4<br> <b>Doxorubicin</b> 10 mg/m<sup>2</sup>/d CIVI, days 1-4<br> <b>Etoposide</b> 40 mg/m<sup>2</sup>/d CIVI, days 1-4",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Doxorubicin:<br>No dose reduction </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>",
      "references": [
        {
          "id": 629,
          "referenceValue": "Lee CK, Barlogie B, Munshi N, et al. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma."
        },
        {
          "id": 630,
          "referenceValue": "J Clin Oncol. 2003;21(14):2732-2739."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 285,
      "name": "<b>Lenalidomide/Dexamethasone</b>",
      "schedule": "<b>Lenalidomide</b> 25 mg/d PO, days 1-21<br> <b>Dexamethasone</b> 40 mg/d PO, days 1-4, 9-12, 17-20<br> Repeat every 28 days for 4 cycles",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Lenalidomide:<br>Unknown </li></ul><b>Renal Impairment</b><ul><li>Lenalidomide:<br>Substantially excreted by kidney. Trials excluded patients with renal insufficiency </li></ul>",
      "references": [
        {
          "id": 631,
          "referenceValue": "Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma."
        },
        {
          "id": 632,
          "referenceValue": "N Engl J Med. 2007;357(21):2123-2132."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 286,
      "name": "<b>Melphalan/Prednisone (MP)</b>",
      "schedule": "<b>Melphalan</b> 8 - 10 mg per m<sup>2</sup>  on days 1 - 4<br> <b>Prednisone</b> 60 mg/m<sup>2</sup> days 1 - 4<br> Repeat cycle every 42 days",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Melphalan:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Melphalan:<br>PO: if CrCl < 30 mL/min, consider dose reduction  <br> IV: if BUN > 30 mg/dL, reduce dose by 50%</li></ul>",
      "references": [
        {
          "id": 633,
          "referenceValue": "Southwest Oncology Group Study. Arch Intern Med 1975;135:147-152"
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 287,
      "name": "<b>Melphalan/Prednisone/Talidomide (MPT)</b>",
      "schedule": "<b>Melphalan</b> 0.25 mg/kg PO, daily for 5 days<br> <b>Prednisone</b> 1 mg/kg PO, daily for 5 days<br> Repeat every 28 days for 8 cycles<br> <b>Thalidomide 50 - 100 mg PO, daily ",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Melphalan:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Melphalan:<br>PO: if CrCl < 30 mL/min, consider dose reduction  <br> IV: if BUN > 30 mg/dL, reduce dose by 50%</li></ul>",
      "references": [
        {
          "id": 634,
          "referenceValue": "Palumbo A, et al. Lancet 2006;28:367-835."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 288,
      "name": "<b>RVD</b>",
      "schedule": "<b>Lenalidomide</b> 25 mg/d PO, days 1-14<br> <b> Bortezomib</b> 1.3 mg/m<sup>2</sup> IV, bolus days 1, 4, 8, 11<br> <b>Dexamethasone</b> 20 mg/d PO days 1, 2, 4, 5, 8, 9, 11, 12 (cycles 1-4)<br> Repeat every 21 days for 8 cycles",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Lenalidomide:<br>Unknown </li></ul><b>Renal Impairment</b><ul><li>Bortezomib:<br>No dose reduction </li><li>Lenalidomide:<br>Substantially excreted by kidney. Trials excluded patients with renal insufficiency </li></ul>",
      "references": [
        {
          "id": 635,
          "referenceValue": "Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma."
        },
        {
          "id": 636,
          "referenceValue": "Blood. 2010;116(5):679-686."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 289,
      "name": "<b>VAD</b>",
      "schedule": "<b>Vincristine</b> 0.4 mg/d CIVI, days 1-4<br> <b>Doxorubicin</b> 9 mg/m<sup>2</sup>/d CIVI, days 1-4<br> <b>Dexamethasone</b> 40 mg/d PO, days 1-4, 9-12, 17-20<br> Repeat every 25 days",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Doxorubicin:<br>No dose reduction </li><li>Vincristine:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 637,
          "referenceValue": "Segeren CM, Sonneveld P, Holt V, et al. Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma."
        },
        {
          "id": 638,
          "referenceValue": "Br J Haematol. 1999;105(1):127-130."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 290,
      "name": "<b>VMP</b>",
      "schedule": "<b>Bortezomib</b> 1.3 mg/m<sup>2</sup> IV, bolus days 1, 4, 8, 11, 22, 25, 29, 32 cycles 1-4<br> <b>FOLLOWED BY</b><br> <b>Bortezomib</b> 1.3 mg/m<sup>2</sup> IV, bolus days 1, 8, 22, 29 cycles 5-9<br> <b>Melphalan</b> 9 mg/m<sup>2</sup> PO, days 1-4<br> <b>Prednisone</b> 60 mg/m<sup>2</sup> PO, days 1-4<br> Repeat every 6 weeks for 9 cycles",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Melphalan:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Bortezomib:<br>No dose reduction </li><li>Melphalan:<br>PO: if CrCl < 30 mL/min, consider dose reduction  <br> IV: if BUN > 30 mg/dL, reduce dose by 50%</li></ul>",
      "references": [
        {
          "id": 639,
          "referenceValue": "San Miguel JF, Schalg R, Khuageva NK, et al. MMY-3002 a phase 3 study comparing bortezomib-melphalan-prednisone (VMP) with melphalan-prednisone (MP) in newly diagnosed multiple myeloma."
        },
        {
          "id": 640,
          "referenceValue": "Blood. 2007;110(11 pt 1): Abstract 78."
        },
        {
          "id": 641,
          "referenceValue": "<br> San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma."
        },
        {
          "id": 642,
          "referenceValue": "N Engl J Med. 2008;359(9):906-917."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 291,
      "name": "<b>Bortezomib</b>",
      "schedule": "<b>Bortezomib</b> 1.3 mg/m<sup>2</sup>/d IV bolus, days 1, 4, 8, 11<br> Repeat every 21 days ",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul><li>Bortezomib:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 643,
          "referenceValue": "Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma."
        },
        {
          "id": 644,
          "referenceValue": "N Engl J Med. 2003;348(26):2609-2617."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 292,
      "name": "<b>Dexamethasone</b>",
      "schedule": "<b>Dexamethasone</b> 20 mg/m<sup>2</sup>/d PO, days 1-4, 9-12, 17-20<br> Repeat after 14-day rest period",
      "emetogenicPotential": "N/A",
      "dosageModifications": "<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>",
      "references": [
        {
          "id": 645,
          "referenceValue": "Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B. Primary dexamethasone treatment of multiple myeloma."
        },
        {
          "id": 646,
          "referenceValue": "Blood. 1992;80(4):887-890."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 293,
      "name": "<b>Thalidomide</b>",
      "schedule": "<b>Thalidomide</b> 200 mg/d PO at bedtime (increased dose every 2 weeks for 6 weeks up to a dose of 800 mg/d)",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>",
      "references": [
        {
          "id": 647,
          "referenceValue": "Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma."
        },
        {
          "id": 648,
          "referenceValue": "N Engl J Med. 1999;341(21):1565-1571."
        },
        {
          "id": 649,
          "referenceValue": "Erratum in N Engl J Med. 2000;342(5):364."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 294,
      "name": "<b>Carfilzomib</b>",
      "schedule": "<b>Carfilzomib</b> 20 mg/m<sup>2</sup>, Days 1,2,8,9,15, and 16, followed by a 12 day rest period<br> Repeat cycle every 28 days",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Carfilzomib:<br>The safety, efficacy and pharmacokinetics of Carfilzomib have not been evaluated in patients with baseline hepatic impairment.<br> Patients with the following laboratory values were excluded from the KYPROLIS clinical trials: ALT/AST = 3 × upper limit of normal (ULN) and bilirubin = 2 × ULN</li></ul><b>Renal Impairment</b><ul><li>Carfilzomib:<br>No dose adjustment recommended</li></ul>",
      "references": [
        {
          "id": 650,
          "referenceValue": "Siegel DS, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma."
        },
        {
          "id": 651,
          "referenceValue": "Blood. 2012 Oct 4;120(14):2817-25. doi: 10.1182/blood-2012-05-425934. Epub 2012 Jul 25"
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 295,
      "name": "<b>Pomalidamide</b>",
      "schedule": "<b>Pomalidamide</b>4 mg PO daily, from Day 1-21 <br>Repeat cycle every 28 days",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Pomalidamide:<br>Avoid POMALYST in patients with serum bilirubin greater than 2.0 mg/dL and AST/ALTgreater than 3.0 x ULN.</li></ul><b>Renal Impairment</b><ul><li>Pomalidamide:<br>Avoid Pomalidamide in patients with a serum creatinine greater than 3.0 mg/dL.</li></ul>",
      "references": [
        {
          "id": 652,
          "referenceValue": "Leleu X, et al. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02."
        },
        {
          "id": 653,
          "referenceValue": "Blood. 2013 Mar 14;121(11):1968-75. doi: 10.1182/blood-2012-09-452375. Epub 2013 Jan 14"
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 296,
      "name": "<b>CDDP/VP-16</b>",
      "schedule": "<b>Cisplatin</b> 90 mg/m<sup>2</sup> IV, day 1<br> <b>Etoposide</b> 150 mg/m<sup>2</sup>/d IV, days 3, 4<br> Repeat every 21 days for 4 courses",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>",
      "references": [
        {
          "id": 654,
          "referenceValue": "Kovnar EH, Kellie SJ, Horowitz ME, et al. Preirradiation cisplatin and etoposide in the treatment of high-risk medulloblastoma and other malignant embryonal tumors of the central nervous system: a phase II study."
        },
        {
          "id": 655,
          "referenceValue": "J Clin Oncol. 1990;8(2):330-336."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 297,
      "name": "<b>COPE or \"Baby Brain I\"</b>",
      "schedule": "<u>CYCLE A</u><br> <b>Vincristine</b> 0.065 mg/kg/d (maximum, 1.5 mg) IV, days 1, 8<br> <b>Cyclophosphamide</b> 65 mg/kg/d IV over 30 minutes, day 1<br> <u>CYCLE B</u><br> <b>Cisplatin</b> 4 mg/kg/d IV over 6 hours, day 1<br> <b>Etoposide</b> 6.5 mg/kg/d IV over 1 hour, days 3, 4<br> Regimens given in alternating 28-day cycles in the sequence AABAAB",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li><li>Vincristine:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 656,
          "referenceValue": "Duffner id, Horowitz ME, Krischer JP, et al. Postoperative chemotherapy and delayed radiation in children less than 3 years of age with malignant brain tumors."
        },
        {
          "id": 657,
          "referenceValue": "N Engl J Med. 1993;328(24):1725-1731."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 298,
      "name": "Vincristine/Cyclophosphamide/Cisplatin",
      "schedule": "<b>Vincristine</b> 1.5 mg/m<sup>2</sup> IV, day 1<br> <b>Cisplatin</b> 75 mg/m<sup>2</sup> IV, day 1<br> <b>Cyclophosphamide</b> 1,000 mg/m<sup>2</sup> IV, day 1<br> Repeat every 6 weeks for 8 cycles",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Vincristine:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 658,
          "referenceValue": "Douglas JG, Barker JL, Ellenbogen RG, et al. Concurrent chemotherapy and reduced-dose cranial spinal irradiation followed by conformal posterior fossa tumor bed boost for average-risk medulloblastoma: efficacy and patterns of failure."
        },
        {
          "id": 659,
          "referenceValue": "Int J Radiat Oncol Biol Phys. 2004;58(4):1161-1164."
        },
        {
          "id": 660,
          "referenceValue": "<br> National Cancer Institute. Phase III randomized study of adjuvant lomustine/cisplatin/vincristine vs cyclophosphamide/cisplatin/vincristine following craniospinal radiotherapy in children with newly diagnosed, average-risk medulloblastoma."
        },
        {
          "id": 661,
          "referenceValue": "http://cancer.gov.clinicaltrials.CCG-A9961. Accessed January 27, 2012."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 328,
      "name": "<b>6-MP/ MTX</b>",
      "schedule": "<b>Mercaptopurine</b> 25 mg/m<sup>2</sup>/d PO, days 1-56<br> <b>Methotrexate</b> 5,000 mg/m<sup>2</sup> IV over 24 hours, days 8, 22, 36, 50<br> <b>Methotrexate</b> 12 mg/d IT (adjust dose for children<3 years), days 8, 22, 36, 50",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>",
      "references": [
        {
          "id": 662,
          "referenceValue": "Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group."
        },
        {
          "id": 663,
          "referenceValue": "Blood. 2000;95(11):3310-3322."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 343,
      "name": "<b>Pembrolizumab</b>",
      "schedule": "<b>Pembrolizumab</b> 2 mg /kg IV<br> Every 21 days",
      "emetogenicPotential": "Minimal",
      "dosageModifications": "",
      "references": [
        {
          "id": 664,
          "referenceValue": "Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small cell lung cancer."
        },
        {
          "id": 665,
          "referenceValue": "N Engl J Med 2015; 372:2018-2028."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 344,
      "name": "<b>ibrutinib</b>",
      "schedule": "<b>Ibrutinib</b> 560 mg PO daily (for Mantle Cell Lymphoma)<br>420 mg PO daily for Waldenstrom's <br> ",
      "emetogenicPotential": "Minimal",
      "dosageModifications": "",
      "references": [
        {
          "id": 666,
          "referenceValue": "Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma."
        },
        {
          "id": 667,
          "referenceValue": "N Engl J Med. 2013 Aug 8;369(6):507-16."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 345,
      "name": "<b>Afatinib</b>",
      "schedule": "<b>Afatinib</b> 40 mg PO daily",
      "emetogenicPotential": "Minimal",
      "dosageModifications": "",
      "references": [
        {
          "id": 668,
          "referenceValue": "Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations."
        },
        {
          "id": 669,
          "referenceValue": "J Clin Oncol. 2013 Sep 20;31(27):3327-34."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 299,
      "name": "<b>Carbo/VP-16/Vincristine</b>",
      "schedule": "<u>CYCLES 1 AND 3 (3-WEEK CYCLES)</u><br> <b>Vincristine</b> 1.5 mg/m<sup>2</sup> IV, days 1, 7, 14<br> <b>Etoposide</b> 100 mg/m<sup>2</sup> IV, days 1-3<br> <b>Carboplatin</b> 500 mg/m<sup>2</sup> IV, days 1, 2<br><br> <u>CYCLES 2 AND 4 (3-WEEK CYCLES)</u><br> <b>Vincristine<sup>d</sup></b> 1.5 mg/m<sup>2</sup> IV, days 1, 7, 14<br> <b>Etoposide</b> 100 mg/m<sup>2</sup> IV, days 1-3<br> <b>Cyclophosphamide</b> 1,500 mg/m<sup>2</sup> IV, day 1<br> <b>Mesna</b> 750 mg/m<sup>2</sup> IV, 15 minutes before and 4 and 8 hours after cyclophosphamide",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Mesna:<br>No dose reduction</li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li><li>Vincristine:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 670,
          "referenceValue": "Taylor RE, Bailey CC, Robinson K, et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: the International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 study."
        },
        {
          "id": 671,
          "referenceValue": "J Clin Oncol. 2003;21(8):1581-1591."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 300,
      "name": "<b>POC</b>",
      "schedule": "<b>Prednisone</b> 40 mg/m<sup>2</sup>/d PO, days 1-14<br> <b>Lomustine</b> 100 mg/m<sup>2</sup> PO, day 1<br> <b>Vincristine</b> 1.5 mg/m<sup>2</sup>/d IV, days 1, 8, 15",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Lomustine:<br>No dose reduction</li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Lomustine:<br>If CrCl < 60 mL/min, do not use</li><li>Vincristine:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 672,
          "referenceValue": "Finlay JL, Bayett JM, Yates AJ, et al. Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen."
        },
        {
          "id": 673,
          "referenceValue": "J Clin Oncol. 1995;13(1):112-123."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 301,
      "name": "<b>Carboplatin</b>",
      "schedule": "<b>Carboplatin</b> 560 mg/m<sup>2</sup> IV over 1 hour<br> Repeat every 28 days",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li></ul>",
      "references": [
        {
          "id": 674,
          "referenceValue": "Friedman HS, Krischer JP, Burger P, et al. Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: a Pediatric Oncology Group randomized phase II study."
        },
        {
          "id": 675,
          "referenceValue": "J Clin Oncol. 2000;18(22):3819-3828."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 302,
      "name": "<b>A<sub>1</sub></b>",
      "schedule": "<b>Cyclophosphamide</b> 1,200 mg/m<sup>2</sup> IV, day 1<br> <b>Doxorubicin</b> 40 mg/m<sup>2</sup> IV, day 3<br> <b>Etoposide</b> 100 mg/m<sup>2</sup>/d IV, days 1-5<br> <b>Cisplatin</b> 90 mg/m<sup>2</sup> IV, day 5",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>",
      "references": [
        {
          "id": 676,
          "referenceValue": "Kaneko M, Tsuchida Y, Mugishima H, et al. Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification."
        },
        {
          "id": 677,
          "referenceValue": "J Pediatr Hematol Oncol. 2002;24(8):613-621."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 303,
      "name": "<b>A<sub>3</sub></b>",
      "schedule": "<b>Cyclophosphamide</b> 1,200 mg/m<sup>2</sup>/d IV, days 1, 2<br> <b>Doxorubicin</b> 40 mg/m<sup>2</sup> IV, day 3<br> <b>Etoposide</b> 100 mg/m<sup>2</sup>/d IV, days 1-5<br> <b>Cisplatin</b> 25 mg/m<sup>2</sup>/d CIVI, days 1-5",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>",
      "references": [
        {
          "id": 678,
          "referenceValue": "Kaneko M, Tsuchida Y, Mugishima H, et al. Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification."
        },
        {
          "id": 679,
          "referenceValue": "J Pediatr Hematol Oncol. 2002;24(8):613-621."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 304,
      "name": "<b>CAV + P/VP</b>",
      "schedule": "<u>CAV (COURSES 1, 2, 4, 6)</u><br> <b>Cyclophosphamide</b> 70 mg/kg/d IV over 6 hours, days 1, 2<br> <b>Doxorubicin</b> 25 mg/m<sup>2</sup>/d CIVI for 72 hours<br><b>Vincristine</b>0.033mg/kg/d CIVI for 72 hours<br> <b>Vincristine</b> 1.5 mg/m<sup>2</sup> IV bolus, day 9<br> <br><u>P/VP (COURSES 3, 5, 7)</u><br> <b>Etoposide</b> 200 mg/m<sup>2</sup>/d IV over 2 hours, days 1-3<br> <b>Cisplatin</b> 50 mg/m<sup>2</sup>/d IV over 1 hour, days 1-4",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li><li>Vincristine:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 680,
          "referenceValue": "Kushner BH, LaQuaglia MP, Bonilla MA, et al. Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age."
        },
        {
          "id": 681,
          "referenceValue": "J Clin Oncol. 1994;12(12):2607-2613."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 305,
      "name": "<b>High-risk neuroblastoma</b>",
      "schedule": "<b>Cisplatin</b> 60 mg/m<sup>2</sup> IV over 6 hours, day 0<br> <b>Doxorubicin</b> 30 mg/m<sup>2</sup> IV, day 2<br> <b>Etoposide</b> 100 mg/m<sup>2</sup>/d IV, days 2, 5<br> <b>Cyclophosphamide</b> 1,000 mg/m<sup>2</sup>/d IV, days 3, 4<br> Repeat every 28 days for 5 cycles",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>",
      "references": [
        {
          "id": 682,
          "referenceValue": "Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cisretinoic acid."
        },
        {
          "id": 683,
          "referenceValue": "N Engl J Med. 1999;341(16):1165-1173."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 306,
      "name": "<b>Chemoreduction</b>",
      "schedule": "<b>Vincristine</b> 0.05 mg/kg (for age <12 months)<br> <b>OR</b> 1.5-2 mg/m<sup>2</sup> (for age >12 months)<br> <b>Carboplatin</b> 20 mg/kg (for age <12 months)<br> <b>OR 550-600 mg/m<sup>2</sup> (for age >12 months)<br> <b>Etoposide phosphate</b> 5 mg/kg (for age <12 months) or 150 mg/m2 (for age >12 months)",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li><li>Vincristine:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 684,
          "referenceValue": "Sussman DA, Escalona-Benz E, Benz MS, et al. Comparison of retinoblastoma reduction for chemotherapy vs external beam radiotherapy."
        },
        {
          "id": 685,
          "referenceValue": "Arch Ophthalmol. 2003;121(7):979-984."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 307,
      "name": "<b>CD</b>",
      "schedule": "<b>Cisplatin</b> 80 mg/m<sup>2</sup> CI over 24 hours (>1 year of age) <b>OR</b> 3 mg/kg (<1 year of age) IV over 6 hours with post-hydration fluid<br> <br>Doxorubicin</b> 30 mg/m<sup>2</sup>/d CIVI over 48 hours, days 2, 3<br> Administer 4 cycles before surgery, 2 cycles after surgery",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Doxorubicin:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 686,
          "referenceValue": "Pritchard J, Brown J, Shafford E, et al. Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: a successful approach- results of the first prospective study of the International Society of Pediatric Oncology."
        },
        {
          "id": 687,
          "referenceValue": "J Clin Oncol. 2000;18(22):3819-3828."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 308,
      "name": "<b>VAD</b>",
      "schedule": "<b>Vincristine</b> 1.5 mg/m<sup>2</sup> IV weekly for 10 weeks, then every 3 weeks for 15 weeks<br> <b>Dactinomycin</b> 1.5 mg/m<sup>2</sup> IV every 6 weeks for 26 weeks<br> <b>ALTERNATING WITH</b><br> <b>Doxorubicin</b> 40 mg/m<sup>2</sup> IV every 6 weeks for 1 year (stage III)<br> <b>OR</b><br> <b>Vincristine</b> 1.5 mg/m<sup>2</sup> IV, day 1<br> <b>Dactinomycin</b> 15 mcg/kg/d IV, days 1-5 or 60 mcg/kg IV, day 1<br> Repeat every 6 weeks; if stage III or IV, add:<br> <b>Doxorubicin</b> 20 mg/m<sup>2</sup> IV, day 1, and RT",
      "emetogenicPotential": "Vincristine plus dactinomycin, high; vincristine plus doxorubicin, or doxorubicin-containing, moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Dactinomycin:<br>If bilirubin > 3 mg/dL, reduce dose by 50%</li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Doxorubicin:<br>No dose reduction </li><li>Vincristine:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 688,
          "referenceValue": "Pritchard J, Imeson J , Barnes J, et al. Results of the United Kingdom Children's Cancer Study Group first Wilms' tumor study."
        },
        {
          "id": 689,
          "referenceValue": "J Clin Oncol. 1995; 13(1):124-133."
        },
        {
          "id": 690,
          "referenceValue": "<br>  de Camargo B, Franco EL. A randomized clinical trial of single-dose versus fractionated-dose dactinomycin in the treatment of Wilms' tumor."
        },
        {
          "id": 691,
          "referenceValue": "Cancer. 1994;73(12):3081-3086."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 309,
      "name": "<b>IFoVP</b>",
      "schedule": "<b>Ifosfamide</b> 1,800 mg/m<sup>2</sup>/d IV, days 1-5<br> <b>Etoposide</b> 100 mg/m<sup>2</sup>/d IV over 1 hour, days 1-5<br> <b>Mesna</b> 2,880 mg/m<sup>2</sup>/d IV, days 1-5<br> Repeat every 21 days",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Ifosfamide:<br>No dose reduction</li><li>Mesna:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>",
      "references": [
        {
          "id": 692,
          "referenceValue": "Miser JS, Kinsella TJ, Triche TJ, et al. Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults."
        },
        {
          "id": 693,
          "referenceValue": "J Clin Oncol. 1987;5(8):1191-1198."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 329,
      "name": "<b>MTX/6-MP</b>",
      "schedule": "<b>Methotrexate</b> 20 mg/m<sup>2</sup> IM weekly, weeks 25-130<br> <b>Mercaptopurine</b> 50 mg/m<sup>2</sup>/d PO, weeks 25-130",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>",
      "references": [
        {
          "id": 694,
          "referenceValue": "Camitta B, Leventhal B, Lauer S, et al. Intermediate-dose intravenous methotrexate and mercaptopurine therapy for non-T, non-B acute lymphocytic leukemia of chldhood: a Pediatric Oncology Group study."
        },
        {
          "id": 695,
          "referenceValue": "J Clin Oncol. 1989;7(10):1539-1544."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 346,
      "name": "<b>Gefitinib</b>",
      "schedule": "<b>Gefitinib</b> 250 mg PO daily",
      "emetogenicPotential": "Minimal",
      "dosageModifications": "",
      "references": [
        {
          "id": 696,
          "referenceValue": "Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small cell lung cancer with mutated EGFR."
        },
        {
          "id": 697,
          "referenceValue": "N Engl J Med. 2010 Jun 24;362(25):2380-8."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 310,
      "name": "<b>MTX-CDDP/Adr</b>",
      "schedule": "<b>Methotrexate</b> 12,000 mg/m<sup>2</sup> IV weekly for 2 weeks; escalate dose by 1,000 mg/m<sup>2</sup> in subsequent courses until peak level of 10-8 M is reached (reduce dose to 8,000 mg/m<sup>2</sup> IV for patients >12 years)<br> <b>Leucovorin calcium</b> 20 mg/m<sup>2</sup> IV every 3 hours for 8 doses beginning 16 hours after completion of methotrexate, <b>THEN</b> every 6 hours PO for 8 doses<br> <b>ALTERNATING WITH</b><br> <b>Cisplatin</b> 75 mg/m<sup>2</sup> IV, day 15 of cycles 1-7,<br> <b>THEN</b> 120 mg/m<sup>2</sup> for cycles 8-10<br> <b>Doxorubicin</b> 25 mg/m<sup>2</sup>/d IV, days 15-17 of cycles 1-7",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cisplatin:<br>No dose reduction</li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Leucovorin:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Cisplatin:<br>If CrCl 30-60 mL/min, reduce dose by 50%  <br>                                                                    If CrCl < 30 mL/min, do not use</li><li>Doxorubicin:<br>No dose reduction </li><li>Leucovorin:<br>No dose reduction</li></ul>",
      "references": [
        {
          "id": 698,
          "referenceValue": "Weiner MA, Harris MB, Lewis M, et al. Neoadjuvant high-dose methotrexate, cisplatin, and doxorubicin for the management of patients with nonmetastatic osteosarcoma."
        },
        {
          "id": 699,
          "referenceValue": "Cancer Treat Rep. 1986;70(12):1431-1432."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 311,
      "name": "<b>VP/high-dose Ifos</b>",
      "schedule": "<b>Etoposide</b> 100 mg/m<sup>2</sup> days 1-5<br> <b>Ifosfamide</b> 3,500 mg/m<sup>2</sup> days 1-5<br> <b>Mesna</b> 700 mg/m<sup>2</sup> over 4 hours, <b>THEN</b> mesna 700 mg/m<sup>2</sup> at hour 4, 7, 10, 13, days 1-5<br> <b>GCF</b> 5 mcg/kg/d begin day 6<br> Repeat in 3 weeks for a total of 2 courses",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Ifosfamide:<br>No dose reduction</li><li>Mesna:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>",
      "references": [
        {
          "id": 700,
          "referenceValue": "Goorin AM, Harris MB, Bernstein M, et al. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial."
        },
        {
          "id": 701,
          "referenceValue": "J Clin Oncol. 2002;20(2):426-433."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 312,
      "name": "<b>ICE</b>",
      "schedule": "<b>Ifosfamide</b> 1,800 mg/m<sup>2</sup>/d IV over 1 hour, days 0-4<br> <b>Carboplatin</b> 400 mg/m<sup>2</sup>/d IV over 1 hour, days 0, 1<br> <b>Etoposide 100 mg/m<sup>2</sup>/d IV over 1 hour, days 0-4",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Carboplatin:<br>No dose reduction</li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Ifosfamide:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Carboplatin:<br>Dosing based on AUC </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>",
      "references": [
        {
          "id": 702,
          "referenceValue": "Cairo MS. The use of ifosfamide, carboplatin, and etoposide in children with solid tumors."
        },
        {
          "id": 703,
          "referenceValue": "Semin Oncol. 1995;22(3 suppl 7):23-27."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 313,
      "name": "<b>VCR/Cyclophosphamide</b>",
      "schedule": "<b>Vincristine</b> 2 mg/m<sup>2</sup> IV, day 1<br> <b>Doxorubicin</b> 75 mg/m<sup>2</sup> IV bolus, day 1<br> <b>Cyclophosphamide</b> 1,200 mg/m<sup>2</sup> IV, day 1<br> Repeat every 21 days",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Vincristine:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 704,
          "referenceValue": "Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone."
        },
        {
          "id": 705,
          "referenceValue": "N Engl J Med. 2003;348(8):694-701."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 314,
      "name": "<b>P6</b>",
      "schedule": "<u>CYCLES 1, 2, 3 AND 6</u><br> <b>Cyclophosphamide</b> 2,100 mg/m<sup>2</sup>/d IV, days 1, 2<br> <b>Doxorubicin</b> 25 mg/m<sup>2</sup> CIVI, days 1-3<br> <b>Vincristine</b> 0.67 mg/m2 (maximum, 2 mg/cycle0 CIVI, days 1-3<br><br> <u>CYCLES 4, 5 AND 7</u><br> <b>Ifosfamide</b> 1,800 mg/m<sup>2</sup>/d IV, days 1-5<br> <b>Etoposide</b> 100 mg/m<sup>2</sup>/d IV, days 1-5",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Ifosfamide:<br>No dose reduction</li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li><li>Vincristine:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 706,
          "referenceValue": "Kolb EA, Kushner BH, Gorlick R, et al. Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults."
        },
        {
          "id": 707,
          "referenceValue": "J Clin Oncol. 2003;21(18):3423-3430."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 330,
      "name": "<b>CA</b>",
      "schedule": "<b>Cytarabine</b> 3,000 mg/m<sup>2</sup> IV over 3 hours every 12 hours for 4 doses<br> <b>Asparaginase</b> 6,000 units/m<sup>2</sup> IM 3 hours after last dose of cytarabine<br> Repeat 28 days after initial cycle or after recovery of blood counts, whichever is later",
      "emetogenicPotential": "high",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cytarabine:<br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>                                           If bilirubin > 3 mg/dL, reduce dose by 50%</li></ul><b>Renal Impairment</b><ul></ul>",
      "references": [
        {
          "id": 708,
          "referenceValue": "Woods WG, Ruymann FB, Lampkin BC, et al. The role of timing of high-dose cytosine arabinoside intensification and of maintenance therapy in the treatment of children with acute nonlymphocytic leukemia."
        },
        {
          "id": 709,
          "referenceValue": "Cancer. 2006;66(6):1106-1113."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 315,
      "name": "<b>Topo/CTX</b>",
      "schedule": "<b>Cyclophosphamide</b> 250 mg/m<sup>2</sup>/d IV, days 1-5<br> <b>FOLLOWED BY</b><br> <b>Topotecan</b> 0.6-0.75 mg/m<sup>2</sup>/d IV as an escalating dose, days 1-5",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Topotecan:<br>No dose reduction </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Topotecan:<br>If CrCl > 40 mL/min, no dose reduction   <br>                                                                          If CrCl 20-39 mL/min, reduce to 0.75 mg/m2 </li></ul>",
      "references": [
        {
          "id": 710,
          "referenceValue": "Saylors RL, Stewart CF, Zamboni WC, et al. Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: a Pediatric Oncolgy Group study."
        },
        {
          "id": 711,
          "referenceValue": "J Clin Oncol. 1998;16(3):945-952."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 316,
      "name": "<b>VAC</b>",
      "schedule": "<b>Vincristine</b> 1.5 mg/m<sup>2</sup> IV weekly for 3 weeks<br> <b>Dactinomycin</b> 0.015 mg/kg/d (maximum, 0.5 mg/kg/d) IV for 5 days<br> <b>Cyclophosphamide</b> 2,200 mg/m<sup>2</sup> IV, day 1",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Dactinomycin:<br>If bilirubin > 3 mg/dL, reduce dose by 50%</li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Vincristine:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 712,
          "referenceValue": "Crist WM, Anderson JR, Meza JL, et al. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease."
        },
        {
          "id": 713,
          "referenceValue": "J Clin Oncol. 2001;19(12):3091-3102."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 317,
      "name": "<b>ABVD</b>",
      "schedule": "<b>Doxorubicin</b> 25 mg/m<sup>2</sup>/d IV, days 1, 15<br> <b>Bleomycin</b> 10 units/m<sup>2</sup>/d IV, days 1, 15<br> <b>Vinblastine</b> 6 mg/m<sup>2</sup>/d IV, days 1, 15<br> <b>Dacarbazine</b> 375 mg/m<sup>2</sup>/d IV, days 1, 15<br> Repeat every 14 days for 12 courses",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Bleomycin:<br>No dose reduction</li><li>Dacarbazine:<br>No dose reduction</li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Vinblastine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Bleomycin:<br>If CrCl 10-50 mL/min, reduce dose by 25% <br>                                                                     If CrCl < 10 mL/min, reduce dose by 50% </li><li>Dacarbazine:<br>If CrCl 10-50 mL/min, reduce dose by 25%    <br>                                                                  If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Vinblastine:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 714,
          "referenceValue": "Fryer CJ, Hutchinson RJ, Krailo M, et al. Efficacy and toxicity of 12 courses of ABVD therapy followed by low-dose regional radiation in advanced Hodgkin's disease in children: a report from the Children's Cancer Study Group."
        },
        {
          "id": 715,
          "referenceValue": "J Clin Oncol. 1990;8(12):1971-1980."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 318,
      "name": "<b>BEACOPP</b>",
      "schedule": "<b>Bleomycin</b> 10 units/m<sup>2</sup> IV, day 7<br> <b>Etoposide</b> 200 mg/m<sup>2</sup>/d IV, days 0-2<br> <b>Doxorubicin</b> 35 mg/m<sup>2</sup> IV, day 0<br> <b>Cyclophosphamide</b> 1,200 mg/m<sup>2</sup> IV, day 0<br> <b>Vincristine</b> 2 mg/m<sup>2</sup> IV, day 7<br> <b>Procarbazine</b> 100 mg/m<sup>2</sup>/d PO, days 0-6<br> <b>Prednisone</b> 40 mg/m<sup>2</sup>/d PO, days 0-13<br> Repeat every 21 days",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Bleomycin:<br>No dose reduction</li><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Bleomycin:<br>If CrCl 10-50 mL/min, reduce dose by 25% <br>                                                                     If CrCl < 10 mL/min, reduce dose by 50% </li><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li><li>Procarbazine:<br>If CrCl < 30 mL/min, do not use</li><li>Vincristine:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 716,
          "referenceValue": "Kelly KM, Hutchinson RJ, Sposto R, et al. Feasibility of upfront dose-intensive chemotherapy in children with advanced-stage Hodgkin's lymphoma: preliminary results from the Children's Cancer Group Study Ccg-59704."
        },
        {
          "id": 717,
          "referenceValue": "Ann Oncol. 2002;13(suppl 1):107-111."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 319,
      "name": "<b>CHOP</b>",
      "schedule": "<b>Cyclophosphamide</b> 750 mg/m<sup>2</sup>/d IV, days 1, 22<br> <b>Doxorubicin</b> 40 mg/m<sup>2</sup>/d IV, days 1, 22<br> <b>Vincristine</b> 1.5 mg/m<sup>2</sup> IV weekly for 6 doses<br> <b>Prednisone</b> 40 mg/m<sup>2</sup>/d PO for 28 days",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Vincristine:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 718,
          "referenceValue": "Link MP, Donaldson SS, Berard CW, Shuster JJ, Murphy JB. Results of treatment of childhood localized non-Hodgkin's lymphoma with combination chemotherapy with or without radiotherapy."
        },
        {
          "id": 719,
          "referenceValue": "N Engl J Med. 1990;322(17):1169-1174."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 331,
      "name": "<b>DA</b>",
      "schedule": "<b>Daunorubicin</b> 45 mg/m<sup>2</sup>/d IV, days 1-3<br> <b>Cytarabine</b> 100 mg/m<sup>2</sup>/d CIVI, days 1-7",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cytarabine:<br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>                                           If bilirubin > 3 mg/dL, reduce dose by 50%</li><li>Daunorubicin:<br>If bilurubin 1.5-3 mg/dL, reduce dose by 25% <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 50%  <br>                                         If bilirubin >5 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Daunorubicin:<br>If Cr > 3 mg/dL, reduce dose by 50%</li></ul>",
      "references": [
        {
          "id": 720,
          "referenceValue": "Woods WG, Ruymann FB, Lampkin BC, et al. The role of timing of high-dose cytosine arabinoside intensification and of maintenance therapy in the treatment of children with acute nonlymphocytic leukemia."
        },
        {
          "id": 721,
          "referenceValue": "Cancer. 2006;66(6):1106-1113."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 320,
      "name": "<b>SNCCL/B-ALL</b>",
      "schedule": "<u>INITIAL PHASE</u><br> <b>Cytarabine</b> 50 mg/m<sup>2</sup>/d (maximum, 50 mg/d) IT, days 1, 2, 3, 11<br> <b>Methotrexate</b> 12 mg/m<sup>2</sup>/d (maximum, 12 mg/d) IT, days 4, 11<br> <b>Cyclophosphamide</b> 300 mg/m<sup>2</sup> IV push every 12 hours for 6 doses, days 1-3<br> <b>Doxorubicin</b> 50 mg/m<sup>2</sup> IV, day 4<br> <b>Vincristine</b> 1.5 mg/m<sup>2</sup>/d IV, days 4, 11<br> <b>ALTERNATING WITH</b><br><br> <u>SECONDARY PHASE</u><br> <b>Cytarabine</b> 50 mg/m<sup>2</sup> (maximum, 50 mg) IT, day 1<br> <b>Methotrexate</b> 12 mg/m<sup>2</sup> (maximum, 12 mg) IT, day 1<br> <b>Methotrexate</b> 200 mg/m<sup>2</sup> IV bolus,<br> <b>THEN</b> 800 mg/m<sup>2</sup> CIVI<br> <b>Cytarabine</b> 3,000 mg/m<sup>2</sup> IV over 3 hours every 12 hours for 4 doses, days 2, 3<br> <b>Leucovorin calcium</b> 30 mg/m<sup>2</sup> IV at hour 42, then 3 mg/m<sup>2</sup> IV at hours 54, 66, 78",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cyclophosphamide:<br>If bilirubin 3-5 mg/dL or SGOT > 180 mg/dL, reduce dose by 25%  <br>    If bilirubin >5 mg/dL, do not use </li><li>Cytarabine:<br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>                                           If bilirubin > 3 mg/dL, reduce dose by 50%</li><li>Doxorubicin:<br>If bilirubin 1.2-3 mg/dL, reduce dose by 50%  <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 75%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Leucovorin:<br>No dose reduction</li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Cyclophosphamide:<br>If CrCl 10-50 mL/min, reduce dose by 25%<br>                                                                      If CrCl < 10 mL/min, reduce dose by 50% </li><li>Doxorubicin:<br>No dose reduction </li><li>Leucovorin:<br>No dose reduction</li><li>Vincristine:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 722,
          "referenceValue": "Bowman WP, Shuster JJ, Cook B, et al. Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: a Pediatric Oncology Group study."
        },
        {
          "id": 723,
          "referenceValue": "J Clin Oncol. 1996;14(4):1252-1261."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 321,
      "name": "<b>VCR/Asparaginase/Dex/MTX</b>",
      "schedule": "<b>Vincristine</b> 1.5 mg/m<sup>2</sup> IV, days 0,7, 14, 21<br> <b>Asparaginase</b> 6,000 units/m<sup>2</sup> IM, 3 times weekly for 9 doses, starting on days 2-4<br> <b>Dexamethasone</b> 6 mg/m<sup>2</sup>/d PO in 3 equal doses (was substituted for prednisone)<br> <b>Methotrexate</b> 8, 10, or 12 mg IT, age-adjusted, days 0, 14 (also days 7, 21 for patients with CNS disease at diagnosis)<br> <b>Prednisone</b> 40 mg/m<sup>2</sup>/d PO",
      "emetogenicPotential": "Moderate for MTX agent IT, minimal for others",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Vincristine:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 724,
          "referenceValue": "Bostrom BC, Sensel MR, Sather HN, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group."
        },
        {
          "id": 725,
          "referenceValue": "Blood 2003;101(10):3809-3817."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 322,
      "name": "<b>VCR/Prednisone/Pegaspargase/Cytarabine/MTX</b>",
      "schedule": "<b>Vincristine</b> 1.5 mg/m<sup>2</sup> IV, days 0, 7, 14, 21<br> <b>Prednisone</b> 40 mg/m<sup>2</sup> PO, days 0-28, then 10-day taper<br> <b>Pegaspargase</b> 2,500 units/m<sup>2</sup> IM, day 3<br> <b>Cytarabine</b> 30, 50, or 70 mg IT, age-adjusted, day 0<br> <b>Methotrexate</b> 8, 10, <b>OR</b> 12 mg IT, age-adjusted, days 7, 28",
      "emetogenicPotential": "Moderate for MTX agent IT, minimal for others",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cytarabine:<br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>                                           If bilirubin > 3 mg/dL, reduce dose by 50%</li><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Vincristine:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 726,
          "referenceValue": "Avramis VI, Sencer S, Periclou AP, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group Study."
        },
        {
          "id": 727,
          "referenceValue": "Blood. 2002;99(6):1986-1994."
        },
        {
          "id": 728,
          "referenceValue": "Erratum in: Blood. 2002; 100(6):1531."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 323,
      "name": "<b>Nelarabine</b>",
      "schedule": "<b>Nelarabine</b> 650 mg/m<sup>2</sup>/d IV, over 1 hour for 5 consecutive days<br> Repeat every 21 days",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>",
      "references": [
        {
          "id": 729,
          "referenceValue": "Arranon [package insert]."
        },
        {
          "id": 730,
          "referenceValue": "Research Triangle Park, NC: GlaxoSmithKline; 2011."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 324,
      "name": "<b>OD</b>",
      "schedule": "<b>Dexamethasone</b> 6 mg/m<sup>2</sup>/d PO, days 1-28<br> <b>Asparaginase</b> 6,000 units/m<sup>2</sup> IM, 3 times weekly for 9 doses<br> <b>Vincristine</b> 1.5 mg/m<sup>2</sup> IV, days 0, 7, 14, 21<br> <b>Methotrexate</b> 8-12 mg IT, age-adjusted dosing schedule",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Vincristine:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br> If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Vincristine:<br>No dose reduction </li></ul>",
      "references": [
        {
          "id": 731,
          "referenceValue": "Bostrom BC, Sensel MR, Sather HN, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group."
        },
        {
          "id": 732,
          "referenceValue": "Blood 2003;101(10):3809-3817."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 325,
      "name": "<b>PVDA</b>",
      "schedule": "<b>Prednisone</b> 40 mg/m<sup>2</sup>/d PO, days 1-28<br> <b>Vincristine</b> 1.5 mg/m<sup>2</sup>/d IV, days 2, 8, 15, 22<br> <b>Daunorubicin</b> 25 mg/m<sup>2</sup>/d IV, days 2, 8, 15, 22<br> <b>Asparaginase</b> 5,000 units/m<sup>2</sup>/d IM, days 2, 5, 8, 12, 15, 19",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>",
      "references": [
        {
          "id": 733,
          "referenceValue": "Lauer SJ, Camitta BM, Leventhal BG, et al. Intensive alternating drug pairs for treatment of hgh-risk chidhood acute lymphoblastic leukemia. Apediatric Oncology Group pilot study."
        },
        {
          "id": 734,
          "referenceValue": "Cancer. 1993;71(9):2854-2861."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 326,
      "name": "<b>TIT (CNS Prophylaxis)</b>",
      "schedule": "<u>Regimen <%0B>Age 1y <%0B>Age 2y <%0B>Age>=3y</u><br> <b>Methotrexate</b> <%0B>10 mg <%0B>12.5 mg <%0B>15 mg<br> <b>Cytarabine</b> <%0B>20 mg <%0B>25 mg <%0B>30 mg<br> <b>Hydrocortisone</b> <%0B>10 mg <%0B>12.5 mg <%0B>15 mg<br> <b>Administer</b> IT on day 1, then at weeks 1, 2, 3, 6, 11, 16, 21, 26, 31, then every 12 weeks",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cytarabine:<br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>                                           If bilirubin > 3 mg/dL, reduce dose by 50%</li></ul><b>Renal Impairment</b><ul></ul>",
      "references": [
        {
          "id": 735,
          "referenceValue": "Lauer SJ, Camitta BM, Leventhal BG, et al. Intensive alternating drug pairs for treatment of hgh-risk chidhood acute lymphoblastic leukemia. Apediatric Oncology Group pilot study."
        },
        {
          "id": 736,
          "referenceValue": "Cancer. 1993;71(9):2854-2861."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 327,
      "name": "<b>IDMTX</b>",
      "schedule": "<u>WEEK 1</u><br> <b>Methotrexate</b> 1,000 mg/m<sup>2</sup> IV over 24 hours<br> <b>FOLLOWED BY</b><br> <b>Mercaptopurine</b> 1,000 mg/m<sup>2</sup> IV over 6 hours<br> <b>THEN</b> (48 hours after the start of Methotrexate)<br> <b>Leucovorin calcium</b> 5 mg/m<sup>2</sup> IV every 6 hours for at least 5 doses<br> <u>WEEK 2</u><br> <b>Methotrexate</b> 20 mg/m<sup>2</sup> IM, day 1<br> <b>Mercaptopurine</b> 50 mg/m<sup>2</sup>/d PO, days 1-7<br> Repeat 2-week cycle times 12",
      "emetogenicPotential": "Week 1, high; week 2, minimal",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Leucovorin:<br>No dose reduction</li></ul><b>Renal Impairment</b><ul><li>Leucovorin:<br>No dose reduction</li></ul>",
      "references": [
        {
          "id": 737,
          "referenceValue": "Mahoney DH, Shuster JJ, Nitschke R, et al. Intensification with intermediate-dose intravenous methotrexate is effectie therapy for children with lower-risk B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group study."
        },
        {
          "id": 738,
          "referenceValue": "J Clin Oncol. 2000;18(6):1285-1294."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 332,
      "name": "<b>DAT</b>",
      "schedule": "<b>Daunorubicin</b> 45 mg/m<sup>2</sup>/d IV, days 1-3<br> <b>Cytarabine</b> 100 mg/m<sup>2</sup>/d IV, days 1-7<br> <b>Thioguanine</b> 100 mg/m<sup>2</sup>/d PO, days 1-7",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cytarabine:<br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>                                           If bilirubin > 3 mg/dL, reduce dose by 50%</li><li>Daunorubicin:<br>If bilurubin 1.5-3 mg/dL, reduce dose by 25% <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 50%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Thioguanine:<br>If bilirubin > 5 mg/dL, do not use</li></ul><b>Renal Impairment</b><ul><li>Daunorubicin:<br>If Cr > 3 mg/dL, reduce dose by 50%</li></ul>",
      "references": [
        {
          "id": 739,
          "referenceValue": "Ravindranath Y, Steuber CP, Krischer J, et al. High-dose cytarabine for intensification of early therapy of childhood acute myeloid leukemia: a Pediatric Oncology Group study."
        },
        {
          "id": 740,
          "referenceValue": "J Clin Oncol. 1991;9(4):572-580."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 333,
      "name": "<b>DCTER</b>",
      "schedule": "<b>Dexamethasone</b> 6 mg/m<sup>2</sup>/d (if age < 3 yeras 0.2mg/kg/d) PO tid, days 0-4<br> <b>Cytarabine</b> 200 mg/m<sup>2</sup>/d (if age < 3 yeras 6.7 mg/kg/d) CIVI, days 0-4<br> <b>Thioguanine</b> 100 mg/m<sup>2</sup>/d (if age < 3 yeras 3.3 mg/kg/d) PO bid, days 0-4<br> <b>Etoposide</b> 100 mg/m<sup>2</sup>/d (if age < 3 yeras 3.3 mg/kg/d) CIVI, days 0-4<br> <b>Daunorubicin</b> 20 mg/m<sup>2</sup>/d (if age < 3 yeras 0.67 mg/kg/d) CIVI, days 0-4<br> <b>Cytarabine</b> IT (age-based doses)<br> Doses in parentheses used for children <3 years of age",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cytarabine:<br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>                                           If bilirubin > 3 mg/dL, reduce dose by 50%</li><li>Daunorubicin:<br>If bilurubin 1.5-3 mg/dL, reduce dose by 25% <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 50%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li><li>Thioguanine:<br>If bilirubin > 5 mg/dL, do not use</li></ul><b>Renal Impairment</b><ul><li>Daunorubicin:<br>If Cr > 3 mg/dL, reduce dose by 50%</li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>",
      "references": [
        {
          "id": 741,
          "referenceValue": "Woods WG, Kobrinsky N, Buckley JD, et al. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group."
        },
        {
          "id": 742,
          "referenceValue": "Blood. 1996;87(12):4979-4989."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 334,
      "name": "<b>HI-C DAZE</b>",
      "schedule": "<b>Daunorubicin</b> 30 mg/m<sup>2</sup>/d IV, days 1-3<br> <b>Cytarabine</b> 3,000 mg/m<sup>2</sup>/d IV every 12 hours, days 1-4<br> <b>Etoposide</b> 200 mg/m<sup>2</sup>/d IV, days 1-3, 6-8<br> <b>Azacitidine</b> 150 mg/m<sup>2</sup>/d IV, days 3-5, 8-10",
      "emetogenicPotential": "High",
      "dosageModifications": "<b>Hepatic Impairment</b><ul><li>Cytarabine:<br>If bilirubin 1.5-3 mg/dL, reduce dose by 25%<br>                                           If bilirubin > 3 mg/dL, reduce dose by 50%</li><li>Daunorubicin:<br>If bilurubin 1.5-3 mg/dL, reduce dose by 25% <br>                                         If bilirubin 3.1-5 mg/dL, reduce dose by 50%  <br>                                         If bilirubin >5 mg/dL, do not use </li><li>Etoposide:<br>If bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br>  If bilirubin > 3 mg/dL or SGOT > 180 mg/dL, do not use </li></ul><b>Renal Impairment</b><ul><li>Daunorubicin:<br>If Cr > 3 mg/dL, reduce dose by 50%</li><li>Etoposide:<br>If CrCl 10-50 mL/min, reduce dose by 25%   <br>                                                                   If CrCl < 10 mL/min, reduce dose by 50% </li></ul>",
      "references": [
        {
          "id": 743,
          "referenceValue": "Hurwitz CA, Mounce KG, Grier HE. Treatment of patients with acute myelogenous leukemia: review of clinical trials of the past decade."
        },
        {
          "id": 744,
          "referenceValue": "J Pediatr Hematol Oncol. 1995;17(3):185-197."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 335,
      "name": "<b>MACE/consolidation</b>",
      "schedule": "<b>Amsacrine</b> 100 mg/m<sup>2</sup> IV (1-hour infusion), days 1-5<br> <b>Cytarabine</b> 200 mg/m<sup>2</sup> CIVI, days 1-5<br> <b>Etoposide</b> 100 mg/m<sup>2</sup> IV (1-hour infusion), days 1-5",
      "emetogenicPotential": "Low",
      "dosageModifications": "<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>",
      "references": [
        {
          "id": 745,
          "referenceValue": "Stevens RF, Hann IM, Wheatley K, Gray RG. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukaemia: results of the United Kingdom Medical Research Council's 10th AML trial."
        },
        {
          "id": 746,
          "referenceValue": "Br J Haematol. 1998;101(1):130-140."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 336,
      "name": "<b>MidAC</b>",
      "schedule": "<b>Mitoxantrone</b> 10 mg/m<sup>2</sup> IV (short infusion), days 1-5<br> <b>Cytarabine</b> 1,000 mg/m<sup>2</sup> IV (2-hour infusion), every 12 hours, days 1-3",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<b>Hepatic Impairment</b><ul></ul><b>Renal Impairment</b><ul></ul>",
      "references": [
        {
          "id": 747,
          "referenceValue": "Stevens RF, Hann IM, Wheatley K, Gray RG. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukaemia: results of the United Kingdom Medical Research Council's 10th AML trial."
        },
        {
          "id": 748,
          "referenceValue": "Br J Haematol. 1998;101(1):130-140."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 337,
      "name": "<b>Nivolumab</b>",
      "schedule": "<b>Nivolumab</b> 3 mg/kg IV<br> Repeat Every 14 Days<br> Until disease progression or Unacceptable toxicity",
      "emetogenicPotential": "Minimal",
      "dosageModifications": "",
      "references": [
        {
          "id": 749,
          "referenceValue": "Rizvi, NA, Mazieres J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial."
        },
        {
          "id": 750,
          "referenceValue": "Lancet Oncol. 2015 Mar;16(3):257-65."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 338,
      "name": "<b>Docetaxel/Ramucirumab</b>",
      "schedule": "<b>Docetaxel</b>75 mg/m <sup>2</sup>IV<br> Repeat Every 21 Days<br> <b>Ramucirumab</b> 10 mg/kg IV  <br> Repeat Every 21 days<br>Until disease pogression or Unacceptable toxicity",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "",
      "references": [
        {
          "id": 751,
          "referenceValue": "Garon EB, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial."
        },
        {
          "id": 752,
          "referenceValue": "Lancet. 2014 Aug 23;384(9944):665-73."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 339,
      "name": "<b>Alectinib</b>",
      "schedule": "<b>Alectinib</b> 600 mg PO BID<br>",
      "emetogenicPotential": "Minimal",
      "dosageModifications": "",
      "references": [
        {
          "id": 753,
          "referenceValue": "Ou SI, Ahn Js, Petris LD, et al. Alectinib in Crizotinib refractory ALK-rearranged non-small cell lung cancer: A phase II global study."
        },
        {
          "id": 754,
          "referenceValue": "J Clin Oncol. 2015 Nov 23. pii: JCO639443."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 340,
      "name": "<b>Ceritinib</b>",
      "schedule": "<b>Ceritinib</b> 750 mg  PO daily<br> ",
      "emetogenicPotential": "Minimal",
      "dosageModifications": "",
      "references": [
        {
          "id": 755,
          "referenceValue": "Shaw AT, Kim DW, Mehra R, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer."
        },
        {
          "id": 756,
          "referenceValue": "N Engl J Med. 2014 Mar 27;370(13):1189-97."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 341,
      "name": "<b>Necitumumab<br>Gemcitabine<br>Cisplatin</b>",
      "schedule": "<b>Necitumumab</b> 800 mg IV Day 1 and 8<br><b>Gemcitabine</b>1250 mg/m <sup>2</sup> IV<br><b>Cisplatin</b> 75 mg/m<sup>2</sup>IV<br>Repeat every 21 days<br>Continue Necitumumab until disease progression or intolerable toxicity",
      "emetogenicPotential": "Severe",
      "dosageModifications": "",
      "references": [
        {
          "id": 757,
          "referenceValue": "Thatcher N, Hirsch FR, Luft AV, et al. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first line therapy in patients with stage IV sqaumous non-small cell lung cancer (SQUIRE): an open label, randomised, controlled phase 3 trial."
        },
        {
          "id": 758,
          "referenceValue": "Lancet Oncol. 2015 Jul;16(7):763-74. doi: 10.1016/S1470-2045(15)00021-2. Epub 2015 Jun 1."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 348,
      "name": "<b>Brentuximab Vedotin</b>",
      "schedule": "<b>Bretuximab Vedotin</b> 1.8 mg/ kg<br> Repeat every 21 days",
      "emetogenicPotential": "Minimal",
      "dosageModifications": "",
      "references": [
        {
          "id": 47,
          "referenceValue": "Moscowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression: a randomised, double-blind, placebo-controlled, phase 3 trial."
        },
        {
          "id": 48,
          "referenceValue": "Lancet. 2015 May 9;385(9980):1853-62."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 349,
      "name": "<b>Idelalisib/Rituximab</b>",
      "schedule": "<b>Idelalisib</b> 150 mg  po BID <br> Rituximab 375 mg/m<sup>2</sup> Repeat every 21 days",
      "emetogenicPotential": "Minimal",
      "dosageModifications": "",
      "references": [
        {
          "id": 73,
          "referenceValue": "Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia."
        },
        {
          "id": 74,
          "referenceValue": "N Engl J Med. 2014 Mar 13;370(11):997-1007."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 350,
      "name": "<b>Ibrutinib</b>",
      "schedule": "<b>Ibrutinib</b> 420 mg PO daily",
      "emetogenicPotential": "Minimal",
      "dosageModifications": "",
      "references": [
        {
          "id": 111,
          "referenceValue": "Byrd JC, Brown JR, O'Brien S .Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia."
        },
        {
          "id": 112,
          "referenceValue": "N Engl J Med. 2014 Jul 17;371(3):213-23."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 351,
      "name": "<b>Ofatumumab<br>Chlorambucil</b>",
      "schedule": "<b>Ofatumumab</b> 300mg IV on Day 1 and 1000 mg on day 8, Cycle 1. Subsequent cycles 1000 mg IV on Day 1 only <br><b>Chlorambucil</b> PO 10 mg/m<sup>2</sup>, day 1 to 7. Repeat every 28 days",
      "emetogenicPotential": "Minimal",
      "dosageModifications": "",
      "references": [
        {
          "id": 196,
          "referenceValue": "Hillmen P, Robak T, Janssens A, et al. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukemia  (Complimet1 (: A rondomised, multicentre, open-label phase 3 trial."
        },
        {
          "id": 197,
          "referenceValue": "Lancet. 2015 May 9;385(9980):1873-83."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 352,
      "name": "<b>Blinatumomab</b>",
      "schedule": "<b>Blinatumomab</b> 9  mcg/day on days 1-7, 28 mcg/day on days 8-28 of the first 42 day cycle<br>28 mcg/day on day1-28 in later cycles",
      "emetogenicPotential": "Minimal",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 353,
      "name": "<b>Ixazomib/Lenolidamide/Dexamethasone</b>",
      "schedule": "<b>Ixazomib</b> 4 mg PO  on days 1,8,15<br> <br> <b>Lenalidomide</b> 25mg PO on day 1 thru 21<br> <b>Dexamethasone</b> 40 mg PO, days 1,8,15,22<br> Repeat every 28 days",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "",
      "references": [
        {
          "id": 264,
          "referenceValue": "Kumar SK, Berdeja JG, Niesvizky, R. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously unreated multiple myeloma ."
        },
        {
          "id": 265,
          "referenceValue": "Lancet Oncol. 2014 Dec;15(13):1503-12."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 354,
      "name": "<b>Daratumumab</b>",
      "schedule": "<b>Daratumumab</b> 16 mg/kg  every 7 days x 8 weeks <br> every 14 days x 16 weeks<br>then every 4 weeks until disease progression",
      "emetogenicPotential": "Minimal ",
      "dosageModifications": "",
      "references": [
        {
          "id": 280,
          "referenceValue": "Lokhorst HM, Plesner T, Laubach JP, et al Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma."
        },
        {
          "id": 281,
          "referenceValue": "N Engl J Med. 2015 Sep 24;373(13):1207-19."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 355,
      "name": "<b>Nivolumab</b>",
      "schedule": "<b>Nivolumab</b> 3 mg/kg IV<br> Repeat Every 14 Days<br> Until disease progression or Unacceptable toxicity",
      "emetogenicPotential": "Minimal",
      "dosageModifications": "",
      "references": [
        {
          "id": 349,
          "referenceValue": "N Engl J Med. 2015 Nov 5;373(19):1803-13."
        },
        {
          "id": 348,
          "referenceValue": "Motzer RJ, Escudier B, McDermott DF, et al.  Nivolumab versus Everolimus in Advanced Renal Cell Carcinoma."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 356,
      "name": "<b>Axitinib</b>",
      "schedule": "<b>Axitinib <br>5 mg po BID",
      "emetogenicPotential": "Minimal",
      "dosageModifications": "",
      "references": [
        {
          "id": 370,
          "referenceValue": "Motzer RJ, Escudier B, Tomczak P et al. Axitinib versus Sorafenib as second-line treatment for advanced renal cell carcinoma: Overall survival analysis and updated results from a randomised phase 3 trial."
        },
        {
          "id": 371,
          "referenceValue": "Lancet Oncol. 2013 May;14(6):552-62."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 357,
      "name": "<b>Vemurafinib</b>",
      "schedule": "<b>Vemurafenib</b> 960 mg po BID",
      "emetogenicPotential": "Minimal",
      "dosageModifications": "",
      "references": [
        {
          "id": 372,
          "referenceValue": "Sosman JA, Kim KB, Schuchter L, Survival in BRAF V600-Mutant advanced Melanoma treated with Vemurafenib."
        },
        {
          "id": 373,
          "referenceValue": "N Engl J Med. 2012 Feb 23; 366(8): 707–714 ."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 358,
      "name": "<b>Ipilumimab</b>",
      "schedule": "<b>Ipilumimab</b>  IV 3 mg/kg  every 3 weks upto 4 doses",
      "emetogenicPotential": "Minimal",
      "dosageModifications": "",
      "references": [
        {
          "id": 392,
          "referenceValue": "Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with Ipilumimab in patients with Metastatic Melanoma."
        },
        {
          "id": 393,
          "referenceValue": "N Engl J Med 2010; 363:711-723."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 359,
      "name": "<b>Ipilumimab/Nivolumab</b>",
      "schedule": "<b>Ipilumimab</b> 3mg/kg  IV <br> Nivolumab </b> 1 mg/kg IV<br> every 3 weeks  x 4 cycles <br> followed by Nivolumab 3 mg/kg  every 3 weeks until disease progression on unaccceptable toxicity",
      "emetogenicPotential": "Minimal",
      "dosageModifications": "",
      "references": [
        {
          "id": 452,
          "referenceValue": "Postow, MA, Chesney J, Pavlick AC, et al. Nivolumab and Ipilumimab versus Ipilumimab in untreated melanoma."
        },
        {
          "id": 453,
          "referenceValue": "N Engl J Med. 2015 May 21;372(21):2006-17."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 360,
      "name": "<b>Dabrafenib/Trametinib</b>",
      "schedule": "<bDabrafenibt</b> 150 mg PO  BID <br> Trametinib</b>2 mg once daily ",
      "emetogenicPotential": "Minimal",
      "dosageModifications": "",
      "references": [
        {
          "id": 472,
          "referenceValue": "Robert c, Karaszewska B, Schachter J, et al. Improved overall Survival in Melanoma with combines Dabrafenib and Trametinib."
        },
        {
          "id": 473,
          "referenceValue": "N Engl J Med. 2015 Jan 1;372(1):30-9."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 361,
      "name": "<b>Cobimetinib/Vemurafenib</b>",
      "schedule": "<b>Cobimetinib</b> 60 mg once daily<br>Vemurafenib</b>960 mg twice a day from day1-21, on a 28 day cycle ",
      "emetogenicPotential": "Minimal",
      "dosageModifications": "",
      "references": [
        {
          "id": 489,
          "referenceValue": "Larkin J, Ascierto PA, Dreno B. Combined Vemurafenib and Cobimetinib in BRAF-mutated Melanoma."
        },
        {
          "id": 490,
          "referenceValue": "N Engl J Med. 2014 Nov 13;371(20):1867-76."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 362,
      "name": "<b>Pembrolizumab</b>",
      "schedule": "<b>Pembrolizumab</b> 2 mg /kg IV<br> Every 21 days",
      "emetogenicPotential": "Minimal",
      "dosageModifications": "",
      "references": [
        {
          "id": 602,
          "referenceValue": "Robert C, Schachter J, Long GV, et al.  Pembrolizumab versus Ipilumimab in Advanced Melanoma."
        },
        {
          "id": 603,
          "referenceValue": "N Engl J Med 2015; 372:2521-2532."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 363,
      "name": "<b>Elotuzumab<br>Lenalidomide<br>Dexamethasone</b>",
      "schedule": "<b>Elotuzumab</b> 10 mg/Kg IV  Weekly x2 and then Every 2 weeks<br> <b>Lenalidomide</b> 25 mg po daily  from day 1-21 (3 weeks)<br> <b>Dexamethasone </b> 8 mg IV prior to Elotuzumab infusion and then 28 mg orally, In weeks without Elotuzumab  40 mg PO every week",
      "emetogenicPotential": "Minimal",
      "dosageModifications": "",
      "references": [
        {
          "id": 759,
          "referenceValue": "Lonial S, Dimopoulous M, Palumbo A, et al. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma ."
        },
        {
          "id": 760,
          "referenceValue": "N Engl J Med. 2015 Aug 13;373(7):621-31."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 364,
      "name": "<b>Trifluridine/Tipiracil</b>",
      "schedule": "<b>Trifluridine/Tipiracil</b>  35  mg/m<sup>2</sup>  PO twice daily days 1 through 5 and 8 through 12<br> Repeat every 28 days",
      "emetogenicPotential": "Minimal",
      "dosageModifications": "",
      "references": [
        {
          "id": 761,
          "referenceValue": "Mayer RJ, Van Cutsem E, Falcone A, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer."
        },
        {
          "id": 762,
          "referenceValue": "N Engl J Med. 2015 May 14;372(20):1909-19.."
        },
        {
          "id": 763,
          "referenceValue": "Lancet Oncol. 2014 Oct;15(11):1195-206."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 365,
      "name": "<b>Ramicirumab/FOLFIRI</b>",
      "schedule": "<b>Ramicirumab</b> 8 mg/kg IV <br> <b>Irinotecan  </b> 180 mg/m<sup>2</sup>  over 90 minutes <br> <b>Leucovorin</b> Calcium 400 mg/m<sup>2</sup> IV<br>FOLLOWED BY<br><b>Fluorouracil</b> 400 mg<sup>2</sup> IV<br> <b>Fluorouracil</b> 2,400 mg<sup>2</sup>  CIVI over 46 hours<br>Repeat every 14 days",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "",
      "references": [
        {
          "id": 764,
          "referenceValue": "Tabernero J, Yoshino T, Cohn Al, et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study."
        },
        {
          "id": 765,
          "referenceValue": "Lancet Oncol. 2015 May;16(5):499-508."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 716,
      "name": "",
      "schedule": "<p><strong>Capecitabine:&nbsp;</strong>1,250 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-14</p>\n\n<p>May decrease dose to 850-1,000 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-14 to reduce the risk of toxicity without compromising clinical efficacy.</p>\n\n<p>Repeat cycle every 21 days.</p>\n\n<p>&nbsp;</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 366,
      "name": "<b>Ramucirumab/Paclitaxel</b>",
      "schedule": "<b>Ramucirumab</b> 8 mg/kg IV  on days 1 and 15<br>  <b>Paclitaxel</b> 80 mg/m<sup>2</sup>  IV on days 1, 8, 15<br>Repeat every 28 days",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "",
      "references": [
        {
          "id": 766,
          "referenceValue": "Wilke H, Muro K, Van Custem E, et al. Ramucirumab plus paclitaxel versus placebo plus palcitaxel in patients with previously treated advanced gastric or gastro-esophageal junction adenocarcinoma I RAINBOW): a double-blind, randomised phase 3 trial."
        },
        {
          "id": 767,
          "referenceValue": "Lancet Oncol. 2014 Oct;15(11):1224-35."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 367,
      "name": "<b>Ramucirumab</b>",
      "schedule": "<b>Ramucirumab</b> 8 mg/kg IV  every 2 weeks<br>  ",
      "emetogenicPotential": "Minimal",
      "dosageModifications": "",
      "references": [
        {
          "id": 768,
          "referenceValue": "Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-esophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial."
        },
        {
          "id": 769,
          "referenceValue": "Lancet. 2014 Jan 4;383(9911):31-9."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 368,
      "name": "<b>Irinotecan liposome<br>Fluorouracil<br>Leucovorin</b>",
      "schedule": "<b>Irinotecan liposome</b> 70 mg/m<sup>2</sup> IV <br> <b>Fluorouracil</b> 2400 mg/m<sup>2</sup>  IV over 46 hours<br> <b>Leucovorin</b> 400mg/m<sup>2</sup> IV <br> Repeat every 14 days",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "",
      "references": [
        {
          "id": 770,
          "referenceValue": "Wang-Gillam A, Li CP, Bodoky G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open label, phase 3 trial."
        },
        {
          "id": 771,
          "referenceValue": "Lancet. 2015 Nov 20. pii: S0140-6736(15)00986-1."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 369,
      "name": "<b>nab-Paclitaxel/Gemcitabine</b>",
      "schedule": "<b>nab-Paclitaxel</b> 125 mg/m<sup>2</sup> IV<br> <br> <b>Gemcitabine</b>  1000 mg/m<sup>2</sup>  days 1, 8, 15<br> Repeat every 28 days",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "",
      "references": [
        {
          "id": 772,
          "referenceValue": "Von Hoff DD, Ervin T, Arena FP, et al. Incrased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine."
        },
        {
          "id": 773,
          "referenceValue": "N Engl J Med. 2013 Oct 31;369(18):1691-703."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 370,
      "name": "<b>Pablociclib/Letrozole</b>",
      "schedule": "<b>Pablociclib</b>125 mg PO  on days 1 through 21<br>  <b>Letrozole</b> 2.5 mg PO daily<br> Repeat every 28 days",
      "emetogenicPotential": "Minimal",
      "dosageModifications": "",
      "references": [
        {
          "id": 774,
          "referenceValue": "Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/Trio-18): a randomised phase 2 study."
        },
        {
          "id": 775,
          "referenceValue": "Lancet Oncol. 2015 Jan;16(1):25-35."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 371,
      "name": "<b>Everolimus/Exemestane</b>",
      "schedule": "<b>Everolimus</b> 10 mg PO daily <br>  <b>Exemestane</b> 25 mg PO daily",
      "emetogenicPotential": "Minimal",
      "dosageModifications": "",
      "references": [
        {
          "id": 776,
          "referenceValue": "Beck JT, Hortobogyi GN, Campone M, et al. Everolimus plus exemestane as first-line therapy in HR +, HER2 - advanced breast cancer in BOLERO-2."
        },
        {
          "id": 777,
          "referenceValue": "Breast Cancer Res Treat. 2014 Feb;143(3):459-67."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 372,
      "name": "<b>Pertuzumab/Trastuzumab/Docetaxel</b>",
      "schedule": "<b>Pertuzuamb</b>840  mg IV loading dose followed by 420 mg <br><b>Docetaxel</b> 75 mg/m<sup>2</sup> IV<br> <b>Trastuzumab</b> 8 mg/kg loading dose followed by 6 mg/kg<br> Repeat every 21 days",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "",
      "references": [
        {
          "id": 778,
          "referenceValue": "Baselga J, Cortes J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer."
        },
        {
          "id": 779,
          "referenceValue": "N Engl J Med. 2012 Jan 12;366(2):109-19. S"
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 373,
      "name": "<b>ado-trastuzumab</b>",
      "schedule": "<b>ado-trastuzumab</b>3.6 mg/kg IV every 21 days",
      "emetogenicPotential": "Minimal",
      "dosageModifications": "",
      "references": [
        {
          "id": 780,
          "referenceValue": "Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer."
        },
        {
          "id": 781,
          "referenceValue": "N Engl J Med. 2012 Nov 8;367(19):1783-91."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 374,
      "name": "<b>Bosutinib</b>",
      "schedule": "<b>Bosutinib</b> 500 mg po daily",
      "emetogenicPotential": "Minimal",
      "dosageModifications": "",
      "references": [
        {
          "id": 782,
          "referenceValue": "Cortes JE, et al. Bosutinib versus Imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial."
        },
        {
          "id": 783,
          "referenceValue": "J Clin Oncol.2012  October 30;(28):3486-3492."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 375,
      "name": "<b>Ponatinib</b>",
      "schedule": "<b>Ponatinib</b> 45 mg po daily",
      "emetogenicPotential": "Minimal",
      "dosageModifications": "",
      "references": [
        {
          "id": 784,
          "referenceValue": "Cortes JE, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemia."
        },
        {
          "id": 785,
          "referenceValue": "N Engl J Med.2013 Nov 7;369(19):1783-96."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 376,
      "name": "<b>Omacetaxine</b>",
      "schedule": "<b>Omacetaxine</b> 1.25 mg<sup>2</sup>  SQ twice daily for 14 days on a 28 day cycle (Induction)<br>1.25 mg<sup>2</sup>  SQ twice daily for 7 days on a 28 day cycle (maintenance)",
      "emetogenicPotential": "Minimal",
      "dosageModifications": "",
      "references": [
        {
          "id": 786,
          "referenceValue": "Cortes JE, et al. phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phaseCML with T315I mutation."
        },
        {
          "id": 787,
          "referenceValue": "Blood.2012 Sep;120(13):2573-2580."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 377,
      "name": "<b>Obinutuzumab/Chlorambucil</b>",
      "schedule": "<b>Obinutuzumab/Chlorambucil</b><br><b>Cycle 1:</b><br>100 mg IV on day 1 and 900 mg IV on day 2, 1,000 mg on day 8 and 15<br><b>Cycle 2-6:</b><br>1,000 mg IV on day 1<br><b>Chlorambucil</b><br>0.5 mg/kg on Day 1 and 15 of each cycle",
      "emetogenicPotential": "Minimal",
      "dosageModifications": "",
      "references": [
        {
          "id": 788,
          "referenceValue": "Goede V, et. al. Obinutuzumab plus chlorambulcil in patients with CLL and coexisting conditions."
        },
        {
          "id": 789,
          "referenceValue": "N Engl J Med. 2014 Mar 20;370(12):1101-10."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 602,
      "name": "",
      "schedule": "<p><strong>Oxaliplatin:&nbsp;</strong>100 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV bolus on day 1, followed by 2,400 mg/m<sup>2&nbsp;</sup>IV continuous infusion for 46 hours</p>\n\n<p><strong>Leucovorin:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV on day 1 as a 2-hour infusion before 5-fluorouracil</p>\n\n<p>Repeat cycle every 2 weeks</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 379,
      "name": "",
      "schedule": "<h4>Chemotherapy</h4>\n\n<ul>\n\t<li>Cisplatin (Platinol)&nbsp;35 mg/m<sup>2</sup>&nbsp;IV once per day on days 1 &amp; 8</li>\n\t<li>Gemcitabine (Gemzar)&nbsp;1000 mg/m<sup>2</sup>&nbsp;IV once per day on days 1 &amp; 8</li>\n</ul>\n\n<p><strong>21-day cycle for 4 cycles</strong></p>\n",
      "emetogenicPotential": "severe",
      "dosageModifications": "<table cellspacing=\"0\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td><strong>Myelotoxicity</strong></td>\n\t\t\t<td colspan=\"3\">\n\t\t\t<ul>\n\t\t\t\t<li>Each cycle should not begin until the WBC is &ge;3000/microL and platelet count is &ge;100,000/microL.Gemcitabine should be withheld on day 8 and/or day 15 of the scheduled treatment if the WBC is &lt;2000/microL or the platelet count is &lt;50,000/microL.&nbsp;If the day 8 or 15 dose of gemcitabine is omitted, the treatment cycle may be shortened to 21 days.</li>\n\t\t\t</ul>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td><strong>Neurologic toxicity</strong></td>\n\t\t\t<td colspan=\"3\">\n\t\t\t<ul>\n\t\t\t\t<li>Neuropathy usually is seen with cumulative doses of cisplatin &gt;400 mg/m<sup>2</sup>, although there is marked interindividual variation. Patients with mild neuropathy can continue to receive full cisplatin doses. However, if the neuropathy interferes with function, the risk of potentially disabling neurotoxicity must be weighed against the benefit of continued treatment.</li>\n\t\t\t</ul>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td><strong>Pulmonary toxicity</strong></td>\n\t\t\t<td colspan=\"3\">\n\t\t\t<ul>\n\t\t\t\t<li>A variety of manifestations of pulmonary toxicity have been reported. Discontinue gemcitabine immediately and permanently.</li>\n\t\t\t</ul>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td><strong>Hepatotoxicity</strong></td>\n\t\t\t<td colspan=\"3\">\n\t\t\t<ul>\n\t\t\t\t<li>Gemcitabine is commonly associated with a transient rise in serum transaminases, but these are seldom of clinical significance. There is insufficient information from clinical studies to allow clear dose recommendations in these patients.</li>\n\t\t\t</ul>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td><strong>Nephrotoxicity</strong></td>\n\t\t\t<td colspan=\"3\">\n\t\t\t<ul>\n\t\t\t\t<li>Hold cisplatin until serum creatinine &lt;1.5 mg/dL and/or blood urea nitrogen &lt;25 mg/dL. For grade &ge;2 nephrotoxicity during treatment (creatinine &gt;1.5 times normal value despite adequate hydration), creatinine clearance should be determined prior to next cycle, and cisplatin dose reduced if &lt;60 mL/min.</li>\n\t\t\t</ul>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td><strong>Thrombotic microangiopathy</strong></td>\n\t\t\t<td colspan=\"3\">\n\t\t\t<ul>\n\t\t\t\t<li>Thrombotic microangiopathy (TMA, also sometimes called thrombotic thrombocytopenic purpura [TTP] or hemolytic uremic syndrome [HUS]) has been associated with gemcitabine, in individuals who have received a large or small cumulative dose. Consider the possibility of TMA if the patient develops Coombs-negative hemolysis, thrombocytopenia, renal failure, and/or neurologic findings. Management consists of drug discontinuation and supportive care, without plasma exchange, as long as there is high confidence in a drug-induced etiology rather than TTP.</li>\n\t\t\t</ul>\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table>\n",
      "references": [
        {
          "id": 790,
          "referenceValue": "Dash A, Pettus JA 4th, Herr HW, Bochner BH, Dalbagni G, Donat SM, Russo P, Boyle MG, Milowsky MI, Bajorin DF. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer. 2008 Nov 1;113(9):2471-7."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 2,
          "level": "NEOADJUVANT"
        }
      ]
    },
    {
      "id": 381,
      "name": "",
      "schedule": "<h4>Immunotherapy</h4>\n\n<ul>\n\t<li>Atezolizumab (Tecentriq)&nbsp;1200 mg IV once on day 1</li>\n</ul>\n\n<p><strong>21-day cycles</strong></p>\n",
      "emetogenicPotential": "none",
      "dosageModifications": "<p>none</p>\n",
      "references": [
        {
          "id": 791,
          "referenceValue": "Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, Dawson NA, van der Heijden MS, Dreicer R, Srinivas S, Retz MM, Joseph RW, Drakaki A, Vaishampayan UN, Sridhar SS, Quinn DI, Durán I, Shaffer DR, Eigl BJ, Grivas PD, Yu EY, Li S, Kadel EE 3rd, Boyd Z, Bourgon R, Hegde PS, Mariathasan S, Thåström A, Abidoye OO, Fine GD, Bajorin DF; IMvigor210 Study Group. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017 Jan 7;389(10064):67-76. Epub 2016 Dec 8."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 633,
      "name": "",
      "schedule": "<p><strong>Binimetinib:&nbsp;</strong>45 mg PO twice daily</p>\n\n<p><strong>Encorafenib:&nbsp;</strong>300 mg PO daily</p>\n\n<p><strong>Cetuximab:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV loading dose, then 250 mg/m<sup>2</sup>&nbsp;IV weekly</p>\n\n<p>Continue treatment until disease progression. Use only for patients with&nbsp;<em>BRAF</em> V600E-mutant mCRC.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 378,
      "name": "",
      "schedule": "<p>Variant 1: -- 3 or 4 cycles&nbsp;</p>\n\n<h4>Chemotherapy</h4>\n\n<ul>\n\t<li>Methotrexate (MTX)&nbsp;30 mg/m<sup>2</sup>&nbsp;IV over 30 minutes once on day 1</li>\n\t<li>Vinblastine (Velban)&nbsp;3 mg/m<sup>2</sup>&nbsp;IV push once on day 2</li>\n\t<li>Doxorubicin (Adriamycin)&nbsp;30 mg/m<sup>2</sup>&nbsp;IV push once on day 2</li>\n\t<li>Cisplatin (Platinol)&nbsp;70 mg/m<sup>2</sup>&nbsp;IV in 1 liter normal saline once on day 2\n\t<ul>\n\t\t<li>Split dose could be used at physician discretion for patients with CrCl less than 60 mL/min/1.73m<sup>2</sup>: 35 mg/m<sup>2</sup>&nbsp;IV once per day on days 1 &amp; 2</li>\n\t</ul>\n\t</li>\n</ul>\n\n<h4>Supportive medications</h4>\n\n<ul>\n\t<li>Pegfilgrastim (Neulasta)&nbsp;6 mg SC once, 24 to 48 hours after completion of chemotherapy</li>\n\t<li>Antiemetics used often included&nbsp;Aprepitant (Emend),&nbsp;Ondansetron (Zofran), and&nbsp;Dexamethasone (Decadron)&nbsp;but were not specified by the trial.</li>\n</ul>\n\n<p><strong>14-day cycle for 3 or 4&nbsp;cycles</strong></p>\n",
      "emetogenicPotential": "severe",
      "dosageModifications": "<table cellspacing=\"0\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td><strong>Myelotoxicity</strong></td>\n\t\t\t<td colspan=\"3\">\n\t\t\t<ul>\n\t\t\t\t<li>Delay treatment cycle until the WBC count is &gt;3000/mm<sup>3</sup>&nbsp;and platelet count is &gt;90,000 mm<sup>3</sup>. Methotrexate and doxorubicin doses should be reduced by 33% in patients who have a nadir WBC &lt;2000/mm<sup>3</sup>.</li>\n\t\t\t</ul>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td><strong>Neurologic toxicity</strong></td>\n\t\t\t<td colspan=\"3\">\n\t\t\t<ul>\n\t\t\t\t<li>Cisplatin therapy should be discontinued when neurologic symptoms are first observed.&nbsp;The manufacturer recommends a dose reduction of vinblastine by 1 mg/m<sup>2</sup>&nbsp;in patients with severe neurotoxicity.</li>\n\t\t\t\t<li>For severe paresthesias and/or constipation, the dose of vinblastine should be reduced by 50%.&nbsp;Vinblastine should be discontinued permanently if an adynamic ileus occurs.</li>\n\t\t\t</ul>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td><strong>Mucositis</strong></td>\n\t\t\t<td colspan=\"3\">\n\t\t\t<ul>\n\t\t\t\t<li>Doses of methotrexate should be reduced by 33% in patients who develop grade 3 or grade 4 mucositis.</li>\n\t\t\t</ul>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td><strong>Cardiotoxicity</strong></td>\n\t\t\t<td colspan=\"3\">\n\t\t\t<ul>\n\t\t\t\t<li>Discontinue doxorubicin in patients who develop signs/symptoms of cardiomyopathy.</li>\n\t\t\t\t<li>Monitor cumulative doxorubicin dose and reassess LVEF periodically during MVAC therapy as clinically indicated.</li>\n\t\t\t</ul>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td><strong>Renal dysfunction</strong></td>\n\t\t\t<td colspan=\"3\">\n\t\t\t<ul>\n\t\t\t\t<li>Hold cisplatin until serum creatinine &lt;1.5 mg/dL or CrCl &gt;55 mL/min and/or BUN &lt;25 mg/dL.</li>\n\t\t\t</ul>\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table>\n",
      "references": [
        {
          "id": 792,
          "referenceValue": "Choueiri TK, Jacobus S, Bellmunt J, Qu A, Appleman LJ, Tretter C, Bubley GJ, Stack EC, Signoretti S, Walsh M, Steele G, Hirsch M, Sweeney CJ, Taplin ME, Kibel AS, Krajewski KM, Kantoff PW, Ross RW, Rosenberg JE. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol. 2014 Jun 20;32(18):1889-94. Epub 2014 May 12."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 2,
          "level": "NEOADJUVANT"
        }
      ]
    },
    {
      "id": 380,
      "name": "",
      "schedule": "<h4>Chemotherapy</h4>\n\n<ul>\n\t<li>Cisplatin (Platinol)&nbsp;35 mg/m<sup>2</sup>&nbsp;IV once per day on days 1 &amp; 8</li>\n\t<li>Gemcitabine (Gemzar)&nbsp;1000 mg/m<sup>2</sup>&nbsp;IV once per day on days 1 &amp; 8</li>\n</ul>\n\n<p><strong>21-day cycle for 4 cycles</strong></p>\n",
      "emetogenicPotential": "severe",
      "dosageModifications": "<table cellspacing=\"0\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td><strong>Myelotoxicity</strong></td>\n\t\t\t<td colspan=\"3\">\n\t\t\t<ul>\n\t\t\t\t<li>Each cycle should not begin until the WBC is &ge;3000/microL and platelet count is &ge;100,000/microL.Gemcitabine should be withheld on day 8 and/or day 15 of the scheduled treatment if the WBC is &lt;2000/microL or the platelet count is &lt;50,000/microL.&nbsp;If the day 8 or 15 dose of gemcitabine is omitted, the treatment cycle may be shortened to 21 days.</li>\n\t\t\t</ul>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td><strong>Neurologic toxicity</strong></td>\n\t\t\t<td colspan=\"3\">\n\t\t\t<ul>\n\t\t\t\t<li>Neuropathy usually is seen with cumulative doses of cisplatin &gt;400 mg/m<sup>2</sup>, although there is marked interindividual variation. Patients with mild neuropathy can continue to receive full cisplatin doses. However, if the neuropathy interferes with function, the risk of potentially disabling neurotoxicity must be weighed against the benefit of continued treatment.</li>\n\t\t\t</ul>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td><strong>Pulmonary toxicity</strong></td>\n\t\t\t<td colspan=\"3\">\n\t\t\t<ul>\n\t\t\t\t<li>A variety of manifestations of pulmonary toxicity have been reported. Discontinue gemcitabine immediately and permanently.</li>\n\t\t\t</ul>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td><strong>Hepatotoxicity</strong></td>\n\t\t\t<td colspan=\"3\">\n\t\t\t<ul>\n\t\t\t\t<li>Gemcitabine is commonly associated with a transient rise in serum transaminases, but these are seldom of clinical significance. There is insufficient information from clinical studies to allow clear dose recommendations in these patients.</li>\n\t\t\t</ul>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td><strong>Nephrotoxicity</strong></td>\n\t\t\t<td colspan=\"3\">\n\t\t\t<ul>\n\t\t\t\t<li>Hold cisplatin until serum creatinine &lt;1.5 mg/dL and/or blood urea nitrogen &lt;25 mg/dL. For grade &ge;2 nephrotoxicity during treatment (creatinine &gt;1.5 times normal value despite adequate hydration), creatinine clearance should be determined prior to next cycle, and cisplatin dose reduced if &lt;60 mL/min.</li>\n\t\t\t</ul>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td><strong>Thrombotic microangiopathy</strong></td>\n\t\t\t<td colspan=\"3\">\n\t\t\t<ul>\n\t\t\t\t<li>Thrombotic microangiopathy (TMA, also sometimes called thrombotic thrombocytopenic purpura [TTP] or hemolytic uremic syndrome [HUS]) has been associated with gemcitabine, in individuals who have received a large or small cumulative dose. Consider the possibility of TMA if the patient develops Coombs-negative hemolysis, thrombocytopenia, renal failure, and/or neurologic findings. Management consists of drug discontinuation and supportive care, without plasma exchange, as long as there is high confidence in a drug-induced etiology rather than TTP.</li>\n\t\t\t</ul>\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table>\n",
      "references": [
        {
          "id": 793,
          "referenceValue": "Dash A, Pettus JA 4th, Herr HW, Bochner BH, Dalbagni G, Donat SM, Russo P, Boyle MG, Milowsky MI, Bajorin DF. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer. 2008 Nov 1;113(9):2471-7"
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 2,
          "level": "NEOADJUVANT"
        }
      ]
    },
    {
      "id": 382,
      "name": "",
      "schedule": "<h4>Immunotherapy</h4>\n\n<ul>\n\t<li>Pembrolizumab (Keytruda)&nbsp;200 mg IV once on day 1</li>\n</ul>\n\n<p><strong>21-day cycles</strong></p>\n",
      "emetogenicPotential": "none",
      "dosageModifications": "",
      "references": [
        {
          "id": 794,
          "referenceValue": "KEYNOTE-052: Balar AV, Castellano D, O'Donnell PH, Grivas P, Vuky J, Powles T, Plimack ER, Hahn NM, de Wit R, Pang L, Savage MJ, Perini RF, Keefe SM, Bajorin D, Bellmunt J. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017 Nov;18(11):1483-1492. Epub 2017 Sep 26."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 383,
      "name": "",
      "schedule": "<h4>Chemotherapy</h4>\n\n<ul>\n\t<li>Gemcitabine (Gemzar)&nbsp;2500 mg/m<sup>2</sup>&nbsp;IV over 30 minutes once on day 1,&nbsp;<strong>given second</strong></li>\n\t<li>Paclitaxel (Taxol)&nbsp;150 mg/m<sup>2</sup>&nbsp;IV over 3 hours once on day 1,&nbsp;<strong>given first</strong></li>\n</ul>\n\n<p><strong>14-day cycle for 6 to 12 cycles</strong></p>\n",
      "emetogenicPotential": "moderate",
      "dosageModifications": "<table cellspacing=\"0\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td><strong>Myelotoxicity</strong></td>\n\t\t\t<td colspan=\"3\">\n\t\t\t<ul>\n\t\t\t\t<li><strong>Do not administer</strong>&nbsp;paclitaxel and gemcitabine on day 1 of each new cycle unless ANC is &gt;1500/microL and platelet count is &gt;100,000/microL.&nbsp;For patients who develop neutropenic fever OR ANC &lt;500/microL for &gt;7 days or delay of next cycle by &gt;7 days or thrombocytopenia, withhold treatment until counts recover to an ANC of at least 1500/microL and platelet count of at least 100,000/microL on day 1, or to an ANC of at least 500/microL and platelet count of at least 50,000/microL on days 8 or 15 of the cycle.&nbsp;Upon resumption of therapy, reduce both drugs by 20 to 25% upon the first occurrence, an additional 20 to 25% on the second recurrence, and discontinue treatment for a third occurrence.</li>\n\t\t\t</ul>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td><strong>Sepsis</strong></td>\n\t\t\t<td colspan=\"3\">\n\t\t\t<ul>\n\t\t\t\t<li>Sepsis has occurred in patients with or without neutropenia (risk factors are biliary obstruction or presence of a biliary stent). Initiate broad-spectrum antibiotics in the presence of fever, even if not neutropenic. Interrupt paclitaxel and gemcitabine until sepsis resolves and, if neutropenic, until neutrophils are at least 1500/microL, then resume at lower doses.</li>\n\t\t\t</ul>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td><strong>Thrombotic microangiopathy</strong></td>\n\t\t\t<td colspan=\"3\">\n\t\t\t<ul>\n\t\t\t\t<li>Thrombotic microangiopathy (TMA; also sometimes called thrombotic thrombocytopenic purpura [TTP] or hemolytic uremic syndrome [HUS]) has been associated with gemcitabine in individuals who have received a large or small cumulative dose.&nbsp;Consider the possibility of TMA if the patient develops Coombs-negative hemolysis, thrombocytopenia, renal failure, and/or neurologic findings. Management consists of drug discontinuation and supportive care, without plasma exchange, as long as there is high confidence in a drug-induced etiology rather than TTP.</li>\n\t\t\t</ul>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td><strong>Peripheral neuropathy</strong></td>\n\t\t\t<td colspan=\"3\">\n\t\t\t<ul>\n\t\t\t\t<li>For days 1,8, and 15: withhold paclitaxel for grade&nbsp;3 or 4 neuropathy.<span style=\"font-size:13.3333px\"> </span>Resume paclitaxel at 20 to 25 percent reduced doses when peripheral neuropathy improves to grade&nbsp;&le;2 or completely resolves .&nbsp;Upon resumption of therapy, reduce paclitaxel by 20 to 25% for the first occurrence of grade 3 or 4 peripheral neuropathy, and an additional 20 to 25% for the second occurrence<sup>.&nbsp;</sup>Discontinue treatment for a third occurrence.&nbsp;For grade 2 peripheral neuropathy, decrease paclitaxel dose by 20 to 25%.</li>\n\t\t\t</ul>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td><strong>Hepatotoxicity</strong></td>\n\t\t\t<td colspan=\"3\">\n\t\t\t<ul>\n\t\t\t\t<li>Gemcitabine is commonly associated with a transient rise in serum transaminases, but these are seldom of clinical significance. There is insufficient information from clinical studies to allow clear gemcitabine dose recommendations in these patients.</li>\n\t\t\t\t<li>Reduced starting doses of paclitaxel are recommended for individuals with pre-existing moderate to severe hepatic impairment; the need for further dose adjustments in subsequent courses based upon ongoing hepatotoxicity should be based on individual tolerance and clinician judgment.</li>\n\t\t\t\t<li>One protocol recommends the following:&nbsp;on days 1, 8, and 15, for serum bilirubin elevations &ge;grade 2, withhold both drugs until toxicity resolves to grade &le;1; resume treatment at the same dose as before. If not resolved, discontinue therapy.</li>\n\t\t\t</ul>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td><strong>Pulmonary toxicity</strong></td>\n\t\t\t<td colspan=\"3\">\n\t\t\t<ul>\n\t\t\t\t<li>A variety of manifestations of pulmonary toxicity have been reported with gemcitabine. Pneumonitis has occurred with the use of paclitaxel in combination with gemcitabine. Permanently discontinue treatment with both agents.</li>\n\t\t\t</ul>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td><strong>Other toxicity</strong></td>\n\t\t\t<td colspan=\"3\">\n\t\t\t<ul>\n\t\t\t\t<li>On days 1, 8, and 15: for grade 3 cutaneous toxicity, hold both drugs until recovered to &le;grade 2, and reduce paclitaxel dose by 20 to 25% and gemcitabine dose by 20%.<span style=\"font-size:13.3333px\"> </span>For grade 3 mucositis or diarrhea, withhold therapy until it&nbsp;improves to &le;grade 1, then resume with reduction of paclitaxel dose by 20 to 25% and gemcitabine dose by 20%.</li>\n\t\t\t</ul>\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table>\n",
      "references": [
        {
          "id": 795,
          "referenceValue": "Calabrò F, Lorusso V, Rosati G, Manzione L, Frassineti L, Sava T, Di Paula ED, Alonso S, Sternberg CN. Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma. Cancer. 2009 Jun 15;115(12):2652-9"
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 384,
      "name": "",
      "schedule": "<h4>Chemotherapy</h4>\n\n<ul>\n\t<li>Gemcitabine (Gemzar)&nbsp;1000 mg/m<sup>2</sup>&nbsp;IV once per day on days 1, 8, 15</li>\n\t<li>Paclitaxel (Taxol)&nbsp;200 mg/m<sup>2</sup>&nbsp;IV over 3 hours once on day 1</li>\n</ul>\n\n<p><strong>21-day cycle for up to 6 cycles</strong></p>\n",
      "emetogenicPotential": "moderate",
      "dosageModifications": "<table cellspacing=\"0\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td><strong>Myelotoxicity</strong></td>\n\t\t\t<td colspan=\"3\">\n\t\t\t<ul>\n\t\t\t\t<li><strong>Do not administer</strong>&nbsp;paclitaxel and gemcitabine on day 1 of each new cycle unless ANC is &gt;1500/microL and platelet count is &gt;100,000/microL.&nbsp;For patients who develop neutropenic fever OR ANC &lt;500/microL for &gt;7 days or delay of next cycle by &gt;7 days or thrombocytopenia, withhold treatment until counts recover to an ANC of at least 1500/microL and platelet count of at least 100,000/microL on day 1, or to an ANC of at least 500/microL and platelet count of at least 50,000/microL on days 8 or 15 of the cycle.&nbsp;Upon resumption of therapy, reduce both drugs by 20 to 25% upon the first occurrence, an additional 20 to 25% on the second recurrence, and discontinue treatment for a third occurrence.</li>\n\t\t\t</ul>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td><strong>Sepsis</strong></td>\n\t\t\t<td colspan=\"3\">\n\t\t\t<ul>\n\t\t\t\t<li>Sepsis has occurred in patients with or without neutropenia (risk factors are biliary obstruction or presence of a biliary stent). Initiate broad-spectrum antibiotics in the presence of fever, even if not neutropenic. Interrupt paclitaxel and gemcitabine until sepsis resolves and, if neutropenic, until neutrophils are at least 1500/microL, then resume at lower doses.</li>\n\t\t\t</ul>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td><strong>Thrombotic microangiopathy</strong></td>\n\t\t\t<td colspan=\"3\">\n\t\t\t<ul>\n\t\t\t\t<li>Thrombotic microangiopathy (TMA; also sometimes called thrombotic thrombocytopenic purpura [TTP] or hemolytic uremic syndrome [HUS]) has been associated with gemcitabine in individuals who have received a large or small cumulative dose.&nbsp;Consider the possibility of TMA if the patient develops Coombs-negative hemolysis, thrombocytopenia, renal failure, and/or neurologic findings. Management consists of drug discontinuation and supportive care, without plasma exchange, as long as there is high confidence in a drug-induced etiology rather than TTP.</li>\n\t\t\t</ul>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td><strong>Peripheral neuropathy</strong></td>\n\t\t\t<td colspan=\"3\">\n\t\t\t<ul>\n\t\t\t\t<li>For days 1,8, and 15: withhold paclitaxel for grade&nbsp;3 or 4 neuropathy.<span style=\"font-size:13.3333px\"> </span>Resume paclitaxel at 20 to 25 percent reduced doses when peripheral neuropathy improves to grade&nbsp;&le;2 or completely resolves .&nbsp;Upon resumption of therapy, reduce paclitaxel by 20 to 25% for the first occurrence of grade 3 or 4 peripheral neuropathy, and an additional 20 to 25% for the second occurrence<sup>.&nbsp;</sup>Discontinue treatment for a third occurrence.&nbsp;For grade 2 peripheral neuropathy, decrease paclitaxel dose by 20 to 25%.</li>\n\t\t\t</ul>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td><strong>Hepatotoxicity</strong></td>\n\t\t\t<td colspan=\"3\">\n\t\t\t<ul>\n\t\t\t\t<li>Gemcitabine is commonly associated with a transient rise in serum transaminases, but these are seldom of clinical significance. There is insufficient information from clinical studies to allow clear gemcitabine dose recommendations in these patients.</li>\n\t\t\t\t<li>Reduced starting doses of paclitaxel are recommended for individuals with pre-existing moderate to severe hepatic impairment; the need for further dose adjustments in subsequent courses based upon ongoing hepatotoxicity should be based on individual tolerance and clinician judgment.</li>\n\t\t\t\t<li>One protocol recommends the following:&nbsp;on days 1, 8, and 15, for serum bilirubin elevations &ge;grade 2, withhold both drugs until toxicity resolves to grade &le;1; resume treatment at the same dose as before. If not resolved, discontinue therapy.</li>\n\t\t\t</ul>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td><strong>Pulmonary toxicity</strong></td>\n\t\t\t<td colspan=\"3\">\n\t\t\t<ul>\n\t\t\t\t<li>A variety of manifestations of pulmonary toxicity have been reported with gemcitabine. Pneumonitis has occurred with the use of paclitaxel in combination with gemcitabine. Permanently discontinue treatment with both agents.</li>\n\t\t\t</ul>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td><strong>Other toxicity</strong></td>\n\t\t\t<td colspan=\"3\">\n\t\t\t<ul>\n\t\t\t\t<li>On days 1, 8, and 15: for grade 3 cutaneous toxicity, hold both drugs until recovered to &le;grade 2, and reduce paclitaxel dose by 20 to 25% and gemcitabine dose by 20%.<span style=\"font-size:13.3333px\"> </span>For grade 3 mucositis or diarrhea, withhold therapy until it&nbsp;improves to &le;grade 1, then resume with reduction of paclitaxel dose by 20 to 25% and gemcitabine dose by 20%.</li>\n\t\t\t</ul>\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table>\n",
      "references": [
        {
          "id": 796,
          "referenceValue": "Meluch AA, Greco FA, Burris HA 3rd, O'Rourke T, Ortega G, Steis RG, Morrissey LH, Johnson V, Hainsworth JD. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. J Clin Oncol. 2001 Jun 15;19(12):3018-24."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 385,
      "name": "",
      "schedule": "<h4>Immunotherapy</h4>\n\n<ul>\n\t<li>Nivolumab (Opdivo)&nbsp;3 mg/kg IV once on day 1\n\t<ul>\n\t\t<li><em>The FDA-approved dose which is listed in the package insert is 240 mg IV over 60 minutes once on day 1</em></li>\n\t</ul>\n\t</li>\n</ul>\n\n<p><strong>14-day cycles</strong></p>\n",
      "emetogenicPotential": "none",
      "dosageModifications": "<p>none</p>\n",
      "references": [
        {
          "id": 797,
          "referenceValue": "CheckMate 275: Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, Plimack ER, Vaena D, Grimm MO, Bracarda S, Arranz JÁ, Pal S, Ohyama C, Saci A, Qu X, Lambert A, Krishnan S, Azrilevich A, Galsky MD. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017 Mar;18(3):312-322. Epub 2017 Jan 25."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 386,
      "name": "",
      "schedule": "<p>&nbsp;</p>\n\n<h4>Chemotherapy</h4>\n\n<ul>\n\t<li>Paclitaxel (Taxol)&nbsp;175 mg/m<sup>2</sup>&nbsp;IV once on day 1</li>\n</ul>\n\n<p><strong>21-day cycles</strong></p>\n",
      "emetogenicPotential": "moderate",
      "dosageModifications": "<table border=\"1\" cellpadding=\"1\" cellspacing=\"1\" style=\"width:100%\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td style=\"text-align:center\">Hepatic Impairment</td>\n\t\t\t<td>\n\t\t\t<p>Transaminases &lt;10 times ULN and bilirubin level &le;1.25 times ULN: 175 mg/m<sup>2</sup></p>\n\n\t\t\t<p>Transaminases &lt;10 times ULN and bilirubin level 1.26 to 2 times ULN: 135 mg/m<sup>2</sup></p>\n\n\t\t\t<p>Transaminases &lt;10 times ULN and bilirubin level 2.01 to 5 times ULN: 90 mg/m<sup>2</sup></p>\n\n\t\t\t<p>Transaminases &ge;10 times ULN or bilirubin level &gt;5 times ULN: Avoid use</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"text-align:center\">Renal Impairement</td>\n\t\t\t<td style=\"text-align:center\">none</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"text-align:center\">Myelosuppression</td>\n\t\t\t<td>Courses of paclitaxel should not be repeated until the neutrophil count is &ge;1,500/mm<sup>3</sup>&nbsp;and the platelet count is &ge;100,000/mm<sup>3</sup>; reduce dosage by 20% for patients experiencing severe peripheral neuropathy or severe neutropenia (neutrophil &lt;500/mm<sup>3</sup>&nbsp;for a week or longer)</td>\n\t\t</tr>\n\t</tbody>\n</table>\n\n<p>&nbsp;</p>\n\n<p>&nbsp;</p>\n",
      "references": [
        {
          "id": 799,
          "referenceValue": "Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF; KEYNOTE-045 Investigators. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017 Mar 16;376(11):1015-1026. Epub 2017 Feb 17"
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 392,
      "name": "",
      "schedule": "<h4>Chemotherapy</h4>\n\n<ul>\n\t<li>Carboplatin (Paraplatin)&nbsp;AUC 5 IV over 30 to 60 minutes once on day 2</li>\n\t<li>Gemcitabine (Gemzar)&nbsp;1250 mg/m<sup>2</sup>&nbsp;IV over 30 to 60 minutes once per day on days 1 &amp; 8</li>\n</ul>\n\n<p><strong>21-day cycle for up to 6 cycles</strong></p>\n",
      "emetogenicPotential": "moderate",
      "dosageModifications": "<table cellspacing=\"0\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td><strong>Myelotoxicity</strong></td>\n\t\t\t<td colspan=\"3\">\n\t\t\t<ul>\n\t\t\t\t<li>Chemotherapy should be delayed for one week if the ANC is &lt;1000/microL and/or the platelet count is &lt;75,000/microL prior to the start of each cycle. Doses for subsequent cycles are reduced by 25% if the ANC is 1000 to 1499/microL or platelets are 75,000 to 99,000/microL on day 22 after the preceding cycle, or if the nadir ANC was &lt;500/microL. A 50% dose reduction should be considered if the platelet nadir is &lt;50,000/microL. Consider discontinuing therapy if a patient qualifies for a third dose reduction or a cycle is delayed by more than 21 days.</li>\n\t\t\t\t<li>Omissions or reductions of the gemcitabine dose on day 8 of a cycle are allowed and are based upon the same criteria as on day 1. Dose reductions should be maintained for subsequent cycles.</li>\n\t\t\t</ul>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td><strong>Thrombotic microangiopathy</strong></td>\n\t\t\t<td colspan=\"3\">\n\t\t\t<ul>\n\t\t\t\t<li>Thrombotic microangiopathy (TMA, also sometimes called thrombotic thrombocytopenic purpura [TTP] or hemolytic uremic syndrome [HUS]) has been associated with gemcitabine, in individuals who have received a large or small cumulative dose.&nbsp;Consider the possibility of TMA if the patient develops Coombs-negative hemolysis, thrombocytopenia, renal failure, and/or neurologic findings. Management consists of drug discontinuation and supportive care, without plasma exchange, as long as there is high confidence in a drug-induced etiology rather than TTP.</li>\n\t\t\t</ul>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td><strong>Pulmonary toxicity</strong></td>\n\t\t\t<td colspan=\"3\">\n\t\t\t<ul>\n\t\t\t\t<li>A variety of manifestations of pulmonary toxicity have been reported. Discontinue gemcitabine immediately and permanently.</li>\n\t\t\t</ul>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td><strong>Other nonhematologic toxicity<sup>&sect;</sup></strong></td>\n\t\t\t<td colspan=\"3\">\n\t\t\t<ul>\n\t\t\t\t<li>Creatinine clearance should be &ge;45 mL/min and grade 3 or 4 toxicities should be resolved prior to beginning therapy. A delay in therapy by one week should be considered if toxicities are not resolved or the creatinine clearance &le;45 mL/min. It is recommended that subsequent cycles be dose reduced by 25% if the patient has grade 3 or 4 toxicity (excluding grade 3 or 4 mucositis, in which a 50% dose reduction is warranted) and discontinued if a patient qualifies for a third dose reduction or a cycle is delayed by more than 21 days.</li>\n\t\t\t\t<li>Omissions or reductions of the gemcitabine dose on day 8 of a cycle are allowed. Dose reductions should be maintained for subsequent cycles.</li>\n\t\t\t</ul>\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table>\n",
      "references": [
        {
          "id": 806,
          "referenceValue": "Dogliotti L, Cartenì G, Siena S, Bertetto O, Martoni A, Bono A, Amadori D, Onat H, Marini L. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol. 2007 Jul;52(1):134-41. Epub 2006 Dec 26"
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 634,
      "name": "",
      "schedule": "<p><strong>Nivolumab:&nbsp;</strong>3 mg/kg IV on day 1</p>\n\n<p><strong>Ipilimumab:&nbsp;</strong>1 mg/kg IV on day 1</p>\n\n<p>Repeat cycle every 21 days for 4 cycles and then treat with nivolumab at 3 mg/kg or 240 mg IV every 14 days until disease progression or toxicity.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 387,
      "name": "",
      "schedule": "<h4>Chemotherapy</h4>\n\n<ul>\n\t<li>Docetaxel (Taxotere)&nbsp;75 mg/m<sup>2</sup>&nbsp;IV once on day 1</li>\n</ul>\n\n<p><strong>21-day cycles</strong></p>\n",
      "emetogenicPotential": "low",
      "dosageModifications": "<table cellspacing=\"0\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td><strong>Myelotoxicity</strong></td>\n\t\t\t<td colspan=\"3\">\n\t\t\t<ul>\n\t\t\t\t<li>Docetaxel should only be administered if the absolute neutrophil count is &gt;1500 cells/microL. Reduce docetaxel to 60 mg/m<sup>2</sup>&nbsp;for subsequent cycles for severe prolonged neutropenia (&lt;500 cells/microL lasting seven days or more), febrile neutropenia, or an infection with life-threatening consequences.</li>\n\t\t\t</ul>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td><strong>Cutaneous, mucosal, and neurologic toxicity</strong></td>\n\t\t\t<td colspan=\"3\">\n\t\t\t<ul>\n\t\t\t\t<li>For severe or cumulative cutaneous reactions (erythema, desquamation), grade 3 or 4 stomatitis or &gt;grade 2 neurosensory signs and/or symptoms, reduce docetaxel dose to 60 mg/m<sup>2</sup>&nbsp;Discontinue docetaxel if toxicity persists at the lower dose.</li>\n\t\t\t</ul>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td><strong>Hepatotoxicity</strong></td>\n\t\t\t<td colspan=\"3\">\n\t\t\t<ul>\n\t\t\t\t<li>Docetaxel dose reduction may be needed for patients who develop significant alterations in transaminases and alkaline phosphatase during therapy. Docetaxel should not be administered to patients with a serum bilirubin above the ULN or to patients with transaminase elevations &gt;1.5 times the ULN in conjunction with alkaline phosphatase &gt;2.5 times the ULN.</li>\n\t\t\t</ul>\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table>\n",
      "references": [
        {
          "id": 800,
          "referenceValue": "McCaffrey JA, Hilton S, Mazumdar M, Sadan S, Kelly WK, Scher HI, Bajorin DF. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol. 1997 May;15(5):1853-7"
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 388,
      "name": "",
      "schedule": "<h4>Immunotherapy</h4>\n\n<ul>\n\t<li>Durvalumab (Imfinzi)&nbsp;10 mg/kg IV over 60 minutes once on day 1</li>\n</ul>\n\n<p><strong>14-day cycle for up to 26 cycles (1 year)</strong>. Patients could receive another 12 months of treatment if they experienced disease progression, had not received other anticancer treatment, and did not meet criteria for discontinuation.</p>\n",
      "emetogenicPotential": "low",
      "dosageModifications": "<p>none</p>\n",
      "references": [
        {
          "id": 801,
          "referenceValue": "Study 1108: Massard C, Gordon MS, Sharma S, Rafii S, Wainberg ZA, Luke J, Curiel TJ, Colon-Otero G, Hamid O, Sanborn RE, O'Donnell PH, Drakaki A, Tan W, Kurland JF, Rebelatto MC, Jin X, Blake-Haskins JA, Gupta A, Segal NH. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol. 2016 Sep 10;34(26):3119-25. Epub 2016 Jun 6."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 389,
      "name": "",
      "schedule": "<h4>Immunotherapy</h4>\n\n<ul>\n\t<li>Avelumab (Bavencio)&nbsp;10 mg/kg IV over 60 minutes once on day 1</li>\n</ul>\n",
      "emetogenicPotential": "low",
      "dosageModifications": "<p>none</p>\n",
      "references": [
        {
          "id": 802,
          "referenceValue": "Phase 1: Apolo AB, Infante JR, Balmanoukian A, Patel MR, Wang D, Kelly K, Mega AE, Britten CD, Ravaud A, Mita AC, Safran H, Stinchcombe TE, Srdanov M, Gelb AB, Schlichting M, Chin K, Gulley JL. Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: Results from a multicenter, phase Ib study. J Clin Oncol. 2017 Jul 1;35(19):2117-2124. Epub 2017 Apr 4."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 390,
      "name": "",
      "schedule": "<h4>Biomarker eligibility criteria</h4>\n\n<ul>\n\t<li>Alterations: FGFR3 mutation, FGFR2 fusion, or FGFR3 fusion</li>\n</ul>\n\n<h4>Chemotherapy</h4>\n\n<ul>\n\t<li>Erdafitinib (Balversa)&nbsp;8 mg PO once per day\n\t<ul>\n\t\t<li>If serum phosphorus level and tolerability are acceptable at days 14 to 21, increase to 9 mg PO once per day</li>\n\t\t<li>Additional dose adjustments per package insert</li>\n\t</ul>\n\t</li>\n</ul>\n",
      "emetogenicPotential": "low",
      "dosageModifications": "<table border=\"1\" cellpadding=\"1\" cellspacing=\"1\" style=\"width:100%\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td>Renal Impairement</td>\n\t\t\t<td>none</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>Hepatic Impairement</td>\n\t\t\t<td>none</td>\n\t\t</tr>\n\t</tbody>\n</table>\n\n<p><strong>Dose at the time of toxicity: 8 mg once daily.</strong></p>\n\n<p>First dose reduction level: 6 mg once daily.</p>\n\n<p>Second dose reduction level: 5 mg once daily.</p>\n\n<p>Third dose reduction level: 4 mg once daily.</p>\n\n<p>Discontinue if unable to tolerate 4 mg once daily.</p>\n\n<p>&nbsp;</p>\n\n<table border=\"1\" cellpadding=\"1\" cellspacing=\"1\" style=\"width:100%\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td><em>Hyperphosphatemia:</em>&nbsp;<strong>Note:&nbsp;</strong>Restrict phosphate intake to 600 to 800 mg daily; if serum phosphate is &gt;7 mg/dL, consider initiating an oral phosphate binder until phosphate level is &lt;5.5 mg/dL.</td>\n\t\t\t<td>\n\t\t\t<p>Phosphate level 5.6 to 6.9 mg/dL: Continue erdafitinib at current dose.</p>\n\n\t\t\t<p>Phosphate level 7 to 9 mg/dL: Interrupt erdafitinib therapy and assess serum phosphate weekly; when level is &lt;5.5 mg/dL (or baseline), reinitiate erdafitinib at the same dose. If hyperphosphatemia persisted for &gt;1 week, consider dose reduction.</p>\n\n\t\t\t<p>Phosphate level &gt;9 mg/dL: Interrupt erdafitinib therapy and assess serum phosphate weekly; when level is &lt;5.5 mg/dL (or baseline), may reinitiate erdafitinib at the next lower dose level.</p>\n\n\t\t\t<p>Phosphate level &gt;10 mg/dL, or significant alteration in baseline renal function, or grade 3 hypercalcemia: Interrupt erdafitinib therapy and assess serum phosphate weekly; when level is &lt;5.5 mg/dL (or baseline), may reinitiate erdafitinib at 2 dose levels lower.</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td><em>Ocular toxicity (central serous retinopathy/retinal pigment epithelial detachment)</em></td>\n\t\t\t<td>\n\t\t\t<p>Grade 1 (asymptomatic; clinical or diagnostic observations only): Interrupt erdafitinib therapy until resolution; if resolves within 4 weeks, reinitiate erdafitinib at the next lower dose level. If no recurrence for one month, may consider re-escalating the dose. If central serous retinopathy/retinal pigment epithelial detachment is stable for 2 consecutive eye exams (but not resolved), reinitiate erdafitinib at the next lower dose level.</p>\n\n\t\t\t<p>Grade 2 (visual acuity &ge;20/40 or &le;3 lines of decreased vision from baseline): Interrupt erdafitinib therapy until resolution; if resolves within 4 weeks, may reinitiate erdafitinib at the next lower dose level.</p>\n\n\t\t\t<p>Grade 3 (visual acuity &lt;20/40 or &gt;3 lines of decreased vision from baseline): Interrupt erdafitinib therapy until resolution; if resolves within 4 weeks, may reinitiate erdafitinib at 2 dose levels lower. If grade 3 toxicity recurs, consider permanent discontinuation.</p>\n\n\t\t\t<p>Grade 4 (visual acuity &le;20/200 in affected eye): Permanently discontinue erdafitinib.</p>\n\n\t\t\t<p>Dry eye symptoms: Administer dry eye prophylaxis (with ocular demulcents) as needed.</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td><em>Other toxicity:</em></td>\n\t\t\t<td>\n\t\t\t<p>Grade 3: Interrupt erdafitinib therapy until improvement to grade 1 or baseline, then may reinitiate at the next lower dose level.</p>\n\n\t\t\t<p>Grade 4: Permanently discontinue erdafitinib.</p>\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table>\n\n<p>&nbsp;</p>\n",
      "references": [
        {
          "id": 803,
          "referenceValue": "BLC2001: Loriot Y, Necchi A, Park SH, Garcia-Donas J, Huddart R, Burgess E, Fleming M, Rezazadeh A, Mellado B, Varlamov S, Joshi M, Duran I, Tagawa ST, Zakharia Y, Zhong B, Stuyckens K, Santiago-Walker A, De Porre P, O'Hagan A, Avadhani A, Siefker-Radtke AO; BLC2001 Study Group. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. 2019 Jul 25;381(4):338-348."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 391,
      "name": "",
      "schedule": "<h4>Chemotherapy</h4>\n\n<ul>\n\t<li>Carboplatin (Paraplatin)&nbsp;AUC 4.5 IV over 60 minutes once on day 1,&nbsp;<strong>given second</strong></li>\n\t<li>Gemcitabine (Gemzar)&nbsp;1000 mg/m<sup>2</sup>&nbsp;IV over 30 minutes once per day on days 1 &amp; 8,&nbsp;<strong>given first</strong></li>\n</ul>\n\n<p><strong>21-day cycles</strong></p>\n\n<p><em>Patients who achieved complete response were given two additional cycles of treatment.</em></p>\n",
      "emetogenicPotential": "moderate",
      "dosageModifications": "<table cellspacing=\"0\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td><strong>Myelotoxicity</strong></td>\n\t\t\t<td colspan=\"3\">\n\t\t\t<ul>\n\t\t\t\t<li>Chemotherapy should be delayed for one week if the ANC is &lt;1000/microL and/or the platelet count is &lt;75,000/microL prior to the start of each cycle. Doses for subsequent cycles are reduced by 25% if the ANC is 1000 to 1499/microL or platelets are 75,000 to 99,000/microL on day 22 after the preceding cycle, or if the nadir ANC was &lt;500/microL. A 50% dose reduction should be considered if the platelet nadir is &lt;50,000/microL. Consider discontinuing therapy if a patient qualifies for a third dose reduction or a cycle is delayed by more than 21 days.</li>\n\t\t\t\t<li>Omissions or reductions of the gemcitabine dose on day 8 of a cycle are allowed and are based upon the same criteria as on day 1. Dose reductions should be maintained for subsequent cycles.</li>\n\t\t\t</ul>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td><strong>Thrombotic microangiopathy</strong></td>\n\t\t\t<td colspan=\"3\">\n\t\t\t<ul>\n\t\t\t\t<li>Thrombotic microangiopathy (TMA, also sometimes called thrombotic thrombocytopenic purpura [TTP] or hemolytic uremic syndrome [HUS]) has been associated with gemcitabine, in individuals who have received a large or small cumulative dose.&nbsp;Consider the possibility of TMA if the patient develops Coombs-negative hemolysis, thrombocytopenia, renal failure, and/or neurologic findings. Management consists of drug discontinuation and supportive care, without plasma exchange, as long as there is high confidence in a drug-induced etiology rather than TTP.</li>\n\t\t\t</ul>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td><strong>Pulmonary toxicity</strong></td>\n\t\t\t<td colspan=\"3\">\n\t\t\t<ul>\n\t\t\t\t<li>A variety of manifestations of pulmonary toxicity have been reported. Discontinue gemcitabine immediately and permanently.</li>\n\t\t\t</ul>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td><strong>Other nonhematologic toxicity<sup>&sect;</sup></strong></td>\n\t\t\t<td colspan=\"3\">\n\t\t\t<ul>\n\t\t\t\t<li>Creatinine clearance should be &ge;45 mL/min and grade 3 or 4 toxicities should be resolved prior to beginning therapy. A delay in therapy by one week should be considered if toxicities are not resolved or the creatinine clearance &le;45 mL/min. It is recommended that subsequent cycles be dose reduced by 25% if the patient has grade 3 or 4 toxicity (excluding grade 3 or 4 mucositis, in which a 50% dose reduction is warranted) and discontinued if a patient qualifies for a third dose reduction or a cycle is delayed by more than 21 days.</li>\n\t\t\t\t<li>Omissions or reductions of the gemcitabine dose on day 8 of a cycle are allowed. Dose reductions should be maintained for subsequent cycles.</li>\n\t\t\t</ul>\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table>\n",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 708,
      "name": "",
      "schedule": "<p><strong>Gemcitabine:&nbsp;</strong>750 mg/m<sup>2</sup>&nbsp;IV over 75 minutes on days 4 and 11</p>\n\n<p><strong>Docetaxel:&nbsp;</strong>30 mg/m<sup>2</sup>&nbsp;IV on days 4 and 11</p>\n\n<p><strong>Capecitabine:&nbsp;</strong>750 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-14</p>\n\n<p>Repeat cycle every 3 weeks.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 393,
      "name": "",
      "schedule": "<h4>Chemotherapy</h4>\n\n<ul>\n\t<li>Enfortumab vedotin (Padcev)&nbsp;1.25 mg/kg (maximum dose of 125 mg) IV over 30 minutes once per day on days 1, 8, 15</li>\n</ul>\n\n<p><strong>28-day cycles</strong></p>\n",
      "emetogenicPotential": "moderate",
      "dosageModifications": "<table align=\"center\" border=\"1\" cellpadding=\"1\" cellspacing=\"1\" style=\"width:100%\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td style=\"text-align:center\">Renal Impairment</td>\n\t\t\t<td style=\"text-align:center\">none</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\"text-align:center\">Hepatic Impairment</td>\n\t\t\t<td style=\"text-align:center\">none</td>\n\t\t</tr>\n\t</tbody>\n</table>\n\n<p>&nbsp;</p>\n\n<table border=\"1\">\n\t<thead>\n\t\t<tr>\n\t\t\t<th colspan=\"2\">\n\t\t\t<p><strong>Recommended Enfortumab Vedotin Dosage Reduction Levels</strong></p>\n\t\t\t</th>\n\t\t</tr>\n\t</thead>\n\t<tbody>\n\t\t<tr>\n\t\t\t<td>\n\t\t\t<p>Initial (usual) dose</p>\n\t\t\t</td>\n\t\t\t<td>\n\t\t\t<p>1.25 mg/kg up to a maximum of 125 mg</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>\n\t\t\t<p>First dose reduction level</p>\n\t\t\t</td>\n\t\t\t<td>\n\t\t\t<p>1 mg/kg up to a maximum of 100 mg</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>\n\t\t\t<p>Second dose reduction level</p>\n\t\t\t</td>\n\t\t\t<td>\n\t\t\t<p>0.75 mg/kg up to a maximum of 75 mg</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>\n\t\t\t<p>Third dosage reduction level</p>\n\t\t\t</td>\n\t\t\t<td>\n\t\t\t<p>0.5 mg/kg up to a maximum of 50 mg</p>\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table>\n\n<table border=\"1\">\n\t<thead>\n\t\t<tr>\n\t\t\t<th colspan=\"3\">\n\t\t\t<p><strong>Enfortumab Vedotin Dosage Adjustment for Toxicities</strong></p>\n\t\t\t</th>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<th>\n\t\t\t<p><strong>Toxicity</strong></p>\n\t\t\t</th>\n\t\t\t<th>\n\t\t\t<p>Severity<sup>a</sup></p>\n\t\t\t</th>\n\t\t\t<th>\n\t\t\t<p>Enfortumab Vedotin Dose Modification</p>\n\t\t\t</th>\n\t\t</tr>\n\t</thead>\n\t<tfoot>\n\t\t<tr>\n\t\t\t<td colspan=\"3\">\n\t\t\t<p><sup>a</sup>Grade 1 is mild, grade 2 is moderate, grade 3 is severe, and grade 4 is life-threatening.</p>\n\t\t\t</td>\n\t\t</tr>\n\t</tfoot>\n\t<tbody>\n\t\t<tr>\n\t\t\t<td rowspan=\"2\">\n\t\t\t<p>Hematologic toxicities</p>\n\t\t\t</td>\n\t\t\t<td>\n\t\t\t<p>Grade 3, or grade 2 thrombocytopenia</p>\n\t\t\t</td>\n\t\t\t<td>\n\t\t\t<p>Withhold enfortumab vedotin until &le; grade 1, then resume treatment at the same dose level or consider dose reduction by 1 dose level.</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>\n\t\t\t<p>Grade 4</p>\n\t\t\t</td>\n\t\t\t<td>\n\t\t\t<p>Withhold enfortumab vedotin until &le; grade 1, then reduce dose by 1 dose level or discontinue treatment.</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>\n\t\t\t<p>Hyperglycemia</p>\n\t\t\t</td>\n\t\t\t<td>\n\t\t\t<p>Blood glucose &gt;250 mg/dL</p>\n\t\t\t</td>\n\t\t\t<td>\n\t\t\t<p>Withhold enfortumab vedotin until elevated blood glucose has improved to &le;250 mg/dL, then resume treatment at the same dose level.</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td rowspan=\"2\">\n\t\t\t<p>Peripheral neuropathy</p>\n\t\t\t</td>\n\t\t\t<td>\n\t\t\t<p>Grade 2</p>\n\t\t\t</td>\n\t\t\t<td>\n\t\t\t<p>Withhold enfortumab vedotin until &le; grade 1, then resume treatment at the same dose level (if first occurrence). For a recurrence, withhold until &le; grade 1, then resume treatment with the dose reduced by one dose level.</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>\n\t\t\t<p>Grade 3 or higher</p>\n\t\t\t</td>\n\t\t\t<td>\n\t\t\t<p>Permanently discontinue enfortumab vedotin.</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td rowspan=\"2\">\n\t\t\t<p>Dermatologic toxicity (skin reactions)</p>\n\t\t\t</td>\n\t\t\t<td>\n\t\t\t<p>Grade 3 (severe)</p>\n\t\t\t</td>\n\t\t\t<td>\n\t\t\t<p>Withhold enfortumab vedotin until &le; grade 1, then resume treatment at the same dose level or consider dose reduction by 1 dose level.</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>\n\t\t\t<p>Grade 4 or recurrent grade 3</p>\n\t\t\t</td>\n\t\t\t<td>\n\t\t\t<p>Permanently discontinue enfortumab vedotin.</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td rowspan=\"2\">\n\t\t\t<p>Other nonhematologic toxicity</p>\n\t\t\t</td>\n\t\t\t<td>\n\t\t\t<p>Grade 3</p>\n\t\t\t</td>\n\t\t\t<td>\n\t\t\t<p>Withhold enfortumab vedotin until &le; grade 1, then resume treatment at the same dose level or consider dose reduction by 1 dose level.</p>\n\t\t\t</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td>\n\t\t\t<p>Grade 4</p>\n\t\t\t</td>\n\t\t\t<td>\n\t\t\t<p>Permanently discontinue enfortumab vedotin.</p>\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table>\n",
      "references": [
        {
          "id": 805,
          "referenceValue": "Rosenberg JE, O'Donnell PH, Balar AV, McGregor BA, Heath EI, Yu EY, Galsky MD, Hahn NM, Gartner EM, Pinelli JM, Liang SY, Melhem-Bertrandt A, Petrylak DP. Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy. J Clin Oncol. 2019 Oct 10;37(29): 2592-2600. Epub 2019 Jul 29."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 628,
      "name": "",
      "schedule": "<p><strong>Irinotecan:&nbsp;</strong>180 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV bolus on day 1, followed by 2,400 mg/m<sup>2</sup>&nbsp;IV continuous infusion for 46 hours on days 1 and 2</p>\n\n<p><strong>Leucovorin:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV on day 1 as a 2-hour infusion prior to 5-fluorouracil</p>\n\n<p><strong>Bevacizumab:&nbsp;</strong>5 mg/kg IV every 2 weeks</p>\n\n<p>Repeat cycle every 2 weeks.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 114,
      "name": "<b>AC/Docetaxel</b>",
      "schedule": "<p><span style=\"font-family:Times New Roman,Times,serif\"><strong>Doxorubicin</strong> 60mg/m<sup>2</sup> IV, day 1<br />\n<strong>Cyclophosphamide</strong> 600mg/m<sup>2</sup> IV, day 1<br />\nRepeat every 21 days for 4 cycles<br />\n<br />\n<strong>FOLLOWED BY</strong><br />\n<br />\n<strong>Docetaxel</strong> 100 mg/m<sup>2</sup> IV, day 1<br />\nRepeat every 21 days for 4 cycles</span></p>\n",
      "emetogenicPotential": "High for AC, low for docetaxel",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li>Cyclophosphamide:<br />\n\tIf bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use</li>\n\t<li>Docetaxel:<br />\n\tIf bilirubin &gt; upper normal limit, do not use<br />\n\tIf&nbsp;SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li>\n\t<li>Doxorubicin:<br />\n\tIf bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />\n\tIf bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />\n\tIf bilirubin &gt;5 mg/dL, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li>Cyclophosphamide:<br />\n\tIf CrCl 10-50 mL/min, reduce dose by 25%<br />\n\tIf CrCl &lt; 10 mL/min, reduce dose by 50%</li>\n\t<li>Docetaxel:<br />\n\tNo dose reduction</li>\n\t<li>Doxorubicin:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 807,
          "referenceValue": "Swain SM, Jeong JH, et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med. 2010;362(22):2053-2065."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 398,
      "name": "",
      "schedule": "<p><strong>Doxorubicin</strong> 60mg/m<sup>2</sup> IV, day 1<br />\n<strong>Cyclophosphamide</strong> 600mg/m<sup>2</sup> IV, day 1<br />\nRepeat every 21 days for 4 cycles<br />\n<br />\n<strong>FOLLOWED BY</strong><br />\n<br />\n<strong>Docetaxel</strong> 100 mg/m<sup>2</sup> IV, day 1<br />\nRepeat every 21 days for 4 cycles</p>\n",
      "emetogenicPotential": "High for AC, low for docetaxel",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li>Cyclophosphamide:<br />\n\tIf bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use</li>\n\t<li>Docetaxel:<br />\n\tIf bilirubin &gt; upper normal limit, do not use<br />\n\tIf&nbsp;SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li>\n\t<li>Doxorubicin:<br />\n\tIf bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />\n\tIf bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />\n\tIf bilirubin &gt;5 mg/dL, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li>Cyclophosphamide:<br />\n\tIf CrCl 10-50 mL/min, reduce dose by 25%<br />\n\tIf CrCl &lt; 10 mL/min, reduce dose by 50%</li>\n\t<li>Docetaxel:<br />\n\tNo dose reduction</li>\n\t<li>Doxorubicin:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 808,
          "referenceValue": "Swain SM, Jeong JH, et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med. 2010;362(22):2053-2065."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 2,
          "level": "NEOADJUVANT"
        }
      ]
    },
    {
      "id": 399,
      "name": "",
      "schedule": "<p><strong>Docetaxel</strong>: 75mg/m<sup>2</sup>&nbsp;on day 1<br />\n<strong>Carboplatin</strong>: AUC 6, IV on day 1<br />\n<strong>Pertuzumab</strong>: 840mg IV loading dose on day 1 and then 420mg IV every 3 weeks<br />\n<strong>Trastuzumab</strong>: 8mg/kg IV loading dose on day 1 and then 6mg/kg IV every 3 weeks</p>\n\n<p>Repeat every 21 days for 6 cycles.</p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Carboplatin</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Docetaxel</strong>:<br />\n\tIf bilirubin &gt; upper normal limit, do not use<br />\n\tIf&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Carboplatin</strong>:<br />\n\tDosing based on AUC</li>\n\t<li><strong>Docetaxel</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 809,
          "referenceValue": "Schneeweiss A, Chia S, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24(9):2278-84."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 2,
          "level": "NEOADJUVANT"
        }
      ]
    },
    {
      "id": 603,
      "name": "",
      "schedule": "<p><strong>Oxaliplatin:&nbsp;</strong>130 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>5-Fluorouracil:&nbsp;</strong>2,400 mg/m<sup>2</sup>&nbsp;IV continous infusion on days 1 and 2 for 46 hours</p>\n\n<p><strong>Leucovorin:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV on day 1 as a 2-hour infusion before 5-fluorouracil</p>\n\n<p><strong>OR</strong></p>\n\n<p><strong>L-Leucovorin:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil</p>\n\n<p>Repeat cycle every 2 weeks</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 493,
      "name": "",
      "schedule": "<p><strong>Everolimus</strong>&nbsp;10mg PO daily<br />\n<strong>Exemestane</strong> 25mg PO daily</p>\n",
      "emetogenicPotential": "Minimal",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Everolimus</strong><br />\n\tMild (Child Pugh A): Decrease dose to 7.5 mg daily<br />\n\tModerate (Child Pugh B): Decrease dose to 5 mg daily<br />\n\tSevere (Child Pugh C): Decrease dose to 2.5 mg daily</li>\n\t<li><strong>Exemestane</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Everolimus</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Exemestane</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 798,
          "referenceValue": "Baselga J, Campone M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.  N Engl J Med. 2012;366(6):520-9."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 410,
      "name": "",
      "schedule": "<p><strong>5-Fluorouracil</strong> 500 mg/m<sup>2</sup> IV on day 1<br />\n<strong>Epirubicin</strong> 100 mg/m<sup>2</sup> IV on&nbsp;day 1<br />\n<strong>Cyclophosphamide</strong> 500 mg/m<sup>2</sup> IV on day 1</p>\n\n<p>Repeat every 21 days for 6&nbsp;cycles.</p>\n\n<p><strong>FOLLOWED BY</strong></p>\n\n<p><strong>Docetaxel</strong>&nbsp;100mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat every 21 days for 3 cycles.</p>\n",
      "emetogenicPotential": "High for FEC, low for docetaxel",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>5-Fluorouracil</strong>:<br />\n\tIf bilirubin &lt; 5 mg/dL, no dose reduction<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use<br />\n\tNo dose reduction for infusional administration</li>\n\t<li><strong>Epirubicin</strong>:<br />\n\tIf bilirubin 1.2-3 mg/dL or SGOT 2 to 4 times upper limit normal: reduce dose by 50%<br />\n\tIf bilirubin &gt; 3mg/dL or SGOT &gt; 4 times upper limit normal: reduce dose by 75%&nbsp;</li>\n\t<li><strong>Cyclophosphamide</strong>:<br />\n\tIf bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use</li>\n\t<li><strong>Docetaxel</strong>:<br />\n\tIf bilirubin &gt; upper normal limit, do not use<br />\n\tIf&nbsp;SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>5-Fluorouracil</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Epirubicin</strong><br />\n\tIf serum Cr &gt;&nbsp;5 mg/dL, reduce dose by 50%</li>\n\t<li><strong>Cyclophosphamide</strong>:<br />\n\tIf CrCl 10-50 mL/min, reduce dose by 25%<br />\n\tIf CrCl &lt; 10 mL/min, reduce dose by 50%</li>\n\t<li><strong>Docetaxel</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 810,
          "referenceValue": "Roche H, Fumoleau P, et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol. 2006;24(36):5664-71."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 1,
          "level": "ADJUVANT"
        }
      ]
    },
    {
      "id": 499,
      "name": "",
      "schedule": "<p><strong>Abemaciclib</strong>&nbsp;150mg PO BID<br />\n<strong>Anastrozole</strong>&nbsp;1mg PO daily</p>\n\n<p>Repeat cycle every 28 days.</p>\n",
      "emetogenicPotential": "Minimal",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Abemaciclib</strong><br />\n\tChild-Pugh C: Reduce dosing frequency to once daily</li>\n\t<li><strong>Anastrozole</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Anastrozole</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 841,
          "referenceValue": "Goetz MP, Toi M, et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol. 2017;35(32):3638-3646."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 437,
      "name": "",
      "schedule": "<p><strong>Everolimus</strong>&nbsp;10mg PO daily<br />\n<strong>Exemestane</strong> 25mg PO daily</p>\n",
      "emetogenicPotential": "Minimal",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Everolimus</strong><br />\n\tMild (Child Pugh A): Decrease dose to 7.5 mg daily<br />\n\tModerate (Child Pugh B): Decrease dose to 5 mg daily<br />\n\tSevere (Child Pugh C): Decrease dose to 2.5 mg daily</li>\n\t<li><strong>Exemestane</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Everolimus</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Exemestane</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 811,
          "referenceValue": "Baselga J, Campone M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.  N Engl J Med. 2012;366(6):520-9."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 1,
          "level": "ADJUVANT"
        }
      ]
    },
    {
      "id": 411,
      "name": "",
      "schedule": "<p><strong>Doxorubicin</strong>&nbsp;60mg/m<sup>2</sup>&nbsp;IV on day 1<br />\n<strong>Cyclophosphamide</strong>&nbsp;600mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat every 14 days for 4 cycles.</p>\n\n<p><strong>FOLLOWED BY</strong></p>\n\n<p><strong>Paclitaxel</strong>&nbsp;175mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat every 14 days for 4 cycles.</p>\n",
      "emetogenicPotential": "High for AC, low for paclitaxel",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Cyclophosphamide</strong>:<br />\n\tIf bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use</li>\n\t<li><strong>Doxorubicin</strong>:<br />\n\tIf bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />\n\tIf bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use</li>\n\t<li><strong>Paclitaxel</strong>:<br />\n\tFor 3-hour infusion:<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m<sup>2</sup>)<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m<sup>2</sup><br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m<sup>2</sup><br />\n\tIf transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />\n\tFor 24-hour infusion:<br />\n\tIf transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m<sup>2</sup>)<br />\n\tIf transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m<sup>2</sup><br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m<sup>2</sup><br />\n\tIf transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Cyclophosphamide</strong>:<br />\n\tIf CrCl 10-50 mL/min, reduce dose by 25%<br />\n\tIf CrCl &lt; 10 mL/min, reduce dose by 50%</li>\n\t<li><strong>Doxorubicin</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Paclitaxel</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 812,
          "referenceValue": "Burstein HJ, Parker LM, et al. Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol. 2005;23(33):8340-7."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 1,
          "level": "ADJUVANT"
        }
      ]
    },
    {
      "id": 494,
      "name": "",
      "schedule": "<p><strong>Palbociclib</strong>&nbsp;125mg PO daily for 21 days<br />\n<strong>Letrozole</strong>&nbsp;2.5mg PO daily</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "Minimal",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Palbociclib</strong><br />\n\tIf Child-Pugh A or B, no dose reduction<br />\n\tIf Child-Pugh C,&nbsp;reduce dose to 75 mg/day</li>\n\t<li><strong>Letrozole</strong>:<br />\n\tIf Child-Pugh A or B, no dose reduction<br />\n\tIf Child-Pugh C, reduce dose by 50%</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Letrozole</strong>:<br />\n\tIf CrCl &gt;10 mL/min, no dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 813,
          "referenceValue": "Finn RS, Crown JP, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16(1):25-35."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 604,
      "name": "",
      "schedule": "<p><strong>Oxaliplatin:&nbsp;</strong>100 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>5-Fluorouracil:&nbsp;</strong>3,000 mg/m<sup>2</sup>&nbsp;IV continuous infusion on days 1 and 2 for 46 hours</p>\n\n<p><strong>Leucovorin:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on day 1 as a 2-hour infusion before 5-fluorouracil</p>\n\n<p>Repeat cycle every 2 weeks</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 605,
      "name": "",
      "schedule": "<p><strong>Irinotecan:&nbsp;</strong>165 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>5-Fluorouracil:&nbsp;</strong>3,200 mg/m<sup>2</sup>&nbsp;IV continuous infusion for 46 hours on days 1 and 2</p>\n\n<p><strong>Leucovorin:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on day 1 as a 2-hour infusion prior to 5-fluorouracil</p>\n\n<p>Repeat cycle every 2 weeks for a total of 12 cycles</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 606,
      "name": "",
      "schedule": "<p><strong>Irinotecan:&nbsp;</strong>165 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>5-Fluorouracil:&nbsp;</strong>3,200 mg/m<sup>2</sup>&nbsp;IV continuous infusion for 46 hours on days 1 and 2</p>\n\n<p><strong>Leucovorin:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on day 1 as a 2-hour infusion prior to 5-fluorouracil</p>\n\n<p><strong>Bevacizumab:&nbsp;</strong>5 mg/kg IV on day 1</p>\n\n<p>Repeat cycle every 2 weeks</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 607,
      "name": "",
      "schedule": "<p><strong>Irinotecan:&nbsp;</strong>150 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>5-Fluorouracil:&nbsp;</strong>3,000 mg/m<sup>2</sup>&nbsp;IV continuous infusion for 46 hours on days 1 and 2</p>\n\n<p><strong>Leucovorin:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on day 1 as a 2-hour infusion prior to 5-fluorouracil</p>\n\n<p><strong>Panitumumab:&nbsp;</strong>6 mg/kg IV on day 1</p>\n\n<p>Repeat cycle every 2 weeks&nbsp;</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 733,
      "name": "",
      "schedule": "<p><strong>Pembrolizumab:&nbsp;</strong>10 mg/kg IV on day 1</p>\n\n<p>Repeat cycle every 14 days. May also give 200 mg IV on day 1 every 3 weeks.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 734,
      "name": "",
      "schedule": "<p><strong>Ramucirumab:&nbsp;</strong>8 mg/kg IV on day 1</p>\n\n<p>Repeat cycle every 14 days.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 400,
      "name": "",
      "schedule": "<p><strong>Doxorubicin</strong>: 60mg/m<sup>2</sup>&nbsp;IV on day 1<br />\n<strong>Cyclophosphamide</strong>: 600mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat every 21 days for 4 cycles.</p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Cyclophosphamide</strong>:<br />\n\tIf bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use</li>\n\t<li><strong>Doxorubicin</strong>:<br />\n\tIf bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />\n\tIf bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Cyclophosphamide</strong>:<br />\n\tIf CrCl 10-50 mL/min, reduce dose by 25%<br />\n\tIf CrCl &lt; 10 mL/min, reduce dose by 50%</li>\n\t<li><strong>Doxorubicin</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 815,
          "referenceValue": "Fisher B, Brown AM, et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol. 1990;8(9):1483-96."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 1,
          "level": "ADJUVANT"
        }
      ]
    },
    {
      "id": 500,
      "name": "",
      "schedule": "<p><strong>Abemaciclib</strong>&nbsp;150mg PO BID<br />\n<strong>Letrozole</strong>&nbsp;2.5mg PO daily</p>\n\n<p>Repeat cycle every 28 days.</p>\n",
      "emetogenicPotential": "Minimal",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Abemaciclib</strong><br />\n\tChild-Pugh C: Reduce dosing frequency to once daily</li>\n\t<li><strong>Letrozole</strong>:<br />\n\tIf Child-Pugh A or B, no dose reduction<br />\n\tIf Child-Pugh C, reduce dose by 50%</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Letrozole</strong>:<br />\n\tIf CrCl &gt;10 mL/min, no dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 814,
          "referenceValue": "Goetz MP, Toi M, et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol. 2017;35(32):3638-3646."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 402,
      "name": "",
      "schedule": "<p><strong>Doxorubicin</strong>: 60mg/m<sup>2</sup>&nbsp;IV on day 1<br />\n<strong>Cyclophosphamide</strong>: 600mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat every 21 days for 4 cycles.</p>\n\n<p><strong>FOLLOWED BY</strong></p>\n\n<p><strong>Paclitaxel</strong>: 80mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat every 7&nbsp;days for 12&nbsp;cycles.</p>\n",
      "emetogenicPotential": "High for AC, low for paclitaxel",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Cyclophosphamide</strong>:<br />\n\tIf bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use</li>\n\t<li><strong>Doxorubicin</strong>:<br />\n\tIf bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />\n\tIf bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use</li>\n\t<li><strong>Paclitaxel</strong>:<br />\n\tFor 3-hour infusion:<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m<sup>2</sup>)<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m<sup>2</sup><br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m<sup>2</sup><br />\n\tIf transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />\n\tFor 24-hour infusion:<br />\n\tIf transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m<sup>2</sup>)<br />\n\tIf transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m<sup>2</sup><br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m<sup>2</sup><br />\n\tIf transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li>Cyclophosphamide:<br />\n\tIf CrCl 10-50 mL/min, reduce dose by 25%<br />\n\tIf CrCl &lt; 10 mL/min, reduce dose by 50%</li>\n\t<li>Doxorubicin:<br />\n\tNo dose reduction</li>\n\t<li>Paclitaxel:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 816,
          "referenceValue": "Sparano JA, Wang M, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008;358(16):1663-71."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 1,
          "level": "ADJUVANT"
        }
      ]
    },
    {
      "id": 404,
      "name": "",
      "schedule": "<p><strong>Doxorubicin</strong> 60mg/m<sup>2</sup> IV on day 1<br />\n<strong>Cyclophosphamide</strong> 600mg/m<sup>2</sup> IV on day 1</p>\n\n<p>Repeat every 21 days for 4 cycles.<br />\n<br />\n<strong>FOLLOWED BY</strong><br />\n<br />\n<strong>Docetaxel</strong>&nbsp;35&nbsp;mg/m<sup>2</sup> IV on day 1</p>\n\n<p>Repeat every 7&nbsp;days for 12&nbsp;cycles.</p>\n",
      "emetogenicPotential": "High for AC, low for docetaxel",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Cyclophosphamide</strong>:<br />\n\tIf bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use</li>\n\t<li><strong>Docetaxel</strong>:<br />\n\tIf bilirubin &gt; upper normal limit, do not use<br />\n\tIf&nbsp;SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li>\n\t<li><strong>Doxorubicin</strong>:<br />\n\tIf bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />\n\tIf bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />\n\tIf bilirubin &gt;5 mg/dL, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Cyclophosphamide</strong>:<br />\n\tIf CrCl 10-50 mL/min, reduce dose by 25%<br />\n\tIf CrCl &lt; 10 mL/min, reduce dose by 50%</li>\n\t<li><strong>Docetaxel</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Doxorubicin</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 817,
          "referenceValue": "Sparano JA, Zhao F, et al. 2014 San Antonio Breast Cancer Symposium Abstracts S3-03."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 1,
          "level": "ADJUVANT"
        }
      ]
    },
    {
      "id": 456,
      "name": "",
      "schedule": "<p><strong>Pembrolizumab</strong> 200 mg IV given on day 1&nbsp;at least 30 minutes prior to chemotherapy<br />\n<strong>Pemetrexed</strong> 500mg/m<sup>2</sup>&nbsp;given on day 1&nbsp;<br />\n<strong>Cisplatin</strong> 75 mg/m<sup>2</sup>&nbsp;given on day 1</p>\n\n<p><strong>Administer in 21 day cycles for 4 cycles</strong></p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><u><strong>Pembrolizumab</strong></u></p>\n\n<p><strong>Renal Impairment:</strong></p>\n\n<p><em>Prior&nbsp;to treatment initiation:</em>&nbsp;No dosage adjustment necessary.&nbsp;</p>\n\n<p><em>During&nbsp;treatment:</em></p>\n\n<ul>\n\t<li>\n\t<p>Grade 2: Withhold pembrolizumab; administer corticosteroids (prednisone 1-2 mg/kg/day [or equivalent] followed by a taper); may resume upon recovery to grade 0 or 1 toxicity.</p>\n\t</li>\n\t<li>\n\t<p>Grade 3 or 4: Permanently discontinue pembrolizumab; administer corticosteroids (prednisone 1-2 mg/kg/day [or equivalent] followed by a taper).</p>\n\t</li>\n</ul>\n\n<p><strong>Hepatic Impairment:</strong></p>\n\n<p><em>Prior to treatment initiation:</em>&nbsp;</p>\n\n<ul>\n\t<li>No dosage adjustment necessary for mild impairment (Bilirubin &le; ULN and AST &gt; ULN OR bilirubin &gt;1 - 1.5 &times; ULN and any AST).</li>\n\t<li>No dosage adjustments provided in manufacturer&rsquo;s labeling for moderate to severe impairment.</li>\n</ul>\n\n<p><em>During treatment:</em></p>\n\n<ul>\n\t<li>\n\t<p>Patients without hepatocellular carcinoma (HCC) or Renal Cell Carcinoma(RCC) also receiving axitinib:</p>\n\n\t<ul>\n\t\t<li>\n\t\t<p>Grade 2 hepatitis: Administer corticosteroids (prednisone 0.5 - 1 mg/kg/day [or equivalent]).</p>\n\t\t</li>\n\t\t<li>\n\t\t<p>Grade 3 or higher hepatitis: prednisone 1 - 2 mg/kg/day [or equivalent], followed by a taper). Withhold or discontinue therapy based on the severity of liver enzyme elevations:</p>\n\n\t\t<ul>\n\t\t\t<li>\n\t\t\t<p>AST or ALT 3 - 5x ULN or bilirubin 1.5 &ndash; 3x ULN: Withhold treatment; may resume therapy upon return to grade 0 or 1 toxicity.</p>\n\t\t\t</li>\n\t\t\t<li>\n\t\t\t<p>AST or ALT &gt;5x ULN or total bilirubin &gt;3x ULN (without liver metastases): Permanently discontinue pembrolizumab.</p>\n\t\t\t</li>\n\t\t\t<li>\n\t\t\t<p>If baseline grade 2 ALT or AST abnormalities with liver metastases, permanently discontinue pembrolizumab if AST or ALT increases by &ge;50% from baseline and persists for at least 1 week.</p>\n\t\t\t</li>\n\t\t</ul>\n\t\t</li>\n\t</ul>\n\t</li>\n</ul>\n\n<p><u><strong>Cisplatin</strong></u></p>\n\n<p><strong>Renal Impairment:</strong></p>\n\n<ul>\n\t<li>CrCl 10 to 50 mL/minute: Administer 75% of dose.</li>\n\t<li>CrCl &lt;10 mL/minute: Administer 50% of dose.</li>\n\t<li>Hemodialysis: Administer 50% of dose posthemodialysis.</li>\n\t<li>Continuous ambulatory peritoneal dialysis: Administer 50% of dose.</li>\n\t<li>Continuous renal replacement therapy: Administer 75% of dose.</li>\n</ul>\n\n<p><strong>Hepatic Impairment</strong>: <em>No Dosage Adjustments&nbsp;</em></p>\n\n<p><u><strong>Pemetrexed</strong></u></p>\n\n<p><strong>Renal Impairment:&nbsp;</strong></p>\n\n<ul>\n\t<li>\n\t<p><span style=\"font-family:Times New Roman,Times,serif\"><span class=\"marker\"><span style=\"background-color:white\"><span style=\"color:#232323\">CrCl &ge;45 mL/minute: No dosage adjustment necessary. If Cr 45- 79 mL/minute with concomitant use of ibuprofen, avoid ibuprofen 2 days prior to treatment, day of treatment, and 2 days following.</span></span></span></span></p>\n\t</li>\n\t<li>\n\t<p><span style=\"font-family:Times New Roman,Times,serif\"><span style=\"background-color:white\"><span style=\"color:#232323\">CrCl &lt;45 mL/minute: Use is not recommended by the manufacturer (has not been studied sufficiently)</span></span></span></p>\n\t</li>\n</ul>\n\n<p><strong><span style=\"font-family:Times New Roman,Times,serif\"><span style=\"background-color:white\"><span style=\"color:#232323\">Hepatic Impairment:&nbsp;</span></span></span></strong><em><span style=\"font-family:Times New Roman,Times,serif\"><span style=\"background-color:white\"><span style=\"color:#232323\">No dosage instructions are provided in manufacturer&#39;s labeling</span></span></span></em></p>\n",
      "references": [
        {
          "id": 818,
          "referenceValue": "KEYNOTE-189: Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC, Garassino MC; KEYNOTE-189 Investigators. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018 May 31;378(22):2078-2092. Epub 2018 Apr 16"
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 495,
      "name": "",
      "schedule": "<p><strong>Ribociclib</strong>&nbsp;600mg PO daily for 21 days<br />\n<strong>Letrozole</strong>&nbsp;2.5mg PO daily</p>\n\n<p>Repeat cycle every 28 days.</p>\n",
      "emetogenicPotential": "Minimal",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Ribociclib</strong><br />\n\tIf Child-Pugh A, no dose reduction<br />\n\tIf&nbsp;Child-Pugh B or C, reduce starting dose to 400 mg/day</li>\n\t<li><strong>Letrozole</strong>:<br />\n\tIf Child-Pugh A or B, no dose reduction<br />\n\tIf Child-Pugh C, reduce dose by 50%</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Ribociclib</strong><br />\n\tIf CrCl &ge;30 mL/min, no dose reduction<br />\n\tIf CrCl 15-30 mL/min, decrease starting dose to 200 mg/day</li>\n\t<li><strong>Letrozole</strong>:<br />\n\tIf CrCl &gt;10 mL/min, no dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 819,
          "referenceValue": "Hortobagyi GN, Stemmer SN, et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med. 2016;375(18):1738-1748."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 567,
      "name": "",
      "schedule": "<p><strong>Gemcitabine</strong>&nbsp;800-1000mg/m<sup>2</sup>&nbsp;IV on days 1 and 8<br />\n<strong>Cisplatin</strong>&nbsp;30mg/m<sup>2</sup>&nbsp;IV on days 1 and 8</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Cisplatin</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Gemcitabine</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Cisplatin</strong>:<br />\n\tIf CrCl 30-60 mL/min, reduce dose by 50%<br />\n\tIf CrCl &lt; 30 mL/min, do not use</li>\n\t<li><strong>Gemcitabine</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 820,
          "referenceValue": "Nagourney RA, Brewer CA, et al. Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients. Gynecol Oncol. 2003;88(1):35-9."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 533,
      "name": "",
      "schedule": "<p><strong>Cisplatin</strong>&nbsp;60mg/m<sup>2</sup>&nbsp;IV on day 1<br />\n<strong>Irinotecan</strong>&nbsp;60mg/m<sup>2</sup>&nbsp;IV on days 1, 8, and 15</p>\n\n<p>Repeat cycle every 28 days.</p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Cisplatin</strong><br />\n\tNo dose reduction</li>\n\t<li><strong>Irinotecan</strong>:<br />\n\tIf bilirubin 1-2 mg/dL, may need to reduce the dose<br />\n\tIf bilurubin &gt; 2 mg/dL, may not use &nbsp;</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Cisplatin</strong>:<br />\n\tIf CrCl 30-60 mL/min, reduce dose by 50%<br />\n\tIf CrCl &lt; 30 mL/min, do not use</li>\n\t<li><strong>Irinotecan</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 822,
          "referenceValue": "Chitapanarux I, Tonusin A, et al. Phase II clinical study of irinotecan and cisplatin as first-line chemotherapy in metastatic or recurrent cervical cancer. Gynecol Oncol. 2003;89(3):402-7."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 405,
      "name": "",
      "schedule": "<p><strong>Docetaxel</strong> 75 mg/m<sup>2</sup> IV on day 1<br />\n<strong>Cyclophosphamide</strong> 600 mg/m<sup>2</sup> IV on day 1</p>\n\n<p>Repeat every 21 days for 4 cycles.</p>\n",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Cyclophosphamide</strong>:<br />\n\tIf bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use</li>\n\t<li><strong>Docetaxel</strong>:<br />\n\tIf bilirubin &gt; upper normal limit, do not use<br />\n\tIf&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Cyclophosphamide</strong>:<br />\n\tIf CrCl 10-50 mL/min, reduce dose by 25%<br />\n\tIf CrCl &lt; 10 mL/min, reduce dose by 50%</li>\n\t<li><strong>Docetaxel</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 823,
          "referenceValue": "Jones SE, Savin MA, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol. 2006;24(34):5381-7."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 1,
          "level": "ADJUVANT"
        }
      ]
    },
    {
      "id": 406,
      "name": "",
      "schedule": "<p><strong>Docetaxel</strong> 75 mg/m<sup>2</sup> IV on day 1<br />\n<strong>Doxorubicin</strong> 50 mg/m<sup>2</sup>&nbsp;IV on day 1<br />\n<strong>Cyclophosphamide</strong> 500 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat every 21 days for 6 cycles.</p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Cyclophosphamide</strong>:<br />\n\tIf bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use</li>\n\t<li><strong>Docetaxel</strong>:<br />\n\tIf bilirubin &gt; upper normal limit, do not use<br />\n\tIf&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li>\n\t<li><strong>Doxorubicin</strong>:<br />\n\tIf bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />\n\tIf bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Cyclophosphamide</strong>:<br />\n\tIf CrCl 10-50 mL/min, reduce dose by 25%<br />\n\tIf CrCl &lt; 10 mL/min, reduce dose by 50%</li>\n\t<li><strong>Docetaxel</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Doxorubicin</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 824,
          "referenceValue": "Martin M, Pienkowski T, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005;352(22):2302-13."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 1,
          "level": "ADJUVANT"
        }
      ]
    },
    {
      "id": 407,
      "name": "",
      "schedule": "<p><strong>Cyclophosphamide</strong>&nbsp;600mg/m<sup>2</sup>&nbsp;IV on day 1<br />\n<strong>Doxorubicin</strong>&nbsp;60 mg/m<sup>2</sup> IV on day 1<br />\n<strong>5-Fluorouracil</strong>&nbsp;600 mg/m<sup>2</sup> IV on day 1</p>\n\n<p>Repeat every 28 days for 4 cycles.</p>\n",
      "emetogenicPotential": "Moderate-High",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Cyclophosphamide</strong>:<br />\n\tIf bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use</li>\n\t<li><strong>Doxorubicin</strong>:<br />\n\tIf bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />\n\tIf bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use</li>\n\t<li><strong>5-Fluorouracil</strong>:<br />\n\tIf bilirubin &lt; 5 mg/dL, no dose reduction<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use<br />\n\tNo dose reduction for infusional administration</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Cyclophosphamide</strong>:<br />\n\tIf CrCl 10-50 mL/min, reduce dose by 25%<br />\n\tIf CrCl &lt; 10 mL/min, reduce dose by 50%</li>\n\t<li><strong>Doxorubicin</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>5-Fluorouracil</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 825,
          "referenceValue": "Budman DR, Berry DA, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst. 1998;90(16):1205-11."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 1,
          "level": "ADJUVANT"
        }
      ]
    },
    {
      "id": 408,
      "name": "",
      "schedule": "<p><strong>Epirubicin</strong>&nbsp;100mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat every 21 days for 4 cycles.</p>\n\n<p><strong>FOLLOWED BY</strong></p>\n\n<p><strong>Cyclophosphamide</strong> 600 mg/m<sup>2</sup> IV on&nbsp;day 1<br />\n<strong>Methotrexate</strong> 40 mg/m<sup>2</sup> IV on&nbsp;day 1<br />\n<strong>5-Fluorouracil</strong> 600 mg/m<sup>2</sup> IV on&nbsp;day 1</p>\n\n<p>Repeat every 21 days for 4 cycles.</p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Epirubicin</strong>:<br />\n\tIf bilirubin 1.2-3 mg/dL or SGOT 2 to 4 times upper limit normal: reduce dose by 50%<br />\n\tIf bilirubin &gt; 3mg/dL or SGOT &gt; 4 times upper limit normal: reduce dose by 75%&nbsp;</li>\n\t<li><strong>Cyclophosphamide</strong>:<br />\n\tIf bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use</li>\n\t<li><strong>Methotrexate</strong>:<br />\n\tIf bilirubin 3.1-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use</li>\n\t<li><strong>5-Fluorouracil</strong>:<br />\n\tIf bilirubin &lt; 5 mg/dL, no dose reduction<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use<br />\n\tNo dose reduction for infusional administration</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Epirubicin</strong><br />\n\tIf serum Cr &gt;&nbsp;5 mg/dL, reduce dose by 50%</li>\n\t<li><strong>Cyclophosphamide</strong>:<br />\n\tIf CrCl 10-50 mL/min, reduce dose by 25%<br />\n\tIf CrCl &lt; 10 mL/min, reduce dose by 50%</li>\n\t<li><strong>Methotrexate</strong>:<br />\n\tIf CrCl 30-60 mL/min, reduce dose by 50%<br />\n\tIf CrCl &lt; 30 mL/min, do not use</li>\n\t<li><strong>5-Fluorouracil</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 826,
          "referenceValue": "Poole CJ, Earl HM, et al. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. N Engl J Med. 2006;355(18):1851-62."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 1,
          "level": "ADJUVANT"
        }
      ]
    },
    {
      "id": 403,
      "name": "",
      "schedule": "<p><strong>Doxorubicin</strong> 60mg/m<sup>2</sup> IV on day 1<br />\n<strong>Cyclophosphamide</strong> 600mg/m<sup>2</sup> IV on day 1</p>\n\n<p>Repeat every 21 days for 4 cycles.<br />\n<br />\n<strong>FOLLOWED BY</strong><br />\n<br />\n<strong>Docetaxel</strong> 100 mg/m<sup>2</sup> IV on day 1</p>\n\n<p>Repeat every 21 days for 4 cycles.</p>\n",
      "emetogenicPotential": "High for AC, low for docetaxel",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Cyclophosphamide</strong>:<br />\n\tIf bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use</li>\n\t<li><strong>Docetaxel</strong>:<br />\n\tIf bilirubin &gt; upper normal limit, do not use<br />\n\tIf&nbsp;SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li>\n\t<li><strong>Doxorubicin</strong>:<br />\n\tIf bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />\n\tIf bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />\n\tIf bilirubin &gt;5 mg/dL, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Cyclophosphamide</strong>:<br />\n\tIf CrCl 10-50 mL/min, reduce dose by 25%<br />\n\tIf CrCl &lt; 10 mL/min, reduce dose by 50%</li>\n\t<li><strong>Docetaxel</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Doxorubicin</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 828,
          "referenceValue": "Sparano JA, Zhao F, et al. 2014 San Antonio Breast Cancer Symposium Abstracts S3-03."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 1,
          "level": "ADJUVANT"
        }
      ]
    },
    {
      "id": 412,
      "name": "",
      "schedule": "<p><strong>Doxorubicin</strong>&nbsp;60mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat every 14 days for 4 cycles.</p>\n\n<p><strong>FOLLOWED BY</strong></p>\n\n<p><strong>Paclitaxel</strong>&nbsp;175mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat every 14 days for 4 cycles.</p>\n\n<p><strong>FOLLOWED BY&nbsp;</strong></p>\n\n<p><strong>Cyclophosphamide</strong>&nbsp;600mg/m<sup>2</sup>&nbsp;on day 1</p>\n\n<p>Repeat every 14 days for 4 cycles.</p>\n",
      "emetogenicPotential": "Moderate, low for paclitaxel",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Cyclophosphamide</strong>:<br />\n\tIf bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use</li>\n\t<li><strong>Doxorubicin</strong>:<br />\n\tIf bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />\n\tIf bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use</li>\n\t<li><strong>Paclitaxel</strong>:<br />\n\tFor 3-hour infusion:<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m<sup>2</sup>)<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m<sup>2</sup><br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m<sup>2</sup><br />\n\tIf transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />\n\tFor 24-hour infusion:<br />\n\tIf transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m<sup>2</sup>)<br />\n\tIf transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m<sup>2</sup><br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m<sup>2</sup><br />\n\tIf transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Cyclophosphamide</strong>:<br />\n\tIf CrCl 10-50 mL/min, reduce dose by 25%<br />\n\tIf CrCl &lt; 10 mL/min, reduce dose by 50%</li>\n\t<li><strong>Doxorubicin</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Paclitaxel</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 829,
          "referenceValue": "Citron ML, Berry DA, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21(8):1431-9."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 1,
          "level": "ADJUVANT"
        }
      ]
    },
    {
      "id": 501,
      "name": "",
      "schedule": "<p><strong>Tamoxifen</strong>&nbsp;20mg PO daily</p>\n",
      "emetogenicPotential": "N/A",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Tamoxifen</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Tamoxifen</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 834,
          "referenceValue": "Jaiyesimi IA, Buzdar AU, et al. Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol. 1995;13(2):513-29."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 413,
      "name": "",
      "schedule": "<p><strong>Doxorubicin</strong>&nbsp;60mg/m<sup>2</sup>&nbsp;IV on day1<br />\n<strong>Cyclophosphamide</strong>&nbsp;600mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat every 14 days for 4 cycles.</p>\n\n<p><strong>FOLLOWED BY</strong></p>\n\n<p><strong>Docetaxel</strong>&nbsp;75mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat every 14 days for 4 cycles.</p>\n",
      "emetogenicPotential": "High for AC, low for docetaxel",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Docetaxel</strong>:<br />\n\tIf bilirubin &gt; upper normal limit, do not use<br />\n\tIf&nbsp;SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li>\n\t<li><strong>Doxorubicin</strong>:<br />\n\tIf bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />\n\tIf bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />\n\tIf bilirubin &gt;5 mg/dL, do not use</li>\n\t<li><strong>Cyclophosphamide</strong>:<br />\n\tIf bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Docetaxel</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Doxorubicin</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Cyclophosphamide</strong>:<br />\n\tIf CrCl 10-50 mL/min, reduce dose by 25%<br />\n\tIf CrCl &lt; 10 mL/min, reduce dose by 50%</li>\n</ul>\n",
      "references": [
        {
          "id": 830,
          "referenceValue": "Puhalla S, Mrozek E, et al. Randomized phase II adjuvant trial of dose-dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node-positive breast cancer. J Clin Oncol. 2008;26(10):1691-7."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 1,
          "level": "ADJUVANT"
        }
      ]
    },
    {
      "id": 414,
      "name": "",
      "schedule": "<p><strong>Docetaxel</strong>&nbsp;75mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat every 14 days for 4 cycles.</p>\n\n<p><strong>Doxorubicin</strong>&nbsp;60mg/m<sup>2</sup>&nbsp;IV on day 1<br />\n<strong>Cyclophosphamide</strong>&nbsp;600mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat every 14 days for 4 cycles.</p>\n",
      "emetogenicPotential": "High for AC, low for docetaxel",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Docetaxel</strong>:<br />\n\tIf bilirubin &gt; upper normal limit, do not use<br />\n\tIf&nbsp;SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li>\n\t<li><strong>Doxorubicin</strong>:<br />\n\tIf bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />\n\tIf bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />\n\tIf bilirubin &gt;5 mg/dL, do not use</li>\n\t<li><strong>Cyclophosphamide</strong>:<br />\n\tIf bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Docetaxel</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Doxorubicin</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Cyclophosphamide</strong>:<br />\n\tIf CrCl 10-50 mL/min, reduce dose by 25%<br />\n\tIf CrCl &lt; 10 mL/min, reduce dose by 50%</li>\n</ul>\n",
      "references": [
        {
          "id": 831,
          "referenceValue": "Puhalla S, Mrozek E, et al. Randomized phase II adjuvant trial of dose-dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node-positive breast cancer. J Clin Oncol. 2008;26(10):1691-7."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 1,
          "level": "ADJUVANT"
        }
      ]
    },
    {
      "id": 542,
      "name": "",
      "schedule": "<p><strong>Gemcitabine</strong>&nbsp;800mg/m<sup>2</sup>&nbsp;IV on days 1, 8, and 15</p>\n\n<p>Repeat cycle every 28 days.</p>\n",
      "emetogenicPotential": "Low",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Gemcitabine</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Gemcitabine</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 832,
          "referenceValue": "Schilder RJ, Blessing J, et al. Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2005;96(1):103-7."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 543,
      "name": "",
      "schedule": "<p><strong>Pembrolizumab</strong>&nbsp;200mg IV on day 1</p>\n\n<p>Repeat cycle every 3 weeks.</p>\n",
      "emetogenicPotential": "Minimal",
      "dosageModifications": "",
      "references": [
        {
          "id": 833,
          "referenceValue": "Schellens JHM, et al. J Clin Oncol 2017;35 (Suppl: abstr 5514)."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 415,
      "name": "",
      "schedule": "<p><em>Recommended for use with concominant RT&nbsp;if Cisplatin + Etoposide is contraindicated or not tolerated.&nbsp;</em></p>\n\n<p><strong>Carboplatin</strong> AUC 5-6 IV over 60 minutes, day 1-&nbsp;<em>given first</em><br />\n<strong>Etoposide</strong> 100mg/m<sup>2&nbsp;</sup>IV over 1-2 hours,&nbsp;days 1, 2, 3-&nbsp;<em>given second</em></p>\n\n<p>&nbsp;</p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><u><strong>Carboplatin</strong></u></p>\n\n<p><strong>Renal</strong>: AUC dosing&nbsp;</p>\n\n<p>Hemodialysis:&nbsp;<em>hemodialysis should occur between 12 to 24 hours after carboplatin dose</em></p>\n\n<p><strong>Hepatic</strong>:&nbsp;There are no dosage adjustments provided in the manufacturer&rsquo;s labeling</p>\n\n<p><u><strong>Etoposide:</strong></u></p>\n\n<p><strong>Hepatic</strong>- No dose adjustments in manufacturers labeling</p>\n\n<p>Hendrayana, Wilmer, Kurth et al, 2017:</p>\n\n<ul>\n\t<li>T.Bil 1.5&ndash;3 mg/dL or AST 60&ndash;180:&nbsp;50% of of full dose</li>\n\t<li>T.Bil &ge; 3 mg/dL or AST &gt; 180:&nbsp;omit</li>\n</ul>\n\n<p><strong>Renal</strong></p>\n\n<ul>\n\t<li>CrCl &gt;50 mL/minute: No adjustment required.</li>\n\t<li>CrCl 15 to 50 mL/minute: Administer 75% of dose</li>\n\t<li>CrCl &lt;15 mL minute: No data available; consider further dose reductions</li>\n</ul>\n",
      "references": [
        {
          "id": 827,
          "referenceValue": "Okamoto H, Watanabe K, Nishiwaki Y, Mori K, Kurita Y, Hayashi I, Masutani M, Nakata K, Tsuchiya S, Isobe H, Saijo N. Phase II study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small-cell lung cancer. J Clin Oncol. 1999 Nov;17(11):3540-5. link to original article contains verified protocol PubMed Skarlos DV, Samantas E, Briassoulis E, Panoussaki E, Pavlidis N, Kalofonos HP, Kardamakis D, Tsiakopoulos E, Kosmidis P, Tsavdaridis D, Tzitzikas J, Tsekeris P, Kouvatseas G, Zamboglou N, Fountzilas G; Hellenic Cooperative Oncology Group. Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: a randomized phase II study of the Hellenic Cooperative Oncology Group (HeCOG). Ann Oncol. 2001 Sep;12(9):1231-8. link to original article contains verified protocol PubMed"
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 502,
      "name": "",
      "schedule": "<p><strong>Toremifene</strong> 60mg PO daily</p>\n",
      "emetogenicPotential": "N/A",
      "dosageModifications": "",
      "references": [
        {
          "id": 1,
          "referenceValue": "Hayes DF, Van Zyl JA, et al. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol. 1995;13(10):2556-66."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 503,
      "name": "",
      "schedule": "<p><strong>Exemestane</strong>&nbsp;25mg PO daily</p>\n",
      "emetogenicPotential": "N/A",
      "dosageModifications": "",
      "references": [
        {
          "id": 4,
          "referenceValue": "Lonning PE, Bajetta E, et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol. 2000;18(11):2234-4."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 504,
      "name": "",
      "schedule": "<p><strong>Anastrozole</strong>&nbsp;1mg PO daily</p>\n",
      "emetogenicPotential": "N/A",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Anastrozole</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Anastrozole</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 842,
          "referenceValue": "Buzdar A, Jonat W, et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. J Clin Oncol. 1996;14(7):2000-11."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 717,
      "name": "",
      "schedule": "<p><strong>Gemcitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;IV on days 1 and 8</p>\n\n<p><strong>Capecitabine:&nbsp;</strong>650 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-14</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 544,
      "name": "",
      "schedule": "<p><strong>Paclitaxel</strong>&nbsp;175mg/m<sup>2</sup>&nbsp;IV over 3 hours on day 1<br />\n<strong>Carboplatin</strong>&nbsp;AUC of 5-7, IV on day 1</p>\n\n<p>Repeat cycle every 28 days.</p>\n",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Carboplatin</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Paclitaxel</strong>:<br />\n\tFor 3-hour infusion:<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m<sup>2</sup>)<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m<sup>2</sup><br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m<sup>2</sup><br />\n\tIf transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />\n\tFor 24-hour infusion:<br />\n\tIf transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m<sup>2</sup>)<br />\n\tIf transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m<sup>2</sup><br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m<sup>2</sup><br />\n\tIf transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Carboplatin</strong>:<br />\n\tDosing based on AUC</li>\n\t<li><strong>Paclitaxel</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 835,
          "referenceValue": "Hoskins PJ, Swenerton KD, et al. Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. J Clin Oncol. 2001;19(20):4048-53."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 545,
      "name": "",
      "schedule": "<p><strong>Doxorubicin</strong>&nbsp;60mg/m<sup>2</sup>&nbsp;IV on day 1<br />\n<strong>Cyclophosphamide</strong>&nbsp;500mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Cyclophosphamide</strong>:<br />\n\tIf bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use</li>\n\t<li><strong>Doxorubicin</strong>:<br />\n\tIf bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />\n\tIf bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Cyclophosphamide</strong>:<br />\n\tIf CrCl 10-50 mL/min, reduce dose by 25%<br />\n\tIf CrCl &lt; 10 mL/min, reduce dose by 50%</li>\n\t<li><strong>Doxorubicin</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 836,
          "referenceValue": "Thigpen JT, Blessing JA, et al. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. J Clin Oncol. 1994;12(7):1408-14."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 546,
      "name": "",
      "schedule": "<p><strong>Doxorubicin</strong>&nbsp;50mg/m<sup>2</sup>&nbsp;IV on day 1<br />\n<strong>Cisplatin</strong>&nbsp;50mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Cisplatin</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Doxorubicin</strong>:<br />\n\tIf bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />\n\tIf bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Cisplatin</strong>:<br />\n\tIf CrCl 30-60 mL/min, reduce dose by 50%<br />\n\tIf CrCl &lt; 30 mL/min, do not use</li>\n\t<li><strong>Doxorubicin</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 837,
          "referenceValue": "Deppe G, Malviya VK, et al. Treatment of recurrent and metastatic endometrial carcinoma with cisplatin and doxorubicin. Eur J Gynaecol Oncol. 1994;15(4):263-6."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 566,
      "name": "",
      "schedule": "<p><strong>Gemcitabine</strong>&nbsp;1000mg/m<sup>2</sup>&nbsp;IV on days 1 and 8<br />\n<strong>Doxorubicin liposome</strong>&nbsp;30mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Gemcitabine</strong><br />\n\tNo dose reduction</li>\n\t<li><strong>Doxorubicin</strong>:<br />\n\tIf bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />\n\tIf bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Gemcitabine</strong><br />\n\tNo dose reduction</li>\n\t<li><strong>Doxorubicin</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 838,
          "referenceValue": "D'Agostino G, Ferrandina G, et al. Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer. Br J Cancer. 2003;89(7):1180-4."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 497,
      "name": "",
      "schedule": "<p><strong>Abemaciclib</strong>&nbsp;150mg PO BID<br />\n<strong>Fulvestrant</strong>&nbsp;500mg IM on days 1 and 15 of first cycle, then 500mg IM on day 1 for all subsequent cycles</p>\n\n<p>Repeat cycle every 28 days.</p>\n",
      "emetogenicPotential": "Minimal",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Abemaciclib</strong><br />\n\tChild-Pugh C: Reduce dosing frequency to once daily</li>\n\t<li><strong>Fulvestrant</strong>:<br />\n\tIf SGOT, SGPT, bilirubin and alkaline phosphatase &lt; 2 upper normal limit, no dose reduction<br />\n\tIf SGOT, SGPT, bilirubin and alkaline phosphatase &gt; 2 upper normal limit, unknown</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Fulvestrant</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 839,
          "referenceValue": "Sledge GW Jr, Toi M, et al. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. J Clin Oncol. 2017;35(25):2875-2884."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 496,
      "name": "",
      "schedule": "<p><strong>Palbociclib</strong>&nbsp;125mg PO daily for 21 days<br />\n<strong>Fulvestrant</strong>&nbsp;500mg IM on days 1 and 15 of first cycle, then 500mg IM on day 1 for all subsequent cycles</p>\n\n<p>Repeat cycle every 28 days.</p>\n",
      "emetogenicPotential": "Minimal",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Palbociclib</strong><br />\n\tIf Child-Pugh A or B, no dose reduction<br />\n\tIf Child-Pugh C,&nbsp;reduce dose to 75 mg/day</li>\n\t<li><strong>Fulvestrant</strong>:<br />\n\tIf SGOT, SGPT, bilirubin and alkaline phosphatase &lt; 2 upper normal limit, no dose reduction<br />\n\tIf SGOT, SGPT, bilirubin and alkaline phosphatase &gt; 2 upper normal limit, unknown</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Fulvestrant</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 840,
          "referenceValue": "Turner NC, Ro J, et al. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2015;373(3):209-19."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 498,
      "name": "",
      "schedule": "<p><strong>Alpelisib</strong>&nbsp;3000mg PO daily<br />\n<strong>Fulvestrant</strong>&nbsp;500mg IM on days 1, 15, and 29 and then once per month</p>\n\n<p>Repeat cycle every 28 days.</p>\n",
      "emetogenicPotential": "Mild",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Fulvestrant</strong>:<br />\n\tIf SGOT, SGPT, bilirubin and alkaline phosphatase &lt; 2 upper normal limit, no dose reduction<br />\n\tIf SGOT, SGPT, bilirubin and alkaline phosphatase &gt; 2 upper normal limit, unknown</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Fulvestrant</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 821,
          "referenceValue": "Andre F, Ciruelos E, et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019;380(20):1929-1940."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 505,
      "name": "",
      "schedule": "<p><strong>Letrozole</strong>&nbsp;2.5mg PO daily</p>\n",
      "emetogenicPotential": "N/A",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Letrozole</strong>:<br />\n\tIf Child-Pugh A or B, no dose reduction<br />\n\tIf Child-Pugh C, reduce dose by 50%</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Letrozole</strong>:<br />\n\tIf CrCl &gt; 10 mL/min, no dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 843,
          "referenceValue": "Dombernowsky P, Smith I, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol. 1998;16(2):453-61."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 420,
      "name": "",
      "schedule": "<p><strong>Doxorubicin</strong>&nbsp;60mg/m<sup>2</sup>&nbsp;IV on day 1<br />\n<strong>Cyclophosphamide</strong>&nbsp;600mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat every 21 days for 4 cycles.</p>\n\n<p><strong>FOLLOWED BY</strong></p>\n\n<p><strong>Paclitaxel</strong>&nbsp;80mg/m<sup>2</sup>&nbsp;IV over 1 hour on day 1<br />\n<strong>Trastuzumab</strong>&nbsp;4mg/kg IV loading dose, then 2mg/kg IV weekly</p>\n\n<p>Repeat every 7 days for 12 cycles.</p>\n\n<p><strong>FOLLOWED BY</strong></p>\n\n<p><strong>Trastuzumab</strong>&nbsp;2mg/kg IV weekly</p>\n\n<p>Repeat every 7 days for 40 cycles.</p>\n",
      "emetogenicPotential": "High for AC, low for paclitaxel and trastuzumab",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Cyclophosphamide</strong>:<br />\n\tIf bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use</li>\n\t<li><strong>Doxorubicin</strong>:<br />\n\tIf bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />\n\tIf bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use</li>\n\t<li><strong>Paclitaxel</strong>:<br />\n\tFor 3-hour infusion:<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m<sup>2</sup>)<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m<sup>2</sup><br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m<sup>2</sup><br />\n\tIf transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />\n\tFor 24-hour infusion:<br />\n\tIf transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m<sup>2</sup>)<br />\n\tIf transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m<sup>2</sup><br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m<sup>2</sup><br />\n\tIf transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Cyclophosphamide</strong>:<br />\n\tIf CrCl 10-50 mL/min, reduce dose by 25%<br />\n\tIf CrCl &lt; 10 mL/min, reduce dose by 50%</li>\n\t<li><strong>Doxorubicin</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Paclitaxel</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 844,
          "referenceValue": "Romond EH, Perez EA, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673-84."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 1,
          "level": "ADJUVANT"
        }
      ]
    },
    {
      "id": 506,
      "name": "",
      "schedule": "<p><strong>Fulvestrant</strong>&nbsp;250mg IM on day 1</p>\n\n<p>Repeat every month.</p>\n\n<p>OR</p>\n\n<p><strong>Fulvestrant</strong>&nbsp;500mg IM loading dose on day 1, then 500mg IM on days 15 and 29</p>\n\n<p>Continue treatment on a monthly basis until disease progression.</p>\n",
      "emetogenicPotential": "N/A",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Fulvestrant</strong>:<br />\n\tIf SGOT, SGPT, bilirubin and alkaline phosphatase &lt; 2 upper normal limit, no dose reduction<br />\n\tIf SGOT, SGPT, bilirubin and alkaline phosphatase &gt; 2 upper normal limit, unknown</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Fulvestrant</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 845,
          "referenceValue": "Howell A. Future use of selective estrogen receptor modulators and aromatase inhibitors. Clin Cancer Res. 2001;7(12 Suppl):4402s-4410s --- Di Leo A, Jerusalem G, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol. 2010;28(30):4594-600."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 397,
      "name": "",
      "schedule": "<p><em>Recommended for use with concominant RT (category I)</em></p>\n\n<p><strong>Cisplatin</strong> 75 mg/m<sup>2</sup>&nbsp;on day 1&nbsp;<br />\n<strong>Etoposide</strong> 100&nbsp;mg/m<sup>2</sup>&nbsp;on days 1, 2, 3&nbsp;<br />\n21 day cycle for 4-6 cycles</p>\n\n<p>OR</p>\n\n<p><strong>Cisplatin</strong> 60&nbsp;mg/m<sup>2</sup>&nbsp;on day 1&nbsp;<br />\n<strong>Etoposide</strong> 120&nbsp;mg/m<sup>2&nbsp;</sup>on days 1, 2, 3<br />\n21 day cycle for 4-6 cycles</p>\n\n<p>OR</p>\n\n<p><strong>Cisplatin</strong> 25 mg/m<sup>2</sup>&nbsp;on days 1, 2, 3<br />\n<strong>Etoposide</strong> 100&nbsp;mg/m<sup>2</sup>&nbsp;on days 1, 2, 3&nbsp;<br />\n21 day cycle for 4-6 cycles</p>\n\n<p>&nbsp;</p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><u><strong>Cisplatin</strong></u></p>\n\n<p><strong>Hepatic</strong></p>\n\n<ul>\n\t<li>No Dosage Adjustments</li>\n</ul>\n\n<p><strong>Renal</strong></p>\n\n<ul>\n\t<li>CrCl 10 to 50 mL/minute: Administer 75% of dose.</li>\n\t<li>CrCl &lt;10 mL/minute: Administer 50% of dose.</li>\n\t<li>Hemodialysis: Administer 50% of dose posthemodialysis.</li>\n\t<li>Continuous ambulatory peritoneal dialysis: Administer 50% of dose.</li>\n\t<li>Continuous renal replacement therapy: Administer 75% of dose.</li>\n</ul>\n\n<p><u><strong>Etoposide:</strong></u></p>\n\n<p><strong>Hepatic</strong></p>\n\n<ul>\n\t<li>No dose adjustments in manufacturers labeling</li>\n\t<li>Per Hendrayana, Wilmer, Kurth et al, 2017:\n\t<ul>\n\t\t<li>T.Bil 1.5&ndash;3 mg/dL or AST 60&ndash;180:&nbsp;50% of of full dose</li>\n\t\t<li>T.Bil &ge; 3 mg/dL or AST &gt; 180:&nbsp;omit</li>\n\t</ul>\n\t</li>\n</ul>\n\n<p><strong>Renal</strong></p>\n\n<ul>\n\t<li>CrCl &gt;50 mL/minute: No adjustment required.</li>\n\t<li>CrCl 15 to 50 mL/minute: Administer 75% of dose</li>\n\t<li>CrCl &lt;15 mL minute: No data available; consider further dose reductions</li>\n</ul>\n",
      "references": [
        {
          "id": 846,
          "referenceValue": "Faivre-Finn C, Snee M, Ashcroft L, et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol. 2017;18(8):1116–1125. doi:10.1016/S1470-2045(17)30318-2\n\nSeckl MJ, Ottensmeier CH, Cullen M, et al. Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR). J Clin Oncol. 2017;35(14):1506–1514. doi:10.1200/JCO.2016.69.7391\n\nT. Marcello, Boni L., Ambrosio F. et al. Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial. Journal of Clinical Oncology 2017 35:12, 1281-1287.\n\nAronoff GR, Bennett WM, Berns JS, et al, Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 99, 171.\n\nHendrayana T, Wilmer A, Kurth V, Schmidt-Wolf IG, Jaehde U. Anticancer Dose Adjustment for Patients with Renal and Hepatic Dysfunction: From Scientific Evidence to Clinical Application. Sci Pharm. 2017;85(1):8. Published 2017 Feb 27. doi:10.3390/scipharm85010008"
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 507,
      "name": "",
      "schedule": "<p><strong>Megestrol</strong> 40mg PO QID</p>\n",
      "emetogenicPotential": "N/A",
      "dosageModifications": "",
      "references": [
        {
          "id": 847,
          "referenceValue": "Kimmick GG, Muss HB. Endocrine therapy in metastatic breast cancer. Cancer Treat Res. 1998;94:231-54."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 417,
      "name": "",
      "schedule": "<p><strong>Carboplatin</strong> AUC 5-6 day 1 OR 75-80mg/m<sup>2</sup><br />\n<strong>Etoposide</strong> 80-100 mg/m2 days 1, 2, 3<br />\n<strong>Durvalumab</strong> 1,500 mg day 1&nbsp;</p>\n\n<p><strong>Every 21 days for maximum of 4 cycles</strong></p>\n\n<p>Followed by maintenance <strong>durvalumab</strong> 1,500 mg&nbsp; on day 1, repeat cycle&nbsp;<strong>every 28 days</strong></p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><u><strong>Carboplatin</strong></u></p>\n\n<p><strong>Renal</strong>: AUC dosing&nbsp;</p>\n\n<ul>\n\t<li>Hemodialysis:&nbsp;<em>hemodialysis should occur between 12 to 24 hours after carboplatin dose</em></li>\n</ul>\n\n<p><strong>Hepatic</strong>:&nbsp;There are no dosage adjustments provided in the manufacturer&rsquo;s labeling</p>\n\n<p><u><strong>Etoposide:</strong></u></p>\n\n<p><strong>Hepatic:</strong>&nbsp;No dose adjustments in manufacturers labeling</p>\n\n<p>Hendrayana, Wilmer, Kurth et al, 2017:</p>\n\n<ul>\n\t<li>T.Bil 1.5&ndash;3 mg/dL or AST 60&ndash;180:&nbsp;50% of of full dose</li>\n\t<li>T.Bil &ge; 3 mg/dL or AST &gt; 180:&nbsp;omit</li>\n</ul>\n\n<p><strong>Renal:</strong></p>\n\n<ul>\n\t<li>CrCl &gt;50 mL/minute: No adjustment required.</li>\n\t<li>CrCl 15 to 50 mL/minute: Administer 75% of dose</li>\n\t<li>CrCl &lt;15 mL minute: No data available; consider further dose reductions</li>\n</ul>\n\n<p><u><strong>Etoposide:</strong></u></p>\n\n<p><strong>Hepatic:</strong>&nbsp;No dose adjustments in manufacturers labeling</p>\n\n<p>Hendrayana, Wilmer, Kurth et al, 2017:</p>\n\n<ul>\n\t<li>T.Bil 1.5&ndash;3 mg/dL or AST 60&ndash;180:&nbsp;50% of of full dose</li>\n\t<li>T.Bil &ge; 3 mg/dL or AST &gt; 180:&nbsp;omit</li>\n</ul>\n\n<p><strong>Renal</strong></p>\n\n<ul>\n\t<li>CrCl &gt;50 mL/minute: No adjustment required.</li>\n\t<li>CrCl 15 to 50 mL/minute: Administer 75% of dose</li>\n\t<li>CrCl &lt;15 mL minute: No data available; consider further dose reductions</li>\n</ul>\n\n<p><u><strong>Durvalumab</strong></u></p>\n\n<p><strong>Hepatic</strong>:</p>\n\n<p><em>Hepatic impairment prior to treatment initiation:</em></p>\n\n<ul>\n\t<li>There are no dosage adjustments provided in the manufacturer&#39;s labeling.</li>\n</ul>\n\n<p><em>Hepatotoxicity during treatment:</em></p>\n\n<ul>\n\t<li>ALT or AST &gt;3 - 8 x ULN or total bilirubin &gt;1.5 -&nbsp;5 x ULN: Withhold dose. Administer systemic corticosteroids (prednisone initial dose of 1 to 2 mg/kg/day or equivalent) with subsequent&nbsp;taper. May resume when hepatitis has improved to grade 1 or resolved and corticosteroid dose is &le;10 mg/day prednisone (or equivalent).</li>\n\t<li>ALT or AST &gt;8 times ULN or total bilirubin &gt;5 times ULN: Discontinue permanently. Administer systemic corticosteroids (prednisone initial dose of 1 to 2 mg/kg daily or equivalent) with subsequent taper.&nbsp;</li>\n\t<li>Concurrent ALT or AST &gt;3 x ULN and total bilirubin &gt;2 x ULN without alternate cause: Discontinue permanently. Administer systemic corticosteroids (prednisone initial dose of 1 to 2 mg/kg/day or equivalent) with subsequent taper.&nbsp;</li>\n</ul>\n\n<p><strong>Renal:</strong></p>\n\n<p><em>Renal toxicity prior to initiation of&nbsp;treatment (nephritis):</em></p>\n\n<ul>\n\t<li>There are no dosage adjustments provided in the manufacturer&#39;s labeling.</li>\n</ul>\n\n<p><em>Renal toxicity during treatment (nephritis):</em></p>\n\n<ul>\n\t<li>Creatinine &gt;1.5 - 3x ULN: Withhold dose. Administer systemic corticosteroids (prednisone initial dose of 1 - 2 mg/kg/day or equivalent) followed by a taper. May resume durvalumab when nephritis has improved to grade 1 or resolved and corticosteroid dose is &le;10 mg/day prednisone (or equivalent).</li>\n\t<li>Creatinine &gt;3x&nbsp;ULN: Discontinue permanently. Administer systemic corticosteroids (prednisone initial dose of 1 to 2 mg/kg daily or equivalent) with subsequent taper.</li>\n</ul>\n",
      "references": [
        {
          "id": 848,
          "referenceValue": "CASPIAN: Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Kazarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Shire N, Jiang H, Goldman JW; CASPIAN investigators. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019 Oct 4."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 418,
      "name": "",
      "schedule": "<p><strong>Carboplatin</strong> AUC 5-6 on day 1&nbsp;<br />\n<strong>Etoposide</strong> 100 mg/m<sup>2</sup>&nbsp; on days 1, 2, 3</p>\n\n<p><strong>Maximum of&nbsp;4-6 cycles</strong></p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><u><strong>Carboplatin</strong></u></p>\n\n<p><strong>Renal</strong>:&nbsp; AUC dosing&nbsp;</p>\n\n<ul>\n\t<li>Hemodialysis:&nbsp;<em>hemodialysis should occur between 12 to 24 hours after carboplatin dose</em></li>\n</ul>\n\n<p><strong>Hepatic</strong>:&nbsp;There are no dosage adjustments provided in the manufacturer&rsquo;s labeling</p>\n\n<p><u><strong>Etoposide:</strong></u></p>\n\n<p><strong>Hepatic:</strong>&nbsp;No dose adjustments in manufacturers labeling</p>\n\n<p>Hendrayana, Wilmer, Kurth et al, 2017:</p>\n\n<ul>\n\t<li>T.Bil 1.5&ndash;3 mg/dL or AST 60&ndash;180:&nbsp;50% of of full dose</li>\n\t<li>T.Bil &ge; 3 mg/dL or AST &gt; 180:&nbsp;omit</li>\n</ul>\n\n<p><strong>Renal:</strong></p>\n\n<ul>\n\t<li>CrCl &gt;50 mL/minute: No adjustment required.</li>\n\t<li>CrCl 15 to 50 mL/minute: Administer 75% of dose</li>\n\t<li>CrCl &lt;15 mL minute: No data available; consider further dose reductions</li>\n</ul>\n",
      "references": [
        {
          "id": 849,
          "referenceValue": "Okamoto H, Watanabe K, Kunikane H, et al. Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702. Br J Cancer. 2007;97(2):162–169. doi:10.1038/sj.bjc.6603810"
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 508,
      "name": "",
      "schedule": "<p><strong>Trastuzumab</strong>&nbsp;4mg/kg IV loading dose, then 2mg/kg IV weekly</p>\n\n<p>Repeat cycle weekly for a total of 10 weeks. In the absence of disease progression, continue weekly maintenance dose of 2mg/kg.</p>\n\n<p>OR</p>\n\n<p><strong>Trastuzumab</strong>&nbsp;8mg/kg IV loading dose, then 6mg/kg IV every 3 weeks.</p>\n\n<p>Continue treatment until disease progression.</p>\n",
      "emetogenicPotential": "Low",
      "dosageModifications": "",
      "references": [
        {
          "id": 850,
          "referenceValue": "Baselga J, Tripathy D, et al. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol. 1999;26(4 Suppl 12):78-83. --- Baselga J, Carbonell X, et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol. 2005;23(10):2162-71."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 421,
      "name": "",
      "schedule": "<p><strong>Doxorubicin</strong>&nbsp;60mg/m<sup>2</sup>&nbsp;IV on day 1<br />\n<strong>Cyclophosphamide</strong>&nbsp;600mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat every 14&nbsp;days for 4 cycles.</p>\n\n<p><strong>FOLLOWED BY</strong></p>\n\n<p><strong>Paclitaxel</strong>&nbsp;175mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat every 14 days for 4 cycles.</p>\n\n<p><strong>Trastuzumab</strong>&nbsp;4mg/kg IV loading dose along with paclitaxel and&nbsp;then 2mg/kg IV weekly</p>\n\n<p>Repeat every 7 days for 52 cycles.</p>\n",
      "emetogenicPotential": "High for AC, low for paclitaxel and trastuzumab",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Cyclophosphamide</strong>:<br />\n\tIf bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use</li>\n\t<li><strong>Doxorubicin</strong>:<br />\n\tIf bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />\n\tIf bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use</li>\n\t<li><strong>Paclitaxel</strong>:<br />\n\tFor 3-hour infusion:<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m<sup>2</sup>)<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m<sup>2</sup><br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m<sup>2</sup><br />\n\tIf transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />\n\tFor 24-hour infusion:<br />\n\tIf transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m<sup>2</sup>)<br />\n\tIf transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m<sup>2</sup><br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m<sup>2</sup><br />\n\tIf transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Cyclophosphamide</strong>:<br />\n\tIf CrCl 10-50 mL/min, reduce dose by 25%<br />\n\tIf CrCl &lt; 10 mL/min, reduce dose by 50%</li>\n\t<li><strong>Doxorubicin</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Paclitaxel</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 852,
          "referenceValue": "Romond EH, Perez EA, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673-84."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 1,
          "level": "ADJUVANT"
        }
      ]
    },
    {
      "id": 422,
      "name": "",
      "schedule": "<p><strong>Docetaxel</strong> 75 mg/m<sup>2</sup> IV on&nbsp;day 1<br />\n<strong>Carboplatin</strong> AUC of 6, IV on&nbsp;day 1<br />\n<strong>Trastuzumab&nbsp;</strong>4mg/kg IV loading dose and then 2mg/kg IV weekly during chemotherapy</p>\n\n<p>Repeat every 21 days for 6 cycles.</p>\n\n<p><strong>FOLLOWED BY</strong></p>\n\n<p><strong>Trastuzumab</strong>&nbsp;6mg/kg IV on day 1</p>\n\n<p>Repeat every 21 days for 1 year.</p>\n",
      "emetogenicPotential": "Moderate for TC, low for trastuzumab",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Carboplatin</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Docetaxel</strong>:<br />\n\tIf bilirubin &gt; upper normal limit, do not use<br />\n\tIf&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Carboplatin</strong>:<br />\n\tDosing based on AUC</li>\n\t<li><strong>Docetaxel</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 853,
          "referenceValue": "Slamon D, Eiermann W, et all. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. Breast Cancer Res Treat. 2006; 100 (Abstract #52)."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 1,
          "level": "ADJUVANT"
        }
      ]
    },
    {
      "id": 423,
      "name": "",
      "schedule": "<p><strong>Docetaxel</strong>&nbsp;100mg/m<sup>2</sup>&nbsp;IV on day 1<br />\n<strong>Trastuzumab</strong>&nbsp;4mg/kg IV loading dose on day 1 and then 2mg/kg IV weekly</p>\n\n<p>Repeat every 21 days for 3 cycles.</p>\n\n<p><strong>FOLLOWED BY</strong></p>\n\n<p><strong>5-Fluorouracil</strong>&nbsp;600mg/m<sup>2</sup>&nbsp;IV on day 1<br />\n<strong>Epirubicin</strong>&nbsp;60mg/m<sup>2</sup>&nbsp;IV on day 1<br />\n<strong>Cyclophosphamide&nbsp;</strong>600mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat every 21 days for 3 cycles.</p>\n",
      "emetogenicPotential": "High for FEC",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>5-Fluorouracil</strong>:<br />\n\tIf bilirubin &lt; 5 mg/dL, no dose reduction<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use<br />\n\tNo dose reduction for infusional administration</li>\n\t<li><strong>Epirubicin</strong>:<br />\n\tIf bilirubin 1.2-3 mg/dL or SGOT 2 to 4 times upper limit normal: reduce dose by 50%<br />\n\tIf bilirubin &gt; 3mg/dL or SGOT &gt; 4 times upper limit normal: reduce dose by 75%&nbsp;</li>\n\t<li><strong>Cyclophosphamide</strong>:<br />\n\tIf bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use</li>\n\t<li><strong>Docetaxel</strong>:<br />\n\tIf bilirubin &gt; upper normal limit, do not use<br />\n\tIf&nbsp;SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>5-Fluorouracil</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Epirubicin</strong><br />\n\tIf serum Cr &gt;&nbsp;5 mg/dL, reduce dose by 50%</li>\n\t<li><strong>Cyclophosphamide</strong>:<br />\n\tIf CrCl 10-50 mL/min, reduce dose by 25%<br />\n\tIf CrCl &lt; 10 mL/min, reduce dose by 50%</li>\n\t<li><strong>Docetaxel</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 854,
          "referenceValue": "Joensuu H, Kellokumpu-Lehtinen PL, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006;354(8):809-20."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 1,
          "level": "ADJUVANT"
        }
      ]
    },
    {
      "id": 424,
      "name": "",
      "schedule": "<p><strong>Docetaxel</strong>&nbsp;75mg/m<sup>2</sup>&nbsp;IV on day 1<br />\n<strong>Trastuzumab</strong>&nbsp;8mg/kg IV loading dose on day 1 and then 6mg/kg IV every 3 weeks<br />\n<strong>Pertuzumab</strong>&nbsp;840mg IV loading dose on day 1 and then 420mg IV every 3 weeks</p>\n\n<p>Repeat every 21 days.</p>\n",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Docetaxel</strong>:<br />\n\tIf bilirubin &gt; upper normal limit, do not use<br />\n\tIf&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Docetaxel</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 855,
          "referenceValue": "Baselga J, Cortes J, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2):109-19."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 1,
          "level": "ADJUVANT"
        }
      ]
    },
    {
      "id": 425,
      "name": "",
      "schedule": "<p><strong>Neratinib</strong>&nbsp;240mg PO daily</p>\n\n<p>Repeat daily for 1 year following trastuzumab-based adjuvant therapy.</p>\n",
      "emetogenicPotential": "Minimal",
      "dosageModifications": "<p><strong>Hepatic Impairment:</strong><br />\nSevere (Child-Pugh C): reduce starting dose to 80mg.</p>\n\n<p><strong>Renal Impairment:</strong><br />\nNo dose reduction necessary.</p>\n",
      "references": [
        {
          "id": 856,
          "referenceValue": "Chan A, Delaloge S, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016;17(3):367-377."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 1,
          "level": "ADJUVANT"
        }
      ]
    },
    {
      "id": 426,
      "name": "",
      "schedule": "<p><strong>Ado-trastuzumab emtansine</strong>: 3.6mg/kg IV on day 1</p>\n\n<p>Repeat every 21 days for 14 cycles.</p>\n",
      "emetogenicPotential": "Minimal",
      "dosageModifications": "",
      "references": [
        {
          "id": 151,
          "referenceValue": "von Minckwitz G, Huang CS, et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med. 2019;380(7):617-628."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 1,
          "level": "ADJUVANT"
        }
      ]
    },
    {
      "id": 429,
      "name": "",
      "schedule": "<p><strong>Cisplatin</strong>&nbsp;30mg/m<sup>2&nbsp;</sup>on day 1, 8&nbsp;<br />\n<strong>Irinotecan</strong> 60 mg/m<sup>2</sup>&nbsp;on days 1, 8</p>\n\n<p><strong>For maximum of&nbsp;4-6 cycles</strong></p>\n\n<p>OR</p>\n\n<p><strong>Cisplatin</strong> 60mg/m<sup>2&nbsp;</sup>on day 1&nbsp;<br />\n<strong>Irinotecan</strong> 60 mg/m<sup>2</sup>&nbsp;on days 1, 8, 15</p>\n\n<p><strong>For maximum of&nbsp;4-6 cycles</strong></p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><u><strong>isplatin</strong></u></p>\n\n<p><strong>Hepatic:</strong></p>\n\n<ul>\n\t<li>No Dosage Adjustments</li>\n</ul>\n\n<p><strong>Renal:</strong></p>\n\n<ul>\n\t<li>CrCl 10 to 50 mL/minute: Administer 75% of dose.</li>\n\t<li>CrCl &lt;10 mL/minute: Administer 50% of dose.</li>\n\t<li>Hemodialysis: Administer 50% of dose posthemodialysis.</li>\n\t<li>Continuous ambulatory peritoneal dialysis: Administer 50% of dose.</li>\n\t<li>Continuous renal replacement therapy: Administer 75% of dose.</li>\n</ul>\n\n<p><u><strong>Irinotecan</strong></u></p>\n\n<p><strong>Renal</strong>:&nbsp;There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p>\n\n<ul>\n\t<li><strong>Dialysis</strong>: manufacturer does not recommend use in patients with dialysis.\n\n\t<ul>\n\t\t<li><em>Janus 2010:</em>&nbsp;may consider reduction of&nbsp;weekly dose from 125 mg/m<sup>2</sup>&nbsp;to 50 mg/m<sup>2</sup>&nbsp;and administration&nbsp;after hemodialysis or on nondialysis days</li>\n\t</ul>\n\t</li>\n</ul>\n\n<p><strong>Hepatic:&nbsp;</strong>Per manufacturer&#39;s guidelines:<strong>&nbsp;</strong></p>\n\n<ul>\n\t<li>Bilirubin 1 - 2 mg/dL: increased liklihood of grade 3 or 4 neutropenia. Consider reducing initial dose by one dose level</li>\n\t<li>Bilirubin &gt;2 mg/dL or transaminases &gt; 3 x ULN without liver metastasis or transaminases &gt; 5 x ULN with liver metastasis: Use is not recommended</li>\n</ul>\n",
      "references": [
        {
          "id": 865,
          "referenceValue": "JCOG 9511: Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Yamamoto S, Saijo N; JCOG. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002 Jan 10;346(2):85-91.\nSWOG S0124: Lara PN Jr, Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE, Jett J, Langer CJ, Kuebler JP, Dakhil SR, Chansky K, Gandara DR. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol. 2009 May 20;27(15):2530-5. Epub 2009 Apr 6.\nJCOG 0509: Satouchi M, Kotani Y, Shibata T, Ando M, Nakagawa K, Yamamoto N, Ichinose Y, Ohe Y, Nishio M, Hida T, Takeda K, Kimura T, Minato K, Yokoyama A, Atagi S, Fukuda H, Tamura T, Saijo N. Phase III study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive-disease small-cell lung cancer: JCOG 0509. J Clin Oncol. 2014 Apr 20;32(12):1262-8. Epub 2014 Mar 17."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 522,
      "name": "",
      "schedule": "<p><strong>Talazoparib</strong>&nbsp;1mg PO daily</p>\n\n<p>Repeat cycle every 28 days.</p>\n",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<h4>Renal impairment</h4>\n\n<ul>\n\t<li>CrCl 30-59 mL/min: Reduce dose to 0.75mg daily</li>\n\t<li>CrCl 15-29 mL/min: Reduce dose to 0.5mg daily</li>\n</ul>\n",
      "references": [
        {
          "id": 866,
          "referenceValue": "Litton JK, Rugo HS, et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med. 2018;379(8):753-763."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 416,
      "name": "",
      "schedule": "<p><strong>Carboplatin</strong> AUC 5 IV on day 1<br />\n<strong>Etoposide</strong> 100mg/m<sup>2</sup>&nbsp;IV on days 1, 2, 3<br />\n<strong>Atezolizumab</strong> 1200 mg IV on day one</p>\n\n<p><strong>21-day cycle for 4 cycles</strong></p>\n\n<p><strong>Followed by maintenance atezolizumab: </strong>1,200 mg on day 1 <strong>every 21 days</strong></p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><u><strong>Carboplatin</strong></u></p>\n\n<p><strong>Renal</strong>: AUC dosing&nbsp;</p>\n\n<p>Hemodialysis:&nbsp;<em>hemodialysis should occur between 12 to 24 hours after carboplatin dose</em></p>\n\n<p><strong>Hepatic</strong>:&nbsp;There are no dosage adjustments provided in the manufacturer&rsquo;s labeling</p>\n\n<p>&nbsp;</p>\n\n<p><u><strong>Atezolizumab</strong></u>:</p>\n\n<p><strong>Renal</strong>: No dosing instructions in manufacturer&#39;s labeling</p>\n\n<p><strong>Hepatic</strong>:&nbsp;</p>\n\n<p><em>P</em><em>rior to initiation of treatment:</em></p>\n\n<p>No dosing instructions in manufactureer&#39;s labeling for modifications</p>\n\n<p><em>During treatment:</em></p>\n\n<p>AST or ALT &gt;3 - 8 x ULN&nbsp;<strong>or</strong>&nbsp;total bilirubin &gt;1.5 - 3 x ULN: Withhold treatment and administer&nbsp;high-dose systemic corticosteroids (prednisone 1 - 2 mg/kg/day or equivalent) and subsequent&nbsp;corticosteroid taper. Resume treatment when&nbsp;grade 1 or resolved and prednisone dose is &le;10 mg/day (or equivalent).</p>\n\n<p>AST or ALT &gt;8 x ULN&nbsp;<strong>or</strong>&nbsp;total bilirubin &gt;3 x ULN: Discontinue permanently. Administer high-dose systemic corticosteroids (prednisone 1 - 2 mg/kg/day or equivalent) and subsequent corticosteroid taper.</p>\n",
      "references": [
        {
          "id": 857,
          "referenceValue": "IMpower133: Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, Reck M, Mok T, Lam S, Shames DS, Liu J, Ding B, Lopez-Chavez A, Kabbinavar F, Lin W, Sandler A, Liu SV; IMpower133 Study Group. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018 Dec 6;379(23):2220-2229. Epub 2018 Sep 25. link to original article contains verified protocol PubMed"
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 511,
      "name": "",
      "schedule": "<p><strong>Docetaxel&nbsp;</strong>100mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat cycle every 21 days.</p>\n\n<p>OR</p>\n\n<p><strong>Docetaxel</strong>&nbsp;35-40mg/m<sup>2</sup>&nbsp;IV weekly for 6 weeks.</p>\n\n<p>Repeat cycle every 8 weeks.</p>\n",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Docetaxel</strong>:<br />\n\tIf bilirubin &gt; upper normal limit, do not use<br />\n\tIf&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline Phosphatase &gt; 2.5 upper normal limit, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Docetaxel</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 858,
          "referenceValue": "Chan S. Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy. Oncology (Williston Park). 1997;11(8 Suppl 8):19-24. --- Baselga J, Tabernero JM. Weekly docetaxel in breast cancer: applying clinical data to patient therapy. Oncologist. 2001;6 Suppl 3:26-9."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 427,
      "name": "",
      "schedule": "<p><strong>Cisplatin</strong> 75-80 mg/m<sup>2</sup>&nbsp;on day 1<br />\n<strong>Etoposide</strong> 80-100 mg/m<sup>2</sup>&nbsp;on days 1, 2, 3&nbsp;<br />\n<strong>Durvalumab</strong> 1,500 mg on day 1</p>\n\n<p><strong>Repeat cycle every 21 days x 4 cycles&nbsp;</strong></p>\n\n<p>Followed by maintenance <strong>durvalumab</strong> 1,500 mg on day one, repeat cycle every 28 days</p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><u><strong>Cisplatin</strong></u></p>\n\n<p><strong>Hepatic:</strong></p>\n\n<ul>\n\t<li>No Dosage Adjustments</li>\n</ul>\n\n<p><strong>Renal:</strong></p>\n\n<ul>\n\t<li>CrCl 10 to 50 mL/minute: Administer 75% of dose.</li>\n\t<li>CrCl &lt;10 mL/minute: Administer 50% of dose.</li>\n\t<li>Hemodialysis: Administer 50% of dose posthemodialysis.</li>\n\t<li>Continuous ambulatory peritoneal dialysis: Administer 50% of dose.</li>\n\t<li>Continuous renal replacement therapy: Administer 75% of dose.</li>\n</ul>\n\n<p><u><strong>Etoposide:</strong></u></p>\n\n<p><strong>Hepatic:</strong>&nbsp;No dose adjustments in manufacturers labeling</p>\n\n<p>Hendrayana, Wilmer, Kurth et al, 2017:</p>\n\n<ul>\n\t<li>T.Bil 1.5&ndash;3 mg/dL or AST 60&ndash;180:&nbsp;50% of of full dose</li>\n\t<li>T.Bil &ge; 3 mg/dL or AST &gt; 180:&nbsp;omit</li>\n</ul>\n\n<p><strong>Renal:</strong></p>\n\n<ul>\n\t<li>CrCl &gt;50 mL/minute: No adjustment required.</li>\n\t<li>CrCl 15 to 50 mL/minute: Administer 75% of dose</li>\n\t<li>CrCl &lt;15 mL minute: No data available; consider further dose reductions</li>\n</ul>\n\n<p><u><strong>Etoposide:</strong></u></p>\n\n<p><strong>Hepatic:</strong>&nbsp;No dose adjustments in manufacturers labeling</p>\n\n<p>Hendrayana, Wilmer, Kurth et al, 2017:</p>\n\n<ul>\n\t<li>T.Bil 1.5&ndash;3 mg/dL or AST 60&ndash;180:&nbsp;50% of of full dose</li>\n\t<li>T.Bil &ge; 3 mg/dL or AST &gt; 180:&nbsp;omit</li>\n</ul>\n\n<p><strong>Renal</strong></p>\n\n<ul>\n\t<li>CrCl &gt;50 mL/minute: No adjustment required.</li>\n\t<li>CrCl 15 to 50 mL/minute: Administer 75% of dose</li>\n\t<li>CrCl &lt;15 mL minute: No data available; consider further dose reductions</li>\n</ul>\n\n<p><u><strong>Durvalumab</strong></u></p>\n\n<p><strong>Hepatic</strong>:</p>\n\n<p><em>Hepatic impairment prior to treatment initiation:</em></p>\n\n<ul>\n\t<li>There are no dosage adjustments provided in the manufacturer&#39;s labeling.</li>\n</ul>\n\n<p><em>Hepatotoxicity during treatment:</em></p>\n\n<ul>\n\t<li>ALT or AST &gt;3 - 8 x ULN or total bilirubin &gt;1.5 -&nbsp;5 x ULN: Withhold dose. Administer systemic corticosteroids (prednisone initial dose of 1 to 2 mg/kg/day or equivalent) with subsequent&nbsp;taper. May resume when hepatitis has improved to grade 1 or resolved and corticosteroid dose is &le;10 mg/day prednisone (or equivalent).</li>\n\t<li>ALT or AST &gt;8 times ULN or total bilirubin &gt;5 times ULN: Discontinue permanently. Administer systemic corticosteroids (prednisone initial dose of 1 to 2 mg/kg daily or equivalent) with subsequent taper.&nbsp;</li>\n\t<li>Concurrent ALT or AST &gt;3 x ULN and total bilirubin &gt;2 x ULN without alternate cause: Discontinue permanently. Administer systemic corticosteroids (prednisone initial dose of 1 to 2 mg/kg/day or equivalent) with subsequent taper.&nbsp;</li>\n</ul>\n\n<p><strong>Renal:</strong></p>\n\n<p><em>Renal toxicity prior to initiation of&nbsp;treatment (nephritis):</em></p>\n\n<ul>\n\t<li>There are no dosage adjustments provided in the manufacturer&#39;s labeling.</li>\n</ul>\n\n<p><em>Renal toxicity during treatment (nephritis):</em></p>\n\n<ul>\n\t<li>Creatinine &gt;1.5 - 3x ULN: Withhold dose. Administer systemic corticosteroids (prednisone initial dose of 1 - 2 mg/kg/day or equivalent) followed by a taper. May resume durvalumab when nephritis has improved to grade 1 or resolved and corticosteroid dose is &le;10 mg/day prednisone (or equivalent).</li>\n\t<li>Creatinine &gt;3x&nbsp;ULN: Discontinue permanently. Administer systemic corticosteroids (prednisone initial dose of 1 to 2 mg/kg daily or equivalent) with subsequent taper.</li>\n</ul>\n",
      "references": [
        {
          "id": 859,
          "referenceValue": "CASPIAN: Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Kazarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Shire N, Jiang H, Goldman JW; CASPIAN investigators. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019 Oct 4. [Epub ahead of print]"
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 419,
      "name": "",
      "schedule": "<p><strong>Cisplatin</strong> 75 mg/m<sup>2</sup>&nbsp;day 1<br />\n<strong>Etoposide</strong> 100&nbsp;mg/m<sup>2</sup>&nbsp;days 1, 2, 3</p>\n\n<p><strong>For maximum of&nbsp;4-6 cycles</strong></p>\n\n<p>OR</p>\n\n<p><strong>Cisplatin</strong> 80&nbsp;mg/m<sup>2</sup>&nbsp;day 1<br />\n<strong>Etoposide</strong> 80&nbsp;mg/m<sup>2</sup>&nbsp;days 1, 2, 3</p>\n\n<p><strong>For maximum of&nbsp;4-6 cycles</strong>OR</p>\n\n<p><strong>Cisplatin</strong> 25 mg/m<sup>2</sup>&nbsp;days 1, 2, 3&nbsp;<br />\n<strong>Etoposide</strong> 100&nbsp;mg/m<sup>2</sup>&nbsp;days 1, 2, 3</p>\n\n<p><strong>For maximum of&nbsp;4-6 cycles</strong></p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><u><strong>Cisplatin</strong></u></p>\n\n<p><strong>Hepatic</strong></p>\n\n<ul>\n\t<li>No Dosage Adjustments</li>\n</ul>\n\n<p><strong>Renal</strong></p>\n\n<ul>\n\t<li>CrCl 10 to 50 mL/minute: Administer 75% of dose.</li>\n\t<li>CrCl &lt;10 mL/minute: Administer 50% of dose.</li>\n\t<li>Hemodialysis: Administer 50% of dose posthemodialysis.</li>\n\t<li>Continuous ambulatory peritoneal dialysis: Administer 50% of dose.</li>\n\t<li>Continuous renal replacement therapy: Administer 75% of dose.</li>\n</ul>\n\n<p><u><strong>Etoposide:</strong></u></p>\n\n<p><strong>Hepatic</strong></p>\n\n<ul>\n\t<li>No dose adjustments in manufacturers labeling</li>\n\t<li>Per Hendrayana, Wilmer, Kurth et al, 2017:\n\t<ul>\n\t\t<li>T.Bil 1.5&ndash;3 mg/dL or AST 60&ndash;180:&nbsp;50% of of full dose</li>\n\t\t<li>T.Bil &ge; 3 mg/dL or AST &gt; 180:&nbsp;omit</li>\n\t</ul>\n\t</li>\n</ul>\n\n<p><strong>Renal</strong></p>\n\n<ul>\n\t<li>CrCl &gt;50 mL/minute: No adjustment required.</li>\n\t<li>CrCl 15 to 50 mL/minute: Administer 75% of dose</li>\n\t<li>CrCl &lt;15 mL minute: No data available; consider further dose reductions</li>\n</ul>\n",
      "references": [
        {
          "id": 860,
          "referenceValue": "Marcello I., Boni L., Ambrosio F. et al. Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial. Journal of Clinical Oncology 2017 35:12, 1281-1287.\n\nSundstrom, S., Bremnes RM., Kaasa, S., et al. Cisplatin and Etoposide Regimen Is Superior to Cyclophosphamide, Epirubicin, and Vincristine Regimen in Small-Cell Lung Cancer: Results From a Randomized Phase III Trial With 5 Years’ Follow-Up. Journal of Clinical Oncology 2002 20:24, 4665-4672.\n\nNiell, H.B., Herndon II, J.E, Miller, A.A., et al. Randomized Phase III Intergroup Trial of Etoposide and Cisplatin With or Without Paclitaxel and Granulocyte Colony-Stimulating Factor in Patients With Extensive-Stage Small-Cell Lung Cancer: Cancer and Leukemia Group B Trial 9732. Journal of Clinical Oncology 2005 23:16, 3752-3759.\n\nIhde D.C., Mulshine J.L., Kramer, B.S., et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer.Journal of Clinical Oncology 1994 12:10, 2022-2034."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 510,
      "name": "",
      "schedule": "<p><strong>Capecitabine</strong>&nbsp;1250mg/m<sup>2</sup>&nbsp;PO BID for 2 weeks followed by 1-week rest period</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "Low",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Capecitabine</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Capecitabine</strong>:<br />\n\tIf CrCl 30-50 mL/min, reduce dose by 25%<br />\n\tIf CrCl &lt; 30 mL/min, do not use</li>\n</ul>\n",
      "references": [
        {
          "id": 861,
          "referenceValue": "Blum JL, Jones SE, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1999;17(2):485-93."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 552,
      "name": "",
      "schedule": "<p><strong>Cisplatin</strong>&nbsp;20mg/m<sup>2</sup>/day IV on days 1-4<br />\n<strong>Ifosfamide</strong>&nbsp;1500mg/m<sup>2</sup>/day IV on day 1<br />\n<strong>Mesna</strong>&nbsp;120mg/m<sup>2</sup>&nbsp;IV loading dose followed by 1500mg/m<sup>2</sup>/day for 24 hours</p>\n\n<p>Repeat cycle every 21 days for 3 cycles.</p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Cisplatin</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Ifosfamide</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Cisplatin</strong>:<br />\n\tIf CrCl 30-60 mL/min, reduce dose by 50%<br />\n\tIf CrCl &lt; 30 mL/min, do not use</li>\n</ul>\n",
      "references": [
        {
          "id": 862,
          "referenceValue": "Wolfson AH, et al. J Clin Oncol 2006;24(18S):5001."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 553,
      "name": "",
      "schedule": "<p><strong>Gemcitabine</strong>&nbsp;900mg/m<sup>2</sup>&nbsp;IV on days 1 and 8<br />\n<strong>Docetaxel</strong>&nbsp;100mg/m<sup>2</sup>&nbsp;IV on day 8</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "Low",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Docetaxel</strong>:<br />\n\tIf bilirubin &gt; upper normal limit, do not use<br />\n\tIf&nbsp;SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li>\n\t<li><strong>Gemcitabine</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Docetaxel</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Gemcitabine</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 864,
          "referenceValue": "Hensley ML, Blessing JA, et al. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol. 2008;109(3):329-34."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 554,
      "name": "",
      "schedule": "<p><strong>Doxorubicin</strong>&nbsp;60mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Doxorubicin</strong>:<br />\n\tIf bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />\n\tIf bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Doxorubicin</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 867,
          "referenceValue": "Muss HB. Chemotherapy of metastatic endometrial cancer. Semin Oncol. 1994;21(1):107-13."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 523,
      "name": "",
      "schedule": "<p><strong>Radiation therapy&nbsp;</strong>1.8-2 Gy per fraction (total dose, 45 Gy)<br />\n<strong>Cisplatin</strong>&nbsp;40mg/m<sup>2</sup>&nbsp;IV weekly (maximal dose, 70mg per week)</p>\n\n<p>Cisplatin is given 4 hours before radiation therapy on weeks 1-6.</p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Cisplatin</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Cisplatin</strong>:<br />\n\tIf CrCl 30-60 mL/min, reduce dose by 50%<br />\n\tIf CrCl &lt; 30 mL/min, do not use</li>\n</ul>\n",
      "references": [
        {
          "id": 868,
          "referenceValue": "Rose PG, Bundy BN, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340(15):1144-53."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 524,
      "name": "",
      "schedule": "<p><strong>Paclitaxel</strong>&nbsp;135mg/m<sup>2</sup>&nbsp;IV over 24 hours on day 1<br />\n<strong>Cisplatin</strong>&nbsp;75mg/m<sup>2</sup>&nbsp;IV on day 2</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Cisplatin</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Paclitaxel</strong>:<br />\n\tFor 3-hour infusion:<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2<br />\n\tIf transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />\n\tFor 24-hour infusion:<br />\n\tIf transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)<br />\n\tIf transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2<br />\n\tIf transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Cisplatin</strong>:<br />\n\tIf CrCl 30-60 mL/min, reduce dose by 50%<br />\n\tIf CrCl &lt; 30 mL/min, do not use</li>\n\t<li><strong>Paclitaxel</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 869,
          "referenceValue": "Morris M, Eifel PJ, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999;340(15):1137-43."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 525,
      "name": "",
      "schedule": "<p><strong>Cisplatin</strong>&nbsp;50mg/m<sup>2</sup>&nbsp;IV on day 1<br />\n<strong>Topotecan</strong>&nbsp;0.75mg/m<sup>2</sup>/day IV on days 1-3</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Cisplatin</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Topotecan</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Cisplatin</strong>:<br />\n\tIf CrCl 30-60 mL/min, reduce dose by 50%<br />\n\tIf CrCl &lt; 30 mL/min, do not use</li>\n\t<li><strong>Topotecan</strong>:<br />\n\tIf CrCl &gt; 40 mL/min, no dose reduction<br />\n\tIf CrCl 20-39 mL/min, reduce to 0.75 mg/m2</li>\n</ul>\n",
      "references": [
        {
          "id": 870,
          "referenceValue": "Fiorica J, Holloway R, et al. Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix. Gynecol Oncol. 2002;85(1):89-94."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 555,
      "name": "",
      "schedule": "<p><strong>Megestrol</strong>&nbsp;160mg PO daily</p>\n\n<p>Continue until disease progression or undue toxicity.</p>\n",
      "emetogenicPotential": "N/A",
      "dosageModifications": "",
      "references": [
        {
          "id": 871,
          "referenceValue": "Thigpen JT, Brady MF, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol. 1999;17(6):1736-44."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 556,
      "name": "",
      "schedule": "<p><strong>Paclitaxel</strong>&nbsp;200mg/m<sup>2</sup>&nbsp;IV over 3 hours on day 1</p>\n\n<p>Repeat cycle every 21 days. Reduce dose to 175mg/m<sup>2</sup> IV for patients with prior pelvic radiation therapy.</p>\n",
      "emetogenicPotential": "Low",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Paclitaxel</strong>:<br />\n\tFor 3-hour infusion:<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m<sup>2</sup>)<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m<sup>2</sup><br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m<sup>2</sup><br />\n\tIf transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />\n\tFor 24-hour infusion:<br />\n\tIf transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m<sup>2</sup>)<br />\n\tIf transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m<sup>2</sup><br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m<sup>2</sup><br />\n\tIf transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Paclitaxel</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 872,
          "referenceValue": "Ball HG, Blessing JA, et al. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 1996;62(2):278-81."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 438,
      "name": "",
      "schedule": "<p><strong>Doxorubicin&nbsp;</strong>50mg/m<sup>2</sup>&nbsp;IV on day 1<br />\n<strong>Paclitaxel</strong>&nbsp;150mg/m<sup>2</sup>&nbsp;IV over 24 hours on day 1</p>\n\n<p>Repeat cycle every 21 days.<br />\n&nbsp;</p>\n\n<p><strong>OR</strong></p>\n\n<p><br />\n<strong>Doxorubicin</strong>&nbsp;60mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat cycle every 21 days up to a maximum of 8 cycles.</p>\n\n<p><strong>FOLLOWED BY</strong></p>\n\n<p><strong>Paclitaxel</strong>&nbsp;175mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat cycle every 21 days until disease progression.</p>\n\n<p><br />\n<strong>OR</strong></p>\n\n<p><br />\n<strong>Paclitaxel</strong>&nbsp;175mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat cycle every 21 days until disease progression.</p>\n\n<p><strong>FOLLOWED BY</strong></p>\n\n<p><strong>Doxorubicin</strong>&nbsp;60mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat cycle every 21 days up to a maximum of 8 cycles.</p>\n",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Doxorubicin</strong>:<br />\n\tIf bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />\n\tIf bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use</li>\n\t<li><strong>Paclitaxel</strong>:<br />\n\tFor 3-hour infusion:<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m<sup>2</sup>)<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m<sup>2</sup><br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m<sup>2</sup><br />\n\tIf transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />\n\tFor 24-hour infusion:<br />\n\tIf transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m<sup>2</sup>)<br />\n\tIf transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m<sup>2</sup><br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m<sup>2</sup><br />\n\tIf transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Doxorubicin</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Paclitaxel</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 881,
          "referenceValue": "Sledge GW, Neuberg D, et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol. 2003;21(4):588-92."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 428,
      "name": "",
      "schedule": "<p><strong>Carboplatin</strong> AUC 5 on day 1&nbsp;<br />\n<strong>Irinotecan</strong> 50mg/m<sup>2</sup>&nbsp;on days 1, 8, 15&nbsp;</p>\n\n<p><strong>For maximum of&nbsp;4-6 cycles</strong></p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "<p><u><strong>Carboplatin</strong></u></p>\n\n<p><strong>Renal</strong>: AUC dosing&nbsp;</p>\n\n<ul>\n\t<li>Hemodialysis:&nbsp;<em>hemodialysis should occur between 12 to 24 hours after carboplatin dose</em></li>\n</ul>\n\n<p><strong>Hepatic</strong>:&nbsp;There are no dosage adjustments provided in the manufacturer&rsquo;s labeling</p>\n\n<p><u><strong>Irinotecan</strong></u></p>\n\n<p><strong>Renal</strong>:&nbsp;There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p>\n\n<ul>\n\t<li><strong>Dialysis</strong>: manufacturer does not recommend use in patients with dialysis.\n\n\t<ul>\n\t\t<li><em>Janus 2010:</em>&nbsp;may consider reduction of&nbsp;weekly dose from 125 mg/m<sup>2</sup>&nbsp;to 50 mg/m<sup>2</sup>&nbsp;and administration&nbsp;after hemodialysis or on nondialysis days</li>\n\t</ul>\n\t</li>\n</ul>\n\n<p><strong>Hepatic:&nbsp;</strong>Per manufacturer&#39;s guidelines:<strong>&nbsp;</strong></p>\n\n<ul>\n\t<li>Bilirubin 1 - 2 mg/dL: increased liklihood of grade 3 or 4 neutropenia. Consider reducing initial dose by one dose level</li>\n\t<li>Bilirubin &gt;2 mg/dL or transaminases &gt; 3 x ULN without liver metastasis or transaminases &gt; 5 x ULN with liver metastasis: Use is not recommended</li>\n</ul>\n",
      "references": [
        {
          "id": 873,
          "referenceValue": "Schmittel A, Sebastian M, Fischer von Weikersthal L, Martus P, Gauler TC, Kaufmann C, Hortig P, Fischer JR, Link H, Binder D, Fischer B, Caca K, Eberhardt WE, Keilholz U; Arbeitsgemeinschaft Internistische Onkologie Thoracic Oncology Study Group. A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer. Ann Oncol. 2011 Aug;22(8):1798-804. Epub 2011 Jan 25.\n\nHermes A, Bergman B, Bremnes R, Ek L, Fluge S, Sederholm C, Sundstrøm S, Thaning L, Vilsvik J, Aasebø U, Sörenson S. Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. J Clin Oncol. 2008 Sep 10;26(26):4261-7."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 431,
      "name": "",
      "schedule": "<p><strong>Anastrozole</strong>&nbsp;1mg PO daily</p>\n\n<p>Repeat daily for 5 years in patients with ER+ tumors or ER status unknown.</p>\n",
      "emetogenicPotential": "N/A",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Anastrozole</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Anastrozole</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 874,
          "referenceValue": "Howell A, Cuzick J, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005;365(9453):60-2."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 1,
          "level": "ADJUVANT"
        }
      ]
    },
    {
      "id": 430,
      "name": "",
      "schedule": "<p><strong>Tamoxifen</strong>&nbsp;20mg PO daily</p>\n\n<p>Repeat daily for 5 years in patients with ER+ tumors or ER status unknown.</p>\n",
      "emetogenicPotential": "N/A",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Tamoxifen</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Tamoxifen</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 875,
          "referenceValue": "Fisher B, Dignam J, et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst. 1997;89(22):1673-82."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 1,
          "level": "ADJUVANT"
        }
      ]
    },
    {
      "id": 432,
      "name": "",
      "schedule": "<p><strong>Letrozole</strong>&nbsp;2.5mg PO daily</p>\n\n<p>Repeat daily for 5 years in patients with ER+ or PR+ tumors.</p>\n",
      "emetogenicPotential": "N/A",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Letrozole</strong>:<br />\n\tIf Child-Pugh A or B, no dose reduction<br />\n\tIf Child-Pugh C, reduce dose by 50%</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Letrozole</strong>:<br />\n\tIf CrCl &gt; 10 mL/min, no dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 876,
          "referenceValue": "BIG 1-98 Collaborative Group, Mouridsen H, et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med. 2009;361(8):766-76."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 1,
          "level": "ADJUVANT"
        }
      ]
    },
    {
      "id": 433,
      "name": "",
      "schedule": "<p><strong>Tamoxifen</strong>&nbsp;20mg PO daily for 5 years</p>\n\n<p><strong>FOLLOWED BY</strong></p>\n\n<p><strong>Letrozole&nbsp;</strong>2.5mg PO daily for 5 years</p>\n",
      "emetogenicPotential": "N/A",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Tamoxifen</strong><br />\n\tNo dose reduction</li>\n\t<li><strong>Letrozole</strong>:<br />\n\tIf Child-Pugh A or B, no dose reduction<br />\n\tIf Child-Pugh C, reduce dose by 50%</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Tamoxifen</strong><br />\n\tNo dose reduction</li>\n\t<li><strong>Letrozole</strong>:<br />\n\tIf CrCl &gt; 10 mL/min, no dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 877,
          "referenceValue": "Goss PE, Ingle JN, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97(17):1262-71."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 1,
          "level": "ADJUVANT"
        }
      ]
    },
    {
      "id": 434,
      "name": "",
      "schedule": "<p><strong>Tamoxifen</strong>&nbsp;20mg PO daily for 2-3 years</p>\n\n<p><strong>FOLLOWED BY</strong></p>\n\n<p><strong>Exemestane</strong>&nbsp;25mg PO daily for the remainder of 5 years</p>\n",
      "emetogenicPotential": "N/A",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Tamoxifen</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Exemestane</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Tamoxifen</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Exemestane</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 878,
          "referenceValue": "Coombes RC, Hall E, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350(11):1081-92."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 1,
          "level": "ADJUVANT"
        }
      ]
    },
    {
      "id": 435,
      "name": "",
      "schedule": "<p><strong>Tamoxifen</strong>&nbsp;20mg PO daily<br />\n<strong>Goserelin</strong>&nbsp;3.6mg SC every 28 days<br />\n<strong>Zoledronic acid</strong>&nbsp;4mg IV every 6 months</p>\n\n<p>Continue treatment for 3 years.</p>\n",
      "emetogenicPotential": "N/A",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Tamoxifen</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Goserelin</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Zoledronic acid</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Tamoxifen</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Goserelin</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Zoledronic acid</strong>:<br />\n\tCrCl &gt;60 mL/min: 4 mg<br />\n\tCrCl 50-60 mL/min: 3.5 mg<br />\n\tCrCl 40-49 mL/min: 3.3 mg<br />\n\tCrCl 30-39 mL/min: 3 mg<br />\n\tCrCl &lt;30 mL/min: Not recommended</li>\n</ul>\n",
      "references": [
        {
          "id": 879,
          "referenceValue": "Gnant M, Mlineritsch B, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009;360(7):679-91."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 1,
          "level": "ADJUVANT"
        }
      ]
    },
    {
      "id": 436,
      "name": "",
      "schedule": "<p><strong>Anastrozole</strong> 1mg PO daily<br />\n<strong>Goserelin</strong>&nbsp;3.6mg SC every 28 days<br />\n<strong>Zoledronic acid</strong>&nbsp;4mg IV every 6 months</p>\n\n<p>Continue treatment for 3 years.</p>\n",
      "emetogenicPotential": "N/A",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Anastrozole</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Goserelin</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Zoledronic acid</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Anastrozole</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Goserelin</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Zoledronic acid</strong>:<br />\n\tCrCl &gt;60 mL/min: 4 mg<br />\n\tCrCl 50-60 mL/min: 3.5 mg<br />\n\tCrCl 40-49 mL/min: 3.3 mg<br />\n\tCrCl 30-39 mL/min: 3 mg<br />\n\tCrCl &lt;30 mL/min: Not recommended</li>\n</ul>\n",
      "references": [
        {
          "id": 880,
          "referenceValue": "Gnant M, Mlineritsch B, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009;360(7):679-91."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 1,
          "level": "ADJUVANT"
        }
      ]
    },
    {
      "id": 439,
      "name": "",
      "schedule": "<p><strong>Cyclophosphamide</strong>&nbsp;600mg/m<sup>2</sup>&nbsp;IV on day 1<br />\n<strong>Doxorubicin</strong>&nbsp;60 mg/m<sup>2</sup> IV on day 1<br />\n<strong>5-Fluorouracil</strong>&nbsp;600 mg/m<sup>2</sup> IV on day 1</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "Moderate-High",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Cyclophosphamide</strong>:<br />\n\tIf bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use</li>\n\t<li><strong>Doxorubicin</strong>:<br />\n\tIf bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />\n\tIf bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use</li>\n\t<li><strong>5-Fluorouracil</strong>:<br />\n\tIf bilirubin &lt; 5 mg/dL, no dose reduction<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use<br />\n\tNo dose reduction for infusional administration</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Cyclophosphamide</strong>:<br />\n\tIf CrCl 10-50 mL/min, reduce dose by 25%<br />\n\tIf CrCl &lt; 10 mL/min, reduce dose by 50%</li>\n\t<li><strong>Doxorubicin</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>5-Fluorouracil</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 882,
          "referenceValue": "Budman DR, Berry DA, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst. 1998;90(16):1205-11."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 440,
      "name": "",
      "schedule": "<p><strong>Cyclophosphamide</strong>&nbsp;75mg/m<sup>2</sup>&nbsp;PO on days 1-14<br />\n<strong>Epirubicin</strong>&nbsp;60mg/m<sup>2</sup>&nbsp;IV on days 1 and 8<br />\n<strong>5-Fluorouracil</strong>&nbsp;500mg/m<sup>2</sup>&nbsp;IV on days 1 and 8</p>\n\n<p>Repeat cycle every 28 days.</p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>5-Fluorouracil</strong>:<br />\n\tIf bilirubin &lt; 5 mg/dL, no dose reduction<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use<br />\n\tNo dose reduction for infusional administration</li>\n\t<li><strong>Epirubicin</strong>:<br />\n\tIf bilirubin 1.2-3 mg/dL or SGOT 2 to 4 times upper limit normal: reduce dose by 50%<br />\n\tIf bilirubin &gt; 3mg/dL or SGOT &gt; 4 times upper limit normal: reduce dose by 75%&nbsp;</li>\n\t<li><strong>Cyclophosphamide</strong>:<br />\n\tIf bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>5-Fluorouracil</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Epirubicin</strong><br />\n\tIf serum Cr &gt;&nbsp;5 mg/dL, reduce dose by 50%</li>\n\t<li><strong>Cyclophosphamide</strong>:<br />\n\tIf CrCl 10-50 mL/min, reduce dose by 25%<br />\n\tIf CrCl &lt; 10 mL/min, reduce dose by 50%</li>\n</ul>\n",
      "references": [
        {
          "id": 883,
          "referenceValue": "Levine MN, Bramwell VH, et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1998;16(8):2651-8."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 441,
      "name": "",
      "schedule": "<p><strong>Cyclophosphamide</strong>&nbsp;600mg/m<sup>2</sup>&nbsp;IV on day 1<br />\n<strong>Methotrexate</strong>&nbsp;40mg/m<sup>2</sup>&nbsp;IV on day 1<br />\n<strong>5-Fluorouracil</strong>&nbsp;600mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Cyclophosphamide</strong>:<br />\n\tIf bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use</li>\n\t<li><strong>Methotrexate</strong>:<br />\n\tIf bilirubin 3.1-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use</li>\n\t<li><strong>5-Fluorouracil</strong>:<br />\n\tIf bilirubin &lt; 5 mg/dL, no dose reduction<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use<br />\n\tNo dose reduction for infusional administration</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Cyclophosphamide</strong>:<br />\n\tIf CrCl 10-50 mL/min, reduce dose by 25%<br />\n\tIf CrCl &lt; 10 mL/min, reduce dose by 50%</li>\n\t<li><strong>Methotrexate</strong>:<br />\n\tIf CrCl 30-60 mL/min, reduce dose by 50%<br />\n\tIf CrCl &lt; 30 mL/min, do not use</li>\n\t<li><strong>5-Fluorouracil</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 884,
          "referenceValue": "Poole CJ, Earl HM, et al. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. N Engl J Med. 2006;355(18):1851-62."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 442,
      "name": "",
      "schedule": "<p><strong>Capecitabine</strong>&nbsp;1250mg/m<sup>2</sup>&nbsp;PO BID on days 1-14<br />\n<strong>Docetaxel</strong>&nbsp;75mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "Low ",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Capecitabine</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Docetaxel</strong>:<br />\n\tIf bilirubin &gt; upper normal limit, do not use<br />\n\tIf&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Capecitabine</strong>:<br />\n\tIf CrCl 30-50 mL/min, reduce dose by 25%<br />\n\tIf CrCl &lt; 30 mL/min, do not use</li>\n\t<li><strong>Docetaxel</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 885,
          "referenceValue": "O'Shaughnessy J, Miles D, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 2002;20(12):2812-23."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 629,
      "name": "",
      "schedule": "<p><strong>Irinotecan:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>Capecitabine:&nbsp;</strong>800 mg/m<sup>2</sup>&nbsp;PO on days 1-14</p>\n\n<p><strong>Bevacizumab:&nbsp;</strong>7.5 mg/kg IV on day 1</p>\n\n<p>Repeat cycle every 3 weeks.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 448,
      "name": "",
      "schedule": "<p><strong>5-Fluorouracil</strong> 500 mg/m<sup>2</sup> IV on day 1<br />\n<strong>Epirubicin</strong> 75 mg/m<sup>2</sup> IV on&nbsp;day 1<br />\n<strong>Cyclophosphamide</strong> 500 mg/m<sup>2</sup> IV on day 1</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>5-Fluorouracil</strong>:<br />\n\tIf bilirubin &lt; 5 mg/dL, no dose reduction<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use<br />\n\tNo dose reduction for infusional administration</li>\n\t<li><strong>Epirubicin</strong>:<br />\n\tIf bilirubin 1.2-3 mg/dL or SGOT 2 to 4 times upper limit normal: reduce dose by 50%<br />\n\tIf bilirubin &gt; 3mg/dL or SGOT &gt; 4 times upper limit normal: reduce dose by 75%&nbsp;</li>\n\t<li><strong>Cyclophosphamide</strong>:<br />\n\tIf bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>5-Fluorouracil</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Epirubicin</strong><br />\n\tIf serum Cr &gt;&nbsp;5 mg/dL, reduce dose by 50%</li>\n\t<li><strong>Cyclophosphamide</strong>:<br />\n\tIf CrCl 10-50 mL/min, reduce dose by 25%<br />\n\tIf CrCl &lt; 10 mL/min, reduce dose by 50%</li>\n</ul>\n",
      "references": [
        {
          "id": 893,
          "referenceValue": "A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. The French Epirubicin Study Group. J Clin Oncol. 1991;9(2):305-12."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 443,
      "name": "",
      "schedule": "<p><strong>Capecitabine</strong>&nbsp;825mg/m<sup>2</sup>&nbsp;PO BID on days 1-14<br />\n<strong>Paclitaxel</strong>&nbsp;175mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "Low",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Capecitabine</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Paclitaxel</strong>:<br />\n\tFor 3-hour infusion:<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m<sup>2</sup>)<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m<sup>2</sup><br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m<sup>2</sup><br />\n\tIf transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />\n\tFor 24-hour infusion:<br />\n\tIf transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m<sup>2</sup>)<br />\n\tIf transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m<sup>2</sup><br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m<sup>2</sup><br />\n\tIf transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Capecitabine</strong>:<br />\n\tIf CrCl 30-50 mL/min, reduce dose by 25%<br />\n\tIf CrCl &lt; 30 mL/min, do not use</li>\n\t<li><strong>Paclitaxel</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 886,
          "referenceValue": "Biganzoli L, Martin M, et al. Moving forward with capecitabine: a glimpse of the future. Oncologist. 2002;7 Suppl 6:29-35."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 444,
      "name": "",
      "schedule": "<p><strong>Capecitabine</strong>&nbsp;1000mg/m<sup>2</sup>&nbsp;PO BID on days 1-14<br />\n<strong>Vinorelbine</strong>&nbsp;25mg/m<sup>2</sup>&nbsp;IV on days 1 and 8</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Capecitabine</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Vinorelbine</strong>:<br />\n\tIf bilirubin 2-3 mg/dL, reduce dose by 50%<br />\n\tIf bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Capecitabine</strong>:<br />\n\tIf CrCl 30-50 mL/min, reduce dose by 25%<br />\n\tIf CrCl &lt; 30 mL/min, do not use</li>\n\t<li><strong>Vinorelbine</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 887,
          "referenceValue": "Biganzoli L, Martin M, et al. Moving forward with capecitabine: a glimpse of the future. Oncologist. 2002;7 Suppl 6:29-35."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 445,
      "name": "",
      "schedule": "<p><strong>Capecitabine</strong>&nbsp;1000mg/m<sup>2</sup>&nbsp;PO BID on days 1-14<br />\n<strong>Ixabepilone</strong>&nbsp;40mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repaet cycle every 21 days.</p>\n",
      "emetogenicPotential": "Low",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Capecitabine</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Ixabepilone</strong>:<br />\n\tIf AST and ALT &lt; 2.5 upper normal limit, and bilirubin &lt; 1 upper normal limit, use 40 mg/m<sup>2</sup><br />\n\tIf AST or ALT &gt; 2.5 upper normal limit, or bilirubin &gt; 1 upper normal limit, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Capecitabine</strong>:<br />\n\tIf CrCl 30-50 mL/min, reduce dose by 25%<br />\n\tIf CrCl &lt; 30 mL/min, do not use</li>\n\t<li><strong>Ixabepilone</strong>:<br />\n\tIf CrCl &gt; 30 mL/min, no dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 888,
          "referenceValue": "Thomas ES, Gomez HL, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007;25(33):5210-7."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 446,
      "name": "",
      "schedule": "<p><strong>Docetaxel</strong>&nbsp;75mg/m<sup>2</sup>&nbsp;IV on day 1<br />\n<strong>Doxorubicin</strong>&nbsp;50mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Docetaxel</strong>:<br />\n\tIf bilirubin &gt; upper normal limit, do not use<br />\n\tIf&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li>\n\t<li><strong>Doxorubicin</strong>:<br />\n\tIf bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />\n\tIf bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Docetaxel</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Doxorubicin</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 890,
          "referenceValue": "Dieras V. Review of docetaxel/doxorubicin combination in metastatic breast cancer. Oncology (Williston Park). 1997;11(8 Suppl 8):31-3."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 447,
      "name": "",
      "schedule": "<p><strong>Doxorubicin liposome</strong>&nbsp;30mg/m<sup>2</sup>&nbsp;on day 1<br />\n<strong>Docetaxel</strong>&nbsp;60mg/m<sup>2</sup>&nbsp;on day 1</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Docetaxel</strong>:<br />\n\tIf bilirubin &gt; upper normal limit, do not use<br />\n\tIf&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li>\n\t<li><strong>Doxorubicin</strong>:<br />\n\tIf bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />\n\tIf bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Docetaxel</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Doxorubicin</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 891,
          "referenceValue": "Dieras V. Review of docetaxel/doxorubicin combination in metastatic breast cancer. Oncology (Williston Park). 1997;11(8 Suppl 8):31-3."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 409,
      "name": "",
      "schedule": "<p><strong>5-Fluorouracil</strong> 500 mg/m<sup>2</sup> IV on day 1<br />\n<strong>Epirubicin</strong> 100 mg/m<sup>2</sup> IV on&nbsp;day 1<br />\n<strong>Cyclophosphamide</strong> 500 mg/m<sup>2</sup> IV on day 1</p>\n\n<p>Repeat every 21 days for 6&nbsp;cycles.</p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>5-Fluorouracil</strong>:<br />\n\tIf bilirubin &lt; 5 mg/dL, no dose reduction<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use<br />\n\tNo dose reduction for infusional administration</li>\n\t<li><strong>Epirubicin</strong>:<br />\n\tIf bilirubin 1.2-3 mg/dL or SGOT 2 to 4 times upper limit normal: reduce dose by 50%<br />\n\tIf bilirubin &gt; 3mg/dL or SGOT &gt; 4 times upper limit normal: reduce dose by 75%&nbsp;</li>\n\t<li><strong>Cyclophosphamide</strong>:<br />\n\tIf bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>5-Fluorouracil</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Epirubicin</strong><br />\n\tIf serum Cr &gt;&nbsp;5 mg/dL, reduce dose by 50%</li>\n\t<li><strong>Cyclophosphamide</strong>:<br />\n\tIf CrCl 10-50 mL/min, reduce dose by 25%<br />\n\tIf CrCl &lt; 10 mL/min, reduce dose by 50%</li>\n</ul>\n",
      "references": [
        {
          "id": 892,
          "referenceValue": "Levine MN, Bramwell VH, et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1998;16(8):2651-8."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 1,
          "level": "ADJUVANT"
        }
      ]
    },
    {
      "id": 449,
      "name": "",
      "schedule": "<p><strong>5-Fluorouracil</strong> 500 mg/m<sup>2</sup> IV on day 1<br />\n<strong>Epirubicin</strong> 50 mg/m<sup>2</sup> IV on&nbsp;day 1<br />\n<strong>Cyclophosphamide</strong> 500 mg/m<sup>2</sup> IV on day 1</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>5-Fluorouracil</strong>:<br />\n\tIf bilirubin &lt; 5 mg/dL, no dose reduction<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use<br />\n\tNo dose reduction for infusional administration</li>\n\t<li><strong>Epirubicin</strong>:<br />\n\tIf bilirubin 1.2-3 mg/dL or SGOT 2 to 4 times upper limit normal: reduce dose by 50%<br />\n\tIf bilirubin &gt; 3mg/dL or SGOT &gt; 4 times upper limit normal: reduce dose by 75%&nbsp;</li>\n\t<li><strong>Cyclophosphamide</strong>:<br />\n\tIf bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>5-Fluorouracil</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Epirubicin</strong><br />\n\tIf serum Cr &gt;&nbsp;5 mg/dL, reduce dose by 50%</li>\n\t<li><strong>Cyclophosphamide</strong>:<br />\n\tIf CrCl 10-50 mL/min, reduce dose by 25%<br />\n\tIf CrCl &lt; 10 mL/min, reduce dose by 50%</li>\n</ul>\n",
      "references": [
        {
          "id": 894,
          "referenceValue": "A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. The French Epirubicin Study Group. J Clin Oncol. 1991;9(2):305-12."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 401,
      "name": "",
      "schedule": "<p><strong>Doxorubicin</strong>: 60mg/m<sup>2</sup>&nbsp;IV on day 1<br />\n<strong>Cyclophosphamide</strong>: 600mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat every 21 days for 4 cycles.</p>\n\n<p><strong>FOLLOWED BY</strong></p>\n\n<p><strong>Paclitaxel</strong>: 175mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat every 21 days for 4&nbsp;cycles.</p>\n",
      "emetogenicPotential": "High for AC, low for paclitaxel",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Cyclophosphamide</strong>:<br />\n\tIf bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use</li>\n\t<li><strong>Doxorubicin</strong>:<br />\n\tIf bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />\n\tIf bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use</li>\n\t<li><strong>Paclitaxel</strong>:<br />\n\tFor 3-hour infusion:<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m<sup>2</sup>)<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m<sup>2</sup><br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m<sup>2</sup><br />\n\tIf transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />\n\tFor 24-hour infusion:<br />\n\tIf transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m<sup>2</sup>)<br />\n\tIf transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m<sup>2</sup><br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m<sup>2</sup><br />\n\tIf transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Cyclophosphamide</strong>:<br />\n\tIf CrCl 10-50 mL/min, reduce dose by 25%<br />\n\tIf CrCl &lt; 10 mL/min, reduce dose by 50%</li>\n\t<li><strong>Doxorubicin</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Paclitaxel</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 895,
          "referenceValue": "Citron ML, Berry DA, et al. Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21(8):1431-9."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 1,
          "level": "ADJUVANT"
        }
      ]
    },
    {
      "id": 450,
      "name": "",
      "schedule": "<p><strong>Gemcitabine</strong>&nbsp;1250mg/m<sup>2</sup>&nbsp;IV on days 1 and 8<br />\n<strong>Paclitaxel</strong>&nbsp;175mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Gemcitabine</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Paclitaxel</strong>:<br />\n\tFor 3-hour infusion:<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m<sup>2</sup>)<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m<sup>2</sup><br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m<sup>2</sup><br />\n\tIf transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />\n\tFor 24-hour infusion:<br />\n\tIf transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m<sup>2</sup>)<br />\n\tIf transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m<sup>2</sup><br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m<sup>2</sup><br />\n\tIf transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Gemcitabine</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Paclitaxel</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 896,
          "referenceValue": "O'Shaughnessy J. Gemcitabine combination chemotherapy in metastatic breast cancer: phase II experience. Oncology (Williston Park). 2003;17(12 Suppl 14):15-21."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 735,
      "name": "",
      "schedule": "<p><strong>Capecitabine:&nbsp;</strong>1,250 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-14</p>\n\n<p>Repeat cycle every 21 days. Dose may be decreased to 850-1,000 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-14 to reduce risk of toxicity without compromising clinical efficacy.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 7,
          "level": "HEPATIC ARTERY INFUSION"
        }
      ]
    },
    {
      "id": 736,
      "name": "",
      "schedule": "<p><strong>CPT-11:&nbsp;</strong>125 mg/m<sup>2</sup>&nbsp;IV over 90 minutes weekly for 4 weeks</p>\n\n<p>Repeat cycle every 6 weeks.</p>\n\n<p><strong>OR</strong></p>\n\n<p><strong>CPT-11:&nbsp;</strong>125 mg/m<sup>2</sup>&nbsp;IV over 90 minutes weekly for 2 weeks</p>\n\n<p>Repeat cycle every 3 weeks.</p>\n\n<p><strong>OR</strong></p>\n\n<p><strong>CPT-11:&nbsp;</strong>175 mg/m<sup>2</sup>&nbsp;IV on days 1 and 10</p>\n\n<p>Repeat cycle every 3 weeks.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 7,
          "level": "HEPATIC ARTERY INFUSION"
        }
      ]
    },
    {
      "id": 737,
      "name": "",
      "schedule": "<p><strong>CPT-11:&nbsp;</strong>350 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat cycle every 3 weeks.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 7,
          "level": "HEPATIC ARTERY INFUSION"
        }
      ]
    },
    {
      "id": 738,
      "name": "",
      "schedule": "<p><strong>Cetuximab:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV loading dose, then 250 mg/m<sup>2</sup>&nbsp;IV weekly</p>\n\n<p>Repeat cycle on a weekly basis.</p>\n\n<p><strong>OR</strong></p>\n\n<p><strong>Cetuximab:&nbsp;</strong>500 mg/m<sup>2</sup>&nbsp;IV every 2 weeks (no loading dose is necessary)</p>\n\n<p>Repeat cycle every 2 weeks.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 7,
          "level": "HEPATIC ARTERY INFUSION"
        }
      ]
    },
    {
      "id": 473,
      "name": "",
      "schedule": "<p><strong>Ipilimumab</strong> 1 mg/kg IV on day 1<br />\n<strong>Nivolumab</strong> 3 mg/kg IV on day 1, 15, 29</p>\n\n<p><strong>42-day (6 week) cycles for up to 4 cycles </strong></p>\n\n<p>&nbsp;</p>\n",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<p><strong><u><span style=\"font-family:Times\">Ipilimumab</span></u></strong></p>\n\n<p><strong><span style=\"font-family:Times\">Renal Impairment</span></strong></p>\n\n<p><em><span style=\"font-family:Times\">Prior to treatment:</span></em><span style=\"font-family:Times\"> No dosage adjustment necessary.</span></p>\n\n<p><em><span style=\"font-family:Times\">Renal toxicity (immune mediated nephritis) during treatment:</span></em></p>\n\n<ul>\n\t<li><span style=\"font-family:Times\">Grade 2 or 3 creatinine elevation: Withhold treatment; administer corticosteroids (prednisone 0.5 - 1 mg/kg/day [or equivalent]) followed by a corticosteroid taper. </span>\n\n\t<ul style=\"list-style-type:circle\">\n\t\t<li><span style=\"font-family:Times\">If toxicity worsens or does not improve, increase corticosteroid dose to prednisone 1 - 2 mg/kg/day (or equivalent).</span></li>\n\t</ul>\n\t</li>\n\t<li><span style=\"font-family:Times\">Grade 4 creatinine elevation: Permanently discontinue; administer systemic corticosteroids (prednisone 1 - 2 mg/kg/day [or equivalent]) followed by a corticosteroid taper.</span></li>\n</ul>\n\n<p><strong><span style=\"font-family:Times\">Hepatic Impairment</span></strong></p>\n\n<p><em><span style=\"font-family:Times\">Prior to treatment:</span></em></p>\n\n<ul>\n\t<li><span style=\"font-family:Times\">Mild impairment (bilirubin 1 - 1.5 x ULN or AST &gt;ULN): No dosage adjustment necessary.</span></li>\n\t<li><span style=\"font-family:Times\">Moderate or severe impairment (total bilirubin &gt;1.5 x ULN and any AST): insufficient data, there are no dosage adjustments provided in the manufacturer&#39;s labeling.</span></li>\n</ul>\n\n<p><em><span style=\"font-family:Times\">Hepatic impairment during treatment:</span></em></p>\n\n<ul>\n\t<li><span style=\"font-family:Times\">Grade 2: Temporarily withhold treatment.</span></li>\n\t<li><span style=\"font-family:Times\">Grade 3 or 4: Permanently discontinue treatment. Administer systemic corticosteroids (prednisone 1 - 2 mg/kg/day [or equivalent]) followed by 1 month corticosteroid taper when LFTs show sustained improvement or return to baseline. </span></li>\n</ul>\n\n<p><strong><u>Nivolumab</u></strong></p>\n\n<p><strong>Renal Impairment: </strong></p>\n\n<ul>\n\t<li>Creatitine 1.5-6 x ULN- withhold dose</li>\n\t<li>Creatinine &gt; 6 x ULN- permanently discontinue<strong> </strong></li>\n</ul>\n\n<p><strong>Hepatic Impairment: </strong></p>\n\n<ul>\n\t<li>Transaminases 3 - 5 x ULN or bilirubin 1.5-3 x ULN- withhold dose</li>\n\t<li>Transaminases &gt; 5 x ULN or bilirubin &gt; 3 x ULN - permnently discontinue</li>\n</ul>\n",
      "references": [
        {
          "id": 902,
          "referenceValue": "Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, Park K, Alexandru A, Lupinacci L, de la Mora Jimenez E, Sakai H, Albert I, Vergnenegre A, Peters S, Syrigos K, Barlesi F, Reck M, Borghaei H, Brahmer JR, O'Byrne KJ, Geese WJ, Bhagavatheeswaran P, Rabindran SK, Kasinathan RS, Nathan FE, Ramalingam SS. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019 Nov 21;381(21):2020-2031. Epub 2019 Sep 28.\n\nOpdivo (Nivolumab) Medication Guide. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125554s070lbl.pdf\n\nYervoy (Ipilimumab) Medication Guide. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125377s073lbl.pdf"
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 631,
      "name": "",
      "schedule": "<p><strong>Irinotecan:&nbsp;</strong>180 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV bolus on day 1, followed by 2,400 mg/m<sup>2</sup>&nbsp;IV continuous infusion for 46 hours on days 1 and 2</p>\n\n<p><strong>Leucovorin:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV on day 1 as a 2-hour infusion prior to 5-fluorouracil</p>\n\n<p><strong>Ramucirumab:&nbsp;</strong>8 mg/kg IV on day 1</p>\n\n<p>Repeat cycle every 2 weeks.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 451,
      "name": "",
      "schedule": "<p><strong>Carboplatin</strong>&nbsp;AUC of 6, IV on day 1<br />\n<strong>Paclitaxel</strong>&nbsp;200mg/m<sup>2</sup>&nbsp;IV over 3 hours on day 1</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Carboplatin</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Paclitaxel</strong>:<br />\n\tFor 3-hour infusion:<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m<sup>2</sup>)<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m<sup>2</sup><br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m<sup>2</sup><br />\n\tIf transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />\n\tFor 24-hour infusion:<br />\n\tIf transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m<sup>2</sup>)<br />\n\tIf transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m<sup>2</sup><br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m<sup>2</sup><br />\n\tIf transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Carboplatin</strong>:<br />\n\tDosing based on AUC</li>\n\t<li><strong>Paclitaxel</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 897,
          "referenceValue": "Perez EA, Hillman DW, et al. A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma. Cancer. 2000;88(1):124-31."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 452,
      "name": "",
      "schedule": "<p><strong>Carboplatin</strong>&nbsp;AUC of 6, IV on day 1<br />\n<strong>Docetaxel</strong>&nbsp;75mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Carboplatin</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Docetaxel</strong>:<br />\n\tIf bilirubin &gt; upper normal limit, do not use<br />\n\tIf&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Carboplatin</strong>:<br />\n\tDosing based on AUC</li>\n\t<li><strong>Docetaxel</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 898,
          "referenceValue": "Fitch V, et al. Proc Am Soc Clin Oncol 2003;22:23 (abstract 90)."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 453,
      "name": "",
      "schedule": "<p><strong>Paclitaxel</strong>&nbsp;90mg/m<sup>2</sup>&nbsp;IV on days 1, 8, and 15<br />\n<strong>Bevacizumab</strong>&nbsp;10mg/kg on days 1 and 15</p>\n\n<p>Repeat cycle every 28 days.</p>\n",
      "emetogenicPotential": "Low",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Paclitaxel</strong>:<br />\n\tFor 3-hour infusion:<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m<sup>2</sup>)<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m<sup>2</sup><br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m<sup>2</sup><br />\n\tIf transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />\n\tFor 24-hour infusion:<br />\n\tIf transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m<sup>2</sup>)<br />\n\tIf transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m<sup>2</sup><br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m<sup>2</sup><br />\n\tIf transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Paclitaxel</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 899,
          "referenceValue": "Miller K, Wang M, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357(26):2666-76."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 454,
      "name": "",
      "schedule": "<p><strong>Atezolizumab</strong>&nbsp;840mg IV on days 1 and 15<br />\n<strong>Nab-paclitaxel</strong>&nbsp;100mg/m<sup>2</sup>&nbsp;IV on days 1, 8, and 15</p>\n\n<p>Repeat cycle every 28 days.</p>\n",
      "emetogenicPotential": "Low",
      "dosageModifications": "",
      "references": [
        {
          "id": 900,
          "referenceValue": "Schmid P, Rugo HS, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(1):44-59."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 455,
      "name": "",
      "schedule": "<p><strong>Pembrolizumab</strong>&nbsp;200 mg IV given on day 1.&nbsp;Administer at least 30 minutes prior to chemotherapy<br />\n<strong>Carboplatin</strong> AUC 5 given on day 1<br />\n<strong>Pemetrexed</strong> 500 mg/m<sup>2</sup>&nbsp;IV given on day 1</p>\n\n<p><strong>21-day cycle for 4 cycles</strong></p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><u><strong>Pembrolizumab</strong></u></p>\n\n<p><strong>Renal Impairment:</strong></p>\n\n<p><em>Prior&nbsp;to treatment initiation:</em>&nbsp;No dosage adjustment necessary.&nbsp;</p>\n\n<p><em>During&nbsp;treatment:</em></p>\n\n<ul>\n\t<li>\n\t<p>Grade 2: Withhold pembrolizumab; administer corticosteroids (prednisone 1-2 mg/kg/day [or equivalent] followed by a taper); may resume upon recovery to grade 0 or 1 toxicity.</p>\n\t</li>\n\t<li>\n\t<p>Grade 3 or 4: Permanently discontinue pembrolizumab; administer corticosteroids (prednisone 1-2 mg/kg/day [or equivalent] followed by a taper).</p>\n\t</li>\n</ul>\n\n<p><strong>Hepatic Impairment:</strong></p>\n\n<p><em>Prior to treatment initiation:</em>&nbsp;</p>\n\n<ul>\n\t<li>No dosage adjustment necessary for mild impairment (Bilirubin &le; ULN and AST &gt; ULN OR bilirubin &gt;1 - 1.5 &times; ULN and any AST).</li>\n\t<li>No dosage adjustments provided in manufacturer&rsquo;s labeling for moderate to severe impairment.</li>\n</ul>\n\n<p><em>During treatment:</em></p>\n\n<ul>\n\t<li>\n\t<p>Patients without hepatocellular carcinoma (HCC) or Renal Cell Carcinoma(RCC) also receiving axitinib:</p>\n\n\t<ul>\n\t\t<li>\n\t\t<p>Grade 2 hepatitis: Administer corticosteroids (prednisone 0.5 - 1 mg/kg/day [or equivalent]).</p>\n\t\t</li>\n\t\t<li>\n\t\t<p>Grade 3 or higher hepatitis: prednisone 1 - 2 mg/kg/day [or equivalent], followed by a taper). Withhold or discontinue therapy based on the severity of liver enzyme elevations:</p>\n\n\t\t<ul>\n\t\t\t<li>\n\t\t\t<p>AST or ALT 3 - 5x ULN or bilirubin 1.5 &ndash; 3x ULN: Withhold treatment; may resume therapy upon return to grade 0 or 1 toxicity.</p>\n\t\t\t</li>\n\t\t\t<li>\n\t\t\t<p>AST or ALT &gt;5x ULN or total bilirubin &gt;3x ULN (without liver metastases): Permanently discontinue pembrolizumab.</p>\n\t\t\t</li>\n\t\t\t<li>\n\t\t\t<p>If baseline grade 2 ALT or AST abnormalities with liver metastases, permanently discontinue pembrolizumab if AST or ALT increases by &ge;50% from baseline and persists for at least 1 week.</p>\n\t\t\t</li>\n\t\t</ul>\n\t\t</li>\n\t</ul>\n\t</li>\n</ul>\n\n<p><u><strong>Carboplatin</strong></u></p>\n\n<p><strong>Renal Impairment</strong>: AUC dosing</p>\n\n<p><em>Hemodialysis</em>: hemodialysis should occur between 12 to 24 hours after carboplatin dose</p>\n\n<p><strong>Hepatic Impairment</strong>: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling</p>\n\n<p><u><strong>Pemetrexed</strong></u></p>\n\n<p><strong>Renal Impairment:&nbsp;</strong></p>\n\n<ul>\n\t<li>\n\t<p><span style=\"font-family:Times New Roman,Times,serif\"><span class=\"marker\"><span style=\"background-color:white\"><span style=\"color:#232323\">CrCl &ge;45 mL/minute: No dosage adjustment necessary. If Cr 45- 79 mL/minute with concomitant use of ibuprofen, avoid ibuprofen 2 days prior to treatment, day of treatment, and 2 days following.</span></span></span></span></p>\n\t</li>\n\t<li>\n\t<p><span style=\"font-family:Times New Roman,Times,serif\"><span style=\"background-color:white\"><span style=\"color:#232323\">CrCl &lt;45 mL/minute: Use is not recommended by the manufacturer (has not been studied sufficiently)</span></span></span></p>\n\t</li>\n</ul>\n\n<p><strong><span style=\"font-family:Times New Roman,Times,serif\"><span style=\"background-color:white\"><span style=\"color:#232323\">Hepatic Impairment:</span></span></span></strong></p>\n\n<ul>\n\t<li><span style=\"font-family:Times New Roman,Times,serif\"><span style=\"background-color:white\"><span style=\"color:#232323\">No dosage instructions are provided in manufacturer&#39;s labeling</span></span></span></li>\n</ul>\n",
      "references": [
        {
          "id": 901,
          "referenceValue": "KEYNOTE-189: Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC, Garassino MC; KEYNOTE-189 Investigators. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018 May 31;378(22):2078-2092. Epub 2018 Apr 16\n\nKEYNOTE-021: Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Yang JC, Gubens M, Sequist LV, Awad MM, Fiore J, Ge Y, Raftopoulos H, Gandhi L; KEYNOTE-021 investigators. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016 Nov;17(11):1497-1508. Epub 2016 Oct 10.\n\nCarboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 608,
      "name": "",
      "schedule": "<p><strong>Cetuximab:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV loading dose, then 250 mg/m<sup>2</sup>&nbsp;IV weekly</p>\n\n<p><strong>Irinotecan:&nbsp;</strong>350 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat cycle every 21 days</p>\n\n<p><strong>OR</strong></p>\n\n<p><strong>Cetuximab:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV loading dose, then 250 mg/m<sup>2</sup>&nbsp;IV weekly</p>\n\n<p><strong>Irinotecan:&nbsp;</strong>180 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat cycle every 14 days</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 609,
      "name": "",
      "schedule": "<p><strong>Capecitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-14</p>\n\n<p><strong>Oxaliplatin:&nbsp;</strong>130 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat cycle every 21 days. May decrease dose of capecitabine to 850 mg/m<sup>2</sup>&nbsp;PO twice daily and dose of oxaliplatin to 100 mg/m<sup>2</sup>&nbsp;IV to reduce risk of toxicity without compromising clinical efficacy.</p>\n\n<p><strong>OR</strong></p>\n\n<p><strong>Capecitabine:&nbsp;</strong>1,750 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-7</p>\n\n<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat cycle every 14 days. May decrease dose of capecitabine to 1,000-1,250 mg/m<sup>2</sup>&nbsp;PO twice daily to reduce risk of toxicity without compromising clinical efficacy.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 457,
      "name": "",
      "schedule": "<p><strong>Atezolizumab</strong>&nbsp;1,200 mg given on day 1,&nbsp; <em>given first</em><br />\n<strong>Bevacizumab</strong> 15 mg/kg&nbsp;given on day 1<br />\n<strong>Paclitaxel</strong>&nbsp;200 mg/m<sup>2</sup>&nbsp;given on day 1 OR 175 mg/m<sup>2</sup> in Asian patients<br />\n<strong>Carboplatin</strong> AUC &nbsp;6 given on day 1&nbsp;</p>\n\n<p><strong>21-day cycle for a maximum of 4 or 6 cycles</strong></p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><u><strong>Atezolizumab</strong></u></p>\n\n<p><strong><span style=\"font-family:Times\">Renal </span></strong></p>\n\n<ul>\n\t<li><span style=\"background-color:white\"><span style=\"font-family:Times\"><span style=\"color:#232323\">eGFR &ge;30 mL/minute/1.73 m<sup>2</sup>: no clinically significant effect on the systemic exposure of atezolizumab. There are no dosage adjustments provided in the manufacturer&#39;s labeling.</span></span></span></li>\n\t<li><span style=\"background-color:white\"><span style=\"font-family:Times\"><span style=\"color:#232323\">eGFR &lt;30 mL/minute: effect on pharmacokinetics is unknown. There are no dosage adjustments provided in the manufacturer&#39;s labeling (has not been studied).</span></span></span></li>\n</ul>\n\n<p><strong><u><span style=\"font-family:Times\">Hepatic impairment</span></u></strong></p>\n\n<p style=\"margin-left:0in; margin-right:0in\"><span style=\"background-color:white\"><em><span style=\"font-family:Times\"><span style=\"color:#232323\">Prior to treatment:</span></span></em></span></p>\n\n<ul>\n\t<li><span style=\"background-color:white\"><span style=\"font-family:Times\"><span style=\"color:#232323\">Mild impairment: (bilirubin &le; ULN and AST &gt; ULN <strong>or</strong> bilirubin &gt;1 - 1.5 x ULN and any AST):&nbsp;no clinically significant effect on the systemic exposure of atezolizumab and no dosage instructions provided in manufacturer&#39;s labeling.</span></span></span></li>\n\t<li><span style=\"background-color:white\"><span style=\"font-family:Times\"><span style=\"color:#232323\">Moderate to severe impairment: effect on pharmacokinetics is unknown. There are no dosage adjustments provided in the manufacturer&#39;s labeling.</span></span></span></li>\n</ul>\n\n<p><span style=\"background-color:white\"><em><span style=\"font-family:Times\"><span style=\"color:#232323\">During treatment:</span></span></em></span></p>\n\n<p style=\"margin-left:48.0pt; margin-right:0in\"><span style=\"background-color:white\"><span style=\"font-family:Times\"><span style=\"color:#232323\">AST or ALT &gt;3 - 8 x ULN or bilirubin &gt;1.5 - 3 x ULN: Withhold treatment. Administer corticosteroids (prednisone 1 - 2 mg/kg/day or equivalent) followed by a corticosteroid taper. May resume when &le; grade 1 toxicity and prednisone dose is &le;10 mg/day (or equivalent).</span></span></span></p>\n\n<p style=\"margin-left:48.0pt; margin-right:0in\"><span style=\"background-color:white\"><span style=\"font-family:Times\"><span style=\"color:#232323\">AST or ALT &gt;8 x ULN <strong>or</strong> bilirubin &gt;3 x ULN: Discontinue permanently. Administer corticosteroids (prednisone 1 - 2 mg/kg daily or equivalent) followed by a corticosteroid taper.</span></span></span></p>\n\n<p><u><strong>Carboplatin</strong></u></p>\n\n<p><strong>Renal Impairment</strong>: AUC dosing</p>\n\n<p><em>Hemodialysis</em>: hemodialysis should occur between 12 to 24 hours after carboplatin dose</p>\n\n<p><strong>Hepatic Impairment</strong>: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling</p>\n\n<p><strong><u><span style=\"font-family:Times\">Paclitaxel</span></u></strong></p>\n\n<p><span style=\"font-family:Times\"><strong>Renal Impairment:</strong> There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. </span></p>\n\n<p><span style=\"font-family:Times\"><strong>Hepatic Impairment:</strong> </span></p>\n\n<ul>\n\t<li><span style=\"font-family:Times\">Transaminases &lt;10 x ULN and bilirubin &le;1.25 x ULN: 175 mg/m2</span></li>\n\t<li><span style=\"font-family:Times\">Transaminases &lt;10 x ULN and bilirubin 1.26 to 2 x ULN: 135 mg/m2</span></li>\n\t<li><span style=\"font-family:Times\">Transaminases &lt;10 x ULN and bilirubin 2.01 to 5 x ULN: 90 mg/m2</span></li>\n\t<li><span style=\"font-family:Times\">Transaminases &ge;10 x ULN or bilirubin &gt;5 x ULN: Use is not recommended</span></li>\n</ul>\n\n<p><strong><u><span style=\"font-family:Times\">Bevacizumab</span></u></strong></p>\n\n<p><strong><span style=\"font-family:Times\">Renal impairment:</span></strong></p>\n\n<p><span style=\"background-color:white\"><em><span style=\"font-family:Times\"><span style=\"color:#232323\">Renal impairment prior to treatment:</span></span></em><span style=\"font-family:Times\"><span style=\"color:#232323\"> There are no recommended dosage adjustments.</span></span></span></p>\n\n<p><span style=\"background-color:white\"><em><span style=\"font-family:Times\"><span style=\"color:#232323\">Renal toxicity during treatment:</span></span></em></span></p>\n\n<ul>\n\t<li><span style=\"font-family:Times\"><span style=\"color:#232323\">If Proteinuria &ge;2 g/24 hours: Withhold bevacizumab until proteinuria &lt;2 g/24 hours. </span></span>The safety of continued Avastin treatment in patients with moderate to severe proteinuria has not been evaluated</li>\n\t<li><span style=\"font-family:Times\"><span style=\"color:#232323\">Discontinue in patients with nephrotic syndrome. &nbsp;</span></span></li>\n</ul>\n\n<p><strong><span style=\"font-family:Times\">Hepatic Impairment: </span></strong><span style=\"font-family:Times\"><span style=\"color:#232323\">There are no recommended dosage adjustments.</span></span></p>\n\n<p>&nbsp;</p>\n",
      "references": [
        {
          "id": 903,
          "referenceValue": "Martin Reck, Geetha Shankar, Anthony Lee, Shelley Coleman, Mark McCleland, Vassiliki A. Papadimitrakopoulou, Mark A. Socinski & Alan Sandler (2020) Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations, Expert Review of Respiratory Medicine, 14:2, 125-136, DOI: 10.1080/17476348.2020.1701439\n\nCarboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 557,
      "name": "",
      "schedule": "<p><strong>Topotecan</strong>&nbsp;1.0mg/m<sup>2</sup>/day IV on days 1-5</p>\n\n<p>Repeat cycle every 21 days. Reduce dose to 0.8mg/m<sup>2</sup>/day IV on days 1-3 in patients with prior pelvic radiation therapy.</p>\n",
      "emetogenicPotential": "Low",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Topotecan</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Topotecan</strong>:<br />\n\tIf CrCl &gt; 40 mL/min, no dose reduction<br />\n\tIf CrCl 20-39 mL/min, reduce to 0.75 mg/m<sup>2</sup></li>\n</ul>\n",
      "references": [
        {
          "id": 863,
          "referenceValue": "Wadler S, Levy DE, et al. Topotecan is an active agent in the first-line treatment of metastatic or recurrent endometrial carcinoma: Eastern Cooperative Oncology Group Study E3E93. J Clin Oncol. 2003;21(11):2110-4."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 474,
      "name": "",
      "schedule": "<p><strong>Carboplatin</strong> AUC 6 IV once on day 1</p>\n\n<p><strong>nab-Paclitaxel</strong> 100 mg/m<sup>2</sup>&nbsp;IV once per day on days 1, 8, 15</p>\n\n<p><strong>21-day cycle for 4 cycles</strong></p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><strong><u>Carboplatin</u></strong></p>\n\n<p><strong>Renal Impairment</strong>: AUC dosing</p>\n\n<p><em>Hemodialysis</em>: hemodialysis should occur between 12 to 24 hours after carboplatin dose</p>\n\n<p><strong>Hepatic Impairment</strong>: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling</p>\n\n<p>&nbsp;</p>\n\n<p><strong><u><span style=\"font-size:9.0pt\"><span style=\"font-family:Times\">Nanoparticle albumin bound paclitaxel</span></span></u></strong></p>\n\n<p><strong><span style=\"font-size:9.0pt\"><span style=\"font-family:Times\">Renal Impairment</span></span></strong></p>\n\n<ul>\n\t<li><span style=\"font-size:9.0pt\"><span style=\"font-family:Times\">CrCl 30-90 mL/min: No dosage adjustment necessary.</span></span></li>\n\t<li><span style=\"font-size:9.0pt\"><span style=\"font-family:Times\">CrCl &lt;30 mL/min and ESRD: Insufficient clinical data to date. No dosage adjustments provided in the manufacturer&#39;s labeling.</span></span></li>\n</ul>\n\n<p><strong><span style=\"font-size:9.0pt\"><span style=\"font-family:Times\">Hepatic Impairment</span></span></strong></p>\n\n<ul>\n\t<li><span style=\"font-size:9.0pt\"><span style=\"font-family:Times\">Mild impairment (AST &le;10 x ULN and bilirubin 1 -1.25 x ULN): No dosage adjustment necessary.</span></span></li>\n\t<li><span style=\"font-size:9.0pt\"><span style=\"font-family:Times\">Moderate impairment (AST &le;10 x ULN and bilirubin 1.5 - 3 x ULN): Reduce dose to 80 mg/m2; may increase up to 100 mg/m2 in subsequent cycles if the reduced dose is tolerated for 2 cycles.</span></span></li>\n\t<li><span style=\"font-size:9.0pt\"><span style=\"font-family:Times\">Severe impairment: AST &le;10 x ULN and bilirubin 3-5 x ULN: Reduce dose to 80 mg/m2; may increase up to 100 mg/m2 in subsequent cycles if the reduced dose is tolerated for 2 cycles.</span></span></li>\n\t<li><span style=\"font-size:9.0pt\"><span style=\"font-family:Times\">Severe impairment: AST &gt;10 x ULN or bilirubin &gt;5 x ULN: Use not recommended.</span></span></li>\n</ul>\n",
      "references": [
        {
          "id": 904,
          "referenceValue": "KEYNOTE-407: Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, Rodríguez-Cid J, Wilson J, Sugawara S, Kato T, Lee KH, Cheng Y, Novello S, Halmos B, Li X, Lubiniecki GM, Piperdi B, Kowalski DM; KEYNOTE-407 Investigators. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018 Nov 22;379(21):2040-2051. Epub 2018 Sep 25.\n\nCarboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.\n\nAbraxane for Injectable Suspension. (paclitaxel protein-bound\nparticles for injectable suspension) (albumin-bound). U.S. Food and Drug Administraton. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021660s037lbl.pdf"
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 472,
      "name": "",
      "schedule": "<p><strong>Carboplatin</strong>&nbsp;AUC 6 IV once on day 1<br />\n<strong>Paclitaxal</strong>, nanoparticle albumin bound, 100 mg/m<sup>2</sup>&nbsp;IV once per day on days 1, 8, 15<br />\n<strong>Pembrolizumab</strong>&nbsp;200 mg IV once on day 1,&nbsp;<em>administered&nbsp;first</em></p>\n\n<p><strong>21-day cycle for 4 cycles</strong></p>\n\n<p><strong>Followed by pembrolizumab monotherapy</strong></p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><span style=\"font-size:12px\"><strong><u><span style=\"font-family:&quot;Times New Roman&quot;\">Pembrolizumab</span></u></strong></span></p>\n\n<p><span style=\"font-size:12px\"><strong><span style=\"font-family:&quot;Times New Roman&quot;\">Renal Impairment:</span></strong></span></p>\n\n<p><span style=\"font-size:12px\"><em><span style=\"font-family:&quot;Times New Roman&quot;\">Prior to treatment initiation:</span></em><span style=\"font-family:&quot;Times New Roman&quot;\"> No dosage adjustment necessary. </span></span></p>\n\n<p><span style=\"font-size:12px\"><em><span style=\"font-family:&quot;Times New Roman&quot;\">During treatment:</span></em></span></p>\n\n<ul>\n\t<li><span style=\"font-size:12px\"><span style=\"font-family:&quot;Times New Roman&quot;\">Grade 2: Withhold pembrolizumab; administer corticosteroids (prednisone 1-2 mg/kg/day [or equivalent] followed by a taper); may resume upon recovery to grade 0 or 1 toxicity.</span></span></li>\n\t<li><span style=\"font-size:12px\"><span style=\"font-family:&quot;Times New Roman&quot;\">Grade 3 or 4: Permanently discontinue pembrolizumab; administer corticosteroids (prednisone 1-2 mg/kg/day [or equivalent] followed by a taper).</span></span></li>\n</ul>\n\n<p><span style=\"font-size:12px\"><strong><span style=\"font-family:&quot;Times New Roman&quot;\">Hepatic Impairment:</span></strong></span></p>\n\n<p><span style=\"font-size:12px\"><em><span style=\"font-family:&quot;Times New Roman&quot;\">Prior to treatment initiation:</span></em></span></p>\n\n<ul>\n\t<li><span style=\"font-size:12px\"><span style=\"font-family:&quot;Times New Roman&quot;\">No dosage adjustment necessary for mild impairment (Bilirubin &le; ULN and AST &gt; ULN OR bilirubin &gt;1 - 1.5 &times; ULN and any AST).</span></span></li>\n\t<li><span style=\"font-size:12px\"><span style=\"font-family:&quot;Times New Roman&quot;\">No dosage adjustments provided in manufacturer&rsquo;s labeling for moderate to severe impairment.</span></span></li>\n</ul>\n\n<p><span style=\"font-size:12px\"><em><span style=\"font-family:&quot;Times New Roman&quot;\">During treatment:</span></em></span></p>\n\n<ul>\n\t<li><span style=\"font-size:12px\"><span style=\"font-family:&quot;Times New Roman&quot;\">Patients without hepatocellular carcinoma (HCC) or Renal Cell Carcinoma(RCC) also receiving axitinib:</span></span>\n\n\t<ul style=\"list-style-type:circle\">\n\t\t<li><span style=\"font-size:12px\"><span style=\"font-family:&quot;Times New Roman&quot;\">Grade 2 hepatitis: Administer corticosteroids (prednisone 0.5 - 1 mg/kg/day [or equivalent]).</span></span></li>\n\t\t<li><span style=\"font-size:12px\"><span style=\"font-family:&quot;Times New Roman&quot;\">Grade 3 or higher hepatitis: prednisone 1 - 2 mg/kg/day [or equivalent], followed by a taper). Withhold or discontinue therapy based on the severity of liver enzyme elevations:</span></span>\n\t\t<ul style=\"list-style-type:square\">\n\t\t\t<li><span style=\"font-size:12px\"><span style=\"font-family:&quot;Times New Roman&quot;\">AST or ALT 3 - 5x ULN or bilirubin 1.5 &ndash; 3x ULN: Withhold treatment; may resume therapy upon return to grade 0 or 1 toxicity.</span></span></li>\n\t\t\t<li><span style=\"font-size:12px\"><span style=\"font-family:&quot;Times New Roman&quot;\">AST or ALT &gt;5x ULN or total bilirubin &gt;3x ULN (without liver metastases): Permanently discontinue pembrolizumab.</span></span></li>\n\t\t\t<li><span style=\"font-size:12px\"><span style=\"font-family:&quot;Times New Roman&quot;\">If baseline grade 2 ALT or AST abnormalities with liver metastases, permanently discontinue pembrolizumab if AST or ALT increases by &ge;50% from baseline and persists for at least 1 week.</span></span></li>\n\t\t</ul>\n\t\t</li>\n\t</ul>\n\t</li>\n</ul>\n\n<p><span style=\"font-size:12px\"><strong><u>Carboplatin</u></strong></span></p>\n\n<p><span style=\"font-size:12px\"><strong>Renal Impairment</strong>: AUC dosing</span></p>\n\n<p><span style=\"font-size:12px\"><em>Hemodialysis</em>: hemodialysis should occur between 12 to 24 hours after carboplatin dose</span></p>\n\n<p><span style=\"font-size:12px\"><strong>Hepatic Impairment</strong>: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling</span></p>\n\n<p><span style=\"font-size:12px\"><strong><u><span style=\"font-family:Times\">Nanoparticle albumin bound paclitaxel</span></u></strong></span></p>\n\n<p><span style=\"font-size:12px\"><strong><span style=\"font-family:Times\">Renal Impairment</span></strong></span></p>\n\n<ul>\n\t<li><span style=\"font-size:12px\"><span style=\"font-family:Times\">CrCl 30-90 mL/min: No dosage adjustment necessary.</span></span></li>\n\t<li><span style=\"font-size:12px\"><span style=\"font-family:Times\">CrCl &lt;30 mL/min and ESRD: Insufficient clinical data to date. No dosage adjustments provided in the manufacturer&#39;s labeling.</span></span></li>\n</ul>\n\n<p><span style=\"font-size:12px\"><strong><span style=\"font-family:Times\">Hepatic Impairment</span></strong></span></p>\n\n<ul>\n\t<li><span style=\"font-size:12px\"><span style=\"font-family:Times\">Mild impairment (AST &le;10 x ULN and bilirubin 1 -1.25 x ULN): No dosage adjustment necessary.</span></span></li>\n\t<li><span style=\"font-size:12px\"><span style=\"font-family:Times\">Moderate impairment (AST &le;10 x ULN and bilirubin 1.5 - 3 x ULN): Reduce dose to 80 mg/m2; may increase up to 100 mg/m2 in subsequent cycles if the reduced dose is tolerated for 2 cycles.</span></span></li>\n\t<li><span style=\"font-size:12px\"><span style=\"font-family:Times\">Severe impairment: AST &le;10 x ULN and bilirubin 3-5 x ULN: Reduce dose to 80 mg/m2; may increase up to 100 mg/m2 in subsequent cycles if the reduced dose is tolerated for 2 cycles.</span></span></li>\n\t<li><span style=\"font-size:12px\"><span style=\"font-family:Times\">Severe impairment: AST &gt;10 x ULN or bilirubin &gt;5 x ULN: Use not recommended.</span></span></li>\n</ul>\n",
      "references": [
        {
          "id": 905,
          "referenceValue": "KEYNOTE-407: Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, Rodríguez-Cid J, Wilson J, Sugawara S, Kato T, Lee KH, Cheng Y, Novello S, Halmos B, Li X, Lubiniecki GM, Piperdi B, Kowalski DM; KEYNOTE-407 Investigators. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018 Nov 22;379(21):2040-2051. Epub 2018 Sep 25.\n\nCarboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 558,
      "name": "",
      "schedule": "<p><strong>Temsirolimus</strong>&nbsp;25mg IV on day 1</p>\n\n<p>Repeat cycle every 28 days.</p>\n",
      "emetogenicPotential": "Low",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Temsirolimus</strong>:<br />\n\tUnknown</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Temsirolimus</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 906,
          "referenceValue": "Oza AM, Elit L, et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. J Clin Oncol. 2011;29(24):3278-85."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 559,
      "name": "",
      "schedule": "<p><strong>Carboplatin</strong>&nbsp;300mg/m<sup>2</sup>&nbsp;IV on day 1<br />\n<strong>Cyclophosphamide</strong>&nbsp;600mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat cycle every 28 days.</p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Carboplatin</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Cyclophosphamide</strong>:<br />\n\tIf bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Carboplatin</strong>:<br />\n\tDosing based on AUC</li>\n\t<li><strong>Cyclophosphamide</strong>:<br />\n\tIf CrCl 10-50 mL/min, reduce dose by 25%<br />\n\tIf CrCl &lt; 10 mL/min, reduce dose by 50%</li>\n</ul>\n",
      "references": [
        {
          "id": 907,
          "referenceValue": "Swenerton K, Jeffrey J, et al. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1992;10(5):718-26."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 394,
      "name": "",
      "schedule": "<p><strong>5 Fluorouracil:&nbsp;</strong>1,000 mg/m<sup>2</sup>/day IV continuous infusion on days 1-4 and 29-32</p>\n\n<p><strong>Mitomycin-C:&nbsp;</strong>10 mg/m<sup>2</sup>&nbsp;IV (maximum of 20 mg) on days 1 and 29</p>\n\n<p><strong>Radiation Therapy:</strong>&nbsp;180 cGy/day, 5 days/week for a total of 5 weeks (total dose, 4,500 cGy)</p>\n\n<p>Chemotherapy is given concurrently with radiation therapy.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 571,
      "name": "",
      "schedule": "<p><strong>Altretamine</strong>&nbsp;260mg/m<sup>2</sup>/day PO in 4 divided doses after meals and at bedtime</p>\n",
      "emetogenicPotential": "Moderate-High",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Altretamine</strong>:<br />\n\tNo dose reduction&nbsp;</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Altretamine</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 914,
          "referenceValue": "Markman M, Blessing JA, et al. Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial. Gynecol Oncol. 1998;69(3):226-9."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 632,
      "name": "",
      "schedule": "<p><strong>Vemurafenib:&nbsp;</strong>960 mg PO twice daily</p>\n\n<p><strong>Irinotecan:&nbsp;</strong>180 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>Cetuximab:&nbsp;</strong>500 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat cycle every 2 weeks. Use only for patients with <em>BRAF</em> V600E-mutant mCRC.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 480,
      "name": "",
      "schedule": "<p><strong>Cisplatin</strong>&nbsp;75 mg/m<sup>2</sup>&nbsp;IV over 30 minutes once on day 1<br />\n<strong>Gemcitabine</strong>&nbsp;1250 mg/m<sup>2</sup>&nbsp;IV over 2 hours once per day on days 1 &amp; 8</p>\n\n<p><strong>21-day cycle for up to 6 cycles</strong></p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><strong><u>Cisplatin</u></strong></p>\n\n<p><strong>Renal Impairment:</strong></p>\n\n<ul>\n\t<li>CrCl 10 to 50 mL/minute: Administer 75% of dose.</li>\n\t<li>CrCl &lt;10 mL/minute: Administer 50% of dose.</li>\n\t<li>Hemodialysis: Administer 50% of dose posthemodialysis.</li>\n\t<li>Continuous ambulatory peritoneal dialysis: Administer 50% of dose.</li>\n\t<li>Continuous renal replacement therapy: Administer 75% of dose.</li>\n</ul>\n\n<p><strong>Hepatic Impairment</strong>: <em>No Dosage Adjustments </em></p>\n\n<p><strong><u>Gemcitabine</u></strong></p>\n\n<p><strong>Renal Impairment: </strong></p>\n\n<ul>\n\t<li>Discontinue permanently for Hemolytic Uremic Syndrome</li>\n\t<li>Hemodialysis should begin 6 to 12 hours after gemcitabine infusion</li>\n</ul>\n\n<p><strong>Hepatic Impairment: </strong><em>No dosage modifications provided in manufacturer&#39;s labeling</em></p>\n",
      "references": [
        {
          "id": 908,
          "referenceValue": "SQUIRE: Thatcher N, Hirsch FR, Luft AV, Szczesna A, Ciuleanu TE, Dediu M, Ramlau R, Galiulin RK, Bálint B, Losonczy G, Kazarnowicz A, Park K, Schumann C, Reck M, Depenbrock H, Nanda S, Kruljac-Letunic A, Kurek R, Paz-Ares L, Socinski MA; SQUIRE Investigators. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2015 Jul;16(7):763-74. Epub 2015 Jun 1."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 460,
      "name": "",
      "schedule": "<p><strong>Carboplatin</strong> AUC 6 IV over 15 to 30 minutes once on day <strong>Paclitaxel</strong>&nbsp;200 mg/m<sup>2</sup>&nbsp;IV over 3 hours once on day 1,&nbsp;<strong>given first<br />\nBevacizumb</strong> 15 mg/kg IV once on day 1, given third</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "<p><strong><u><span style=\"font-family:Times\">Bevacizumab</span></u></strong></p>\n\n<p><strong><span style=\"font-family:Times\">Renal impairment:</span></strong></p>\n\n<p><span style=\"background-color:white\"><em><span style=\"font-family:Times\"><span style=\"color:#232323\">Renal impairment prior to treatment:</span></span></em><span style=\"font-family:Times\"><span style=\"color:#232323\"> There are no recommended dosage adjustments.</span></span></span></p>\n\n<p><span style=\"background-color:white\"><em><span style=\"font-family:Times\"><span style=\"color:#232323\">Renal toxicity during treatment:</span></span></em></span></p>\n\n<ul>\n\t<li><span style=\"font-family:Times\"><span style=\"color:#232323\">If Proteinuria &ge;2 g/24 hours: Withhold bevacizumab until proteinuria &lt;2 g/24 hours. </span></span>The safety of continued Avastin treatment in patients with moderate to severe proteinuria has not been evaluated</li>\n\t<li><span style=\"font-family:Times\"><span style=\"color:#232323\">Discontinue in patients with nephrotic syndrome. &nbsp;</span></span></li>\n</ul>\n\n<p><strong><span style=\"font-family:Times\">Hepatic Impairment: </span></strong><span style=\"font-family:Times\"><span style=\"color:#232323\">There are no recommended dosage adjustments.</span></span></p>\n\n<p><u><strong>Carboplatin</strong></u></p>\n\n<p><strong>Renal Impairment</strong>: AUC dosing</p>\n\n<p><em>Hemodialysis</em>: hemodialysis should occur between 12 to 24 hours after carboplatin dose</p>\n\n<p><strong>Hepatic Impairment</strong>: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling</p>\n\n<p><strong><u><span style=\"font-family:Times\">Paclitaxel</span></u></strong></p>\n\n<p><span style=\"font-family:Times\"><strong>Renal Impairment:</strong> There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. </span></p>\n\n<p><span style=\"font-family:Times\"><strong>Hepatic Impairment:</strong> </span></p>\n\n<ul>\n\t<li><span style=\"font-family:Times\">Transaminases &lt;10 x ULN and bilirubin &le;1.25 x ULN: 175 mg/m2</span></li>\n\t<li><span style=\"font-family:Times\">Transaminases &lt;10 x ULN and bilirubin 1.26 to 2 x ULN: 135 mg/m2</span></li>\n\t<li><span style=\"font-family:Times\">Transaminases &lt;10 x ULN and bilirubin 2.01 to 5 x ULN: 90 mg/m2</span></li>\n\t<li><span style=\"font-family:Times\">Transaminases &ge;10 x ULN or bilirubin &gt;5 x ULN: Use is not recommended</span></li>\n</ul>\n",
      "references": [
        {
          "id": 910,
          "referenceValue": "Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF 3rd, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004 Jun 1;22(11):2184-91\n\nCarboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 458,
      "name": "",
      "schedule": "<p><strong>Carboplatin</strong> AUC 6 IV on day 1<br />\n<strong>Paclitaxel</strong>&nbsp;(<strong>nanoparticle albumin-bound)</strong> 100mg/m<sup>2&nbsp;</sup>IV on days 1, 8, 15<br />\n<strong>Atezolizumab</strong> 1200mg IV on day 1&nbsp;</p>\n\n<p><strong>21 day cycle for 4-6 cycles</strong></p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><u><strong>Atezolizumab</strong></u></p>\n\n<p><strong><span style=\"font-family:Times\">Renal Impairment</span></strong></p>\n\n<ul>\n\t<li><span style=\"background-color:white\"><span style=\"font-family:Times\"><span style=\"color:#232323\">eGFR &ge;30 mL/minute/1.73 m<sup>2</sup>: no clinically significant effect on the systemic exposure of atezolizumab. There are no dosage adjustments provided in the manufacturer&#39;s labeling.</span></span></span></li>\n\t<li><span style=\"background-color:white\"><span style=\"font-family:Times\"><span style=\"color:#232323\">eGFR &lt;30 mL/minute: effect on pharmacokinetics is unknown. There are no dosage adjustments provided in the manufacturer&#39;s labeling (has not been studied).</span></span></span></li>\n</ul>\n\n<p><strong><span style=\"font-family:Times\">Hepatic impairment:</span></strong></p>\n\n<p style=\"margin-left:0in; margin-right:0in\"><span style=\"background-color:white\"><em><span style=\"font-family:Times\"><span style=\"color:#232323\">Prior to treatment:</span></span></em></span></p>\n\n<ul>\n\t<li><span style=\"background-color:white\"><span style=\"font-family:Times\"><span style=\"color:#232323\">Mild impairment: (bilirubin &le; ULN and AST &gt; ULN <strong>or</strong> bilirubin &gt;1 - 1.5 x ULN and any AST):&nbsp;no clinically significant effect on the systemic exposure of atezolizumab and no dosage instructions provided in manufacturer&#39;s labeling.</span></span></span></li>\n\t<li><span style=\"background-color:white\"><span style=\"font-family:Times\"><span style=\"color:#232323\">Moderate to severe impairment: effect on pharmacokinetics is unknown. There are no dosage adjustments provided in the manufacturer&#39;s labeling.</span></span></span></li>\n</ul>\n\n<p><span style=\"background-color:white\"><em><span style=\"font-family:Times\"><span style=\"color:#232323\">During treatment:</span></span></em></span></p>\n\n<ul>\n\t<li><span style=\"background-color:white\"><span style=\"font-family:Times\"><span style=\"color:#232323\">AST or ALT &gt;3 - 8 x ULN or bilirubin &gt;1.5 - 3 x ULN: Withhold treatment. Administer corticosteroids (prednisone 1 - 2 mg/kg/day or equivalent) followed by a corticosteroid taper. May resume when &le; grade 1 toxicity and prednisone dose is &le;10 mg/day (or equivalent).</span></span></span></li>\n\t<li><span style=\"background-color:white\"><span style=\"font-family:Times\"><span style=\"color:#232323\">AST or ALT &gt;8 x ULN <strong>or</strong> bilirubin &gt;3 x ULN: Discontinue permanently. Administer corticosteroids (prednisone 1 - 2 mg/kg daily or equivalent) followed by a corticosteroid taper.</span></span></span></li>\n</ul>\n\n<p><u><strong>Carboplatin</strong></u></p>\n\n<p><strong>Renal Impairment</strong>: AUC dosing</p>\n\n<p><em>Hemodialysis</em>: hemodialysis should occur between 12 to 24 hours after carboplatin dose</p>\n\n<p><strong>Hepatic Impairment</strong>: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling</p>\n\n<p><strong><u><span style=\"font-family:Times\">Nanoparticle albumin bound paclitaxel</span></u></strong></p>\n\n<p><strong><span style=\"font-family:Times\">Renal Impairment</span></strong></p>\n\n<ul>\n\t<li><span style=\"font-family:Times\">CrCl 30-90 mL/min:&nbsp;No dosage adjustment necessary.</span></li>\n\t<li><span style=\"font-family:Times\">CrCl &lt;30 mL/min&nbsp;and ESRD: Insufficient clinical data to date. No dosage adjustments provided in the manufacturer&#39;s labeling.</span></li>\n</ul>\n\n<p><strong><span style=\"font-family:Times\">Hepatic Impairment</span></strong></p>\n\n<ul>\n\t<li><span style=\"font-family:Times\">Mild impairment (AST &le;10 x ULN and bilirubin 1 -1.25 x ULN): No dosage adjustment necessary.</span></li>\n\t<li><span style=\"font-family:Times\">Moderate impairment (AST &le;10 x ULN and bilirubin 1.5 - 3 x ULN): Reduce dose to 80 mg/m2; may increase up to 100 mg/m2 in subsequent cycles if the reduced dose is tolerated for 2 cycles.</span></li>\n\t<li><span style=\"font-family:Times\">Severe impairment: AST &le;10 x ULN and bilirubin 3-5 x ULN: Reduce dose to 80 mg/m2; may increase up to 100 mg/m2 in subsequent cycles if the reduced dose is tolerated for 2 cycles.</span></li>\n\t<li><span style=\"font-family:Times\">Severe impairment: AST &gt;10 x ULN or bilirubin &gt;5 x ULN: Use not recommended.</span></li>\n</ul>\n\n<p>&nbsp;</p>\n",
      "references": [
        {
          "id": 911,
          "referenceValue": "Power130: West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, Kopp HG, Daniel D, McCune S, Mekhail T, Zer A, Reinmuth N, Sadiq A, Sandler A, Lin W, Ochi Lohmann T, Archer V, Wang L, Kowanetz M, Cappuzzo F. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019 Jul;20(7):924-937. Epub 2019 May 20.\n4.  Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 478,
      "name": "",
      "schedule": "<p><strong>Cisplatin</strong>&nbsp;75 mg/m<sup>2</sup>&nbsp;IV once on day 1<br />\n<strong>Docetaxel</strong>&nbsp;75 mg/m<sup>2</sup>&nbsp;IV once on day 1</p>\n\n<p><strong>21-day cycles</strong></p>\n\n<p>OR</p>\n\n<p><strong>Cisplatin</strong>&nbsp;80 mg/m<sup>2</sup>&nbsp;IV once on day 1<br />\n<strong>Docetaxel</strong>&nbsp;60 mg/m<sup>2</sup>&nbsp;IV once on day 1</p>\n\n<p><strong>21-day cycle for 4 to 6 cycles</strong></p>\n\n<p>&nbsp;</p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><strong><u>Cisplatin</u></strong></p>\n\n<p><strong>Renal Impairment:</strong></p>\n\n<ul>\n\t<li>CrCl 10 to 50 mL/minute: Administer 75% of dose.</li>\n\t<li>CrCl &lt;10 mL/minute: Administer 50% of dose.</li>\n\t<li>Hemodialysis: Administer 50% of dose posthemodialysis.</li>\n\t<li>Continuous ambulatory peritoneal dialysis: Administer 50% of dose.</li>\n\t<li>Continuous renal replacement therapy: Administer 75% of dose.</li>\n</ul>\n\n<p><strong>Hepatic Impairment</strong>: <em>No Dosage Adjustments </em></p>\n\n<p><strong><u>Docetaxel</u></strong></p>\n\n<p><strong>Renal Impairment:</strong> No dosage adjustments per manufacturer&#39;s labeling. Renal excretion is minimal.</p>\n\n<p><strong>Hepatic Impairment: (</strong><em>Normal Baseline LFTs: Transaminases &le;1.5 x ULN or alkaline phosphatase &le;2.5 x ULN or isolated elevations of transaminases or alkaline phosphatase &lt; 5 x ULN)</em></p>\n\n<ul>\n\t<li>Do not use docetaxel if: Bilirubin &gt; ULN or transaminases &gt;1.5 x ULN with alkaline phosphatase &gt;2.5 x ULN.</li>\n\t<li>Isolated transaminase elevations &gt;1.5 times ULN: Consider docetaxel dose modification. Consider dose reduction of 20-40% reduction for grade 2 or 3 toxicity. (Minami 2009)</li>\n</ul>\n",
      "references": [
        {
          "id": 912,
          "referenceValue": "JOG5208L: Shukuya T, Yamanaka T, Seto T, Daga H, Goto K, Saka H, Sugawara S, Takahashi T, Yokota S, Kaneda H, Kawaguchi T, Nagase S, Oguri T, Iwamoto Y, Nishimura T, Hattori Y, Nakagawa K, Nakanishi Y, Yamamoto N; West Japan Oncology Group. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial. Lancet Oncol. 2015 Dec;16(16):1630-8. Epub 2015 Oct 28.\n\n5501068: Lu S, Chen Z, Hu C, Zhang J, Chen Y, Song Y, Zhao Q, Fan Y, Wu G, Ma Z, Fang J, Yu Q, Liu Z. Nedaplatin plus docetaxel versus cisplatin plus docetaxel as first-line chemotherapy for advanced squamous cell carcinoma of the lung - a multicenter, open-label, randomized, phase III trial. J Thorac Oncol. 2018 Nov;13(11):1743-1749. Epub 2018 Jul 11."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 481,
      "name": "",
      "schedule": "<p><strong>Cisplatin</strong> 70 mg/m<sup>2 </sup>IV once on day 1<br />\n<strong>Paclitaxel</strong> 175 mg/m<sup>2</sup> IV once on day 1</p>\n\n<p><strong>21 day cycle for 4 cycles</strong></p>\n\n<p><strong>OR</strong></p>\n\n<p><strong>Cisplatin</strong> 75 mg/m<sup>2</sup> IV once on day 1<br />\n<strong>Paclitaxel</strong> 135 mg/m<sup>2</sup> IV over 3 hours once on day 1</p>\n\n<p><strong>14 day cycle for up to 9 cycles</strong></p>\n\n<p><strong>OR</strong></p>\n\n<p><strong>Cisplatin</strong> 75 mg/m<sup>2</sup> IV once on day 2<br />\n<strong>Paclitaxel</strong> 135 mg/m<sup>2</sup> IV continuous infusion over 24 hours, given on day 1</p>\n\n<p><strong>Administered in 21-day cycles</strong></p>\n\n<p><strong>OR</strong></p>\n\n<p><strong>Cisplatin </strong>80 mg/m2 IV once on day 1<br />\n<strong>Paclitaxel </strong>200ng/m<sup>2</sup> IV over 3 hours on day 1</p>\n\n<p><strong>Administered in 21 day cycles</strong></p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><strong><u>Cisplatin</u></strong></p>\n\n<p><strong>Renal Impairment:</strong></p>\n\n<ul>\n\t<li>CrCl 10 to 50 mL/minute: Administer 75% of dose.</li>\n\t<li>CrCl &lt;10 mL/minute: Administer 50% of dose.</li>\n\t<li>Hemodialysis: Administer 50% of dose posthemodialysis.</li>\n\t<li>Continuous ambulatory peritoneal dialysis: Administer 50% of dose.</li>\n\t<li>Continuous renal replacement therapy: Administer 75% of dose.</li>\n</ul>\n\n<p><strong>Hepatic Impairment</strong>: <em>No Dosage Adjustments </em></p>\n\n<p>&nbsp;</p>\n\n<p><strong><u><span style=\"font-family:Times\">Paclitaxel</span></u></strong></p>\n\n<p><strong><span style=\"font-family:Times\">Renal Impairment:</span></strong><span style=\"font-family:Times\"> There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. </span></p>\n\n<p><strong><span style=\"font-family:Times\">Hepatic Impairment:</span></strong></p>\n\n<ul>\n\t<li><span style=\"font-family:Times\">Transaminases &lt;10 x ULN and bilirubin &le;1.25 x ULN: 175 mg/m<sup>2</sup></span></li>\n\t<li><span style=\"font-family:Times\">Transaminases &lt;10 x ULN and bilirubin 1.26 to 2 x ULN: 135 mg/m<sup>2</sup></span></li>\n\t<li><span style=\"font-family:Times\">Transaminases &lt;10 x ULN and bilirubin 2.01 to 5 x ULN: 90 mg/m<sup>2</sup></span></li>\n\t<li><span style=\"font-family:Times\">Transaminases &ge;10 x ULN or bilirubin &gt;5 x ULN: Use is not recommended</span></li>\n</ul>\n",
      "references": [
        {
          "id": 913,
          "referenceValue": "COG E5592: Bonomi P, Kim K, Fairclough D, Cella D, Kugler J, Rowinsky E, Jiroutek M, Johnson D. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2000 Feb;18(3):623-31.\n\nGatzemeier U, von Pawel J, Gottfried M, ten Velde GP, Mattson K, de Marinis F, Harper P, Salvati F, Robinet G, Lucenti A, Bogaerts J, Gallant G. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2000 Oct 1;18(19):3390-9.\n\nRosell, R. et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Annals of Oncology, Volume 13, Issue 10, 1539 – 1549\n\nEORTC 08975: Smit EF, van Meerbeeck JP, Lianes P, Debruyne C, Legrand C, Schramel F, Smit H, Gaafar R, Biesma B, Manegold C, Neymark N, Giaccone G; EORTC Lung Cancer Group. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organisation for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975. J Clin Oncol. 2003 Nov 1;21(21):3909-17."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 626,
      "name": "",
      "schedule": "<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV bolus followed by 600 mg/m<sup>2</sup>&nbsp;IV continuous infusion for 22 hours on days 1 and 2</p>\n\n<p><strong>Leucovorin:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil</p>\n\n<p><strong>Panitumumab:&nbsp;</strong>6 mg/kg IV on day 1</p>\n\n<p>Repeat cycle every 2 weeks.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 572,
      "name": "",
      "schedule": "<p><strong>Doxorubicin liposome</strong>&nbsp;40-50mg/m<sup>2</sup>&nbsp;IV over 1 hour on day 1</p>\n\n<p>Repeat cycle every 28 days.</p>\n",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Doxorubicin</strong>:<br />\n\tIf bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />\n\tIf bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Doxorubicin</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 915,
          "referenceValue": "Rose PG, Maxson JH, et al. Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages. Gynecol Oncol. 2001;82(2):323-8."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 573,
      "name": "",
      "schedule": "<p><strong>Paclitaxel</strong>&nbsp;135mg/m<sup>2</sup>&nbsp;IV over 3 hours on day 1</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "Low",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Paclitaxel</strong>:<br />\n\tFor 3-hour infusion:<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m<sup>2</sup>)<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m<sup>2</sup><br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m<sup>2</sup><br />\n\tIf transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />\n\tFor 24-hour infusion:<br />\n\tIf transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m<sup>2</sup>)<br />\n\tIf transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m<sup>2</sup><br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m<sup>2</sup><br />\n\tIf transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Paclitaxel</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 916,
          "referenceValue": "McGuire WP, Rowinsky EK, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med. 1989;111(4):273-9."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 627,
      "name": "",
      "schedule": "<p><strong>Irinotecan:&nbsp;</strong>180 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV bolus on day 1, followed by 2,400 mg/m<sup>2</sup>&nbsp;IV continuous infusion for 46 hours on days 1 and 2</p>\n\n<p><strong>Leucovorin:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV on day 1 as a 2-hour infusion before 5-fluorouracil</p>\n\n<p><strong>Panitumumab:&nbsp;</strong>6 mg/kg IV on day 1</p>\n\n<p>Repeat cycle every 2 weeks.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 463,
      "name": "",
      "schedule": "<p><strong>Carboplatin</strong> AUC &nbsp;6 IV&nbsp;once on day 1<br />\n<strong>Paclitaxel</strong>&nbsp;175 mg/m<sup>2</sup>&nbsp;IV over 3 hours once on day 1</p>\n\n<p><strong>21-day cycle for up to&nbsp;6 cycles</strong></p>\n\n<p><strong>OR</strong></p>\n\n<p><strong>Carboplatin</strong> AUC &nbsp;6 IV&nbsp;once on day 1<br />\n<strong>Paclitaxel</strong>&nbsp;200 mg/m<sup>2</sup>&nbsp;IV&nbsp;once on day 1</p>\n\n<p><strong>21-day cycle for 3 or more cycles</strong></p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><u><strong>Carboplatin</strong></u></p>\n\n<p><strong>Renal Impairment</strong>: AUC dosing</p>\n\n<p><em>Hemodialysis</em>: hemodialysis should occur between 12 to 24 hours after carboplatin dose</p>\n\n<p><strong>Hepatic Impairment</strong>: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling</p>\n\n<p><strong><u><span style=\"font-family:Times\">Paclitaxel</span></u></strong></p>\n\n<p><span style=\"font-family:Times\"><strong>Renal Impairment:</strong> There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. </span></p>\n\n<p><span style=\"font-family:Times\"><strong>Hepatic Impairment:</strong> </span></p>\n\n<ul>\n\t<li><span style=\"font-family:Times\">Transaminases &lt;10 x ULN and bilirubin &le;1.25 x ULN: 175 mg/m<sup>2</sup></span></li>\n\t<li><span style=\"font-family:Times\">Transaminases &lt;10 x ULN and bilirubin 1.26 to 2 x ULN: 135 mg/m<sup>2</sup></span></li>\n\t<li><span style=\"font-family:Times\">Transaminases &lt;10 x ULN and bilirubin 2.01 to 5 x ULN: 90 mg/m<sup>2</sup></span></li>\n\t<li><span style=\"font-family:Times\">Transaminases &ge;10 x ULN or bilirubin &gt;5 x ULN: Use is not recommended</span></li>\n</ul>\n",
      "references": [
        {
          "id": 917,
          "referenceValue": "ECOG E4599: Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006 Dec 14;355(24):2542-50.\n\nIPASS: Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009 Sep 3;361(10):947-57. Epub 2009 Aug 19.\n\nMONET1: Scagliotti GV, Vynnychenko I, Park K, Ichinose Y, Kubota K, Blackhall F, Pirker R, Galiulin R, Ciuleanu TE, Sydorenko O, Dediu M, Papai-Szekely Z, Banaclocha NM, McCoy S, Yao B, Hei YJ, Galimi F, Spigel DR. International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1. J Clin Oncol. 2012 Aug 10;30(23):2829-36. Epub 2012 Jul 2.\n\nBEYOND: Zhou C, Wu YL, Chen G, Liu X, Zhu Y, Lu S, Feng J, He J, Han B, Wang J, Jiang G, Hu C, Zhang H, Cheng G, Song X, Lu Y, Pan H, Zheng W, Yin AY. BEYOND: a randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer. J Clin Oncol. 2015 Jul 1;33(19):2197-204. Epub 2015 May 26.\n\nCarboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine.\n\nPaclitaxel injection. United States Prescribing Information. US National Library of Medicine."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 568,
      "name": "",
      "schedule": "<p><strong>Gemcitabine</strong>&nbsp;1000mg/m<sup>2</sup>&nbsp;IV on days 1 and 8<br />\n<strong>Carboplatin</strong>&nbsp;AUC of 4, IV on day 1</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Carboplatin</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Gemcitabine</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Carboplatin</strong>:<br />\n\tDosing based on AUC</li>\n\t<li><strong>Gemcitabine</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 918,
          "referenceValue": "Thigpen T. The role of gemcitabine in first-line treatment of advanced ovarian carcinoma. Semin Oncol. 2006;33(2 Suppl 6):S26-32."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 569,
      "name": "",
      "schedule": "<p><strong>Paclitaxel</strong>&nbsp;135mg/m<sup>2</sup>&nbsp;IV over 24 hours on day 1<br />\n<strong>Cisplatin</strong>&nbsp;100mg/m<sup>2</sup>&nbsp;IP on day 2<br />\n<strong>Paclitaxel</strong>&nbsp;60mg/m<sup>2</sup>&nbsp;IP on day 8</p>\n\n<p>Repeat cycle every 21 days up to 6 cycles.</p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Cisplatin</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Paclitaxel</strong>:<br />\n\tFor 3-hour infusion:<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m<sup>2</sup>)<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m<sup>2</sup><br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m<sup>2</sup><br />\n\tIf transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />\n\tFor 24-hour infusion:<br />\n\tIf transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m<sup>2</sup>)<br />\n\tIf transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m<sup>2</sup><br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m<sup>2</sup><br />\n\tIf transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Cisplatin</strong>:<br />\n\tIf CrCl 30-60 mL/min, reduce dose by 50%<br />\n\tIf CrCl &lt; 30 mL/min, do not use</li>\n\t<li><strong>Paclitaxel</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 919,
          "referenceValue": "Armstrong DK, Bundy B, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34-43."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 570,
      "name": "",
      "schedule": "<p><strong>Pemetrexed</strong>&nbsp;500mg/m<sup>2</sup>&nbsp;IV on day 1<br />\n<strong>Carboplatin</strong>&nbsp;AUC of 5, IV on day 1</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Pemetrexed</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Carboplatin</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Pemetrexed</strong>:<br />\n\tIf CrCl &gt; 45 mL/min, no dose reduction<br />\n\tIf CrCl &lt; 45 mL/min, do not use</li>\n\t<li><strong>Carboplatin</strong>:<br />\n\tDosing based on AUC</li>\n</ul>\n",
      "references": [
        {
          "id": 920,
          "referenceValue": "Matulonis UA, Horowitz NS, et al. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. J Clin Oncol. 2008;26(35):5761-6."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 630,
      "name": "",
      "schedule": "<p><strong>Irinotecan:&nbsp;</strong>180 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV bolus on day 1, followed by 2,400 mg/m<sup>2</sup>&nbsp;IV continuous infusion for 46 hours on days 1 and 2</p>\n\n<p><strong>Leucovorin:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV on day 1 as a 2-hour infusion prior to 5-fluorouracil</p>\n\n<p><strong>Ziv-aflibercept:&nbsp;</strong>4 mg/kg IV on day 1</p>\n\n<p>Repeat cycle every 2 weeks.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 479,
      "name": "",
      "schedule": "<p><strong>Cisplatin</strong>&nbsp;60 mg/m<sup>2</sup>&nbsp;IV once on day 1<br />\n<strong>Etoposide</strong> 120 mg/m<sup>2</sup>&nbsp;IV once per day on days 4, 6, 8</p>\n\n<p><strong>21-day cycles</strong></p>\n\n<p><strong>OR</strong></p>\n\n<p><strong>Cisplatin</strong>&nbsp;75 mg/m<sup>2</sup>&nbsp;IV once on day 1<br />\n<strong>Etoposide</strong> 100 mg/m<sup>2</sup>&nbsp;IV once per day on days 4, 6, 8</p>\n\n<p><strong>21-day cycles</strong></p>\n\n<p><strong>OR</strong></p>\n\n<p><strong>Cisplatin</strong>&nbsp;100 mg/m<sup>2</sup>&nbsp;IV once on day 1<br />\n<strong>Etoposide</strong> 100 mg/m<sup>2</sup>&nbsp;IV once per day on days 4, 6, 8</p>\n\n<p><strong>21-day cycles</strong></p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><strong><u>Cisplatin</u></strong></p>\n\n<p><strong>Renal Impairment:</strong></p>\n\n<ul>\n\t<li>CrCl 10 to 50 mL/minute: Administer 75% of dose.</li>\n\t<li>CrCl &lt;10 mL/minute: Administer 50% of dose.</li>\n\t<li>Hemodialysis: Administer 50% of dose posthemodialysis.</li>\n\t<li>Continuous ambulatory peritoneal dialysis: Administer 50% of dose.</li>\n\t<li>Continuous renal replacement therapy: Administer 75% of dose.</li>\n</ul>\n\n<p><strong>Hepatic Impairment</strong>: <em>No Dosage Adjustments </em></p>\n\n<p><u><strong>Etoposide:</strong></u></p>\n\n<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li>No dose adjustments in manufacturers labeling</li>\n\t<li>Per Hendrayana, Wilmer, Kurth et al, 2017:\n\t<ul>\n\t\t<li>T.Bil 1.5&ndash;3 mg/dL or AST 60&ndash;180:&nbsp;50% of of full dose</li>\n\t\t<li>T.Bil &ge; 3 mg/dL or AST &gt; 180:&nbsp;omit</li>\n\t</ul>\n\t</li>\n</ul>\n\n<p><strong>Renal&nbsp;Impairment</strong></p>\n\n<ul>\n\t<li>CrCl &gt;50 mL/minute: No adjustment required.</li>\n\t<li>CrCl 15 to 50 mL/minute: Administer 75% of dose</li>\n\t<li>CrCl &lt;15 mL minute: No data available; consider further dose reductions</li>\n</ul>\n",
      "references": [
        {
          "id": 921,
          "referenceValue": "ECOG E1581: Ruckdeschel JC, Finkelstein DM, Ettinger DS, Creech RH, Mason BA, Joss RA, Vogl S. A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer. J Clin Oncol. 1986 Jan;4(1):14-22.\n\nEORTC 07861: Klastersky J, Sculier JP, Lacroix H, Dabouis G, Bureau G, Libert P, Richez M, Ravez P, Vandermoten G, Thiriaux J, Cordier R, Finet C, Berchier MC, Sergysels R, Mommen P, Paesmans M. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organisation for Research and Treatment of Cancer Protocol 07861. J Clin Oncol. 1990 Sep;8(9):1556-62.\n\nComella P, Frasci G, De Cataldis G, Panza N, Cioffi R, Curcio C, Belli M, Bianco A, Ianniello G, Maiorino L, Della Vittoria M, Perchard J, Comella G; Gruppo Oncologico Campano. Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small-cell lung cancer: a multicentre randomised trial. Br J Cancer. 1996 Dec;74(11):1805-11.\nCardenal F, López-Cabrerizo MP, Antón A, Alberola V, Massuti B, Carrato A, Barneto I, Lomas M, García M, Lianes P, Montalar J, Vadell C, González-Larriba JL, Nguyen B, Artal A, Rosell R. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 1999 Jan;17(1):12-8.\n Font A, Moyano AJ, Puerto JM, Tres A, Garcia-Giron C, Barneto I, Anton A, Sanchez JJ, Salvador A, Rosell R; Spanish Lung Cancer Group. Increasing dose intensity of cisplatin-etoposide in advanced nonsmall cell lung carcinoma: a phase III randomized trial of the Spanish Lung Cancer Group. Cancer. 1999 Feb 15;85(4):855-63.\n ECOG E5592: Bonomi P, Kim K, Fairclough D, Cella D, Kugler J, Rowinsky E, Jiroutek M, Johnson D. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2000 Feb;18(3):623-31.\n Belani CP, Lee JS, Socinski MA, Robert F, Waterhouse D, Rowland K, Ansari R, Lilenbaum R, Natale RB. Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer. Ann Oncol. 2005 Jul;16(7):1069-75. Epub 2005 Apr 28."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 482,
      "name": "",
      "schedule": "<p><strong>Docetaxel</strong> 85 mg/m<sup>2</sup> IV, 1 hour infusion, given on day 8<br />\n<strong>Gemcitabine</strong> 1,000 mg/m<sup>2</sup> IV, 30-min infusion, given on day 1, 8</p>\n\n<p><strong>Repeat cycle every 21 days</strong></p>\n\n<p><strong>OR</strong></p>\n\n<p><strong>Docetaxel</strong> 75 mg/m<sup>2</sup> IV, 1 hour infusion, given on day 8<br />\n<strong>Gemcitabine</strong> 1,100 mg/m<sup>2</sup> IV, 30-min infusion, given on day 1, 8</p>\n",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<p><strong><u>Gemcitabine</u></strong></p>\n\n<p><strong>Renal Impairment: </strong></p>\n\n<ul>\n\t<li>Discontinue permanently for Hemolytic Uremic Syndrome</li>\n\t<li>Hemodialysis should begin 6 to 12 hours after gemcitabine infusion</li>\n</ul>\n\n<p><strong>Hepatic Impairment: </strong><em>No dosage modifications provided in manufacturer&#39;s labeling</em></p>\n\n<p><strong><u>Docetaxel</u></strong></p>\n\n<p><strong>Renal Impairment:</strong> No dosage adjustments per manufacturer&#39;s labeling. Renal excretion is minimal.</p>\n\n<p><strong>Hepatic Impairment: (</strong><em>Normal Baseline LFTs: Transaminases &le;1.5 x ULN or alkaline phosphatase &le;2.5 x ULN or isolated elevations of transaminases or alkaline phosphatase &lt; 5 x ULN)</em></p>\n\n<ul>\n\t<li>Do not use docetaxel if: Bilirubin &gt; ULN or transaminases &gt;1.5 x ULN with alkaline phosphatase &gt;2.5 x ULN.</li>\n\t<li>Isolated transaminase elevations &gt;1.5 times ULN: Consider docetaxel dose modification. Consider dose reduction of 20-40% reduction for grade 2 or 3 toxicity. (Minami 2009)</li>\n</ul>\n",
      "references": [
        {
          "id": 909,
          "referenceValue": "Georgoulias V, Androulakis N, Kotsakis A, Hatzidaki D, Syrigos K, Polyzos A, Agelidou A, Varthalitis I, Ziras N, Agelidou M, Chandrinos V, Boukovinas I, Geroyianni A, Vamvakas L, Mavroudis D. Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: a randomized, multicenter phase III trial. Lung Cancer. 2008 Jan;59(1):57-63. Epub 2007 Aug 31.\n\nPujol JL, Breton JL, Gervais R, et al. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. Ann Oncol 2005; 16:602.\n\nMinami, H., Kawada, K., Sasaki, Y., Tahara, M., Igarashi, T., Itoh, K., Fujii, H., Saeki, T., Ozawa, K. and Sato, H. (2009), Population pharmacokinetics of docetaxel in patients with hepatic dysfunction treated in an oncology practice. Cancer Science, 100: 144-149. doi:10.1111/j.1349-7006.2009.00992.x\n\nFloyd J., Kerr T.A. (2020). Chemotherapy hepatotoxicity and dose modification in patients with liver disease. Retrieved April 2020 from https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease.\n\nCasal J, Amenedo M, Mel JR, Antón LM, Rodríguez-López R, López-López R, González-Ageitos A, Castellanos J, Constenla M, Tisaire JL. Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer: a lung cancer Galician group phase II study. Cancer Chemother Pharmacol. 2007 Oct;60(5):725-32. Epub 2007 Feb 2."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 465,
      "name": "",
      "schedule": "<p><strong>Cisplatin</strong> 70 mg/m<sup>2&nbsp;</sup>IV once on day 1<br />\n<strong>Paclitaxel</strong> 175 mg/m<sup>2</sup>&nbsp;IV once on day 1&nbsp;</p>\n\n<p><strong>21 day cycle for 4 cycles</strong></p>\n\n<p><strong>OR</strong></p>\n\n<p><strong>Cisplatin</strong>&nbsp;75 mg/m<sup>2</sup>&nbsp;IV once on day 1<br />\n<strong>Paclitaxel</strong> 135 mg/m<sup>2</sup>&nbsp;IV over 3 hours once on day 1</p>\n\n<p><strong>14 day cycle for up to 9 cycles</strong></p>\n\n<p><strong>OR</strong></p>\n\n<p><strong>Cisplatin</strong>&nbsp;75 mg/m<sup>2</sup>&nbsp;IV once on day 2<br />\n<strong>Paclitaxel</strong>&nbsp;135 mg/m<sup>2</sup>&nbsp;IV continuous infusion over 24 hours, given on day 1</p>\n\n<p><strong>Administered in 21-day cycles</strong></p>\n\n<p><strong>OR</strong></p>\n\n<p><strong>Cisplatin </strong>80 mg/m2 IV once on day 1<br />\n<strong>Paclitaxel </strong>200ng/m<sup>2</sup>&nbsp;IV over 3 hours on day 1</p>\n\n<p><strong>Administered in 21 day cycles</strong></p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><u><strong>Cisplatin</strong></u></p>\n\n<p><strong>Renal Impairment:</strong></p>\n\n<ul>\n\t<li>CrCl 10 to 50 mL/minute: Administer 75% of dose.</li>\n\t<li>CrCl &lt;10 mL/minute: Administer 50% of dose.</li>\n\t<li>Hemodialysis: Administer 50% of dose posthemodialysis.</li>\n\t<li>Continuous ambulatory peritoneal dialysis: Administer 50% of dose.</li>\n\t<li>Continuous renal replacement therapy: Administer 75% of dose.</li>\n</ul>\n\n<p><strong>Hepatic Impairment</strong>: <em>No Dosage Adjustments&nbsp;</em></p>\n\n<p>&nbsp;</p>\n\n<p><strong><u><span style=\"font-family:Times\">Paclitaxel</span></u></strong></p>\n\n<p><span style=\"font-family:Times\"><strong>Renal Impairment:</strong> There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. </span></p>\n\n<p><span style=\"font-family:Times\"><strong>Hepatic Impairment:</strong> </span></p>\n\n<ul>\n\t<li><span style=\"font-family:Times\">Transaminases &lt;10 x ULN and bilirubin &le;1.25 x ULN: 175 mg/m<sup>2</sup></span></li>\n\t<li><span style=\"font-family:Times\">Transaminases &lt;10 x ULN and bilirubin 1.26 to 2 x ULN: 135 mg/m<sup>2</sup></span></li>\n\t<li><span style=\"font-family:Times\">Transaminases &lt;10 x ULN and bilirubin 2.01 to 5 x ULN: 90 mg/m<sup>2</sup></span></li>\n\t<li><span style=\"font-family:Times\">Transaminases &ge;10 x ULN or bilirubin &gt;5 x ULN: Use is not recommended</span></li>\n</ul>\n",
      "references": [
        {
          "id": 922,
          "referenceValue": "COG E5592: Bonomi P, Kim K, Fairclough D, Cella D, Kugler J, Rowinsky E, Jiroutek M, Johnson D. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2000 Feb;18(3):623-31.\n\nGatzemeier U, von Pawel J, Gottfried M, ten Velde GP, Mattson K, de Marinis F, Harper P, Salvati F, Robinet G, Lucenti A, Bogaerts J, Gallant G. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2000 Oct 1;18(19):3390-9.\n\nRosell, R. et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Annals of Oncology, Volume 13, Issue 10, 1539 - 1549"
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 483,
      "name": "",
      "schedule": "<p><strong>Gemcitibine</strong> 1000 mg/m<sup>2</sup> IV once per day on days 1 &amp; 8<br />\n<strong>Vinorelbine</strong> 25 mg/m<sup>2</sup> IV once per day on days 1 &amp; 8</p>\n\n<p><strong>21-day cycles</strong></p>\n\n<p><strong>OR</strong></p>\n\n<p><strong>Gemcitibine </strong>1000 mg/m<sup>2</sup> IV once per day on days 1, 8, and 15<br />\n<strong>Vinorelbine </strong>25 mg/m<sup>2</sup> IV once per day on days 1, 8 and 15</p>\n\n<p><strong>28-day cycles</strong></p>\n\n<p><strong>OR</strong></p>\n\n<p><strong>Gemcitabine</strong> 1000 mg/m<sup>2</sup> IV once per day on days 1 &amp; 8<br />\n<strong>Vinorelbine</strong> 60 mg/m<sup>2</sup> PO once per day on days 1 &amp; 8</p>\n\n<p><strong>21-day cycle for 3 cycles</strong></p>\n",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<p><strong><u>Gemcitabine</u></strong></p>\n\n<p><strong>Renal Impairment: </strong></p>\n\n<ul>\n\t<li>Discontinue permanently for Hemolytic Uremic Syndrome</li>\n\t<li>Hemodialysis should begin 6 to 12 hours after gemcitabine infusion</li>\n</ul>\n\n<p><strong>Hepatic Impairment: </strong><em>No dosage modifications provided in manufacturer&#39;s labeling</em></p>\n\n<p>&nbsp;</p>\n\n<p><strong><u>Vinorelbine</u></strong></p>\n\n<p><strong>Renal Impairment</strong>: There are no dosage adjustments provided in the manufacturer&#39;s labeling.</p>\n\n<ul>\n\t<li>Hemodialysis: Initially reduce dose to 20 mg/m<sup>2 </sup>once a week; administer either post-dialysis (on dialysis days) or on nondialysis days (Janus 2010)</li>\n</ul>\n\n<p><strong>Hepatic Impairment:</strong> Vinorelbine is metabolized substantially by the liver. There is limited data available on use in patients with baseline severe liver dysfunction. Caution is recommended with administration of vinorelbine in patients with baseline hepatic injury or impairment.</p>\n\n<ul>\n\t<li>Total bilirubin &gt;2 - no dose modification</li>\n\t<li>Total bilirubin 2.1-3 - administer 50% of dose</li>\n\t<li>Total bilirubin &gt;3.0 - administer 25% of dose</li>\n</ul>\n",
      "references": [
        {
          "id": 923,
          "referenceValue": "National Center for Biotechnology Information. PubChem Database. Vinorelbine, CID=5311497, https://pubchem.ncbi.nlm.nih.gov/compound/Vinorelbine (accessed on May 1, 2020)\n\nNational Center for Biotechnology Information. PubChem Database. Gemcitabine, CID=60750, https://pubchem.ncbi.nlm.nih.gov/compound/Gemcitabine (accessed on May 1, 2020)\n\nFløtten Ø, Grønberg BH, Bremnes R, Amundsen T, Sundstrøm S, Rolke H, Hornslien K, Wentzel-Larsen T, Aasebø U, von Plessen C; Norwegian Lung Cancer Study Group. Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC: a phase III randomised controlled trial by the Norwegian Lung Cancer Study Group. Br J Cancer. 2012 Jul 24;107(3):442-7. Epub 2012 Jul 3.\n\nGreco FA, Spigel DR, Kuzur ME, Shipley D, Gray JR, Thompson DS, Burris HA, Yardley DA, Pati A, Webb CD, Gandhi JG, Hainsworth JD. Paclitaxel/Carboplatin/gemcitabine versus gemcitabine/vinorelbine in advanced non-small-cell lung cancer: a phase II/III study of the Minnie Pearl Cancer Research Network. Clin Lung Cancer. 2007 Sep;8(8):483-7.\n\nGLOB 2: Tan EH, Szczesna A, Krzakowski M, Macha HN, Gatzemeier U, Mattson K, Wernli M, Reiterer P, Hui R, Pawel JV, Bertetto O, Pouget JC, Burillon JP, Parlier Y, Abratt R; GLOB 2 group. Randomized study of vinorelbine--gemcitabine versus vinorelbine--carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer. 2005 Aug;49(2):233-40.\n\nLaack E, Dickgreber N, Müller T, Knuth A, Benk J, Lorenz C, Gieseler F, Dürk H, Engel-Riedel W, Dalhoff K, Kortsik C, Graeven U, Burk M, Dierlamm T, Welte T, Burkholder I, Edler L, Hossfeld DK; German and Swiss Lung Cancer Study Group. Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: from the German and Swiss Lung Cancer Study Group. J Clin Oncol. 2004 Jun 15;22(12):2348-56.\n\nGridelli C, Gallo C, Shepherd FA, Illiano A, Piantedosi F, Robbiati SF, Manzione L, Barbera S, Frontini L, Veltri E, Findlay B, Cigolari S, Myers R, Ianniello GP, Gebbia V, Gasparini G, Fava S, Hirsh V, Bezjak A, Seymour L, Perrone F; Italian GEMVIN Investigators; NCIC CTG. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2003 Aug 15;21(16):3025-34. Epub 2003 Jul 1.\n\nJanus N, Thariat J, Boulanger H, et al, “Proposal for Dosage Adjustment and Timing of Chemotherapy in Hemodialyzed Patients,” Ann Oncol, 2010, 21(7):1395-403."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 531,
      "name": "",
      "schedule": "<p><strong>Cisplatin</strong>&nbsp;75mg/m<sup>2</sup>&nbsp;IV on day 1<br />\n<strong>5-Fluorouracil</strong>&nbsp;1000mg/m<sup>2</sup>/day IV continuous infusion on days 2-5</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Cisplatin</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>5-Fluorouracil</strong>:<br />\n\tIf bilirubin &lt; 5 mg/dL, no dose reduction<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use<br />\n\tNo dose reduction for infusional administration</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Cisplatin</strong>:<br />\n\tIf CrCl 30-60 mL/min, reduce dose by 50%<br />\n\tIf CrCl &lt; 30 mL/min, do not use</li>\n\t<li><strong>5-Fluorouracil</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 924,
          "referenceValue": "Whitney CW, Sause W, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 1999;17(5):1339-48."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 532,
      "name": "",
      "schedule": "<p><strong>Cisplatin</strong>&nbsp;80mg/m<sup>2</sup>&nbsp;IV on day 1<br />\n<strong>Vinorelbine</strong>&nbsp;25mg/m<sup>2</sup>&nbsp;IV on days 1 and 8</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Cisplatin</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Vinorelbine</strong>:<br />\n\tIf bilirubin 2-3 mg/dL, reduce dose by 50%<br />\n\tIf bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Cisplatin</strong>:<br />\n\tIf CrCl 30-60 mL/min, reduce dose by 50%<br />\n\tIf CrCl &lt; 30 mL/min, do not use</li>\n\t<li><strong>Vinorelbine</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 925,
          "referenceValue": "Pignata S, Silvestro G, et al. Phase II study of cisplatin and vinorelbine as first-line chemotherapy in patients with carcinoma of the uterine cervix. J Clin Oncol. 1999;17(3):756-60."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 584,
      "name": "",
      "schedule": "<p><strong>Niraparib</strong>&nbsp;300mg PO daily</p>\n\n<p>Repeat cycle every 28 days.</p>\n",
      "emetogenicPotential": "Moderate-High",
      "dosageModifications": "<h4>Renal impairment</h4>\n\n<ul>\n\t<li>Mild-to-moderate (CrCl &ge;30 mL/min): No dose adjustment required</li>\n\t<li>Severe or ESRD: Not studied</li>\n</ul>\n\n<h4>Hepatic impairment</h4>\n\n<ul>\n\t<li>Mild: No dose adjustment required</li>\n\t<li>Moderate or severe: Not studied</li>\n</ul>\n",
      "references": [
        {
          "id": 926,
          "referenceValue": "Mirza MN, Monk BJ, et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016;375(22):2154-2164."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 464,
      "name": "",
      "schedule": "<p><strong>Carboplatin</strong> AUC 5 or 6 IV on day 1<br />\n<strong>Pemetrexed</strong> 500mg/m<sup>2</sup>&nbsp;on day 1</p>\n\n<p><strong>21 day cycle for up to 6 cycles</strong></p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "<p><u><strong>Carboplatin</strong></u></p>\n\n<p><strong>Renal Impairment</strong>: AUC dosing</p>\n\n<p><em>Hemodialysis</em>: hemodialysis should occur between 12 to 24 hours after carboplatin dose</p>\n\n<p><strong>Hepatic Impairment</strong>: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling</p>\n\n<p><u><strong>Pemetrexed</strong></u></p>\n\n<p><strong>Renal Impairment:&nbsp;</strong></p>\n\n<ul>\n\t<li>\n\t<p><span style=\"font-family:Times New Roman,Times,serif\"><span class=\"marker\"><span style=\"background-color:white\"><span style=\"color:#232323\">CrCl &ge;45 mL/minute: No dosage adjustment necessary. If Cr 45- 79 mL/minute with concomitant use of ibuprofen, avoid ibuprofen 2 days prior to treatment, day of treatment, and 2 days following.</span></span></span></span></p>\n\t</li>\n\t<li>\n\t<p><span style=\"font-family:Times New Roman,Times,serif\"><span style=\"background-color:white\"><span style=\"color:#232323\">CrCl &lt;45 mL/minute: Use is not recommended by the manufacturer (has not been studied sufficiently)</span></span></span></p>\n\t</li>\n</ul>\n\n<p><strong><span style=\"font-family:Times New Roman,Times,serif\"><span style=\"background-color:white\"><span style=\"color:#232323\">Hepatic Impairment:</span></span></span></strong></p>\n\n<ul>\n\t<li><span style=\"font-family:Times New Roman,Times,serif\"><span style=\"background-color:white\"><span style=\"color:#232323\">No dosage instructions are provided in manufacturer&#39;s labeling</span></span></span></li>\n</ul>\n",
      "references": [
        {
          "id": 927,
          "referenceValue": "Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Vandormael K, Riccio A, Yang J, Pietanza MC, Brahmer JR. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol. 2019 Mar 1;37(7):537-546. Epub 2019 Jan 8.\n\nGrønberg BH, Bremnes RM, Fløtten O, Amundsen T, Brunsvig PF, Hjelde HH, Kaasa S, von Plessen C, Stornes F, Tollåli T, Wammer F, Aasebø U, Sundstrøm S; Norwegian Lung Cancer Study Group. Phase III study by the Norwegian Lung Cancer Study Group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2009 Jul 1;27(19):3217-24. Epub 2009 May 11.\n\nCarboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 461,
      "name": "",
      "schedule": "<p><strong>Carboplatin AUC&nbsp;</strong>AUC 6&nbsp;IV once on day 1</p>\n\n<p><strong>Paclitaxel, nanoparticlealbumin-bound</strong> 100 mg/m<sup>2</sup>&nbsp;IV over 30 minutes once per day on days 1, 8, 15 given first</p>\n\n<p><strong>21-day cycle for 4 cycles</strong></p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "<p><u><strong>Carboplatin</strong></u></p>\n\n<p><strong>Renal Impairment</strong>: AUC dosing</p>\n\n<p><em>Hemodialysis</em>: hemodialysis should occur between 12 to 24 hours after carboplatin dose</p>\n\n<p><strong>Hepatic Impairment</strong>: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling</p>\n\n<p><strong><u><span style=\"font-family:Times\">Nanoparticle albumin bound paclitaxel</span></u></strong></p>\n\n<p><strong><span style=\"font-family:Times\">Renal Impairment</span></strong></p>\n\n<ul>\n\t<li><span style=\"font-family:Times\">CrCl 30-90 mL/min:&nbsp;No dosage adjustment necessary.</span></li>\n\t<li><span style=\"font-family:Times\">CrCl &lt;30 mL/min&nbsp;and ESRD: Insufficient clinical data to date. No dosage adjustments provided in the manufacturer&#39;s labeling.</span></li>\n</ul>\n\n<p><strong><span style=\"font-family:Times\">Hepatic Impairment</span></strong></p>\n\n<ul>\n\t<li><span style=\"font-family:Times\">Mild impairment (AST &le;10 x ULN and bilirubin 1 -1.25 x ULN): No dosage adjustment necessary.</span></li>\n\t<li><span style=\"font-family:Times\">Moderate impairment (AST &le;10 x ULN and bilirubin 1.5 - 3 x ULN): Reduce dose to 80 mg/m2; may increase up to 100 mg/m2 in subsequent cycles if the reduced dose is tolerated for 2 cycles.</span></li>\n\t<li><span style=\"font-family:Times\">Severe impairment: AST &le;10 x ULN and bilirubin 3-5 x ULN: Reduce dose to 80 mg/m2; may increase up to 100 mg/m2 in subsequent cycles if the reduced dose is tolerated for 2 cycles.</span></li>\n\t<li><span style=\"font-family:Times\">Severe impairment: AST &gt;10 x ULN or bilirubin &gt;5 x ULN: Use not recommended.</span></li>\n</ul>\n",
      "references": [
        {
          "id": 928,
          "referenceValue": "CA031: Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, Hon JK, Hirsh V, Bhar P, Zhang H, Iglesias JL, Renschler MF. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol. 2012 Jun 10;30(17):2055-62. Epub 2012 Apr 30."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 486,
      "name": "",
      "schedule": "<p><strong>Carboplatin</strong>&nbsp;AUC of 6, IV on day 1<br />\n<strong>Docetaxel</strong>&nbsp;75mg/m<sup>2</sup>&nbsp;IV on day 1<br />\n<strong>Trastuzumab</strong>&nbsp;4mg/kg IV loading dose on day 1, then 2mg/kg IV on days 8 and 15, then 2mg/kg IV weekly thereafter</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "Moderate for TC, low for trastuzumab",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Carboplatin</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Docetaxel</strong>:<br />\n\tIf bilirubin &gt; upper normal limit, do not use<br />\n\tIf&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Carboplatin</strong>:<br />\n\tDosing based on AUC</li>\n\t<li><strong>Docetaxel</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 929,
          "referenceValue": "Pegram M, Forbes J, et al. BCIRG 007: first overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC). J Clin Oncol 2007; 25: (Abstr LBA1008)."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 488,
      "name": "",
      "schedule": "<p><strong>Trastuzumab</strong>&nbsp;4mg/kg IV loading dose, then 2mg/kg IV weekly<br />\n<strong>Vinorelbine</strong>&nbsp;25mg/m<sup>2</sup>&nbsp;IV weekly</p>\n\n<p>Repeat cycle every week until disease progression.</p>\n",
      "emetogenicPotential": "Low",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Vinorelbine</strong>:<br />\n\tIf bilirubin 2-3 mg/dL, reduce dose by 50%<br />\n\tIf bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />\n\tIf bilirubin &gt;5 mg/dL, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Vinorelbine</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 930,
          "referenceValue": "Burstein HJ, Kuter I, et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2001;19(10):2722-30."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 489,
      "name": "",
      "schedule": "<p><strong>Trastuzumab</strong>&nbsp;4mg/kg IV loading dose, then 2mg/kg IV weekly<br />\n<strong>Gemcitabine</strong>&nbsp;1200mg/m<sup>2</sup>&nbsp;IV weekly for 2 weeks</p>\n\n<p>Repeat cycles every 21 days.</p>\n",
      "emetogenicPotential": "Low",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Gemcitabine</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Gemcitabine</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 931,
          "referenceValue": "O'Shaughnessy JA, Vukelja S, et al. Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer. Clin Breast Cancer. 2004;5(2):142-7."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 664,
      "name": "",
      "schedule": "<p><strong>TAS-102:&nbsp;</strong>35 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-5 and 8-12</p>\n\n<p>Repeat cycle every 28 days.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 665,
      "name": "",
      "schedule": "<p><strong>Pembrolizumab:&nbsp;</strong>200 mg IV on day 1</p>\n\n<p>Repeat cycle every 3 weeks.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 739,
      "name": "",
      "schedule": "<p><strong>Panitumumab:&nbsp;</strong>6 mg/kg IV every 2 weeks</p>\n\n<p>Repeat cycle every 2 weeks.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 7,
          "level": "HEPATIC ARTERY INFUSION"
        }
      ]
    },
    {
      "id": 740,
      "name": "",
      "schedule": "<p><strong>5-Fluorouracil:&nbsp;</strong>2,600 mg/m<sup>2</sup>&nbsp;IV over 24 hours weekly</p>\n\n<p>Repeat cycle weekly for 4 weeks.</p>\n\n<p><strong>OR</strong></p>\n\n<p><strong>5-Fluorouracil:&nbsp;</strong>1,000 mg/m<sup>2</sup>/day IV continuous infusion on days 1-4</p>\n\n<p>Repeat cycle every 21-28 days.</p>\n\n<p><strong>OR</strong></p>\n\n<p><strong>5-Fluorouracil:&nbsp;</strong>200 mg/m<sup>2</sup>/day IV continuous infusion on days 1-4</p>\n\n<p><strong>L-Leucovorin:&nbsp;</strong>5 mg/m<sup>2</sup>/day IV on days 1-14</p>\n\n<p>Repeat cycle every 28 days.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 7,
          "level": "HEPATIC ARTERY INFUSION"
        }
      ]
    },
    {
      "id": 718,
      "name": "",
      "schedule": "<p><strong>Gemcitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>Oxaliplatin:&nbsp;</strong>100 mg/m<sup>2</sup>&nbsp;IV on day 2</p>\n\n<p>Repeat cycle every 14 days.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 466,
      "name": "",
      "schedule": "<p><strong>Cisplatin</strong>&nbsp;70 mg/m<sup>2</sup>&nbsp;IV once on day 1<br />\n<strong>Pemetrexed</strong>&nbsp;500 mg/m<sup>2</sup>&nbsp;IV once on day 1</p>\n\n<p><strong>21-day cycle for up to 4 cycles</strong></p>\n\n<p><strong>OR</strong></p>\n\n<p><strong>Cisplatin&nbsp;</strong>70 mg/m<sup>2</sup>&nbsp;IV once on day 1<br />\n<strong>Pemetrexed</strong>&nbsp;500 mg/m<sup>2</sup>&nbsp;IV once on day 1</p>\n\n<p><strong>21-day cycle for 4-6 cycles</strong></p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "<p><u><strong>Cisplatin</strong></u></p>\n\n<p><strong>Renal Impairment:</strong></p>\n\n<ul>\n\t<li>CrCl 10 to 50 mL/minute: Administer 75% of dose.</li>\n\t<li>CrCl &lt;10 mL/minute: Administer 50% of dose.</li>\n\t<li>Hemodialysis: Administer 50% of dose posthemodialysis.</li>\n\t<li>Continuous ambulatory peritoneal dialysis: Administer 50% of dose.</li>\n\t<li>Continuous renal replacement therapy: Administer 75% of dose.</li>\n</ul>\n\n<p><strong>Hepatic Impairment</strong>: <em>No Dosage Adjustments&nbsp;</em></p>\n\n<p><u><strong>Pemetrexed</strong></u></p>\n\n<p><strong>Renal Impairment:&nbsp;</strong></p>\n\n<ul>\n\t<li>\n\t<p><span style=\"font-family:Times New Roman,Times,serif\"><span class=\"marker\"><span style=\"background-color:white\"><span style=\"color:#232323\">CrCl &ge;45 mL/minute: No dosage adjustment necessary. If Cr 45- 79 mL/minute with concomitant use of ibuprofen, avoid ibuprofen 2 days prior to treatment, day of treatment, and 2 days following.</span></span></span></span></p>\n\t</li>\n\t<li>\n\t<p><span style=\"font-family:Times New Roman,Times,serif\"><span style=\"background-color:white\"><span style=\"color:#232323\">CrCl &lt;45 mL/minute: Use is not recommended by the manufacturer (has not been studied sufficiently)</span></span></span></p>\n\t</li>\n</ul>\n\n<p><strong><span style=\"font-family:Times New Roman,Times,serif\"><span style=\"background-color:white\"><span style=\"color:#232323\">Hepatic Impairment:&nbsp;</span></span></span></strong><em><span style=\"font-family:Times New Roman,Times,serif\"><span style=\"background-color:white\"><span style=\"color:#232323\">No dosage instructions are provided in manufacturer&#39;s labeling</span></span></span></em></p>\n",
      "references": [
        {
          "id": 932,
          "referenceValue": "PARAMOUNT: Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed S, John W, Chouaki N, Zimmermann AH, Visseren-Grul C, Gridelli C. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2012 Mar;13(3):247-55. Epub 2012 Feb 16.\n\nPark CK, Oh IJ, Kim KS, Choi YD, Jang TW, Kim YS, Lee KH, Shin KC, Jung CY, Yang SH, Ryu JS, Jang SH, Yoo SS, Yong SJ, Lee KY, In KH, Lee MK, Kim YC. Randomized phase III study of docetaxel plus cisplatin versus pemetrexed plus cisplatin as first-line treatment of nonsquamous non-small-cell lung cancer: a TRAIL trial. Clin Lung Cancer. 2017 Jul;18(4):e289-e296. Epub 2017 Jan 11."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 490,
      "name": "",
      "schedule": "<p><strong>Trastuzumab</strong>&nbsp;4mg/kg IV loading dose, then 2mg/kg IV weekly<br />\n<strong>Capecitabine</strong>&nbsp;1250mg/m<sup>2</sup>&nbsp;PO BID on days 1-14</p>\n\n<p>Repeat cycle every 21 days.</p>\n\n<p>OR</p>\n\n<p><strong>Trastuzumab</strong>&nbsp;8mg/kg IV loading dose, then 6mg/kg IV on day 1 of all subsequent cycles<br />\n<strong>Capecitabine</strong>&nbsp;1250mg/m<sup>2</sup>&nbsp;PO BID on days 1-14</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "Low",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Capecitabine</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Capecitabine</strong>:<br />\n\tIf CrCl 30-50 mL/min, reduce dose by 25%<br />\n\tIf CrCl &lt; 30 mL/min, do not use</li>\n</ul>\n",
      "references": [
        {
          "id": 933,
          "referenceValue": "Schaller G, Fuchs I, et al. Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes. J Clin Oncol. 2007;25(22):3246-50. --- Bartsch R, Wenzel C, et al. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol. 2007;25(25):3853-8."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 491,
      "name": "",
      "schedule": "<p><strong>Trastuzumab</strong>&nbsp;4mg/kg IV loading dose, then 2mg/kg IV weekly<br />\n<strong>Lapatinib</strong>&nbsp;1000mg PO daily</p>\n\n<p>Continue until disease progression.</p>\n",
      "emetogenicPotential": "Low",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Lapatinib</strong>:<br />\n\tIf Child-Pugh C, reduce dose to 750 mg/d</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Lapatinib</strong>:<br />\n\tNot studied. Only 2% eliminated by kidneys</li>\n</ul>\n",
      "references": [
        {
          "id": 889,
          "referenceValue": "Blackwell KL, Burstein HJ, et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010;28(7):1124-30."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 467,
      "name": "",
      "schedule": "<p><strong>Cabroplatin</strong> AUC 4 IV once on day 1<br />\n<strong>Gemcitabine</strong> 1000mg/m<sup>2</sup>&nbsp;IV over 30 minutes on days 1, 8&nbsp;</p>\n\n<p><strong>21 day cycle for 3 cycles</strong></p>\n\n<p><strong>OR</strong></p>\n\n<p><strong>Cabroplatin</strong> AUC 5 IV once on day 1<br />\n<strong>Gemcitabine</strong> 1000mg/m<sup>2</sup>&nbsp;IV over 30 minutes on days 1, 8&nbsp;</p>\n\n<p><strong>21 day cycle for up to 4&nbsp;cycles</strong></p>\n\n<p><strong>OR</strong></p>\n\n<p><strong>Cabroplatin</strong> AUC 5&nbsp;IV once on day 1<br />\n<strong>Gemcitabine</strong> 1000mg/m<sup>2</sup>&nbsp;IV over 30 minutes on days 1, 8, 15</p>\n\n<p><strong>28-day cycle for 4 cycles</strong></p>\n\n<p><strong>OR</strong></p>\n\n<p><strong>Cabroplatin</strong> AUC 5 IV once on day 1<br />\n<strong>Gemcitabine</strong> 1200mg/m<sup>2</sup>&nbsp;IV over 30 minutes on days 1, 8&nbsp;</p>\n\n<p><strong>21 day cycle for up to 6 cycles</strong></p>\n\n<p><strong>OR</strong></p>\n\n<p><strong>Cabroplatin</strong> AUC 5 IV once on day 1<br />\n​​​​​​​<strong>Gemcitabine</strong> 1250mg/m<sup>2</sup>&nbsp;IV over 30 minutes on days 1, 8&nbsp;</p>\n\n<p><strong>21 day cycle for 4-&nbsp;6 cycles OR 28 day cycle for 4 cycles</strong></p>\n\n<p><strong>OR</strong></p>\n\n<p><strong>Cabroplatin</strong> AUC 6&nbsp;IV once on day 1<br />\n​​​​​​​<strong>Gemcitabine</strong> 1250mg/m<sup>2</sup>&nbsp;IV&nbsp;on days 1, 8&nbsp;</p>\n\n<p><strong>21-day cycle for 4 to 6 cycles</strong>​​​​​​​</p>\n\n<p><strong>OR</strong></p>\n\n<p><strong>Cabroplatin</strong>&nbsp;300mg/m<sup>2</sup>&nbsp;IV once on day 1<br />\n​​​​​​​<strong>Gemcitabine</strong> 1000mg/m<sup>2</sup>&nbsp;IV&nbsp;on days 1, 8</p>\n\n<p><strong>21-day cycle for 4 to 6 cycles</strong></p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><u><strong>Gemcitabine</strong></u></p>\n\n<p><strong>Renal Impairment:&nbsp;</strong></p>\n\n<ul>\n\t<li>Discontinue permanently for Hemolytic Uremic Syndrome</li>\n\t<li>Hemodialysis should begin 6 to 12 hours after gemcitabine infusion</li>\n</ul>\n\n<p><strong>Hepatic Impairment:&nbsp;</strong><em>No dosage modifications provided in manufacturer&#39;s labeling</em></p>\n\n<p><u><strong>Carboplatin</strong></u></p>\n\n<p><strong>Renal Impairment</strong>: AUC dosing</p>\n\n<ul>\n\t<li><em>Hemodialysis</em>: hemodialysis should occur between 12 to 24 hours after carboplatin dose</li>\n</ul>\n\n<p><strong>Hepatic Impairment</strong>: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling</p>\n",
      "references": [
        {
          "id": 934,
          "referenceValue": "Grigorescu AC, Draghici IN, Nitipir C, Gutulescu N, Corlan E. Gemcitabine (GEM) and carboplatin (CBDCA) versus cisplatin (CDDP) and vinblastine (VLB) in advanced non-small-cell lung cancer (NSCLC) stages III and IV: a phase III randomised trial. Lung Cancer. 2002 Jul;37(1):9-14.\n\nZatloukal P, Petruzelka L, Zemanová M, Kolek V, Skricková J, Pesek M, Fojtů H, Grygárková I, Sixtová D, Roubec J, Horenková E, Havel L, Průsa P, Nováková L, Skácel T, Kůta M. Gemcitabine plus cisplatin vs gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial. Lung Cancer. 2003 Sep;41(3):321-31.\n\nSederholm C, Hillerdal G, Lamberg K, Kölbeck K, Dufmats M, Westberg R, Gawande SR; Swedish Lung Cancer Study Group. Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group. J Clin Oncol. 2005 Nov 20;23(33):8380-8.\n\nFerry D, Billingham L, Jarrett H, Dunlop D, Woll PJ, Nicolson M, Shah R, Thompson J, Spicer J, Muthukumar D, Skailes G, Leonard P, Chetiyawardana AD, Wells P, Lewanski C, Crosse B, Hill M, Gaunt P, O'Byrne K; British Thoracic Oncology Group. Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: results from a British Thoracic Oncology Group randomised phase III trial. Eur J Cancer. 2017 Sep;83:302-312. Epub 2017 Aug 4.\n\nGrønberg BH, Bremnes RM, Fløtten O, Amundsen T, Brunsvig PF, Hjelde HH, Kaasa S, von Plessen C, Stornes F, Tollåli T, Wammer F, Aasebø U, Sundstrøm S; Norwegian Lung Cancer Study Group. Phase III study by the Norwegian Lung Cancer Study Group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2009 Jul 1;27(19):3217-24. Epub 2009 May 11.\n\nGrigorescu, Alexandru C. et al. Gemcitabine (GEM) and carboplatin (CBDCA) versus cisplatin (CDDP) and vinblastine (VLB) in advanced non-small-cell lung cancer (NSCLC) stages III and IV: a phase III randomised trial. Lung Cancer, Volume 37, Issue 1, 9 - 14.\n\nCarboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 492,
      "name": "",
      "schedule": "<p><strong>Capecitabine</strong>&nbsp;1000mg/m<sup>2</sup>&nbsp;PO BID on days 1-14<br />\n<strong>Lapatinib</strong>&nbsp;1250mg PO daily</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "Low",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Capecitabine</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Lapatinib</strong>:<br />\n\tIf Child-Pugh C, reduce dose to 750 mg/d</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Capecitabine</strong>:<br />\n\tIf CrCl 30-50 mL/min, reduce dose by 25%<br />\n\tIf CrCl &lt; 30 mL/min, do not use</li>\n\t<li><strong>Lapatinib</strong>:<br />\n\tNot studied. Only 2% eliminated by kidneys</li>\n</ul>\n",
      "references": [
        {
          "id": 935,
          "referenceValue": "Geyer CE, Forster J, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355(26):2733-43."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 468,
      "name": "",
      "schedule": "<p><strong>Docetaxel</strong> 85 mg/m<sup>2</sup>&nbsp;IV, 1 hour&nbsp;infusion, given on day 8<br />\n<strong>Gemcitabine</strong> 1,000 mg/m<sup>2</sup>&nbsp;IV, 30-min&nbsp;infusion, given on&nbsp;day 1, 8</p>\n\n<p><strong>Repeat cycle every 21 days</strong></p>\n\n<p>OR</p>\n\n<p><strong>Docetaxel</strong>&nbsp;75 mg/m<sup>2</sup>&nbsp;IV, 1 hour&nbsp;infusion, given on day 8<br />\n<strong>Gemcitabine</strong> 1,100 mg/m<sup>2</sup>&nbsp;IV, 30-min&nbsp;infusion, given on&nbsp;day 1, 8</p>\n\n<p><strong>Repeat cycle every 21 days</strong></p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><u><strong>Gemcitabine</strong></u></p>\n\n<p><strong>Renal Impairment:&nbsp;</strong></p>\n\n<ul>\n\t<li>Discontinue permanently for Hemolytic Uremic Syndrome</li>\n\t<li>Hemodialysis should begin 6 to 12 hours after gemcitabine infusion</li>\n</ul>\n\n<p><strong>Hepatic Impairment:&nbsp;</strong><em>No dosage modifications provided in manufacturer&#39;s labeling</em></p>\n\n<p><u><strong>Docetaxel</strong></u></p>\n\n<p><strong>Renal Impairment:</strong>&nbsp;No dosage adjustments per manufacturer&#39;s labeling. Renal excretion is minimal.</p>\n\n<p><strong>Hepatic Impairment: (</strong><em>Normal Baseline LFTs: Transaminases &le;1.5 x ULN or alkaline phosphatase &le;2.5 x ULN or isolated elevations of transaminases or alkaline phosphatase &lt;&nbsp;5 x ULN)</em></p>\n\n<ul>\n\t<li>Do not use docetaxel if: Bilirubin &gt; ULN or transaminases&nbsp;&gt;1.5 x ULN with alkaline phosphatase &gt;2.5 x ULN.</li>\n\t<li>Isolated transaminase elevations &gt;1.5 times ULN: Consider docetaxel dose modification. Consider dose reduction of&nbsp;20-40% reduction for grade 2 or 3 toxicity. (Minami 2009)</li>\n</ul>\n",
      "references": [
        {
          "id": 936,
          "referenceValue": "Georgoulias V, Androulakis N, Kotsakis A, Hatzidaki D, Syrigos K, Polyzos A, Agelidou A, Varthalitis I, Ziras N, Agelidou M, Chandrinos V, Boukovinas I, Geroyianni A, Vamvakas L, Mavroudis D. Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: a randomized, multicenter phase III trial. Lung Cancer. 2008 Jan;59(1):57-63. Epub 2007 Aug 31.\n\nPujol JL, Breton JL, Gervais R, et al. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. Ann Oncol 2005; 16:602.\n\nMinami, H., Kawada, K., Sasaki, Y., Tahara, M., Igarashi, T., Itoh, K., Fujii, H., Saeki, T., Ozawa, K. and Sato, H. (2009), Population pharmacokinetics of docetaxel in patients with hepatic dysfunction treated in an oncology practice. Cancer Science, 100: 144-149. doi:10.1111/j.1349-7006.2009.00992.x\n\nFloyd J., Kerr T.A. (2020). Chemotherapy hepatotoxicity and dose modification in patients with liver disease. Retrieved April 2020 from https://www.uptodate.com/contents/chemotherapy-hepatotoxicity-and-dose-modification-in-patients-with-liver-disease.\n\nCasal J, Amenedo M, Mel JR, Antón LM, Rodríguez-López R, López-López R, González-Ageitos A, Castellanos J, Constenla M, Tisaire JL. Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer: a lung cancer Galician group phase II study. Cancer Chemother Pharmacol. 2007 Oct;60(5):725-32. Epub 2007 Feb 2."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 487,
      "name": "",
      "schedule": "<p><strong>Gemcitabine</strong>&nbsp;1500mg/m<sup>2</sup>&nbsp;IV on day 1<br />\n<strong>Carboplatin</strong>&nbsp;AUC of 2.5, IV on day 1<br />\n<strong>Trastuzumab</strong>&nbsp;8mg/kg IV loading dose on day 1, then 4mg/kg IV every 2 weeks</p>\n\n<p>Repeat cycle every 2 weeks.</p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Gemcitabine</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Carboplatin</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Gemcitabine</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Carboplatin</strong>:<br />\n\tDosing based on AUC</li>\n</ul>\n",
      "references": [
        {
          "id": 937,
          "referenceValue": "Loesch D, Asmar L, et al. Phase II trial of gemcitabine/carboplatin (plus trastuzumab in HER2-positive disease) in patients with metastatic breast cancer. Clin Breast Cancer. 2008;8(2):178-86."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 469,
      "name": "",
      "schedule": "<p><strong>Carboplatin</strong>&nbsp;AUC 6 IV once on day 1<br />\n<strong>Docetaxel</strong>&nbsp;75 mg/m<sup>2</sup>&nbsp;IV once on day 1</p>\n\n<p><strong>21-day cycle for maximum of 6 cycles</strong></p>\n",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<p><u><strong>Carboplatin</strong></u></p>\n\n<p><strong>Renal Impairment</strong>: AUC dosing</p>\n\n<p><em>Hemodialysis</em>: hemodialysis should occur between 12 to 24 hours after carboplatin dose</p>\n\n<p><strong>Hepatic Impairment</strong>: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling</p>\n\n<p><u><strong>Docetaxel</strong></u></p>\n\n<p><strong>Renal Impairment:</strong>&nbsp;No dosage adjustments per manufacturer&#39;s labeling. Renal excretion is minimal.</p>\n\n<p><strong>Hepatic Impairment: (</strong><em>Normal Baseline LFTs: Transaminases &le;1.5 x ULN or alkaline phosphatase &le;2.5 x ULN or isolated elevations of transaminases or alkaline phosphatase &lt;&nbsp;5 x ULN)</em></p>\n\n<ul>\n\t<li>Do not use docetaxel if: Bilirubin &gt; ULN or transaminases&nbsp;&gt;1.5 x ULN with alkaline phosphatase &gt;2.5 x ULN.</li>\n\t<li>Isolated transaminase elevations &gt;1.5 times ULN: Consider docetaxel dose modification. Consider dose reduction of&nbsp;20-40% reduction for grade 2 or 3 toxicity. (Minami 2009)</li>\n</ul>\n\n<p>&nbsp;</p>\n",
      "references": [
        {
          "id": 938,
          "referenceValue": "1. Groen HJ, Sietsma H, Vincent A, Hochstenbag MM, van Putten JW, van den Berg A, Dalesio O, Biesma B, Smit HJ, Termeer A, Hiltermann TJ, van den Borne BE, Schramel FM. Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study. J Clin Oncol. 2011 Nov 10;29(32):4320-6. Epub 2011 Oct 11.\n2. Fossella F, et al. J Clin Oncol 2003; 21:3016.\n3. Docetaxel injection. United States Prescribing Information. US National Library of Medicine.\n4.  Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 462,
      "name": "",
      "schedule": "<p><strong>Carboplatin</strong>:&nbsp;325 mg/m<sup>2</sup>&nbsp;IV over 60 minutes once on day 1<br />\n<strong>Etoposide</strong>: 100 mg/m<sup>2</sup>&nbsp;once per day on days 1-3</p>\n\n<p><strong>21 to 28 day cycles</strong></p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "<p><u><strong>Carboplatin</strong></u></p>\n\n<p><strong>Renal Impairment</strong>: AUC dosing</p>\n\n<p><em>Hemodialysis</em>: hemodialysis should occur between 12 to 24 hours after carboplatin dose</p>\n\n<p><strong>Hepatic Impairment</strong>: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling</p>\n\n<p><u><strong>Etoposide:</strong></u></p>\n\n<p><strong>Hepatic</strong></p>\n\n<ul>\n\t<li>No dose adjustments in manufacturers labeling</li>\n\t<li>Per Hendrayana, Wilmer, Kurth et al, 2017:\n\t<ul>\n\t\t<li>T.Bil 1.5&ndash;3 mg/dL or AST 60&ndash;180:&nbsp;50% of of full dose</li>\n\t\t<li>T.Bil &ge; 3 mg/dL or AST &gt; 180:&nbsp;omit</li>\n\t</ul>\n\t</li>\n</ul>\n\n<p><strong>Renal</strong></p>\n\n<ul>\n\t<li>CrCl &gt;50 mL/minute: No adjustment required.</li>\n\t<li>CrCl 15 to 50 mL/minute: Administer 75% of dose</li>\n\t<li>CrCl &lt;15 mL minute: No data available; consider further dose reductions</li>\n</ul>\n",
      "references": [
        {
          "id": 939,
          "referenceValue": "EORTC 07861: Klastersky J, Sculier JP, Lacroix H, Dabouis G, Bureau G, Libert P, Richez M, Ravez P, Vandermoten G, Thiriaux J, Cordier R, Finet C, Berchier MC, Sergysels R, Mommen P, Paesmans M. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organisation for Research and Treatment of Cancer Protocol 07861. J Clin Oncol. 1990 Sep;8(9):1556-62.\n\nCarboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 689,
      "name": "",
      "schedule": "<p><strong>Irinotecan:&nbsp;</strong>250 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat cycle every 3 weeks. Dose of irinotecan can be increased to 350 mg/m<sup>2</sup> based on toxicity.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 470,
      "name": "",
      "schedule": "<p><strong>Gemcitibine</strong>&nbsp;1000 mg/m<sup>2</sup>&nbsp;IV once per day on days 1 &amp; 8<br />\n<strong>Vinorelbine</strong>&nbsp;25 mg/m<sup>2</sup>&nbsp;IV once per day on days 1 &amp; 8</p>\n\n<p><strong>21-day cycles</strong></p>\n\n<p><strong>OR</strong></p>\n\n<p><strong>Gemcitibine&nbsp;</strong>1000 mg/m<sup>2</sup>&nbsp;IV once per day on days 1, 8, and 15<br />\n<strong>Vinorelbine&nbsp;</strong>25 mg/m<sup>2</sup>&nbsp;IV once per day on days 1, 8 and 15</p>\n\n<p><strong>28-day cycles</strong></p>\n\n<p><strong>OR</strong></p>\n\n<p><strong>Gemcitabine</strong> 1000 mg/m<sup>2</sup>&nbsp;IV once per day on days 1 &amp; 8<br />\n<strong>Vinorelbine</strong>&nbsp;60 mg/m<sup>2</sup>&nbsp;PO once per day on days 1 &amp; 8</p>\n\n<p><strong>21-day cycle for 3 cycles</strong></p>\n",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<p><u><strong>Gemcitabine</strong></u></p>\n\n<p><strong>Renal Impairment:&nbsp;</strong></p>\n\n<ul>\n\t<li>Discontinue permanently for Hemolytic Uremic Syndrome</li>\n\t<li>Hemodialysis should begin 6 to 12 hours after gemcitabine infusion</li>\n</ul>\n\n<p><strong>Hepatic Impairment:&nbsp;</strong><em>No dosage modifications provided in manufacturer&#39;s labeling</em></p>\n\n<p>&nbsp;</p>\n\n<p><u><strong>Vinorelbine</strong></u></p>\n\n<p><strong>Renal Impairment</strong>:&nbsp;There are no dosage adjustments provided in the manufacturer&#39;s labeling.</p>\n\n<ul>\n\t<li>Hemodialysis: Initially&nbsp;reduce dose to 20 mg/m<sup>2&nbsp;</sup>once a week; administer either post-dialysis (on dialysis days) or on nondialysis days (Janus 2010)</li>\n</ul>\n\n<p><strong>Hepatic Impairment:</strong> Vinorelbine is metabolized&nbsp;substantially by the liver. There is limited data available on use in patients with baseline severe liver dysfunction. Caution is recommended with administration of vinorelbine in patients with baseline hepatic injury or impairment.</p>\n\n<ul>\n\t<li>Total bilirubin &gt;2 - no dose modification</li>\n\t<li>Total bilirubin 2.1-3&nbsp;&nbsp;- administer 50% of dose</li>\n\t<li>Total bilirubin &gt;3.0 - administer 25% of dose</li>\n</ul>\n",
      "references": [
        {
          "id": 940,
          "referenceValue": "National Center for Biotechnology Information. PubChem Database. Vinorelbine, CID=5311497, https://pubchem.ncbi.nlm.nih.gov/compound/Vinorelbine (accessed on May 1, 2020)\n\nNational Center for Biotechnology Information. PubChem Database. Gemcitabine, CID=60750, https://pubchem.ncbi.nlm.nih.gov/compound/Gemcitabine (accessed on May 1, 2020)\n\nFløtten Ø, Grønberg BH, Bremnes R, Amundsen T, Sundstrøm S, Rolke H, Hornslien K, Wentzel-Larsen T, Aasebø U, von Plessen C; Norwegian Lung Cancer Study Group. Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC: a phase III randomised controlled trial by the Norwegian Lung Cancer Study Group. Br J Cancer. 2012 Jul 24;107(3):442-7. Epub 2012 Jul 3.\n\nGreco FA, Spigel DR, Kuzur ME, Shipley D, Gray JR, Thompson DS, Burris HA, Yardley DA, Pati A, Webb CD, Gandhi JG, Hainsworth JD. Paclitaxel/Carboplatin/gemcitabine versus gemcitabine/vinorelbine in advanced non-small-cell lung cancer: a phase II/III study of the Minnie Pearl Cancer Research Network. Clin Lung Cancer. 2007 Sep;8(8):483-7.\n\nGLOB 2: Tan EH, Szczesna A, Krzakowski M, Macha HN, Gatzemeier U, Mattson K, Wernli M, Reiterer P, Hui R, Pawel JV, Bertetto O, Pouget JC, Burillon JP, Parlier Y, Abratt R; GLOB 2 group. Randomized study of vinorelbine--gemcitabine versus vinorelbine--carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer. 2005 Aug;49(2):233-40.\n\nLaack E, Dickgreber N, Müller T, Knuth A, Benk J, Lorenz C, Gieseler F, Dürk H, Engel-Riedel W, Dalhoff K, Kortsik C, Graeven U, Burk M, Dierlamm T, Welte T, Burkholder I, Edler L, Hossfeld DK; German and Swiss Lung Cancer Study Group. Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: from the German and Swiss Lung Cancer Study Group. J Clin Oncol. 2004 Jun 15;22(12):2348-56.\n\nGridelli C, Gallo C, Shepherd FA, Illiano A, Piantedosi F, Robbiati SF, Manzione L, Barbera S, Frontini L, Veltri E, Findlay B, Cigolari S, Myers R, Ianniello GP, Gebbia V, Gasparini G, Fava S, Hirsh V, Bezjak A, Seymour L, Perrone F; Italian GEMVIN Investigators; NCIC CTG. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2003 Aug 15;21(16):3025-34. Epub 2003 Jul 1.\n\nJanus N, Thariat J, Boulanger H, et al, “Proposal for Dosage Adjustment and Timing of Chemotherapy in Hemodialyzed Patients,” Ann Oncol, 2010, 21(7):1395-403."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 471,
      "name": "",
      "schedule": "<p><strong>Carboplatin</strong>&nbsp;AUC 6 IV once on day 1<br />\n<strong>Paclitaxel</strong>&nbsp;200 mg/m<sup>2</sup>&nbsp;IV once on day 1<br />\n<strong>Pembrolizumab&nbsp;</strong>200 mg IV once on day 1,&nbsp;<strong>given first</strong></p>\n\n<p><strong>21-day cycle for 4 cycles</strong></p>\n\n<p>Followed by pembrolizumab maintenence&nbsp;</p>\n\n<p>&nbsp;</p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><strong><u><span style=\"font-family:&quot;Times New Roman&quot;\">Pembrolizumab</span></u></strong></p>\n\n<p><strong><span style=\"font-family:&quot;Times New Roman&quot;\">Renal Impairment:</span></strong></p>\n\n<p><em><span style=\"font-family:&quot;Times New Roman&quot;\">Prior to treatment initiation:</span></em><span style=\"font-family:&quot;Times New Roman&quot;\"> No dosage adjustment necessary. </span></p>\n\n<p><em><span style=\"font-family:&quot;Times New Roman&quot;\">During treatment:</span></em></p>\n\n<ul>\n\t<li><span style=\"font-family:&quot;Times New Roman&quot;\">Grade 2: Withhold pembrolizumab; administer corticosteroids (prednisone 1-2 mg/kg/day [or equivalent] followed by a taper); may resume upon recovery to grade 0 or 1 toxicity.</span></li>\n\t<li><span style=\"font-family:&quot;Times New Roman&quot;\">Grade 3 or 4: Permanently discontinue pembrolizumab; administer corticosteroids (prednisone 1-2 mg/kg/day [or equivalent] followed by a taper).</span></li>\n</ul>\n\n<p><strong><span style=\"font-family:&quot;Times New Roman&quot;\">Hepatic Impairment:</span></strong></p>\n\n<p><em><span style=\"font-family:&quot;Times New Roman&quot;\">Prior to treatment initiation:</span></em></p>\n\n<ul>\n\t<li><span style=\"font-family:&quot;Times New Roman&quot;\">No dosage adjustment necessary for mild impairment (Bilirubin &le; ULN and AST &gt; ULN OR bilirubin &gt;1 - 1.5 &times; ULN and any AST).</span></li>\n\t<li><span style=\"font-family:&quot;Times New Roman&quot;\">No dosage adjustments provided in manufacturer&rsquo;s labeling for moderate to severe impairment.</span></li>\n</ul>\n\n<p><em><span style=\"font-family:&quot;Times New Roman&quot;\">During treatment:</span></em></p>\n\n<ul>\n\t<li><span style=\"font-family:&quot;Times New Roman&quot;\">Patients without hepatocellular carcinoma (HCC) or Renal Cell Carcinoma(RCC) also receiving axitinib:</span>\n\n\t<ul style=\"list-style-type:circle\">\n\t\t<li><span style=\"font-family:&quot;Times New Roman&quot;\">Grade 2 hepatitis: Administer corticosteroids (prednisone 0.5 - 1 mg/kg/day [or equivalent]).</span></li>\n\t\t<li><span style=\"font-family:&quot;Times New Roman&quot;\">Grade 3 or higher hepatitis: prednisone 1 - 2 mg/kg/day [or equivalent], followed by a taper). Withhold or discontinue therapy based on the severity of liver enzyme elevations:</span>\n\t\t<ul style=\"list-style-type:square\">\n\t\t\t<li><span style=\"font-family:&quot;Times New Roman&quot;\">AST or ALT 3 - 5x ULN or bilirubin 1.5 &ndash; 3x ULN: Withhold treatment; may resume therapy upon return to grade 0 or 1 toxicity.</span></li>\n\t\t\t<li><span style=\"font-family:&quot;Times New Roman&quot;\">AST or ALT &gt;5x ULN or total bilirubin &gt;3x ULN (without liver metastases): Permanently discontinue pembrolizumab.</span></li>\n\t\t\t<li><span style=\"font-family:&quot;Times New Roman&quot;\">If baseline grade 2 ALT or AST abnormalities with liver metastases, permanently discontinue pembrolizumab if AST or ALT increases by &ge;50% from baseline and persists for at least 1 week.</span></li>\n\t\t</ul>\n\t\t</li>\n\t</ul>\n\t</li>\n</ul>\n\n<p><strong><u>Carboplatin</u></strong></p>\n\n<p><strong>Renal Impairment</strong>: AUC dosing</p>\n\n<p><em>Hemodialysis</em>: hemodialysis should occur between 12 to 24 hours after carboplatin dose</p>\n\n<p><strong>Hepatic Impairment</strong>: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling</p>\n\n<p><strong><u><span style=\"font-family:Times\">Paclitaxel</span></u></strong></p>\n\n<p><strong><span style=\"font-family:Times\">Renal Impairment:</span></strong><span style=\"font-family:Times\"> There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. </span></p>\n\n<p><strong><span style=\"font-family:Times\">Hepatic Impairment:</span></strong></p>\n\n<ul>\n\t<li><span style=\"font-family:Times\">Transaminases &lt;10 x ULN and bilirubin &le;1.25 x ULN: 175 mg/m2</span></li>\n\t<li><span style=\"font-family:Times\">Transaminases &lt;10 x ULN and bilirubin 1.26 to 2 x ULN: 135 mg/m2</span></li>\n\t<li><span style=\"font-family:Times\">Transaminases &lt;10 x ULN and bilirubin 2.01 to 5 x ULN: 90 mg/m2</span></li>\n\t<li><span style=\"font-family:Times\">Transaminases &ge;10 x ULN or bilirubin &gt;5 x ULN: Use is not recommended</span></li>\n</ul>\n\n<p><strong><u><span style=\"font-family:Times\">Nanoparticle albumin bound paclitaxel</span></u></strong></p>\n\n<p><strong><span style=\"font-family:Times\">Renal Impairment</span></strong></p>\n\n<ul>\n\t<li><span style=\"font-family:Times\">CrCl 30-90 mL/min:&nbsp;No dosage adjustment necessary.</span></li>\n\t<li><span style=\"font-family:Times\">CrCl &lt;30 mL/min&nbsp;and ESRD: Insufficient clinical data to date. No dosage adjustments provided in the manufacturer&#39;s labeling.</span></li>\n</ul>\n\n<p><strong><span style=\"font-family:Times\">Hepatic Impairment</span></strong></p>\n\n<ul>\n\t<li><span style=\"font-family:Times\">Mild impairment (AST &le;10 x ULN and bilirubin 1 -1.25 x ULN): No dosage adjustment necessary.</span></li>\n\t<li><span style=\"font-family:Times\">Moderate impairment (AST &le;10 x ULN and bilirubin 1.5 - 3 x ULN): Reduce dose to 80 mg/m2; may increase up to 100 mg/m2 in subsequent cycles if the reduced dose is tolerated for 2 cycles.</span></li>\n\t<li><span style=\"font-family:Times\">Severe impairment: AST &le;10 x ULN and bilirubin 3-5 x ULN: Reduce dose to 80 mg/m2; may increase up to 100 mg/m2 in subsequent cycles if the reduced dose is tolerated for 2 cycles.</span></li>\n\t<li><span style=\"font-family:Times\">Severe impairment: AST &gt;10 x ULN or bilirubin &gt;5 x ULN: Use not recommended.</span></li>\n</ul>\n",
      "references": [
        {
          "id": 941,
          "referenceValue": "KEYNOTE-407: Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, Rodríguez-Cid J, Wilson J, Sugawara S, Kato T, Lee KH, Cheng Y, Novello S, Halmos B, Li X, Lubiniecki GM, Piperdi B, Kowalski DM; KEYNOTE-407 Investigators. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018 Nov 22;379(21):2040-2051. Epub 2018 Sep 25.\n\nCarboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 690,
      "name": "",
      "schedule": "<p><strong>Ramucirumab:&nbsp;</strong>8 mg/kg IV on day 1</p>\n\n<p>Repeat cycle every 14 days.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 459,
      "name": "",
      "schedule": "<p><strong>Ipilimumab</strong> 1 mg/kg IV on day 1</p>\n\n<p><strong>Nivolumab</strong> 3 mg/kg IV on day 1, 15, 29</p>\n\n<p><strong>42-day (6 week) cycles for up to 4 cycles&nbsp;</strong></p>\n",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<p><strong><u><span style=\"font-family:Times\">Ipilimumab</span></u></strong></p>\n\n<p><strong><span style=\"font-family:Times\">Renal Impairment</span></strong></p>\n\n<p><span style=\"font-family:Times\"><em>Prior to treatment:</em> No dosage adjustment necessary.</span></p>\n\n<p><em><span style=\"font-family:Times\">Renal toxicity (immune mediated nephritis) during treatment:</span></em></p>\n\n<ul>\n\t<li><span style=\"font-family:Times\">Grade 2 or 3 creatinine elevation: Withhold treatment; administer corticosteroids (prednisone 0.5 - 1 mg/kg/day [or equivalent]) followed by a corticosteroid taper. </span>\n\n\t<ul>\n\t\t<li><span style=\"font-family:Times\">If toxicity worsens or does not improve, increase corticosteroid dose to prednisone 1 - 2 mg/kg/day (or equivalent).</span></li>\n\t</ul>\n\t</li>\n\t<li><span style=\"font-family:Times\">Grade 4&nbsp;creatinine elevation: Permanently discontinue; administer systemic corticosteroids (prednisone 1 - 2 mg/kg/day [or equivalent]) followed by a corticosteroid taper.</span></li>\n</ul>\n\n<p><strong><span style=\"font-family:Times\">Hepatic Impairment</span></strong></p>\n\n<p><em><span style=\"font-family:Times\">Prior to treatment:</span></em></p>\n\n<ul>\n\t<li><span style=\"font-family:Times\">Mild impairment (bilirubin 1 - 1.5 x ULN or AST &gt;ULN): No dosage adjustment necessary.</span></li>\n\t<li><span style=\"font-family:Times\">Moderate or severe impairment (total bilirubin &gt;1.5 x ULN and any AST): insufficient data, there are no dosage adjustments provided in the manufacturer&#39;s labeling.</span></li>\n</ul>\n\n<p><em><span style=\"font-family:Times\">Hepatic impairment during treatment:</span></em></p>\n\n<ul>\n\t<li><span style=\"font-family:Times\">Grade 2: Temporarily withhold treatment.</span></li>\n\t<li><span style=\"font-family:Times\">Grade 3 or 4: Permanently discontinue treatment. Administer systemic corticosteroids (prednisone 1 - 2 mg/kg/day [or equivalent]) followed by&nbsp;1 month corticosteroid taper when LFTs show sustained improvement or return to baseline.&nbsp;&nbsp; </span></li>\n</ul>\n\n<p><u><strong>Nivolumab</strong></u></p>\n\n<p><strong>Renal Impairment:&nbsp;</strong></p>\n\n<ul>\n\t<li>Creatitine 1.5-6 x ULN- withhold dose</li>\n\t<li>Creatinine &gt; 6 x ULN- permanently discontinue<strong>&nbsp;</strong></li>\n</ul>\n\n<p><strong>Hepatic Impairment:&nbsp;</strong></p>\n\n<ul>\n\t<li>Transaminases 3 - 5 x ULN or bilirubin 1.5-3 x ULN- withhold dose</li>\n\t<li>Transaminases &gt; 5 x ULN or bilirubin &gt; 3 x ULN - permnently discontinue</li>\n</ul>\n",
      "references": [
        {
          "id": 942,
          "referenceValue": "Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, Park K, Alexandru A, Lupinacci L, de la Mora Jimenez E, Sakai H, Albert I, Vergnenegre A, Peters S, Syrigos K, Barlesi F, Reck M, Borghaei H, Brahmer JR, O'Byrne KJ, Geese WJ, Bhagavatheeswaran P, Rabindran SK, Kasinathan RS, Nathan FE, Ramalingam SS. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019 Nov 21;381(21):2020-2031. Epub 2019 Sep 28.\n\nOpdivo (Nivolumab) Medication Guide. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125554s070lbl.pdf\n\nYervoy (Ipilimumab) Medication Guide. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125554s070lbl.pdf"
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 691,
      "name": "",
      "schedule": "<p><strong>Pembrolizumab:&nbsp;</strong>200 mg IV on day 1</p>\n\n<p>Repeat cycle every 3 weeks.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 692,
      "name": "",
      "schedule": "<p><strong>TAS-102:&nbsp;</strong>35 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-5 and 8-12</p>\n\n<p>Repeat cycle every 28 days.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 693,
      "name": "",
      "schedule": "<p><strong>Imatinib:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;PO</p>\n\n<p>Continue treatment for a total of 3 years.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 1,
          "level": "ADJUVANT"
        }
      ]
    },
    {
      "id": 694,
      "name": "",
      "schedule": "<p><strong>Imatinib:&nbsp;</strong>400 mg/day PO</p>\n\n<p>Continue treatment until disease progression. May increase dose to 600 mg/day if no response is seen. In patients with KIT exon 9 (or exon 11) mutation, use dose of 800 mg/day (400 mg twice daily).</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 475,
      "name": "",
      "schedule": "<p><strong>Carboplatin</strong> AUC 6 IV once on day 1<br />\n<strong>Docetaxel</strong> 75mg/m<sup>2</sup>&nbsp;IV once on day 1</p>\n\n<p><strong>21-day cycle for up to 6 cycles</strong></p>\n",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<p><strong><u>Carboplatin</u></strong></p>\n\n<p><strong>Renal Impairment</strong>: AUC dosing</p>\n\n<p><em>Hemodialysis</em>: hemodialysis should occur between 12 to 24 hours after carboplatin dose</p>\n\n<p><strong>Hepatic Impairment</strong>: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling</p>\n\n<p><strong><u>Docetaxel</u></strong></p>\n\n<p><strong>Renal Impairment:</strong> No dosage adjustments per manufacturer&#39;s labeling. Renal excretion is minimal.</p>\n\n<p><strong>Hepatic Impairment: (</strong><em>Normal Baseline LFTs: Transaminases &le;1.5 x ULN or alkaline phosphatase &le;2.5 x ULN or isolated elevations of transaminases or alkaline phosphatase &lt; 5 x ULN)</em></p>\n\n<ul>\n\t<li>Do not use docetaxel if: Bilirubin &gt; ULN or transaminases &gt;1.5 x ULN with alkaline phosphatase &gt;2.5 x ULN.</li>\n\t<li>Isolated transaminase elevations &gt;1.5 times ULN: Consider docetaxel dose modification. Consider dose reduction of 20-40% reduction for grade 2 or 3 toxicity (Minami 2009)</li>\n</ul>\n",
      "references": [
        {
          "id": 943,
          "referenceValue": "1. Groen HJ, Sietsma H, Vincent A, Hochstenbag MM, van Putten JW, van den Berg A, Dalesio O, Biesma B, Smit HJ, Termeer A, Hiltermann TJ, van den Borne BE, Schramel FM. Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study. J Clin Oncol. 2011 Nov 10;29(32):4320-6. Epub 2011 Oct 11.\n2. Fossella F, et al. J Clin Oncol 2003; 21:3016.\n3. Docetaxel injection. United States Prescribing Information. US National Library of Medicine.\n4.  Carboplatin- carboplatin injection solution. United States Prescribing Information. US National Library of Medicine."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 476,
      "name": "",
      "schedule": "<p><strong>Carboplatin</strong> AUC 5 IV once on day 1<br />\n<strong>Gemcitabine</strong><sup>&nbsp;</sup>1000 mg/m<sup>2</sup>&nbsp;IV over 30 minutes once per day on days 1 &amp; 8</p>\n\n<p><strong>21-day cycle for up to 6 cycles</strong></p>\n\n<p><strong>OR</strong></p>\n\n<p><strong>Carboplatin</strong> AUC 5.5 IV once on day 1<br />\n<strong>Gemcitabine</strong><sup>&nbsp;</sup>1000 mg/m<sup>2</sup>&nbsp;IV over 30 minutes once per day on days 1 &amp; 8</p>\n\n<p><strong>21-day cycle for up to 6 cycles</strong></p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><strong><u>Carboplatin</u></strong></p>\n\n<p><strong>Renal Impairment</strong>: AUC dosing</p>\n\n<p><em>Hemodialysis</em>: hemodialysis should occur between 12 to 24 hours after carboplatin dose</p>\n\n<p><strong>Hepatic Impairment</strong>: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling</p>\n",
      "references": [
        {
          "id": 944,
          "referenceValue": "Patil V, Noronha V, Joshi A, Chougule A, Kannan S, Bhattacharjee A, Goud S, More S, Chandrasekharan A, Menon N, Srinivas S, Vallathol DH, Dsouza H, Majumdar S, Das S, Zawar A, Khaddar S, Kumar A, Singh G, Kumar KAP, Ravind R, Trivedi V, Behel V, Mahajan A, Janu A, Purandare N, Prabhash K. Phase III non-inferiority study evaluating efficacy and safety of low dose gemcitabine compared to standard dose gemcitabine with platinum in advanced squamous lung cancer. EClinicalMedicine. 2019 Apr 9;9:19-25.\n\nGrønberg BH, Bremnes RM, Fløtten O, Amundsen T, Brunsvig PF, Hjelde HH, Kaasa S, von Plessen C, Stornes F, Tollåli T, Wammer F, Aasebø U, Sundstrøm S; Norwegian Lung Cancer Study Group. Phase III study by the Norwegian Lung Cancer Study Group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2009 Jul 1;27(19):3217-24. Epub 2009 May 11."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 484,
      "name": "",
      "schedule": "<p><strong>Trastuzumab</strong>&nbsp;4mg/kg IV loading dose and then 2mg/kg weekly<br />\n<strong>Paclitaxel</strong>&nbsp;175mg/m<sup>2</sup>&nbsp;over 3 hours on day 1</p>\n\n<p>Repeat cycle every 21 days.</p>\n\n<p>OR</p>\n\n<p><strong>Trastuzumab</strong>&nbsp;4mg/kg IV loading dose and then 2mg/kg weekly<br />\n<strong>Paclitaxel</strong>&nbsp;80mg/m<sup>2&nbsp;</sup>IV weekly</p>\n\n<p>Repeat cycle every 4 weeks.</p>\n",
      "emetogenicPotential": "Low",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Paclitaxel</strong>:<br />\n\tFor 3-hour infusion:<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m<sup>2</sup>)<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m<sup>2</sup><br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m<sup>2</sup><br />\n\tIf transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />\n\tFor 24-hour infusion:<br />\n\tIf transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m<sup>2</sup>)<br />\n\tIf transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m<sup>2</sup><br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m<sup>2</sup><br />\n\tIf transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Paclitaxel</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 945,
          "referenceValue": "Slamon DJ, Leyland-Jones B, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783-92. --- Goldenberg MM. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther. 1999;21(2):309-18."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 477,
      "name": "",
      "schedule": "<p><strong>Carboplatin</strong> AUC 5 IV over 15 to 60 minutes once on day 1<br />\n<strong>Paclitaxel</strong>&nbsp;200 mg/m<sup>2</sup>&nbsp;IV over 3 hours once on day 1</p>\n\n<p><strong>21-day cycle for 4 to 6 cycles</strong></p>\n\n<p><strong>OR</strong></p>\n\n<p><strong>Carboplatin</strong> AUC 6&nbsp;IV over 15 to 60 minutes once on day 1<br />\n<strong>Paclitaxel</strong>&nbsp;175 mg/m<sup>2</sup>&nbsp;IV over 3 hours once on day 1</p>\n\n<p><strong>21-day cycle for up to 6 cycles</strong></p>\n\n<p><strong>OR</strong></p>\n\n<p><strong>Carboplatin</strong> AUC 6&nbsp;IV over 15 to 60 minutes once on day 1<br />\n<strong>Paclitaxel</strong>&nbsp;200 mg/m<sup>2</sup>&nbsp;IV over 3 hours once on day 1</p>\n\n<p><strong>21-day cycle for 4&nbsp;to 6 cycles</strong></p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><strong><u>Carboplatin</u></strong></p>\n\n<p><strong>Renal Impairment</strong>: AUC dosing</p>\n\n<p><em>Hemodialysis</em>: hemodialysis should occur between 12 to 24 hours after carboplatin dose</p>\n\n<p><strong>Hepatic Impairment</strong>: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling</p>\n\n<p><strong><u><span style=\"font-family:Times\">Paclitaxel</span></u></strong></p>\n\n<p><strong><span style=\"font-family:Times\">Renal Impairment:</span></strong><span style=\"font-family:Times\"> There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. </span></p>\n\n<p><strong><span style=\"font-family:Times\">Hepatic Impairment:</span></strong></p>\n\n<ul>\n\t<li><span style=\"font-family:Times\">Transaminases &lt;10 x ULN and bilirubin &le;1.25 x ULN: 175 mg/m2</span></li>\n\t<li><span style=\"font-family:Times\">Transaminases &lt;10 x ULN and bilirubin 1.26 to 2 x ULN: 135 mg/m2</span></li>\n\t<li><span style=\"font-family:Times\">Transaminases &lt;10 x ULN and bilirubin 2.01 to 5 x ULN: 90 mg/m2</span></li>\n\t<li><span style=\"font-family:Times\">Transaminases &ge;10 x ULN or bilirubin &gt;5 x ULN: Use is not recommended</span></li>\n</ul>\n\n<p><strong><u><span style=\"font-family:Times\">Nanoparticle albumin bound paclitaxel</span></u></strong></p>\n\n<p><strong><span style=\"font-family:Times\">Renal Impairment</span></strong></p>\n\n<ul>\n\t<li><span style=\"font-family:Times\">CrCl 30-90 mL/min:&nbsp;No dosage adjustment necessary.</span></li>\n\t<li><span style=\"font-family:Times\">CrCl &lt;30 mL/min&nbsp;and ESRD: Insufficient clinical data to date. No dosage adjustments provided in the manufacturer&#39;s labeling.</span></li>\n</ul>\n\n<p><strong><span style=\"font-family:Times\">Hepatic Impairment</span></strong></p>\n\n<ul>\n\t<li><span style=\"font-family:Times\">Mild impairment (AST &le;10 x ULN and bilirubin 1 -1.25 x ULN): No dosage adjustment necessary.</span></li>\n\t<li><span style=\"font-family:Times\">Moderate impairment (AST &le;10 x ULN and bilirubin 1.5 - 3 x ULN): Reduce dose to 80 mg/m2; may increase up to 100 mg/m2 in subsequent cycles if the reduced dose is tolerated for 2 cycles.</span></li>\n\t<li><span style=\"font-family:Times\">Severe impairment: AST &le;10 x ULN and bilirubin 3-5 x ULN: Reduce dose to 80 mg/m2; may increase up to 100 mg/m2 in subsequent cycles if the reduced dose is tolerated for 2 cycles.</span></li>\n\t<li><span style=\"font-family:Times\">Severe impairment: AST &gt;10 x ULN or bilirubin &gt;5 x ULN: Use not recommended.</span></li>\n</ul>\n",
      "references": [
        {
          "id": 946,
          "referenceValue": "CA184-104: Govindan R, Szczesna A, Ahn MJ, Schneider CP, Gonzalez Mella PF, Barlesi F, Han B, Ganea DE, Von Pawel J, Vladimirov V, Fadeeva N, Lee KH, Kurata T, Zhang L, Tamura T, Postmus PE, Jassem J, O'Byrne K, Kopit J, Li M, Tschaika M, Reck M. Phase III trial of ipilimumab combined with paclitaxel and carboplatin in advanced squamous non-small-cell lung cancer. J Clin Oncol. 2017 Oct 20;35(30):3449-3457. Epub 2017 Aug 30.\n\nEYNOTE-407: Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, Rodríguez-Cid J, Wilson J, Sugawara S, Kato T, Lee KH, Cheng Y, Novello S, Halmos B, Li X, Lubiniecki GM, Piperdi B, Kowalski DM; KEYNOTE-407 Investigators. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018 Nov 22;379(21):2040-2051. Epub 2018 Sep 25.\n\nKEYNOTE-042: Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK, Bondarenko I, Kubota K, Lubiniecki GM, Zhang J, Kush D, Lopes G; KEYNOTE-042 Investigators. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019 May 4;393(10183):1819-1830. Epub 2019 Apr 4."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 485,
      "name": "",
      "schedule": "<p><strong>Trastuzumab</strong>&nbsp;4mg/kg IV loading dose,&nbsp;then 2mg/kg IV on days 8 and 15<br />\n<strong>Docetaxel</strong>&nbsp;35mg/m<sup>2</sup>&nbsp;IV on days 1, 8, and 15</p>\n\n<p>First cycle is administered weekly for 3 weeks, with 1-week rest. For subsequent cycles:</p>\n\n<p><strong>Trastuzumab&nbsp;</strong>2mg/kg IV weekly<br />\n<strong>Docetaxel</strong>&nbsp;35 mg/m<sup>2</sup>&nbsp;IV weekly</p>\n\n<p>Repeat cycle every 4 weeks.</p>\n",
      "emetogenicPotential": "Low",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Docetaxel</strong>:<br />\n\tIf bilirubin &gt; upper normal limit, do not use<br />\n\tIf&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Docetaxel</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 947,
          "referenceValue": "Esteva FJ, Valero V, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20(7):1800-8."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 600,
      "name": "",
      "schedule": "<p><strong>Irinotecan:&nbsp;</strong>180 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV bolus on day 1, followed by 2,400 mg/m<sup>2</sup>&nbsp;IV continuous infusion for 46 hours</p>\n\n<p><strong>Leucovorin:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on day 1 as a 2-hour infusion prior to 5-fluorouracil</p>\n\n<p>Repeat cycle every 2 weeks</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 695,
      "name": "",
      "schedule": "<p><strong>Nilotinib:&nbsp;</strong>400 mg PO twice daily</p>\n\n<p>Continue treatment until disease progression.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 512,
      "name": "",
      "schedule": "<p><strong>Paclitaxel</strong>&nbsp;175mg/m<sup>2</sup>&nbsp;IV over 3 hours on day 1</p>\n\n<p>Repeat cycle every 21 days.</p>\n\n<p>OR</p>\n\n<p><strong>Paclitaxel</strong>&nbsp;80-100mg/m<sup>2</sup>&nbsp;IV weekly for 3 weeks</p>\n\n<p>Repeat cycle every 4 weeks.</p>\n",
      "emetogenicPotential": "Low",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Paclitaxel</strong>:<br />\n\tFor 3-hour infusion:<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2<br />\n\tIf transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />\n\tFor 24-hour infusion:<br />\n\tIf transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)<br />\n\tIf transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2<br />\n\tIf transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Paclitaxel</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 948,
          "referenceValue": "Holmes FA, Walters RS, et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst. 1991;83(24):1797-805. --- Perez EA. Paclitaxel in Breast Cancer. Oncologist. 1998;3(6):373-389."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 513,
      "name": "",
      "schedule": "<p><strong>Ixabepilone</strong>&nbsp;40mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "Low",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Ixabepilone</strong>:<br />\n\tIf AST and ALT &lt; 2.5 upper normal limit, and bilirubin &lt; 1 upper normal limit, use 40 mg/m2<br />\n\tIf AST or ALT &lt; 10 upper normal limit, and bilirubin &lt; 1 upper normal limit, use 32 mg/m2<br />\n\tIf AST and ALT &lt; 10 upper normal limit, and bilirubin 1.5-3 upper normal limit, use 20-30 mg/m2<br />\n\tIf AST or ALT &gt; 10 upper normal limit, or bilirubin &gt; 3 upper normal limit, do not use<br />\n\tIn combination with capecitabine:<br />\n\tIf AST and ALT &lt; 2.5 upper normal limit, and bilirubin &lt; 1 upper normal limit, use 40 mg/m2<br />\n\tIf AST or ALT &gt; 2.5 upper normal limit, or bilirubin &gt; 1 upper normal limit, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Ixabepilone</strong>:<br />\n\tIf CrCl &gt; 30 mL/min, no dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 949,
          "referenceValue": "Perez EA, Lerzo G, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2007;25(23):3407-14."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 514,
      "name": "",
      "schedule": "<p><strong>Vinorelbine</strong>&nbsp;30mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat cycle every 7 days.</p>\n",
      "emetogenicPotential": "Low",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Vinorelbine</strong>:<br />\n\tIf bilirubin 2-3 mg/dL, reduce dose by 50%<br />\n\tIf bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Vinorelbine</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 950,
          "referenceValue": "Fumoleau P, Delozier T, et al. Vinorelbine (Navelbine) in the treatment of breast cancer: the European experience.Semin Oncol. 1995 Apr;22(2 Suppl 5):22-8."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 515,
      "name": "",
      "schedule": "<p><strong>Doxorubicin</strong>&nbsp;20mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat cycle every 7 days.</p>\n",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Doxorubicin</strong>:<br />\n\tIf bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />\n\tIf bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Doxorubicin</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 951,
          "referenceValue": "Torti FM, Bristow MR, et al. Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. Ann Intern Med. 1983;99(6):745-9."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 516,
      "name": "",
      "schedule": "<p><strong>Gemcitabine</strong>&nbsp;725mg/m<sup>2</sup>&nbsp;IV weekly for 3 weeks.</p>\n\n<p>Repeat cycle every 28 days.</p>\n",
      "emetogenicPotential": "Low",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Gemcitabine</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Gemcitabine</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 952,
          "referenceValue": "Carmichael J, Walling J, et al. Phase II activity of gemcitabine in advanced breast cancer. Semin Oncol. 1996;23(5 Suppl 10):77-81."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 517,
      "name": "",
      "schedule": "<p><strong>Doxorubicin liposome</strong>&nbsp;40mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat cycle every 28 days.</p>\n",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Doxorubicin</strong>:<br />\n\tIf bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />\n\tIf bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Doxorubicin</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 953,
          "referenceValue": "Al-Batran SE, Meerpohl HG, et al. Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer. Oncology. 2006;70(2):141-6."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 519,
      "name": "",
      "schedule": "<p><strong>Eribulin</strong>&nbsp;1.4mg/m<sup>2</sup>&nbsp;IV on days 1 and 8</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "Low",
      "dosageModifications": "",
      "references": [
        {
          "id": 954,
          "referenceValue": "Cortes J, O'Shaughnessy J, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377(9769):914-23."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 518,
      "name": "",
      "schedule": "<p><strong>Nab-paclitaxel</strong>&nbsp;260mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat cycle every 21 days.</p>\n\n<p>OR</p>\n\n<p><strong>Nab-paclitaxel</strong>&nbsp;125mg/m<sup>2</sup>&nbsp;IV on days 1, 8, and 15</p>\n\n<p>Repeat cycle every 28 days.</p>\n",
      "emetogenicPotential": "Low",
      "dosageModifications": "",
      "references": [
        {
          "id": 955,
          "referenceValue": "O'Shaughnessy JA, et al. Breast Cancer Res Treat 2003;82:Suppl 1 (abstract 43). --- O'Shaughnessy JA, et al. Breast Cancer Res Treat 2004;88:Suppl 1 (abstract 1070)."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 520,
      "name": "",
      "schedule": "<p><strong>Abemaciclib</strong>&nbsp;150mg PO BID</p>\n\n<p>Repeat cycle every 28 days.</p>\n",
      "emetogenicPotential": "Minimal",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Abemaciclib</strong><br />\n\tChild-Pugh C: Reduce dosing frequency to once daily</li>\n</ul>\n",
      "references": [
        {
          "id": 956,
          "referenceValue": "Dickler MN, Tolaney SM, et al. MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer. Clin Cancer Res. 2017;23(17):5218-5224."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 696,
      "name": "",
      "schedule": "<p><strong>Sunitinib:&nbsp;</strong>50 mg/day PO for 4 weeks</p>\n\n<p>Repeat cycle every 6 weeks.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 697,
      "name": "",
      "schedule": "<p><strong>Sorafenib:&nbsp;</strong>400 mg/day PO twice daily</p>\n\n<p>Continue treatment until disease progression.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 698,
      "name": "",
      "schedule": "<p><strong>Regorafenib:&nbsp;</strong>160 mg/day PO for 21 days</p>\n\n<p>Repeat cycle every 28 days.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 527,
      "name": "",
      "schedule": "<p><strong>Cisplatin&nbsp;</strong>50mg/m<sup>2</sup>&nbsp;IV on day 1<br />\n<strong>Paclitaxel</strong>&nbsp;135-175mg/m<sup>2</sup>&nbsp;IV on day 1<br />\n<strong>Bevacizumab</strong>&nbsp;15mg/kg IV on day 1</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Cisplatin</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Paclitaxel</strong>:<br />\n\tFor 3-hour infusion:<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2<br />\n\tIf transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />\n\tFor 24-hour infusion:<br />\n\tIf transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)<br />\n\tIf transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2<br />\n\tIf transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Cisplatin</strong>:<br />\n\tIf CrCl 30-60 mL/min, reduce dose by 50%<br />\n\tIf CrCl &lt; 30 mL/min, do not use</li>\n\t<li><strong>Paclitaxel</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 957,
          "referenceValue": "Tewari KS, et al. J Clin Oncol 2013;31:Suppl (abstract 3)."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 528,
      "name": "",
      "schedule": "<p><strong>Paclitaxel</strong>&nbsp;175mg/m<sup>2</sup>&nbsp;IV on day 1<br />\n<strong>Topotecan</strong>&nbsp;0.75mg/m<sup>2</sup>&nbsp;IV on days 1-3&nbsp;</p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Paclitaxel</strong>:<br />\n\tFor 3-hour infusion:<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2<br />\n\tIf transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />\n\tFor 24-hour infusion:<br />\n\tIf transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)<br />\n\tIf transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2<br />\n\tIf transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>\n\t<li><strong>Topotecan</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Paclitaxel</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Topotecan</strong>:<br />\n\tIf CrCl &gt; 40 mL/min, no dose reduction<br />\n\tIf CrCl 20-39 mL/min, reduce to 0.75 mg/m<sup>2</sup></li>\n</ul>\n",
      "references": [],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 526,
      "name": "",
      "schedule": "<p><strong>Paclitaxel</strong>&nbsp;175mg/m<sup>2</sup>&nbsp;IV on day 1<br />\n<strong>Topotecan</strong>&nbsp;0.75mg/m<sup>2</sup>/day IV on days 1-3<br />\n<strong>Bevacizumab</strong>&nbsp;15mg/kg IV on day 1</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Paclitaxel</strong>:<br />\n\tFor 3-hour infusion:<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m2)<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m2<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m2<br />\n\tIf transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />\n\tFor 24-hour infusion:<br />\n\tIf transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m2)<br />\n\tIf transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m2<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m2<br />\n\tIf transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>\n\t<li><strong>Topotecan</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Paclitaxel</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Topotecan</strong>:<br />\n\tIf CrCl &gt; 40 mL/min, no dose reduction<br />\n\tIf CrCl 20-39 mL/min, reduce to 0.75 mg/m<sup>2</sup></li>\n</ul>\n",
      "references": [
        {
          "id": 959,
          "referenceValue": "Tewari KS, et al. J Clin Oncol 2013;31:Suppl (abstract 3)."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 529,
      "name": "",
      "schedule": "<p><strong>Bleomycin</strong>&nbsp;30U IV over 24 hours on day 1<br />\n<strong>Ifosfamide</strong>&nbsp;5000mg/m<sup>2</sup>&nbsp;IV over 24 hours on day 2<br />\n<strong>Mesna</strong>&nbsp;6000mg/m<sup>2</sup>&nbsp;IV over 36 hours on day 2<br />\n<strong>Cisplatin</strong>&nbsp;50mg/m<sup>2</sup>&nbsp;IV on day 2</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Bleomycin</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Ifosfamide</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Cisplatin</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li>\n\t<p><strong>Bleomycin</strong><br />\n\tCrCl &gt;50 mL/min: No dose reduction<br />\n\tCrCl 40-50 mL/min: 70% of normal dose<br />\n\tCrCl 30-40 mL/min: 60% of normal dose<br />\n\tCrCl 20-30 mL/min: 55% normal dose<br />\n\tCrCl 10-20 mL/min: 45% normal dose<br />\n\tCrCl 5-10 mL/min: 40% normal dose</p>\n\t</li>\n\t<li>\n\t<p><strong>Cisplatin</strong>:<br />\n\tIf CrCl 30-60 mL/min, reduce dose by 50%<br />\n\tIf CrCl &lt; 30 mL/min, do not use</p>\n\t</li>\n</ul>\n",
      "references": [
        {
          "id": 960,
          "referenceValue": "Buxton EJ, Meanwell CA, et al. Combination bleomycin, ifosfamide, and cisplatin chemotherapy in cervical cancer. J Natl Cancer Inst. 1989;81(5):359-61."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 530,
      "name": "",
      "schedule": "<p><strong>Bleomycin</strong>&nbsp;30U IV on day 1<br />\n<strong>Ifosfamide</strong>&nbsp;2000mg/m<sup>2</sup>&nbsp;IV on days 1-3<br />\n<strong>Mesna</strong>&nbsp;400mg/m<sup>2</sup>&nbsp;IV, 15min before ifosfamide dose, then 400mg/m<sup>2</sup>&nbsp;IV at 4 and 8 hours following ifosfamide<br />\n<strong>Carboplatin&nbsp;</strong>200mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Bleomycin</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Ifosfamide</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Carboplatin</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li>\n\t<p><strong>Bleomycin</strong><br />\n\tCrCl &gt;50 mL/min: No dose reduction<br />\n\tCrCl 40-50 mL/min: 70% of normal dose<br />\n\tCrCl 30-40 mL/min: 60% of normal dose<br />\n\tCrCl 20-30 mL/min: 55% normal dose<br />\n\tCrCl 10-20 mL/min: 45% normal dose<br />\n\tCrCl 5-10 mL/min: 40% normal dose</p>\n\t</li>\n\t<li>\n\t<p><strong>Carboplatin</strong>:<br />\n\tDosing based on AUC</p>\n\t</li>\n</ul>\n",
      "references": [
        {
          "id": 961,
          "referenceValue": "Murad AM, Triginelli SA, et al. Phase II trial of bleomycin, ifosfamide, and carboplatin in metastatic cervical cancer. J Clin Oncol. 1994;12(1):55-9."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 534,
      "name": "",
      "schedule": "<p><strong>Cisplatin</strong>&nbsp;50mg/m<sup>2</sup>&nbsp;IV on day 1<br />\n<strong>Gemcitabine</strong>&nbsp;1000mg/m<sup>2</sup>&nbsp;IV on days 1 and 8</p>\n\n<p>Repeat cycle every 21 days for up to 6 cycles.</p>\n\n<p>OR</p>\n\n<p><strong>Cisplatin</strong>&nbsp;30mg/m<sup>2</sup>&nbsp;IV on day 1<br />\n<strong>Gemcitabine</strong>&nbsp;800mg/m<sup>2</sup>&nbsp;IV on days 1 and 8</p>\n\n<p>Repeat cycle every 28 days.</p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Gemcitabine</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Cisplatin</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Gemcitabine</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Cisplatin</strong>:<br />\n\tIf CrCl 30-60 mL/min, reduce dose by 50%<br />\n\tIf CrCl &lt; 30 mL/min, do not use</li>\n</ul>\n",
      "references": [
        {
          "id": 962,
          "referenceValue": "Monk BJ, et al. Proc Am Soc Clin Oncol 2008;26:(LBA5504). --- Brewer CA, Blessing JA, et al. Cisplatin plus gemcitabine in previously treated squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2006;100(2):385-8."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 535,
      "name": "",
      "schedule": "<p><strong>Carboplatin</strong>&nbsp;AUC of 6, IV on day 1<br />\n<strong>Docetaxel</strong>&nbsp;60mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Carboplatin</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Docetaxel</strong>:<br />\n\tIf bilirubin &gt; upper normal limit, do not use<br />\n\tIf&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Carboplatin</strong>:<br />\n\tDosing based on AUC</li>\n\t<li><strong>Docetaxel</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 958,
          "referenceValue": "Nagao S, Fujiwara K, et al. Combination chemotherapy of docetaxel and carboplatin in advanced or recurrent cervix cancer. A pilot study. Gynecol Oncol. 2005;96(3):805-9."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 536,
      "name": "",
      "schedule": "<p><strong>Cisplatin</strong>&nbsp;50mg/m<sup>2</sup>&nbsp;IV on day 1<br />\n<strong>Pemetrexed</strong>&nbsp;500mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Cisplatin</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Pemetrexed</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Cisplatin</strong>:<br />\n\tIf CrCl 30-60 mL/min, reduce dose by 50%<br />\n\tIf CrCl &lt; 30 mL/min, do not use</li>\n\t<li><strong>Pemetrexed</strong>:<br />\n\tIf CrCl &gt; 45 mL/min, no dose reduction<br />\n\tIf CrCl &lt; 45 mL/min, do not use</li>\n</ul>\n",
      "references": [
        {
          "id": 963,
          "referenceValue": "Miller DS, Blessing JA, et al. Pemetrexed and cisplatin for the treatment of advanced, persistent, or recurrent carcinoma of the cervix: a limited access phase II trial of the gynecologic oncology group. J Clin Oncol. 2014;32(25):2744-9."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 537,
      "name": "",
      "schedule": "<p><strong>Docetaxel</strong>&nbsp;100mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "Low",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Docetaxel</strong>:<br />\n\tIf bilirubin &gt; upper normal limit, do not use<br />\n\tIf&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Docetaxel</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 964,
          "referenceValue": "Levy T, et al. Proc Am Soc Clin Oncnol 1996;15:292a."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 538,
      "name": "",
      "schedule": "<p><strong>Paclitaxel</strong>&nbsp;175mg/m<sup>2</sup>&nbsp;IV over 3 hours on day 1</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "Low",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Paclitaxel</strong>:<br />\n\tFor 3-hour infusion:<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m<sup>2</sup>)<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m<sup>2</sup><br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m<sup>2</sup><br />\n\tIf transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />\n\tFor 24-hour infusion:<br />\n\tIf transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m<sup>2</sup>)<br />\n\tIf transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m<sup>2</sup><br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m<sup>2</sup><br />\n\tIf transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Paclitaxel</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 965,
          "referenceValue": "Thigpen T, Vance R, et al. The role of paclitaxel in the management of patients with carcinoma of the cervix. Semin Oncol. 1997;24(1 Suppl 2):S2-41-S2-46."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 539,
      "name": "",
      "schedule": "<p><strong>Irinotecan</strong>&nbsp;125mg/m<sup>2</sup>&nbsp;IV weekly for 4 weeks</p>\n\n<p>Repeat cycle every 6 weeks.</p>\n",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Irinotecan</strong>:<br />\n\tIf bilirubin 1-2 mg/dL, may need to reduce the dose<br />\n\tIf bilurubin &gt; 2 mg/dL, may not use &nbsp;</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Irinotecan</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 966,
          "referenceValue": "Verschraegen CF, Levy T, et al. Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J Clin Oncol. 1997;15(2):625-31."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 540,
      "name": "",
      "schedule": "<p><strong>Topotecan</strong>&nbsp;1.5mg/m<sup>2</sup>/day on days 1-5</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "Low",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Topotecan</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Topotecan</strong>:<br />\n\tIf CrCl &gt; 40 mL/min, no dose reduction<br />\n\tIf CrCl 20-39 mL/min, reduce to 0.75 mg/m<sup>2</sup></li>\n</ul>\n",
      "references": [
        {
          "id": 967,
          "referenceValue": "Muderspach LI, Blessing JA, et al. A Phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol. 2001;81(2):213-5."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 541,
      "name": "",
      "schedule": "<p><strong>Pemetrexed</strong>&nbsp;500mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "Low",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Pemetrexed</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Pemetrexed</strong>:<br />\n\tIf CrCl &gt; 45 mL/min, no dose reduction<br />\n\tIf CrCl &lt; 45 mL/min, do not use</li>\n</ul>\n",
      "references": [
        {
          "id": 968,
          "referenceValue": "Lorusso D, Ferrandina G, et al. Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group. Ann Oncol. 2010;21(1):61-6."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 699,
      "name": "",
      "schedule": "<p><strong>Gemcitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;IV on days 1, 8, and 15</p>\n\n<p><strong>Capecitabine:&nbsp;</strong>880 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-21</p>\n\n<p>Repeat cycle every 28 days for a total of 6 cycles.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 1,
          "level": "ADJUVANT"
        }
      ]
    },
    {
      "id": 547,
      "name": "",
      "schedule": "<p><strong>Doxorubicin</strong>&nbsp;50mg/m<sup>2</sup>&nbsp;IV on day 1<br />\n<strong>Paclitaxel</strong>&nbsp;150mg/m<sup>2</sup>&nbsp;on day 1</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Doxorubicin</strong>:<br />\n\tIf bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />\n\tIf bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use</li>\n\t<li><strong>Paclitaxel</strong>:<br />\n\tFor 3-hour infusion:<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m<sup>2</sup>)<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m<sup>2</sup><br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m<sup>2</sup><br />\n\tIf transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />\n\tFor 24-hour infusion:<br />\n\tIf transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m<sup>2</sup>)<br />\n\tIf transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m<sup>2</sup><br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m<sup>2</sup><br />\n\tIf transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Doxorubicin</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Paclitaxel</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 969,
          "referenceValue": "Fiorica JV. Update on the treatment of cervical and uterine carcinoma: focus on topotecan. Oncologist. 2002;7 Suppl 5:36-45."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 548,
      "name": "",
      "schedule": "<p><strong>Cisplatin</strong>&nbsp;50mg/m<sup>2</sup>&nbsp;IV on day 1<br />\n<strong>Doxorubicin</strong>&nbsp;45mg/m<sup>2</sup>&nbsp;IV on day 1<br />\n<strong>Paclitaxel</strong>&nbsp;160mg/m<sup>2</sup>&nbsp;over 3 hours on day 2</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Cisplatin</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Doxorubicin</strong>:<br />\n\tIf bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />\n\tIf bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use</li>\n\t<li><strong>Paclitaxel</strong>:<br />\n\tFor 3-hour infusion:<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m<sup>2</sup>)<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m<sup>2</sup><br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m<sup>2</sup><br />\n\tIf transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />\n\tFor 24-hour infusion:<br />\n\tIf transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m<sup>2</sup>)<br />\n\tIf transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m<sup>2</sup><br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m<sup>2</sup><br />\n\tIf transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Cisplatin</strong>:<br />\n\tIf CrCl 30-60 mL/min, reduce dose by 50%<br />\n\tIf CrCl &lt; 30 mL/min, do not use</li>\n\t<li><strong>Doxorubicin</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Paclitaxel</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 970,
          "referenceValue": "Fleming GF, Brunetto VL, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2004;22(11):2159-66."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 549,
      "name": "",
      "schedule": "<p><strong>Cyclophosphamide</strong>&nbsp;500mg/m<sup>2</sup>&nbsp;IV on day 1<br />\n<strong>Doxorubicin</strong>&nbsp;50mg/m<sup>2</sup>&nbsp;IV on day 1<br />\n<strong>Cisplatin</strong>&nbsp;50mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Cisplatin</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Cyclophosphamide</strong>:<br />\n\tIf bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use</li>\n\t<li><strong>Doxorubicin</strong>:<br />\n\tIf bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />\n\tIf bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Cisplatin</strong>:<br />\n\tIf CrCl 30-60 mL/min, reduce dose by 50%<br />\n\tIf CrCl &lt; 30 mL/min, do not use</li>\n\t<li><strong>Cyclophosphamide</strong>:<br />\n\tIf CrCl 10-50 mL/min, reduce dose by 25%<br />\n\tIf CrCl &lt; 10 mL/min, reduce dose by 50%</li>\n\t<li><strong>Doxorubicin</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 971,
          "referenceValue": "Burke TW, Gershenson DM, et al. Postoperative adjuvant cisplatin, doxorubicin, and cyclophosphamide (PAC) chemotherapy in women with high-risk endometrial carcinoma. Gynecol Oncol. 1994;55(1):47-50."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 550,
      "name": "",
      "schedule": "<p><strong>Carboplatin</strong>&nbsp;AUC of 5, IV on day 1<br />\n<strong>Doxorubicin liposome</strong>&nbsp;40mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat cycle every 28 days.</p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Doxorubicin</strong>:<br />\n\tIf bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />\n\tIf bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use</li>\n\t<li><strong>Carboplatin</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Doxorubicin</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Carboplatin</strong>:<br />\n\tDosing based on AUC</li>\n</ul>\n",
      "references": [
        {
          "id": 972,
          "referenceValue": "Pignata S, Scambia G, et al. A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group. Br J Cancer. 2007;96(11):1639-43."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 551,
      "name": "",
      "schedule": "<p><strong>Paclitaxel</strong>&nbsp;135mg/m<sup>2</sup>&nbsp;IV over 3 hours on day 1<br />\n<strong>Ifosfamide</strong>&nbsp;1600mg/m<sup>2</sup>/day IV on days 1-3</p>\n\n<p>Repeat cycle every 21 days for up to 8 cycles.</p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Ifosfamide</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Paclitaxel</strong>:<br />\n\tFor 3-hour infusion:<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m<sup>2</sup>)<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m<sup>2</sup><br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m<sup>2</sup><br />\n\tIf transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />\n\tFor 24-hour infusion:<br />\n\tIf transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m<sup>2</sup>)<br />\n\tIf transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m<sup>2</sup><br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m<sup>2</sup><br />\n\tIf transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Paclitaxel</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 973,
          "referenceValue": "Homesley HD, Filiaci V, et al. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25(5):526-31."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 601,
      "name": "",
      "schedule": "<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV bolus, followed by 600 mg/m<sup>2</sup>&nbsp;IV continuous infusion for 22 hours on days 1 and 2</p>\n\n<p><strong>Leucovorin:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil</p>\n\n<p><strong>OR</strong></p>\n\n<p><strong>L-Leucovorin:&nbsp;</strong>100 mg/m<sup>2</sup>&nbsp;IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil</p>\n\n<p>Repeat cycle every 2 weeks</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 560,
      "name": "",
      "schedule": "<p><strong>Cisplatin</strong>&nbsp;100mg/m<sup>2</sup>&nbsp;IV on day 1<br />\n<strong>Cyclophosphamide</strong>&nbsp;600mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat cycle every 28 days.</p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Cisplatin</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Cyclophosphamide</strong>:<br />\n\tIf bilirubin 3-5 mg/dL or SGOT &gt; 180 mg/dL, reduce dose by 25%<br />\n\tIf bilirubin &gt;5 mg/dL, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li>\n\t<p><strong>Cisplatin</strong>:<br />\n\tIf CrCl 30-60 mL/min, reduce dose by 50%<br />\n\tIf CrCl &lt; 30 mL/min, do not use</p>\n\t</li>\n\t<li>\n\t<p><strong>Cyclophosphamide</strong>:<br />\n\tIf CrCl 10-50 mL/min, reduce dose by 25%<br />\n\tIf CrCl &lt; 10 mL/min, reduce dose by 50%</p>\n\t</li>\n</ul>\n",
      "references": [
        {
          "id": 974,
          "referenceValue": "Alberts DS, Green S, et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol. 1992;10(5):706-17."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 561,
      "name": "",
      "schedule": "<p><strong>Cisplatin</strong>&nbsp;75mg/m<sup>2</sup>&nbsp;IV on day 2<br />\n<strong>Paclitaxel</strong>&nbsp;135mg/m<sup>2</sup>&nbsp;IV over 24 hours on day 1</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Cisplatin</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Paclitaxel</strong>:<br />\n\tFor 3-hour infusion:<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m<sup>2</sup>)<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m<sup>2</sup><br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin2.01-5 upper normal limit, reduce to 90 mg/m<sup>2</sup><br />\n\tIf transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />\n\tFor 24-hour infusion:<br />\n\tIf transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m<sup>2</sup>)<br />\n\tIf transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m<sup>2</sup><br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m<sup>2</sup><br />\n\tIf transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Cisplatin</strong>:<br />\n\tIf CrCl 30-60 mL/min, reduce dose by 50%<br />\n\tIf CrCl &lt; 30 mL/min, do not use</li>\n\t<li><strong>Paclitaxel</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 975,
          "referenceValue": "McGuire WP, Hoskins WJ, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334(1):1-6."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 562,
      "name": "",
      "schedule": "<p><strong>Carboplatin</strong>&nbsp;AUC of 6-7.5, IV on day 1<br />\n<strong>Paclitaxel</strong>&nbsp;175mg/m<sup>2</sup>&nbsp;IV over 3 hours on day</p>\n\n<p>Repeat cycle every 21 days.</p>\n\n<p>OR</p>\n\n<p><strong>Carboplatin</strong>&nbsp;AUC of 2, IV on days 1, 8, and 15<br />\n<strong>Paclitaxel</strong>&nbsp;60mg/m<sup>2</sup>&nbsp;IV on days 1, 8, and 15</p>\n\n<p>Repeat cycle every 28 days.</p>\n",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Carboplatin</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Paclitaxel</strong>:<br />\n\tFor 3-hour infusion:<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin &lt; 1.25 upper normal limit, no dose reduction (175mg/m<sup>2</sup>)<br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 1.26-2 upper normal limit, reduce to 135 mg/m<sup>2</sup><br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 2.01-5 upper normal limit, reduce to 90 mg/m<sup>2</sup><br />\n\tIf transaminase &gt; 10 upper normal limit or bilirubin &gt; 5 upper normal limit, do not use<br />\n\tFor 24-hour infusion:<br />\n\tIf transaminase &lt; 2 upper normal limit or bilirubin &lt; 1.5 mg/mL, no dose reduction (135 mg/m<sup>2</sup>)<br />\n\tIf transaminase 2-10 upper normal limit and bilirubin &lt; 1.5 mg/dL, reduce to 100 mg/m<sup>2</sup><br />\n\tIf transaminase &lt; 10 upper normal limit and bilirubin 1.6-7.5 mg/dL, reduce to 50 mg/m<sup>2</sup><br />\n\tIf transaminase &gt; 10 upper normal limit or bilirubin &gt; 7.5 mg/dL, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Carboplatin</strong>:<br />\n\tDosing based on AUC</li>\n\t<li><strong>Paclitaxel</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 976,
          "referenceValue": "Ozols RF. Combination regimens of paclitaxel and the platinum drugs as first-line regimens for ovarian cancer. Semin Oncol. 1995;22(6 Suppl 15):1-6. --- Pignata S, Breda E, et al. A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study. Crit Rev Oncol Hematol. 2008;66(3):229-36."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 563,
      "name": "",
      "schedule": "<p><strong>Carboplatin</strong>&nbsp;AUC of 6, IV on day 1<br />\n<strong>Paclitaxel</strong>&nbsp;175mg/m<sup>2</sup>&nbsp;IV over 3 hours on day 1<br />\n<strong>Bevacizumab</strong>&nbsp;15mg/kg IV on day 1</p>\n\n<p>Repeat cycle every 21 days for 6 cycles, then maintenance bevacizumab for cycles 7-22.</p>\n",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Bevacizumab</strong><br />\n\tNo dose reduction</li>\n\t<li><strong>Carboplatin</strong><br />\n\tNo dose reduction</li>\n\t<li><strong>Paclitaxel</strong><br />\n\tTransaminases &lt;10 x ULN and bilirubin &le;1.25 x ULN: 175 mg/m<sup>2</sup><br />\n\tTransaminases &lt;10 x ULN and bilirubin 1.26 to 2 x ULN: 135 mg/m<sup>2</sup><br />\n\tTransaminases &lt;10 x ULN and bilirubin 2.01 to 5 x ULN: 90 mg/m<sup>2</sup><br />\n\tTransaminases &ge;10 x ULN or bilirubin &gt;5 x ULN: Use is not recommended</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Bevacizumab</strong><br />\n\tIf proteinuria &ge;2g/24 hours: withhold bevacizumab until proteinuria &lt;2g/24 hours. Discontinue in patients with nephrotic syndrome. &nbsp;</li>\n\t<li><strong>Carboplatin</strong><br />\n\tDosing based on AUC</li>\n\t<li><strong>Paclitaxel</strong><br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 977,
          "referenceValue": "Burger RA, et al. J Clin Oncol 2010:28:946S (LBA1)."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 564,
      "name": "",
      "schedule": "<p><strong>Carboplatin</strong>&nbsp;AUC of 6, IV on day 1<br />\n<strong>Docetaxel</strong>&nbsp;60mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Carboplatin</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Docetaxel</strong>:<br />\n\tIf bilirubin &gt; upper normal limit, do not use<br />\n\tIf&nbsp; SGOT and/or SGPT &gt; 1.5 upper normal limit plus alkaline phosphatase &gt; 2.5 upper normal limit, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Carboplatin</strong>:<br />\n\tDosing based on AUC</li>\n\t<li><strong>Docetaxel</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 978,
          "referenceValue": "Markman M, Kennedy A, et al. Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum. J Clin Oncol. 2001;19(7):1901-5."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 565,
      "name": "",
      "schedule": "<p><strong>Carboplatin</strong>&nbsp;AUC of 5, IV on day 1<br />\n<strong>Doxorubicin liposome</strong>&nbsp;30mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat cycle every 28 days.</p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Carboplatin</strong><br />\n\tNo dose reduction</li>\n\t<li><strong>Doxorubicin</strong>:<br />\n\tIf bilirubin 1.2-3 mg/dL, reduce dose by 50%<br />\n\tIf bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Carboplatin</strong><br />\n\tDosing based on AUC</li>\n\t<li><strong>Doxorubicin</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 979,
          "referenceValue": "Pignant S, et al. J Clin Oncol 2009;27:18S (LBA5509)."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 575,
      "name": "",
      "schedule": "<p><strong>Topotecan</strong>&nbsp;1.5mg/m<sup>2</sup>&nbsp;IV on days 1-5</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "Low",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Topotecan</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Topotecan</strong>:<br />\n\tIf CrCl &gt; 40 mL/min, no dose reduction<br />\n\tIf CrCl 20-39 mL/min, reduce to 0.75 mg/m<sup>2</sup></li>\n</ul>\n",
      "references": [
        {
          "id": 980,
          "referenceValue": "Kudelka AP, Tresukosol D, et al. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol. 1996;14(5):1552-7."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 574,
      "name": "",
      "schedule": "<p><strong>Ixabepilone</strong>&nbsp;20mg/m<sup>2</sup> IV on days 1, 8, and 15</p>\n\n<p>Repeat cycle every 28 days.</p>\n",
      "emetogenicPotential": "Low",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Ixabepilone</strong>:<br />\n\tIf AST and ALT &lt; 2.5 upper normal limit, and bilirubin &lt; 1 upper normal limit, use 40 mg/m<sup>2</sup><br />\n\tIf AST or ALT &lt; 10 upper normal limit, and bilirubin &lt; 1 upper normal limit, use 32 mg/m<sup>2</sup><br />\n\tIf AST and ALT &lt; 10 upper normal limit, and bilirubin 1.5-3 upper normal limit, use 20-30 mg/m<sup>2</sup><br />\n\tIf AST or ALT &gt; 10 upper normal limit, or bilirubin &gt; 3 upper normal limit, do not use<br />\n\tIn combination with capecitabine:<br />\n\tIf AST and ALT &lt; 2.5 upper normal limit, and bilirubin &lt; 1 upper normal limit, use 40 mg/m<sup>2</sup><br />\n\tIf AST or ALT &gt; 2.5 upper normal limit, or bilirubin &gt; 1 upper normal limit, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Ixabepilone</strong>:<br />\n\tIf CrCl &gt; 30 mL/min, no dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 981,
          "referenceValue": "De Geest K, Blessing JA, et al. Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study. J Clin Oncol. 2010;28(1):149-53."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 576,
      "name": "",
      "schedule": "<p><strong>Gemcitabine</strong>&nbsp;800mg/m<sup>2</sup>&nbsp;IV weekly for 3 weeks</p>\n\n<p>Repeat cycle every 4 weeks.</p>\n",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Gemcitabine</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Gemcitabine</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 982,
          "referenceValue": "Lund B, Hansen OP, et al. Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst. 1994;86(20):1530-3."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 577,
      "name": "",
      "schedule": "<p><strong>Etoposide</strong>&nbsp;50mg/m<sup>2</sup>/day PO on days 1-21</p>\n\n<p>Repeat cycle every 28 days.</p>\n",
      "emetogenicPotential": "Low",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Etoposide</strong>:<br />\n\tIf bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br />\n\tIf bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Etoposide</strong>:<br />\n\tIf CrCl 10-50 mL/min, reduce dose by 25%<br />\n\tIf CrCl &lt; 10 mL/min, reduce dose by 50%</li>\n</ul>\n",
      "references": [
        {
          "id": 983,
          "referenceValue": "Ozols RF. Oral etoposide for the treatment of recurrent ovarian cancer. Drugs. 1999;58 Suppl 3:43-9."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 578,
      "name": "",
      "schedule": "<p><strong>Vinorelbine</strong>&nbsp;30mg/m<sup>2</sup>&nbsp;IV on days 1 and 8</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "Low",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Vinorelbine</strong>:<br />\n\tIf bilirubin 2-3 mg/dL, reduce dose by 50%<br />\n\tIf bilirubin 3.1-5 mg/dL, reduce dose by 75%<br />\n\tIf bilirubin &gt; 5 mg/dL, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Vinorelbine</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n",
      "references": [
        {
          "id": 984,
          "referenceValue": "Sorensen P, Hoyer M, et al. Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma. Gynecol Oncol. 2001;81(1):58-62."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 579,
      "name": "",
      "schedule": "<p><strong>Pemetrexed</strong>&nbsp;900mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "Low",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Pemetrexed</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Pemetrexed</strong>:<br />\n\tIf CrCl &gt; 45 mL/min, no dose reduction<br />\n\tIf CrCl &lt; 45 mL/min, do not use</li>\n</ul>\n",
      "references": [
        {
          "id": 985,
          "referenceValue": "Miller DS, et al. J Clin Oncol 2009;27:2686-2691."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 580,
      "name": "",
      "schedule": "<p><strong>Bevacizumab</strong>&nbsp;15mg/kg IV on day 1</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "Low",
      "dosageModifications": "",
      "references": [
        {
          "id": 986,
          "referenceValue": "Burger RA, Sill MW, et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25(33):5165-71."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 581,
      "name": "",
      "schedule": "<p><strong>Capecitabine</strong>&nbsp;1000mg/m<sup>2</sup>&nbsp;PO BID on days 1-14</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "Moderate",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Capecitabine</strong>:<br />\n\tNo dose reduction</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Capecitabine</strong>:<br />\n\tIf CrCl 30-50 mL/min, reduce dose by 25%<br />\n\tIf CrCl &lt; 30 mL/min, do not use</li>\n</ul>\n",
      "references": [
        {
          "id": 987,
          "referenceValue": "Wolf JK, Bodurka DC, et al. A phase II trial of oral capecitabine in patients with platinum--and taxane--refractory ovarian, fallopian tube, or peritoneal cancer. Gynecol Oncol. 2006;102(3):468-74."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 582,
      "name": "",
      "schedule": "<p><strong>Olaparib</strong>&nbsp;400mg PO BID</p>\n\n<p>Repeat cycle every 28 days.</p>\n\n<p>OR&nbsp;</p>\n\n<p><strong>Olaparib&nbsp;</strong>(maintenance after 1st-line chemo) 300mg PO BID</p>\n\n<p>Repeat cycle every 28 days.</p>\n",
      "emetogenicPotential": "Low",
      "dosageModifications": "<h4>Renal impairment</h4>\n\n<ul>\n\t<li><strong>Olaparib</strong><br />\n\tCrCl 31-50 mL/min: Reduce dose to 200mg BID</li>\n</ul>\n",
      "references": [
        {
          "id": 988,
          "referenceValue": "Ledermann J, Harter P, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15(8):852-61. --- Moore K, Colombo N, et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2018;379(26):2495-2505."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 521,
      "name": "",
      "schedule": "<p><strong>Olaparib&nbsp;</strong>300mg PO BID</p>\n\n<p>Repeat cycle every 28 days.</p>\n",
      "emetogenicPotential": "Low",
      "dosageModifications": "<h4>Renal impairment</h4>\n\n<ul>\n\t<li><strong>Olaparib</strong><br />\n\tCrCl 31-50 mL/min: Reduce dose to 200mg BID</li>\n</ul>\n",
      "references": [
        {
          "id": 989,
          "referenceValue": "Robson M, Im SA, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med. 2017;377(6):523-533."
        }
      ],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 583,
      "name": "",
      "schedule": "<p><strong>Rucaparib</strong>&nbsp;600mg PO daily</p>\n\n<p>Repeat cycle every 28 days.</p>\n",
      "emetogenicPotential": "Moderate-High",
      "dosageModifications": "<h4>Hepatic impairment</h4>\n\n<ul>\n\t<li>Mild (total bilirubin &le;upper limit of normal [ULN] and AST &gt;ULN, or total bilirubin between 1-1.5x ULN and any AST): No dose adjustment required</li>\n\t<li>Moderate-to-severe (total bilirubin &gt;1.5x ULN): Lack of data; no recommendation available</li>\n</ul>\n\n<h4>Renal impairment</h4>\n\n<ul>\n\t<li>Mild-to-moderate (CrCl 30-89): No dose adjustment required</li>\n\t<li>Severe (CrCl &lt;30 mL/min) or patients on dialysis: Lack of data; no recommendation available</li>\n</ul>\n",
      "references": [
        {
          "id": 990,
          "referenceValue": "Swisher EM, Lin KK, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2017;18(1):75-87."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 585,
      "name": "",
      "schedule": "<p><strong>Bleomycin</strong>&nbsp;30U IV on days 2, 9, and 16<br />\n<strong>Etoposide</strong>&nbsp;100mg/m<sup>2</sup>&nbsp;IV on days 1-5<br />\n<strong>Cisplatin</strong>&nbsp;20mg/m<sup>2</sup>&nbsp;IV on days 1-5</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "High",
      "dosageModifications": "<p><strong>Hepatic Impairment</strong></p>\n\n<ul>\n\t<li><strong>Bleomycin</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Cisplatin</strong>:<br />\n\tNo dose reduction</li>\n\t<li><strong>Etoposide</strong>:<br />\n\tIf bilirubin 1.5-3 mg/dL or SGOT 60-180 mg/dL, reduce dose by 50%<br />\n\tIf bilirubin &gt; 3 mg/dL or SGOT &gt; 180 mg/dL, do not use</li>\n</ul>\n\n<p><strong>Renal Impairment</strong></p>\n\n<ul>\n\t<li><strong>Bleomycin</strong>:<br />\n\tIf CrCl 10-50 mL/min, reduce dose by 25%<br />\n\tIf CrCl &lt; 10 mL/min, reduce dose by 50%</li>\n\t<li><strong>Cisplatin</strong>:<br />\n\tIf CrCl 30-60 mL/min, reduce dose by 50%<br />\n\tIf CrCl &lt; 30 mL/min, do not use</li>\n\t<li><strong>Etoposide</strong>:<br />\n\tIf CrCl 10-50 mL/min, reduce dose by 25%<br />\n\tIf CrCl &lt; 10 mL/min, reduce dose by 50%</li>\n</ul>\n",
      "references": [
        {
          "id": 991,
          "referenceValue": "Dimopoulos MA, Papadimitriou C, et al. Treatment of ovarian germ cell tumors with a 3-day bleomycin, etoposide, and cisplatin regimen: a prospective multicenter study. Gynecol Oncol. 2004;95(3):695-700."
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 595,
      "name": "",
      "schedule": "<p><strong>Oxaliplatin:&nbsp;</strong>130 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>Capecitabine:</strong>&nbsp;1,000 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-14</p>\n\n<p>Repeat cycle every 3 weeks for a total of 8 cycles (6 months total). Dose may be decreased to 850 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-14 to reduce risk of toxicity without compromising efficacy.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 1,
          "level": "ADJUVANT"
        }
      ]
    },
    {
      "id": 596,
      "name": "",
      "schedule": "<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV bolus, followed by 600 mg/m<sup>2</sup>&nbsp;IV continuous infusion for 22 hours on days 1 and 2</p>\n\n<p><strong>Leucovorin:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil</p>\n\n<p><strong>OR</strong></p>\n\n<p><strong>L-Leucovorin:&nbsp;</strong>100 mg/m<sup>2</sup>&nbsp;IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil</p>\n\n<p>Repeat cycle every 2 weeks for a total of 12 cycles</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 1,
          "level": "ADJUVANT"
        }
      ]
    },
    {
      "id": 597,
      "name": "",
      "schedule": "<p><strong>Capecitabine:&nbsp;</strong>1,250 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-14</p>\n\n<p>Repeat cycle every 21 days for a total of 8 cycles. Does may be decreased to 850-1,000 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-14 to reduce risk of toxicity without compromising clinical efficacy.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 1,
          "level": "ADJUVANT"
        }
      ]
    },
    {
      "id": 598,
      "name": "",
      "schedule": "<p><strong>Irinotecan:&nbsp;</strong>125 mg/m<sup>2</sup>&nbsp;IV over 90 minutes weekly for 2 weeks</p>\n\n<p><strong>5-Fluorouracil:&nbsp;</strong>500 mg/m<sup>2</sup>&nbsp;IV weekly for 2 weeks</p>\n\n<p><strong>Leucovorin:&nbsp;</strong>20 mg/m<sup>2</sup>&nbsp;IV weekly for 2 weeks</p>\n\n<p>Repeat cycle every 3 weeks</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 586,
      "name": "",
      "schedule": "<p><strong>Acalabrutinib 100 mg P.O. Twice Daily</strong></p>\n",
      "emetogenicPotential": "Low",
      "dosageModifications": "<p>Hepatic Impairment:</p>\n\n<p>Mild and Moderate impairment- No dose modification is necessary</p>\n\n<p>Avoid in severe hepatic impairment</p>\n",
      "references": [
        {
          "id": 992,
          "referenceValue": "Sharman et al. 2020 https://doi.org/10.1016/s0140-6736(20)30262-2"
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 599,
      "name": "",
      "schedule": "<p><strong>Irinotecan:&nbsp;</strong>180 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV bolus, followed by 600 g/m<sup>2</sup>&nbsp;IV continuous infusion for 22 hours on days 1 and 2</p>\n\n<p><strong>Leucovorin:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on days 1 and 2 as a 2-hour infusion prior to 5-fluorouracil</p>\n\n<p>Repeat cycle every 2 weeks</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 587,
      "name": "",
      "schedule": "<p>Vismodegib 150 mg P.O. Once&nbsp;a day</p>\n",
      "emetogenicPotential": "Low",
      "dosageModifications": "<p>No Dose Adjustment is necessary in Renal or Hepatic impairment</p>\n",
      "references": [
        {
          "id": 993,
          "referenceValue": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4362529/"
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 588,
      "name": "",
      "schedule": "<p><strong>Sondegib 200 mg P.O. Once a Day</strong></p>\n",
      "emetogenicPotential": "Low",
      "dosageModifications": "<p>No Adjustment is needed in Renal Impairment</p>\n\n<p>No Adjustment is needed in Mild and Moderate Hepatic Impairment</p>\n\n<p>Use Caution in Severe Hepatic Impairment</p>\n",
      "references": [
        {
          "id": 994,
          "referenceValue": "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2815%2970100-2/fulltext"
        }
      ],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 589,
      "name": "",
      "schedule": "<p><strong>5-Fluorouracil:&nbsp;</strong>425 mg/m<sup>2</sup>&nbsp;IV on days 1-5</p>\n\n<p><strong>Leucovorin:&nbsp;</strong>20 mg/m<sup>2</sup>&nbsp;IV on days 1-5, administered before 5-fluorouracil</p>\n\n<p>Repeat cycle every 4-5 weeks for a total of 6 cycles.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 1,
          "level": "ADJUVANT"
        }
      ]
    },
    {
      "id": 590,
      "name": "",
      "schedule": "<p><strong>5-Fluorouracil:&nbsp;</strong>500 mg/m<sup>2</sup>&nbsp;IV weekly for 6 weeks</p>\n\n<p><strong>Leucovorin:&nbsp;</strong>500 mg/m<sup>2</sup>&nbsp;IV over 2 hours weekly for 6 weeks, administered before 5-fluorouracil</p>\n\n<p>Repeat cycle every 8 weeks for a total of 4 cycles (32 weeks total)</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 1,
          "level": "ADJUVANT"
        }
      ]
    },
    {
      "id": 591,
      "name": "",
      "schedule": "<p><strong>5-Fluorouracil:&nbsp;</strong>500 mg/m<sup>2</sup>&nbsp;IV weekly for 6 weeks</p>\n\n<p><strong>Leucovorin:&nbsp;</strong>20 mg/m<sup>2</sup>&nbsp;IV weekly for 6 weeks, administered before 5-fluorouracil</p>\n\n<p>Repeat cycle every 8 weeks for a total of 4 or 6 cycles (32 or 48 weeks total)</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 1,
          "level": "ADJUVANT"
        }
      ]
    },
    {
      "id": 592,
      "name": "",
      "schedule": "<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV bolus, followed by 600 mg/m<sup>2</sup>&nbsp;IV continuous infusion for 22 hours on days 1 and 2</p>\n\n<p><strong>Leucovorin:&nbsp;</strong>&nbsp;200 mg/m<sup>2</sup>&nbsp;IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil</p>\n\n<p>Repeat cycle every 2 weeks for a total of 12 cycles (6 months total)</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 1,
          "level": "ADJUVANT"
        }
      ]
    },
    {
      "id": 593,
      "name": "",
      "schedule": "<p><strong>Oxaliplatin:&nbsp;</strong>100 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>5-Fluorouracil:&nbsp;</strong>3,000 mg/m<sup>2</sup>&nbsp;IV continuous infusion on days 1 and 2 for 46 hours</p>\n\n<p><strong>Leucovorin:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on day 1 as a 2-hour infusion before 5-fluorouracil</p>\n\n<p>Repeat cycle every 2 weeks for a total of 12 cycles (6 months total)</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 1,
          "level": "ADJUVANT"
        }
      ]
    },
    {
      "id": 594,
      "name": "",
      "schedule": "<p><strong>5-Fluorouracil:&nbsp;</strong>500 mg/m<sup>2</sup>&nbsp;IV weekly for 6 weeks, administered 1 hour after LV infusion begun</p>\n\n<p><strong>Leucovorin:&nbsp;</strong>500 mg/m<sup>2</sup>&nbsp;IV over 2 hours weekly for 6 weeks, administered before 5-fluorouracil</p>\n\n<p><strong>Oxaliplatin:</strong>&nbsp;85 mg/m<sup>2</sup>&nbsp;IV administered before 5-fluorouracil and LV and on days 1, 15, and 29</p>\n\n<p>Repeat cycle every 8 weeks for a total of 3 cycles (6 months total)</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 1,
          "level": "ADJUVANT"
        }
      ]
    },
    {
      "id": 719,
      "name": "",
      "schedule": "<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV on day 1, followed by 600 mg/m<sup>2</sup>&nbsp;IV infusion over 22 hours on days 1 and 2</p>\n\n<p><strong>Cisplatin:&nbsp;</strong>50 mg/m<sup>2</sup>&nbsp;IV on day 2</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 610,
      "name": "",
      "schedule": "<p><strong>Capecitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-14</p>\n\n<p><strong>Irinotecan:&nbsp;</strong>250 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat cycle every 21 days. May decrease dose of capecitabine to 850 mg/m<sup>2</sup>&nbsp;PO twice daily and dose of irinotecan to 200 mg/m<sup>2</sup>&nbsp;IV to reduce risk of toxicity without compromising clinical efficacy.</p>\n\n<p><strong>OR</strong></p>\n\n<p><strong>Capecitabine:&nbsp;</strong>1,500 mg/m<sup>2</sup>&nbsp;PO twice daily on days 2-8</p>\n\n<p><strong>Irinotecan:&nbsp;</strong>150 mg/m<sup>2</sup>&nbsp;on day 1</p>\n\n<p>Repeat cycle every 14 days.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 611,
      "name": "",
      "schedule": "<p><strong>Capecitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-14</p>\n\n<p><strong>Mitomycin-C:&nbsp;</strong>7 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat capecitabine every 3 weeks and mitomycin-C every 6 weeks.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 612,
      "name": "",
      "schedule": "<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>Irinotecan:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat cycle every 3 weeks.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 613,
      "name": "",
      "schedule": "<p><strong>5-Fluorouracil:&nbsp;</strong>500 mg/m<sup>2</sup>&nbsp;IV weekly for 6 weeks</p>\n\n<p><strong>Leucovorin:&nbsp;</strong>500 mg/m<sup>2</sup>&nbsp;IV weekly for 6 weeks, administered before 5-fluorouracil</p>\n\n<p>Repeat cycle every 8 weeks.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 614,
      "name": "",
      "schedule": "<p><strong>5-Fluorouracil:&nbsp;</strong>500 mg/m<sup>2</sup>&nbsp;IV weekly for 6 weeks</p>\n\n<p><strong>Leucovorin:&nbsp;</strong>500 mg/m<sup>2</sup>&nbsp;IV weekly for 6 weeks, administered before 5-fluorouracil</p>\n\n<p><strong>Bevacizumab:&nbsp;</strong>5 mg/kg IV every 2 weeks</p>\n\n<p>Repeat cycle every 8 weeks.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 615,
      "name": "",
      "schedule": "<p><strong>5-Fluorouracil:&nbsp;</strong>600 mg/m<sup>2</sup>&nbsp;IV weekly for 6 weeks</p>\n\n<p><strong>Leucovorin:&nbsp;</strong>20 mg/m<sup>2</sup>&nbsp;IV weekly for 6 weeks, administered before 5-fluorouracil</p>\n\n<p>Repeat cycle every 8 weeks.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 616,
      "name": "",
      "schedule": "<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV and then 600 mg/m<sup>2</sup>&nbsp;IV for 22 hours on days 1 and 2</p>\n\n<p><strong>Leucovorin:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil</p>\n\n<p>Repeat cycle every 2 weeks.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 617,
      "name": "",
      "schedule": "<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV bolus, followed by 600 mg/m<sup>2</sup>&nbsp;IV continuous infusion on days 1 and 2</p>\n\n<p><strong>Leucovorin:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil</p>\n\n<p><strong>Bevacizumab:&nbsp;</strong>10 mg/kg IV every 2 weeks</p>\n\n<p>Repeat cycle every 2 weeks.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 618,
      "name": "",
      "schedule": "<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV bolus, followed by 600 mg/m<sup>2</sup>&nbsp;IV continuous infusion on days 1 and 2</p>\n\n<p><strong>Leucovorin:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil</p>\n\n<p><strong>Mitomycin-C:&nbsp;</strong>7 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat 5-FU/LV every 2 weeks and mitomycin-C every 4 weeks</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 619,
      "name": "",
      "schedule": "<p><strong>Capecitabine:&nbsp;</strong>850 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-14</p>\n\n<p><strong>Oxaliplatin:&nbsp;</strong>130 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>Bevacizumab:&nbsp;</strong>7.5 mg/kg every 3 weeks</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 620,
      "name": "",
      "schedule": "<p><strong>Cetuximab:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV loading dose, then 250 mg/m<sup>2</sup>&nbsp;IV weekly</p>\n\n<p><strong>Bevacizumab:</strong>&nbsp;5 mg/kg IV every 2 weeks</p>\n\n<p><strong>Irinotecan:&nbsp;</strong>180 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat cycle every 2 weeks.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 621,
      "name": "",
      "schedule": "<p><strong>Cetuximab:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV loading dose, then 250 mg/m<sup>2</sup>&nbsp;IV weekly</p>\n\n<p><strong>Bevacizumab:&nbsp;</strong>5 mg/kg IV every 2 weeks</p>\n\n<p>Repeat cycle every 2 weeks</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 622,
      "name": "",
      "schedule": "<p><strong>Irinotecan:</strong>&nbsp;125 mg/m<sup>2</sup>&nbsp;IV weekly for 4 weeks</p>\n\n<p><strong>Cetuximab:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV loading dose, then 250 mg/m<sup>2</sup>&nbsp;IV weekly</p>\n\n<p>Repeat cycle every 6 weeks.</p>\n\n<p><strong>OR</strong></p>\n\n<p><strong>Irinotecan:&nbsp;</strong>350 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>Cetuximab:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV loading dose, then 250 mg/m<sup>2</sup>&nbsp;IV weekly</p>\n\n<p>Repeat cycle every 3 weeks.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 623,
      "name": "",
      "schedule": "<p><strong>Irinotecan:&nbsp;</strong>180 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV bolus followed by 2,400 mg/m<sup>2</sup>&nbsp;IV continuous infusion for 46 hours on days 1 and 2</p>\n\n<p><strong>Leucovorin:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV on day 1 as a 2-hour infusion prior to 5-fluorouracil</p>\n\n<p><strong>Cetuximab:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV loading dose, then 250 mg/m<sup>2</sup>&nbsp;IV weekly</p>\n\n<p>Repeat cycle every 2 weeks.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 624,
      "name": "",
      "schedule": "<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV bolus followed by 600 mg/m<sup>2</sup>&nbsp;IV continuous infusion for 22 hours on days 1 and 2</p>\n\n<p><strong>Leucovorin:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on days 1 and 2 as a 2-hour infusion prior to 5-fluorouracil</p>\n\n<p><strong>Cetuximab:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV loading dose, then 250 mg/m<sup>2</sup>&nbsp;IV weekly</p>\n\n<p>Repeat cycle every 2 weeks.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 625,
      "name": "",
      "schedule": "<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV bolus on day 1, followed by 2,400 mg/m<sup>2</sup>&nbsp;IV continuous infusion over 46 hours on days 1 and 2</p>\n\n<p><strong>Leucovorin:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV on day 1 as a 2-hour infusion before 5-fluorouracil</p>\n\n<p><strong>Cetuximab:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV loading dose and then 250 mg/m<sup>2</sup>&nbsp;IV weekly</p>\n\n<p>Repeat cycle every 2 weeks.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 700,
      "name": "",
      "schedule": "<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>Irinotecan:&nbsp;</strong>150 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>Leucovorin:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>5-Fluorouracil:&nbsp;</strong>2,400 mg/m<sup>2</sup>&nbsp;IV continuous infusion over 46 hours on days 1 and 2</p>\n\n<p>Repeat cycle every 2 weeks for a total of 12 cycles.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 1,
          "level": "ADJUVANT"
        }
      ]
    },
    {
      "id": 635,
      "name": "",
      "schedule": "<p><strong>5-Fluorouracil:&nbsp;</strong>200 mg/m<sup>2</sup>/day IV continuous infusion on days 1-26</p>\n\n<p><strong>Mitomycin-C:</strong>&nbsp;10 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>Radiation Therapy:&nbsp;</strong>180 cGy/day, 5 days/week for a total of 4 weeks (total dose, 3,600 cGy)</p>\n\n<p>Chemotherapy is given concurrently with radiation therapy. There is a 2-week break following the completion of this first treatment, after which the second treatment is initiated with concurrent chemotherapy and radiation therapy.</p>\n\n<p><strong>5-Fluorouracil:&nbsp;</strong>200 mg/m<sup>2</sup>/day IV continuous infusion on days 1-17</p>\n\n<p><strong>Mitomycin-C:&nbsp;</strong>10 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>Radiation Therapy:&nbsp;</strong>Total dose, 2,340 cGy over 17 days</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 636,
      "name": "",
      "schedule": "<p><strong>Capecitabine:&nbsp;</strong>825 mg/m<sup>2</sup>&nbsp;PO twice daily on Monday-Friday</p>\n\n<p><strong>Mitomycin-C:&nbsp;</strong>10 mg/m<sup>2</sup>&nbsp;IV on days 1 and 29</p>\n\n<p><strong>Radiation Therapy:&nbsp;</strong>Total dose, 5,500 cGy over 6 weeks</p>\n\n<p>Chemotherapy is given concurrently with radiation therapy.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 637,
      "name": "",
      "schedule": "<p><strong>5-Fluorouracil:&nbsp;</strong>1,000 mg/m<sup>2</sup>/day IV continuous infusion on days 1-4 of each week of radiation therapy</p>\n\n<p><strong>Cisplatin:&nbsp;</strong>75 mg/m<sup>2</sup>&nbsp;on days 1, 29, 57, and 85 during radiation therapy</p>\n\n<p><strong>Radiation Therapy:&nbsp;</strong>Total dose, 4,500 cGy over 5 weeks</p>\n\n<p>Chemotherapy is given concurrently with radiation therapy.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 638,
      "name": "",
      "schedule": "<p><strong>Capecitabine:&nbsp;</strong>825 mg/m<sup>2</sup>&nbsp;PO twice daily on Monday-Friday for 6 weeks</p>\n\n<p><strong>Oxaliplatin:&nbsp;</strong>50 mg/m<sup>2</sup>&nbsp;IV on days 1, 8, 22, 29</p>\n\n<p><strong>Radiation Therapy:&nbsp;</strong>180 cGy/day, 5 days/week for a total of 6 weeks</p>\n\n<p>Chemotherapy is given concurrently with radiation therapy.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 641,
      "name": "",
      "schedule": "<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV bolus on day 1, then 2,400 mg/m<sup>2</sup>&nbsp;IV continuous infusion over 46 hours</p>\n\n<p><strong>Leucovorin:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat cycles every 2 weeks.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 640,
      "name": "",
      "schedule": "<p><strong>Carboplatin:&nbsp;</strong>AUC of 5, IV on day 1</p>\n\n<p><strong>Paclitaxel:&nbsp;</strong>175 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat cycles every 3 weeks.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 639,
      "name": "",
      "schedule": "<p><strong>5-Fluorouracil:&nbsp;</strong>1,000 mg/m<sup>2</sup>/day IV continuous infusion on days 1-5</p>\n\n<p><strong>Cisplatin:&nbsp;</strong>100 mg/m<sup>2</sup>&nbsp;IV on day 2</p>\n\n<p>Repeat cycles every 4 weeks.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 644,
      "name": "",
      "schedule": "<p><strong>Capecitabine:&nbsp;</strong>1,250 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-14</p>\n\n<p>Repeat cycles every 21 days for a total of 8 cycles.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 1,
          "level": "ADJUVANT"
        }
      ]
    },
    {
      "id": 645,
      "name": "",
      "schedule": "<p><strong>Gemcitabine:&nbsp;</strong>1,250 mg/m<sup>2</sup>&nbsp;IV on days 1 and 8</p>\n\n<p><strong>Cisplatin:&nbsp;</strong>75 mg/m<sup>2</sup>&nbsp;on day 1</p>\n\n<p>Repeat cycle every 21 days.</p>\n\n<p><strong>OR</strong></p>\n\n<p><strong>Gemcitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;IV on days 1 and 8</p>\n\n<p><strong>Cisplatin:&nbsp;</strong>25 mg/m<sup>2</sup>&nbsp;on days 1 and 8</p>\n\n<p>Repeat cycle every 21 days for 8 cycles.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 642,
      "name": "",
      "schedule": "<p><strong>Pembrolizumab:&nbsp;</strong>10 mg/kg IV on day 1 or 200 mg IV on day 1</p>\n\n<p>Repeat cycles every 2 weeks if using 10 mg/kg, or every 3 weeks if using 200 mg dosing.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 643,
      "name": "",
      "schedule": "<p><strong>Nivolumab:&nbsp;</strong>480 mg IV on day 1</p>\n\n<p>Repeat cycles every 4 weeks.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 646,
      "name": "",
      "schedule": "<p><strong>Paclitaxel:&nbsp;</strong>50 mg/m<sup>2</sup>&nbsp;IV on days 1, 8, 15, 22 and 29</p>\n\n<p><strong>Carboplatin:&nbsp;</strong>AUC of 2, IV on days 1, 8, 15, 22 and 29</p>\n\n<p>Chemotherapy concurrently with radiation therapy of 1.8 Gy in 23 fractions for total dose of 41.4 Gy over 5 weeks.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 2,
          "level": "NEOADJUVANT"
        }
      ]
    },
    {
      "id": 647,
      "name": "",
      "schedule": "<p><strong>5-Fluorouracil:&nbsp;</strong>1,000 mg/m<sup>2</sup>/day IV continuous infusion on days 1-4</p>\n\n<p><strong>Cisplatin:&nbsp;</strong>75 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat cycle every 28 days for a total of 2 cycles given concurrently with radiation therapy. Two additional cycles are given every 21 days after completion of the combined modality therapy.</p>\n\n<p><strong>Radiation Therapy:&nbsp;</strong>200 cGy/day for 5 days per week to a total dose of 5,000 cGy over 5 weeks</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 2,
          "level": "NEOADJUVANT"
        }
      ]
    },
    {
      "id": 648,
      "name": "",
      "schedule": "<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV bolus on day 1, followed by 1,600 mg/m<sup>2</sup>&nbsp;IV continuous infusion for 46 hours</p>\n\n<p><strong>Leucovorin:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on day 1 as a 2-hour infusion before the bolus 5-fluorouracil dose</p>\n\n<p><strong>Radiation Therapy:&nbsp;</strong>200 cGy/day for 5 days per week to a total dose of 5,000 cGy over 5 weeks</p>\n\n<p>Repeat cycle every 2 weeks for a total of 6 cycles with the first 3 cycles given concurrently with radiation therapy.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 2,
          "level": "NEOADJUVANT"
        }
      ]
    },
    {
      "id": 649,
      "name": "",
      "schedule": "<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on days 1, 15, and 29</p>\n\n<p><strong>Capecitabine:&nbsp;</strong>625 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-5 for 5 weeks</p>\n\n<p><strong>Radiation Therapy:&nbsp;</strong>180 cGy/day for 5 days per week to a total dose of 5,400 cGy</p>\n\n<p>Chemotherapy is given concurrently with radiation therapy, followed by surgical resection</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 2,
          "level": "NEOADJUVANT"
        }
      ]
    },
    {
      "id": 650,
      "name": "",
      "schedule": "<p><strong>5-Fluorouracil:&nbsp;</strong>800 mg/m<sup>2</sup>/day IV continuous infusion on days 1-5</p>\n\n<p><strong>Cisplatin:&nbsp;</strong>15 mg/m<sup>2</sup>&nbsp;IV on days 1-5</p>\n\n<p><strong>Radiation Therapy:&nbsp;</strong>200 cGy/day for 5 days per week to a total dose of 6,600 cGy over 6.5 weeks</p>\n\n<p>Chemotherapy is given concurrently with radiation therapy for 2 cycles starting on days 1 and 22, followed by surgical resection.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 2,
          "level": "NEOADJUVANT"
        }
      ]
    },
    {
      "id": 709,
      "name": "",
      "schedule": "<p><strong>Gemcitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;IV over 100 minutes on day 1</p>\n\n<p><strong>Oxaliplatin:&nbsp;</strong>100 mg/m<sup>2</sup>&nbsp;over 2 hours on day 2</p>\n\n<p>Repeat cycle every 2 weeks.</p>\n\n<p><strong>OR</strong></p>\n\n<p><strong>Gemcitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;IV over 100 minutes on day 1</p>\n\n<p><strong>Oxaliplatin:&nbsp;</strong>100 mg/m<sup>2</sup>&nbsp;over 2 hours on day 1</p>\n\n<p>Repeat cycle every 2 weeks.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 651,
      "name": "",
      "schedule": "<p><strong>5-Fluorouracil:</strong>&nbsp;225 mg/m<sup>2</sup>/day IV continuous infusion on days 1-30</p>\n\n<p><strong>Cisplatin:&nbsp;</strong>20 mg/m<sup>2</sup>/day IV on days 1-5 and 26-30</p>\n\n<p><strong>Radiation Therapy:&nbsp;</strong>200 cGy/day to a total dose of 4,400 cGy</p>\n\n<p>Chemotherapy is given concurrently with radiation therapy. Followed by esophagectomy and then adjuvant chemotherapy in patients who had total gross removal of disease with negative margins.</p>\n\n<p><strong>Adjuvant Chemotherapy:</strong></p>\n\n<p><strong>Paclitaxel:&nbsp;</strong>135 mg/m<sup>2</sup>&nbsp;IV for 24 hours on day 1</p>\n\n<p><strong>Cisplatin:&nbsp;</strong>75 mg/m<sup>2</sup>&nbsp;IV on day 2</p>\n\n<p>Adjuvant chemotherapy is given 8-12 weeks after esophagectomy, and each cycle is given every 21 days for a total of 3 cycles.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 652,
      "name": "",
      "schedule": "<p><strong>Preoperative ECF Chemotherapy:</strong></p>\n\n<p><strong>Epirubicin:&nbsp;</strong>50 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>Cisplatin:&nbsp;</strong>60 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>5-Fluorouracil:&nbsp;</strong>200 mg/m<sup>2</sup>/day IV continuous infusion on days 1-21</p>\n\n<p>Repeat cycle every 21 days for 3 cycles.</p>\n\n<p>Followed by esophagectomy and then adjuvant chemotherapy in patients who had total gross removal of disease with negative margins.</p>\n\n<p><strong>Adjuvant Chemotherapy:</strong></p>\n\n<p><strong>Epirubicin:&nbsp;</strong>50 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>Cisplatin:&nbsp;</strong>60 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>5-Fluorouracil:&nbsp;</strong>200 mg/m<sup>2</sup>/day IV continuous infusion on days 1-21</p>\n\n<p>Repeat cycle every 21 days for 3 cycles.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 653,
      "name": "",
      "schedule": "<p><strong>Preoperative FLOT chemotherapy:</strong></p>\n\n<p><strong>Docetaxel:&nbsp;</strong>50 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>Leucovorin:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>5-Fluorouracil:&nbsp;</strong>2,600 mg/m<sup>2</sup>&nbsp;IV continuous infusion over 24 hours on day 1</p>\n\n<p>Repeat cycle every 2 weeks for 4 cycles. Followed by esophagectomy and then adjuvant chemotherapy in patients who had total gross removal of disease with negative margins.</p>\n\n<p><strong>Adjuvant Chemotherapy:</strong></p>\n\n<p><strong>Docetaxel:&nbsp;</strong>50 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>Leucovorin:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>5-Fluorouracil:&nbsp;</strong>2,600 mg/m<sup>2</sup>&nbsp;IV continuous infusion over 24 hours on day 1</p>\n\n<p>Repeat cycle every 2 weeks for 4 cycles. Note that only patients with resectable gastric or GE junction tumors were included in this trial.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 654,
      "name": "",
      "schedule": "<p><strong>5-Fluorouracil:&nbsp;</strong>1,000 mg/m<sup>2</sup>/day IV continuous infusion on days 1-5</p>\n\n<p><strong>Cisplatin:&nbsp;</strong>100 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat cycle on weeks 1, 5, 8, and 11.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 655,
      "name": "",
      "schedule": "<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV bolus on day 1 followed by 2,400 mg/m<sup>2</sup>&nbsp;IV continuous infusion over 46 hours</p>\n\n<p><strong>Leucovorin:</strong>&nbsp;400 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat cycle every 14 days.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 656,
      "name": "",
      "schedule": "<p><strong>Paclitaxel:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV over 24 hours on day 1</p>\n\n<p><strong>Cisplatin:&nbsp;</strong>75 mg/m<sup>2</sup>&nbsp;IV on day 2</p>\n\n<p>Repeat cycle every 21 days. G-CSF support is recommended.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 657,
      "name": "",
      "schedule": "<p><strong>Capecitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-14</p>\n\n<p><strong>Oxaliplatin:&nbsp;</strong>130 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 658,
      "name": "",
      "schedule": "<p><strong>Epirubicin:&nbsp;</strong>50 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>Cisplatin:&nbsp;</strong>60 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>5-Fluorouracil:&nbsp;</strong>200 mg/m<sup>2</sup>/day IV continuous infusion</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 659,
      "name": "",
      "schedule": "<p><strong>Epirubicin:&nbsp;</strong>50 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>Oxaliplatin:&nbsp;</strong>130 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>5-Fluorouracil:&nbsp;</strong>200 mg/m<sup>2</sup>/day IV continuous infusion</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 660,
      "name": "",
      "schedule": "<p><strong>Epirubicin:&nbsp;</strong>50 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>Cisplatin:&nbsp;</strong>60 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>Capecitabine:&nbsp;</strong>625 mg/m<sup>2</sup>&nbsp;PO twice daily continuously</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 661,
      "name": "",
      "schedule": "<p><strong>Epirubicin:&nbsp;</strong>50 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>Oxaliplatin:&nbsp;</strong>130 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>Capecitabine:&nbsp;</strong>625 mg/m<sup>2</sup>&nbsp;PO twice daily continuously</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 662,
      "name": "",
      "schedule": "<p><strong>Paclitaxel:&nbsp;</strong>250 mg/m<sup>2</sup>&nbsp;IV over 24 hours on day 1</p>\n\n<p>Repeat cycle every 21 days. G-CSF support is recommended.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 663,
      "name": "",
      "schedule": "<p><strong>Docetaxel:&nbsp;</strong>100 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 666,
      "name": "",
      "schedule": "<p><strong>Preoperative FLOT chemotherapy:</strong></p>\n\n<p><strong>Docetaxel:&nbsp;</strong>50 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>Leucovorin:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>5-Fluorouracil:&nbsp;</strong>2,600 mg/m<sup>2</sup>&nbsp;IV continuous infusion over 24 hours on day 1</p>\n\n<p>Repeat cycle every 2 weeks for 4 cycles. Followed by gastrectomy and then adjuvant chemotherapy in patients who had total gross removal of disease with negative margins.</p>\n\n<p><strong>Adjuvant Chemotherapy:</strong></p>\n\n<p><strong>Docetaxel:&nbsp;</strong>50 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>Leucovorin:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>5-Fluorouracil:&nbsp;</strong>2,600 mg/m<sup>2</sup>&nbsp;IV continuous infusion over 24 hours on day 1</p>\n\n<p>Repeat cycle every 2 weeks for 4 cycles. Note that only patients with resectable gastric and GE junction tumors were included in this trial.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 710,
      "name": "",
      "schedule": "<p><strong>Gemcitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;IV weekly for 7 weeks, then 1-week rest; subsequent cycles 1,000 mg/m<sup>2</sup>&nbsp;IV weekly for 3 weeks with 1-week rest</p>\n\n<p><strong>Erlotinib:&nbsp;</strong>100 mg PO daily</p>\n\n<p>Repeat 3-week cycles every 28 days.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 667,
      "name": "",
      "schedule": "<p>One cycle of chemotherapy is administered as follows:</p>\n\n<p><strong>5-Fluorouracil:&nbsp;</strong>&nbsp;425 mg/m<sup>2</sup>&nbsp;IV on days 1-5</p>\n\n<p><strong>Leucovorin:&nbsp;</strong>20 mg/m<sup>2</sup>&nbsp;IV on days 1-5</p>\n\n<p>Chemoradiotherapy is then started 28 days after the start of the initial cycle of chemotherapy as follows:</p>\n\n<p><strong>Radiation Therapy:&nbsp;</strong>180 cGy/day to a total dose of 4,500 cGy, starting on day 28</p>\n\n<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV on days 1-4 and days 23-25 of radiation therapy</p>\n\n<p><strong>Leucovorin:&nbsp;</strong>20 mg/m<sup>2</sup>&nbsp;IV on days 1-4 and days 23-25 of radiation therapy</p>\n\n<p>Chemoradiotherapy is followed by 2 cycles of chemotherapy that are given 1 month apart and include:</p>\n\n<p><strong>5-Fluorouracil:&nbsp;</strong>425 mg/m<sup>2</sup>&nbsp;IV on days 1-5</p>\n\n<p><strong>Leucovorin:&nbsp;</strong>20 mg/m<sup>2</sup> IV on days 1-5</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 1,
          "level": "ADJUVANT"
        }
      ]
    },
    {
      "id": 668,
      "name": "",
      "schedule": "<p><strong>Capecitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-14</p>\n\n<p><strong>Oxaliplatin:&nbsp;</strong>130 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat cycle every 21 days for 6 months.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 1,
          "level": "ADJUVANT"
        }
      ]
    },
    {
      "id": 669,
      "name": "",
      "schedule": "<p><strong>Docetaxel:&nbsp;</strong>75 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>Cisplatin:&nbsp;</strong>75 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>5-Fluorouracil:&nbsp;</strong>750 mg/m<sup>2</sup>/day IV continuous infusion on days 1-5</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 706,
      "name": "",
      "schedule": "<p><strong>5-Fluorouracil:&nbsp;</strong>425 mg/m<sup>2</sup>&nbsp;IV on days 1-5</p>\n\n<p><strong>Leucovorin:&nbsp;</strong>20 mg/m<sup>2</sup>&nbsp;IV on days 1-5</p>\n\n<p>Repeat cycle every 28 days.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 670,
      "name": "",
      "schedule": "<h4 style=\"margin-left:0px; margin-right:0px; text-align:left\">Chemotherapy</h4>\n\n<ul style=\"list-style-type:disc; margin-left:1.6em; margin-right:0px\">\n\t<li><a href=\"https://hemonc.org/wiki/Temozolomide_(Temodar)\" style=\"background-attachment: scroll; background-clip: border-box; background-color: transparent; background-image: none; background-origin: padding-box; background-position-x: 0px; background-position-y: 0px; background-repeat: repeat; background-size: auto; color: rgb(6, 69, 173); text-decoration: none;\" title=\"Temozolomide (Temodar)\">Temozolomide (Temodar)</a> 75 mg/m<sup>2</sup> PO or IV once per day, used starting the first day of radiation therapy until the last day of radiation therapy, and no longer than 49 days</li>\n</ul>\n\n<h4 style=\"margin-left:0px; margin-right:0px; text-align:left\">Supportive medications</h4>\n\n<ul style=\"list-style-type:disc; margin-left:1.6em; margin-right:0px\">\n\t<li>PCP prophylaxis with ONE of the following:\n\t<ul style=\"list-style-type:disc; margin-left:1.6em; margin-right:0px\">\n\t\t<li><a href=\"https://hemonc.org/wiki/Trimethoprim-Sulfamethoxazole_(Bactrim_DS)\" style=\"background-attachment: scroll; background-clip: border-box; background-color: transparent; background-image: none; background-origin: padding-box; background-position-x: 0px; background-position-y: 0px; background-repeat: repeat; background-size: auto; color: rgb(6, 69, 173); text-decoration: none;\" title=\"Trimethoprim-Sulfamethoxazole (Bactrim DS)\">Trimethoprim/Sulfamethoxazole (Bactrim)</a></li>\n\t\t<li><a href=\"https://hemonc.org/wiki/Pentamidine_(Nebupent)\" style=\"background-attachment: scroll; background-clip: border-box; background-color: transparent; background-image: none; background-origin: padding-box; background-position-x: 0px; background-position-y: 0px; background-repeat: repeat; background-size: auto; color: rgb(6, 69, 173); text-decoration: none;\" title=\"Pentamidine (Nebupent)\">Pentamidine (Nebupent)</a> 300 mg nebulized inhaled</li>\n\t</ul>\n\t</li>\n\t<li><a href=\"https://hemonc.org/wiki/Metoclopramide_(Reglan)\" style=\"background-attachment: scroll; background-clip: border-box; background-color: transparent; background-image: none; background-origin: padding-box; background-position-x: 0px; background-position-y: 0px; background-repeat: repeat; background-size: auto; color: rgb(6, 69, 173); text-decoration: none;\" title=\"Metoclopramide (Reglan)\">Metoclopramide (Reglan)</a> or <a href=\"https://hemonc.org/wiki/Category:Serotonin_5-HT3_antagonists\" style=\"background-attachment: scroll; background-clip: border-box; background-color: transparent; background-image: none; background-origin: padding-box; background-position-x: 0px; background-position-y: 0px; background-repeat: repeat; background-size: auto; color: rgb(6, 69, 173); text-decoration: none;\" title=\"Category:Serotonin 5-HT3 antagonists\">5-HT3 antagonist</a> recommended before the initial doses of radiation therapy &amp; temozolomide</li>\n</ul>\n\n<h4 style=\"margin-left:0px; margin-right:0px; text-align:left\">Radiotherapy</h4>\n\n<ul style=\"list-style-type:disc; margin-left:1.6em; margin-right:0px\">\n\t<li>Concurrent <a href=\"https://hemonc.org/wiki/External_beam_radiotherapy\" style=\"background-attachment: scroll; background-clip: border-box; background-color: transparent; background-image: none; background-origin: padding-box; background-position-x: 0px; background-position-y: 0px; background-repeat: repeat; background-size: auto; color: rgb(6, 69, 173); text-decoration: none;\" title=\"External beam radiotherapy\">radiation therapy</a>, 2 Gy fractions x 30 fractions, for a total dose of 60 Gy</li>\n</ul>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 1,
          "level": "ADJUVANT"
        }
      ]
    },
    {
      "id": 701,
      "name": "",
      "schedule": "<p><strong>5-Fluorouracil:&nbsp;</strong>425 mg/m<sup>2</sup>&nbsp;IV on days 1-5</p>\n\n<p><strong>Leucovorin:&nbsp;</strong>20 mg/m<sup>2</sup>&nbsp;IV on days 1-5</p>\n\n<p>Repeat cycle every 28 days for a total of 6 cycles.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 1,
          "level": "ADJUVANT"
        }
      ]
    },
    {
      "id": 702,
      "name": "",
      "schedule": "<p><strong>Gemcitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;IV on days 1, 8, and 15</p>\n\n<p>Repeat cycle every 28 days for a total of 6 cycles.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 1,
          "level": "ADJUVANT"
        }
      ]
    },
    {
      "id": 704,
      "name": "",
      "schedule": "<p><strong>Gemcitabine:&nbsp;</strong>600 mg/m<sup>2</sup>&nbsp;IV weekly for 6 weeks</p>\n\n<p><strong>Radiation Therapy:&nbsp;</strong>180 cGy/day to a total dose of 5,040 cGy. Chemotherapy and radiation therapy started on the same day and given concurrently.</p>\n\n<p><strong>Four weeks after the completion of chemoradiation:</strong></p>\n\n<p><strong>Gemcitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;IV on days 1, 8, and 15</p>\n\n<p>Repeat cycle every 4 weeks for a total of 5 cycles. For patients&nbsp;with locally advanced unresectable pancreatic adenocarcinoma.&nbsp;</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 6,
          "level": "LOCALLY ADVANCED"
        }
      ]
    },
    {
      "id": 703,
      "name": "",
      "schedule": "<p><strong>Gemcitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;IV on days 1, 8, and 15</p>\n\n<p><strong>Followed by concurrent chemoradiation:</strong></p>\n\n<p><strong>5-Fluorouracil:&nbsp;</strong>250 mg/m<sup>2</sup>/day IV continuous infusion during radiation therapy</p>\n\n<p><strong>Radiation Therapy:&nbsp;</strong>180 cGy/day to a total dose of 5,040 cGy</p>\n\n<p>Chemotherapy and radiation therapy started on the same day and given concurrently.</p>\n\n<p><strong>After chemoradiation:</strong></p>\n\n<p><strong>Gemcitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;IV on days 1, 8, and 15</p>\n\n<p>Repeat cycle every 4 weeks for a total of 3 cycles. Adjuvant chemotherapy is given to patients with complete gross total resection of pancreatic adenocarcinoma.</p>\n\n<p>&nbsp;</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 6,
          "level": "LOCALLY ADVANCED"
        }
      ]
    },
    {
      "id": 705,
      "name": "",
      "schedule": "<p><strong>Gemcitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;IV on days 1, 8, and 15</p>\n\n<p><strong>Capecitabine:&nbsp;</strong>830 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-21</p>\n\n<p>Repeat cycle every 28 days for 3 cycles. Patients with stable or responding disease receive one additional cycle, followed by concurrent chemoradiation.</p>\n\n<p><strong>Capecitabine:&nbsp;</strong>830 mg/m<sup>2</sup>&nbsp;PO twice daily Monday-Friday for 6 weeks</p>\n\n<p><strong>Radiation Therapy:&nbsp;</strong>180 cGy/day to a total dose of 5,040 cGy</p>\n\n<p>Chemotherapy and radiation therapy started on the same day and given concurrently.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 6,
          "level": "LOCALLY ADVANCED"
        }
      ]
    },
    {
      "id": 707,
      "name": "",
      "schedule": "<p><strong>Gemcitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;IV on days 1 and 8</p>\n\n<p><strong>Capecitabine:&nbsp;</strong>650 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-14</p>\n\n<p>Repeat cycle every 21 days.</p>\n\n<p><strong>OR</strong></p>\n\n<p><strong>Gemcitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;IV on days 1, 8, and 15</p>\n\n<p><strong>Capecitabine:&nbsp;</strong>830 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-21</p>\n\n<p>Repeat cycle every 28 days.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 711,
      "name": "",
      "schedule": "<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>Irinotecan:&nbsp;</strong>180 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>Leucovorin:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>5-Fluorouracil:&nbsp;</strong>2,400 mg/m<sup>2</sup>&nbsp;IV continuous infusion over 46 hours on days 1 and 2</p>\n\n<p>Repeat cycle every 2 weeks.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 712,
      "name": "",
      "schedule": "<p><strong>Nab-Paclitaxel:&nbsp;</strong>125 mg/m<sup>2</sup>&nbsp;IV on days 1, 8, and 15</p>\n\n<p><strong>Gemcitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;IV on days 1, 8, and 15</p>\n\n<p>Repeat cycle every 28 days.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 713,
      "name": "",
      "schedule": "<p><strong>Liposomal Irinotecan:&nbsp;</strong>70 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>5-Fluorouracil:&nbsp;</strong>2,400 mg/m<sup>2</sup>&nbsp;IV continuous infusion over 46 hours on days 1 and 2</p>\n\n<p><strong>Leucovorin:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat cycle every 2 weeks.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 671,
      "name": "",
      "schedule": "<h4 style=\"margin-left:0px; margin-right:0px; text-align:left\">Chemotherapy</h4>\n\n<ul style=\"list-style-type:disc; margin-left:1.6em; margin-right:0px\">\n\t<li><a href=\"https://hemonc.org/wiki/Cytarabine_(Ara-C)\" style=\"background-attachment: scroll; background-clip: border-box; background-color: transparent; background-image: none; background-origin: padding-box; background-position-x: 0px; background-position-y: 0px; background-repeat: repeat; background-size: auto; color: rgb(6, 69, 173); text-decoration: none;\" title=\"Cytarabine (Ara-C)\">Cytarabine (Ara-C)</a> 200 mg/m<sup>2</sup>/day IV continuous infusion on days 1 to 7 (total dose: 1400 mg/m<sup>2</sup>)</li>\n\t<li><a href=\"https://hemonc.org/wiki/Daunorubicin_(Cerubidine)\" style=\"background-attachment: scroll; background-clip: border-box; background-color: transparent; background-image: none; background-origin: padding-box; background-position-x: 0px; background-position-y: 0px; background-repeat: repeat; background-size: auto; color: rgb(6, 69, 173); text-decoration: none;\" title=\"Daunorubicin (Cerubidine)\">Daunorubicin (Cerubidine)</a> 60 mg/m<sup>2</sup> IV once per day on days 1 to 3</li>\n\t<li><a href=\"https://hemonc.org/wiki/Midostaurin_(Rydapt)\" style=\"background-attachment: scroll; background-clip: border-box; background-color: transparent; background-image: none; background-origin: padding-box; background-position-x: 0px; background-position-y: 0px; background-repeat: repeat; background-size: auto; color: rgb(6, 69, 173); text-decoration: none;\" title=\"Midostaurin (Rydapt)\">Midostaurin (Rydapt)</a> 50 mg PO twice per day on days 8 to 21</li>\n</ul>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 679,
      "name": "",
      "schedule": "<p><strong>Docetaxel:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>Cisplatin:&nbsp;</strong>75 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 672,
      "name": "",
      "schedule": "<h4 style=\"margin-left:0px; margin-right:0px; text-align:left\">Chemotherapy</h4>\n\n<ul style=\"list-style-type:disc; margin-left:1.6em; margin-right:0px\">\n\t<li><a href=\"https://hemonc.org/wiki/Ivosidenib_(Tibsovo)\" style=\"background-attachment: scroll; background-clip: border-box; background-color: transparent; background-image: none; background-origin: padding-box; background-position-x: 0px; background-position-y: 0px; background-repeat: repeat; background-size: auto; color: rgb(6, 69, 173); text-decoration: none;\" title=\"Ivosidenib (Tibsovo)\">Ivosidenib (Tibsovo)</a> 500 mg PO once per day</li>\n</ul>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 673,
      "name": "",
      "schedule": "<h4 style=\"margin-left:0px; margin-right:0px; text-align:left\">Chemotherapy</h4>\n\n<ul style=\"list-style-type:disc; margin-left:1.6em; margin-right:0px\">\n\t<li><a href=\"https://hemonc.org/wiki/Enasidenib_(Idhifa)\" style=\"background-attachment: scroll; background-clip: border-box; background-color: transparent; background-image: none; background-origin: padding-box; background-position-x: 0px; background-position-y: 0px; background-repeat: repeat; background-size: auto; color: rgb(6, 69, 173); text-decoration: none;\" title=\"Enasidenib (Idhifa)\">Enasidenib (Idhifa)</a> 100 mg PO once per day</li>\n</ul>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 674,
      "name": "",
      "schedule": "<p><strong>Cisplatin:&nbsp;</strong>100 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>5-Fluorouracil:&nbsp;</strong>1,000 mg/m<sup>2</sup>/day IV continuous infusion on days 1-5</p>\n\n<p>Repeat cycle every 28 days.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 675,
      "name": "",
      "schedule": "<p><strong>Epirubicin:&nbsp;</strong>50 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>Cisplatin:&nbsp;</strong>60 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>5-Fluorouracil:&nbsp;</strong>200 mg/m<sup>2</sup>/day IV continuous infusion</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 676,
      "name": "",
      "schedule": "<p><strong>Epirubicin:&nbsp;</strong>50 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>Oxaliplatin:&nbsp;</strong>130 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>5-Fluorouracil:&nbsp;</strong>200 mg/m<sup>2</sup>/day IV continuous infusion</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 677,
      "name": "",
      "schedule": "<p><strong>Epirubicin:&nbsp;</strong>50 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>Cisplatin:&nbsp;</strong>60 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>Capecitabine:&nbsp;</strong>625 mg/m<sup>2</sup>&nbsp;PO twice daily continuously</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 678,
      "name": "",
      "schedule": "<p><strong>Epirubicin:&nbsp;</strong>50 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>Oxaliplatin:&nbsp;</strong>130 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>Capecitabine:&nbsp;</strong>625 mg/m<sup>2</sup>&nbsp;PO twice daily continuously</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 680,
      "name": "",
      "schedule": "<p><strong>Capecitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-14</p>\n\n<p><strong>Cisplatin:&nbsp;</strong>80 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 681,
      "name": "",
      "schedule": "<p><strong>Capecitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-14</p>\n\n<p><strong>Cisplatin:&nbsp;</strong>80 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>Trastuzumab:&nbsp;</strong>8 mg/kg IV loading dose, then 6 mg/kg IV every 3 weeks</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 682,
      "name": "",
      "schedule": "<p><strong>5-Fluorouracil:&nbsp;</strong>800 mg/m<sup>2</sup>&nbsp;IV continuous infusion on days 1-5</p>\n\n<p><strong>Cisplatin:&nbsp;</strong>80 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>Trastuzumab:&nbsp;</strong>8 mg/kg IV loading dose, then 6 mg/kg IV every 3 weeks.</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 683,
      "name": "",
      "schedule": "<p><strong>5-Fluorouracil:&nbsp;</strong>2,600 mg/m<sup>2</sup>&nbsp;IV on day 1 as a continuous infusion over 24 hours</p>\n\n<p><strong>Leucovorin:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on day 1 as a 2-hour infusion</p>\n\n<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat cycle every 14 days.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 684,
      "name": "",
      "schedule": "<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV bolus on day 1 followed by 2,400 mg/m<sup>2</sup>&nbsp;IV continuous infusion over 46 hours on days 1-3</p>\n\n<p><strong>Leucovorin:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat cycle every 2 weeks.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 685,
      "name": "",
      "schedule": "<p><strong>Paclitaxel:&nbsp;</strong>80 mg/m<sup>2</sup>&nbsp;IV on days 1, 8, and 15</p>\n\n<p><strong>Ramucirumab:&nbsp;</strong>8 mg/kg IV on days 1 and 15</p>\n\n<p>Repeat cycle every 28 days.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 686,
      "name": "",
      "schedule": "<p><strong>5-Fluorouracil:&nbsp;</strong>500 mg/m<sup>2</sup>&nbsp;IV on days 1-5</p>\n\n<p>Repeat cycle every 28 days.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 687,
      "name": "",
      "schedule": "<p><strong>5-Fluorouracil:&nbsp;</strong>370 mg/m<sup>2</sup>&nbsp;IV on days 1-5</p>\n\n<p><strong>Leucovorin:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on days 1-5</p>\n\n<p>Repeat cycle every 21 days.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 688,
      "name": "",
      "schedule": "<p><strong>Docetaxel:&nbsp;</strong>100 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p>Repeat cycle every 21 days.</p>\n\n<p><strong>OR</strong></p>\n\n<p><strong>Docetaxel:&nbsp;</strong>36 mg/m<sup>2</sup>&nbsp;IV weekly for 6 weeks.</p>\n\n<p>Repeat cycle every 8 weeks.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    },
    {
      "id": 726,
      "name": "",
      "schedule": "<p><strong>Floxuridine (FUDR):&nbsp;</strong>0.3 mg/kg/day HAI on days 1-14</p>\n\n<p><strong>Dexamethasone:&nbsp;</strong>20 mg HAI on days 1-14</p>\n\n<p><strong>Heparin:&nbsp;</strong>50,000 U HAI on days 1-14</p>\n\n<p>Repeat cycle every 14 days.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 7,
          "level": "HEPATIC ARTERY INFUSION"
        }
      ]
    },
    {
      "id": 727,
      "name": "",
      "schedule": "<p><strong>Oxaliplatin:&nbsp;</strong>85 mg/m<sup>2</sup>&nbsp;IV on day 1</p>\n\n<p><strong>5-Fluorouracil:&nbsp;</strong>400 mg/m<sup>2</sup>&nbsp;IV bolus, followed by 600 mg/m<sup>2</sup>&nbsp;IV continuous infusion for 22 hours on days 1 and 2</p>\n\n<p><strong>Leucovorin:&nbsp;</strong>200 mg/m<sup>2</sup>&nbsp;IV on days 1 and 2 as a 2-hour infusion before 5-fluorouracil</p>\n\n<p>Repeat cycle every 2 weeks.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 728,
      "name": "",
      "schedule": "<p><strong>Sorafenib:&nbsp;</strong>400 mg PO twice daily</p>\n\n<p>Continue until disease progression. Dose may be reduced to 400 mg once daily or 400 mg every 2 days.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 729,
      "name": "",
      "schedule": "<p><strong>Lenvatinib:&nbsp;</strong>12 mg PO daily if body weight &gt; 60 kg, or 8 mg PO daily if body weight &lt; 60 kg</p>\n\n<p>Continue until disease progression. Dose may be reduced to 4 mg daily or 4 mg every other day depending on toxicity.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 730,
      "name": "",
      "schedule": "<p><strong>Cabozantinib:</strong>&nbsp;60 mg PO daily</p>\n\n<p>Continue until disease progression. Dose may be reduced to 40 mg daily and 20 mg daily depending on toxicity.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 731,
      "name": "",
      "schedule": "<p><strong>Regorafenib:&nbsp;</strong>160 mg PO daily for 21 days.</p>\n\n<p>Repeat cycle every 28 days.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 732,
      "name": "",
      "schedule": "<p><strong>Nivolumab:&nbsp;</strong>240 mg IV on day 1</p>\n\n<p>Repeat cycle every 2 weeks. May also give 480 mg IV on day 1 every 4 weeks.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": []
    },
    {
      "id": 741,
      "name": "",
      "schedule": "<p><strong>Regorafenib:&nbsp;</strong>160 mg PO daily on days 1-21</p>\n\n<p>Repeat cycle every 28 days.</p>\n\n<p><strong>OR</strong></p>\n\n<p><strong>Regorafenib:&nbsp;</strong>80 mg PO daily on days 1-7. Increase by 40 mg PO daily every week until target dosing of 160 mg is reached depending on tolerability.</p>\n\n<p>Repeat cycle every 28 days.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 7,
          "level": "HEPATIC ARTERY INFUSION"
        }
      ]
    },
    {
      "id": 742,
      "name": "",
      "schedule": "<p><strong>TAS-102:&nbsp;</strong>35 mg/m<sup>2</sup>&nbsp;PO twice daily on days 1-5 and 8-12</p>\n\n<p>Repeat cycle every 28 days.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 7,
          "level": "HEPATIC ARTERY INFUSION"
        }
      ]
    },
    {
      "id": 743,
      "name": "",
      "schedule": "<p><strong>Pembrolizumab:&nbsp;</strong>200 mg IV on day 1</p>\n\n<p>Repeat cycle every 3 weeks.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 7,
          "level": "HEPATIC ARTERY INFUSION"
        }
      ]
    },
    {
      "id": 744,
      "name": "",
      "schedule": "<p><strong>Nivolumab:&nbsp;</strong>3 mg/kg IV on day 1</p>\n\n<p>Repeat cycle every 2 weeks. May also administer using a fixed dose of 240 mg IV on day 1 every 2 weeks or 480 mg IV on day 1 every 4 weeks.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 7,
          "level": "HEPATIC ARTERY INFUSION"
        }
      ]
    },
    {
      "id": 745,
      "name": "",
      "schedule": "<p><strong>5-Fluorouracil:&nbsp;</strong>1,000 mg/m<sup>2</sup>/day IV continuous infusion on days 1-5</p>\n\n<p>Repeat infusional 5-FU on weeks 1 and 5.</p>\n\n<p><strong>Radiation Therapy:&nbsp;</strong>180 cGy/day for 5 days per week (total dose, 5,040 cGy)</p>\n\n<p>Followed by surgical resection and then adjuvant chemotherapy with 5-FU at 500 mg/m<sup>2</sup> IV for 5 days every 28 days for a total of 4 cycles.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 2,
          "level": "NEOADJUVANT"
        }
      ]
    },
    {
      "id": 715,
      "name": "",
      "schedule": "<p><strong>Gemcitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;IV weekly for 7 weeks, then 1-week rest; subsequent cycles 1,000 mg/m<sup>2</sup>&nbsp;IV weekly for 3 weeks with 1-week rest</p>\n\n<p>Repeat 3-week cycle every 28 days.</p>\n\n<p><strong>OR</strong></p>\n\n<p><strong>Gemcitabine:&nbsp;</strong>1,000 mg/m<sup>2</sup>&nbsp;IV over 100 min at 10 mg/m<sup>2</sup>/min on days 1, 8, and 15</p>\n\n<p>Repeat cycle every 28 days.</p>\n",
      "emetogenicPotential": "",
      "dosageModifications": "",
      "references": [],
      "drugs": [],
      "regimenLevels": [
        {
          "id": 3,
          "level": "METASTATIC"
        }
      ]
    }
  ],
  "drugs": [
    {
      "id": 78,
      "genericName": "Necitumumab",
      "drugBrandList": [
        {
          "id": 63,
          "brandName": "Portrazza",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 3,
      "genericName": "Ribociclib",
      "drugBrandList": [
        {
          "id": 3,
          "brandName": "Kisqali",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 81,
      "genericName": "Megestrol",
      "drugBrandList": [
        {
          "id": 66,
          "brandName": "Megace",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 28,
      "genericName": "Methylprednisolone",
      "drugBrandList": [
        {
          "id": 20,
          "brandName": "Depo-Medrol, Solu-Medrol, various",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 41,
      "genericName": "Thioguanine",
      "drugBrandList": [
        {
          "id": 31,
          "brandName": "6-TG",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 4,
      "genericName": "Enfortumab vedotin (Padcev) ",
      "drugBrandList": []
    },
    {
      "id": 5,
      "genericName": "Synribo",
      "drugBrandList": []
    },
    {
      "id": 83,
      "genericName": "Beleodaq",
      "drugBrandList": []
    },
    {
      "id": 84,
      "genericName": "Iclusig",
      "drugBrandList": []
    },
    {
      "id": 156,
      "genericName": "Dacarbazine",
      "drugBrandList": [
        {
          "id": 113,
          "brandName": "DTIC",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 66,
      "genericName": "Sunitinib",
      "drugBrandList": [
        {
          "id": 54,
          "brandName": "Sutent",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 85,
      "genericName": "Pembrolizumab",
      "drugBrandList": [
        {
          "id": 68,
          "brandName": "Keytruda nab-Paclitaxal",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 7,
      "genericName": "Docetaxel (Taxotere)",
      "drugBrandList": []
    },
    {
      "id": 2,
      "genericName": "Lomustine",
      "drugBrandList": [
        {
          "id": 2,
          "brandName": "CCNU",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 10,
      "genericName": "Altretamine",
      "drugBrandList": [
        {
          "id": 7,
          "brandName": "Hexalen",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 11,
      "genericName": "Zykadia",
      "drugBrandList": []
    },
    {
      "id": 86,
      "genericName": "Methotrexate",
      "drugBrandList": [
        {
          "id": 69,
          "brandName": "MTX",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 133,
      "genericName": "Sipuleucel-T",
      "drugBrandList": [
        {
          "id": 101,
          "brandName": "Provenge",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 154,
      "genericName": "Thalidomide",
      "drugBrandList": [
        {
          "id": 111,
          "brandName": "Thalomid",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 65,
      "genericName": "Vinblastine",
      "drugBrandList": [
        {
          "id": 53,
          "brandName": "Velban",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 82,
      "genericName": "Obinutuzumab",
      "drugBrandList": [
        {
          "id": 67,
          "brandName": "Gazyva",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 13,
      "genericName": "Lenalidomide",
      "drugBrandList": [
        {
          "id": 9,
          "brandName": "Revlimid",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 87,
      "genericName": "Nivolumab (Opdivo)",
      "drugBrandList": []
    },
    {
      "id": 89,
      "genericName": "Alecensa",
      "drugBrandList": []
    },
    {
      "id": 71,
      "genericName": "Prednisone",
      "drugBrandList": [
        {
          "id": 58,
          "brandName": "various",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 90,
      "genericName": "Zelboraf",
      "drugBrandList": []
    },
    {
      "id": 37,
      "genericName": "Trametinib",
      "drugBrandList": [
        {
          "id": 28,
          "brandName": "Mekinist",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 61,
      "genericName": "Pentostatin",
      "drugBrandList": [
        {
          "id": 50,
          "brandName": "Nipent",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 93,
      "genericName": "Ipilumimab",
      "drugBrandList": [
        {
          "id": 75,
          "brandName": "Yeroy",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 50,
      "genericName": "Nivolumab",
      "drugBrandList": [
        {
          "id": 39,
          "brandName": "Opdivo",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 95,
      "genericName": "Pembrolizumab (Keytruda)",
      "drugBrandList": []
    },
    {
      "id": 97,
      "genericName": "Toremifene",
      "drugBrandList": [
        {
          "id": 78,
          "brandName": "Fareston",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 99,
      "genericName": "Darzalex",
      "drugBrandList": []
    },
    {
      "id": 100,
      "genericName": "Atezolizumab (Tecentriq)",
      "drugBrandList": []
    },
    {
      "id": 101,
      "genericName": "Alpelisib",
      "drugBrandList": [
        {
          "id": 80,
          "brandName": "Piqray",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 91,
      "genericName": "Ramicurimab",
      "drugBrandList": [
        {
          "id": 73,
          "brandName": "Cyramza",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 102,
      "genericName": "Iressa",
      "drugBrandList": []
    },
    {
      "id": 40,
      "genericName": "Capecitabine",
      "drugBrandList": [
        {
          "id": 30,
          "brandName": "Xeloda",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 104,
      "genericName": "Durvalumab (Imfinzi)",
      "drugBrandList": []
    },
    {
      "id": 18,
      "genericName": "Ofatumumab",
      "drugBrandList": [
        {
          "id": 13,
          "brandName": "Arzerra",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 120,
      "genericName": "Cabazitaxel",
      "drugBrandList": [
        {
          "id": 89,
          "brandName": "Jevtana",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 63,
      "genericName": "Oxaliplatin",
      "drugBrandList": [
        {
          "id": 52,
          "brandName": "Eloxatin, Oxaliplatin, various",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 19,
      "genericName": "Paclitaxel",
      "drugBrandList": [
        {
          "id": 14,
          "brandName": "Taxol",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 20,
      "genericName": "Opdivo",
      "drugBrandList": []
    },
    {
      "id": 21,
      "genericName": "Zoledronic acid",
      "drugBrandList": [
        {
          "id": 15,
          "brandName": "Zometa, various",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 74,
      "genericName": "Ixabepilone",
      "drugBrandList": [
        {
          "id": 60,
          "brandName": "Ixempra",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 107,
      "genericName": "Adcetris",
      "drugBrandList": []
    },
    {
      "id": 23,
      "genericName": "Idelalisib",
      "drugBrandList": [
        {
          "id": 16,
          "brandName": "Zydelig",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 34,
      "genericName": "Prednisolone",
      "drugBrandList": [
        {
          "id": 25,
          "brandName": "Flo-pred, various",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 22,
      "genericName": "paclitaxel",
      "drugBrandList": []
    },
    {
      "id": 108,
      "genericName": "Cotellic",
      "drugBrandList": []
    },
    {
      "id": 59,
      "genericName": "Dexamethasone",
      "drugBrandList": [
        {
          "id": 48,
          "brandName": "Decadron, various",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 25,
      "genericName": "Tagrisso",
      "drugBrandList": []
    },
    {
      "id": 26,
      "genericName": "Anastrozole",
      "drugBrandList": [
        {
          "id": 18,
          "brandName": "Arimidex",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 109,
      "genericName": "Erivedge",
      "drugBrandList": []
    },
    {
      "id": 27,
      "genericName": "Dabrafenib",
      "drugBrandList": [
        {
          "id": 19,
          "brandName": "Tafilnar",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 16,
      "genericName": "Gemcitabine (Gemzar), Cisplatin (Platinum)",
      "drugBrandList": []
    },
    {
      "id": 29,
      "genericName": "Pablociclib",
      "drugBrandList": [
        {
          "id": 21,
          "brandName": "Ibrance",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 119,
      "genericName": "Alemtuzumab",
      "drugBrandList": [
        {
          "id": 88,
          "brandName": "Campath",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 125,
      "genericName": "Estramustine",
      "drugBrandList": [
        {
          "id": 93,
          "brandName": "Estracyte",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 30,
      "genericName": "Tamoxifen",
      "drugBrandList": [
        {
          "id": 22,
          "brandName": "Nolvadex",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 31,
      "genericName": "Cisplatin",
      "drugBrandList": [
        {
          "id": 23,
          "brandName": "CDDP",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 112,
      "genericName": "Nab-paclitaxel",
      "drugBrandList": []
    },
    {
      "id": 143,
      "genericName": "Flutamide",
      "drugBrandList": []
    },
    {
      "id": 113,
      "genericName": "Keytruda",
      "drugBrandList": []
    },
    {
      "id": 35,
      "genericName": "Doxorubicin liposome",
      "drugBrandList": [
        {
          "id": 26,
          "brandName": "Doxil, various",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 98,
      "genericName": "Vorinostat",
      "drugBrandList": [
        {
          "id": 79,
          "brandName": "Zolinza",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 38,
      "genericName": "Methotrexate (Otrexup; Rasuvo; Rheumatrex [DSC]; Trexall; Xatmep). Vinblastine (Vinblastine), Doxorubicin (Adriamycin), (Cisplatin (Platinum)",
      "drugBrandList": []
    },
    {
      "id": 114,
      "genericName": "Ixabepilome",
      "drugBrandList": []
    },
    {
      "id": 161,
      "genericName": "Bicalutamide",
      "drugBrandList": [
        {
          "id": 117,
          "brandName": "Casodex",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 57,
      "genericName": "Procarbazine",
      "drugBrandList": [
        {
          "id": 45,
          "brandName": "Matulane",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 132,
      "genericName": "Abaraterone",
      "drugBrandList": [
        {
          "id": 100,
          "brandName": "Zytiga",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 42,
      "genericName": "Liposomal Irinotecan",
      "drugBrandList": [
        {
          "id": 32,
          "brandName": "Onivyde",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 117,
      "genericName": "Imbruvica",
      "drugBrandList": []
    },
    {
      "id": 118,
      "genericName": "5-Fluorouracil",
      "drugBrandList": []
    },
    {
      "id": 157,
      "genericName": "Carboplatin; Paralatin Paclitaxal",
      "drugBrandList": []
    },
    {
      "id": 126,
      "genericName": "Nilutamide",
      "drugBrandList": [
        {
          "id": 94,
          "brandName": "Nilandron",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 43,
      "genericName": "Temsirolimus",
      "drugBrandList": [
        {
          "id": 33,
          "brandName": "Torisel",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 44,
      "genericName": "Olaparib",
      "drugBrandList": [
        {
          "id": 34,
          "brandName": "Lynparza",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 121,
      "genericName": "Odomzo",
      "drugBrandList": []
    },
    {
      "id": 45,
      "genericName": "Doxorubicin",
      "drugBrandList": [
        {
          "id": 35,
          "brandName": "Adriamycin",
          "manufacturer": ""
        },
        {
          "id": 70,
          "brandName": "Adriamycin, various",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 24,
      "genericName": "Pralatrexate",
      "drugBrandList": [
        {
          "id": 17,
          "brandName": "Folotyn",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 94,
      "genericName": "Degarelix",
      "drugBrandList": [
        {
          "id": 76,
          "brandName": "Firmagon",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 96,
      "genericName": "Fulvestrant",
      "drugBrandList": [
        {
          "id": 77,
          "brandName": "Faslodex",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 123,
      "genericName": "Bevacizumab",
      "drugBrandList": [
        {
          "id": 91,
          "brandName": "Avastin",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 46,
      "genericName": "Bleomycin",
      "drugBrandList": [
        {
          "id": 36,
          "brandName": "Blenoxane",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 127,
      "genericName": "Pertuzumab",
      "drugBrandList": [
        {
          "id": 95,
          "brandName": "Perjeta",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 159,
      "genericName": "Azacitidine",
      "drugBrandList": [
        {
          "id": 115,
          "brandName": "Vidaza",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 128,
      "genericName": "Blincyto",
      "drugBrandList": []
    },
    {
      "id": 130,
      "genericName": "Lapatinib",
      "drugBrandList": [
        {
          "id": 98,
          "brandName": "Tykerb",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 115,
      "genericName": "Cetuximab",
      "drugBrandList": [
        {
          "id": 86,
          "brandName": "Erbitux",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 162,
      "genericName": "Mitoxantrone",
      "drugBrandList": [
        {
          "id": 118,
          "brandName": "Novantrone",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 131,
      "genericName": "Everolimus",
      "drugBrandList": [
        {
          "id": 99,
          "brandName": "Afinitor",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 48,
      "genericName": "Various",
      "drugBrandList": []
    },
    {
      "id": 136,
      "genericName": "Crizotinib",
      "drugBrandList": [
        {
          "id": 103,
          "brandName": "Xalkori",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 47,
      "genericName": "Dasatinib",
      "drugBrandList": [
        {
          "id": 37,
          "brandName": "Sprycel",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 49,
      "genericName": "Eribulin",
      "drugBrandList": [
        {
          "id": 38,
          "brandName": "Halaven",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 103,
      "genericName": "Imatinib",
      "drugBrandList": [
        {
          "id": 81,
          "brandName": "Gleevec",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 150,
      "genericName": "Bexarotene",
      "drugBrandList": [
        {
          "id": 109,
          "brandName": "Targretin",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 79,
      "genericName": "Bortezomib",
      "drugBrandList": [
        {
          "id": 64,
          "brandName": "Velcade",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 1,
      "genericName": "Ifosfamide",
      "drugBrandList": [
        {
          "id": 1,
          "brandName": "Ifex",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 51,
      "genericName": "Rucaparib",
      "drugBrandList": [
        {
          "id": 40,
          "brandName": "Rubraca",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 32,
      "genericName": "Carmustine",
      "drugBrandList": [
        {
          "id": 24,
          "brandName": "BCNU",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 56,
      "genericName": "Docetaxel",
      "drugBrandList": [
        {
          "id": 44,
          "brandName": "Taxotere",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 134,
      "genericName": "Palbociclib",
      "drugBrandList": []
    },
    {
      "id": 116,
      "genericName": "Rituximab",
      "drugBrandList": [
        {
          "id": 87,
          "brandName": "Rituxan",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 53,
      "genericName": "Paclitaxel (Taxol)",
      "drugBrandList": []
    },
    {
      "id": 8,
      "genericName": "Exemestane",
      "drugBrandList": [
        {
          "id": 5,
          "brandName": "Aromasin",
          "manufacturer": ""
        },
        {
          "id": 72,
          "brandName": "Aromasin, various",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 137,
      "genericName": "Carboplatin (Paraplatin), Gemcitabine (Gemzar)",
      "drugBrandList": []
    },
    {
      "id": 54,
      "genericName": "Ixazomib",
      "drugBrandList": [
        {
          "id": 42,
          "brandName": "Ninlaro",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 55,
      "genericName": "Pemetrexed",
      "drugBrandList": [
        {
          "id": 43,
          "brandName": "Alimta",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 138,
      "genericName": "Inlyta",
      "drugBrandList": []
    },
    {
      "id": 139,
      "genericName": "Kadcyla",
      "drugBrandList": []
    },
    {
      "id": 140,
      "genericName": "Abemaciclib",
      "drugBrandList": [
        {
          "id": 104,
          "brandName": "Verzenio",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 12,
      "genericName": "Cyclophosphamide",
      "drugBrandList": [
        {
          "id": 8,
          "brandName": "Cytoxan",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 72,
      "genericName": "Erlotinib",
      "drugBrandList": [
        {
          "id": 59,
          "brandName": "Tarceva",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 110,
      "genericName": "Sorafenib",
      "drugBrandList": [
        {
          "id": 84,
          "brandName": "Nexavar",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 129,
      "genericName": "Pomalidamide",
      "drugBrandList": [
        {
          "id": 97,
          "brandName": "Pomalyst",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 151,
      "genericName": "Cladribine",
      "drugBrandList": [
        {
          "id": 110,
          "brandName": "2-CdA",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 39,
      "genericName": "Carfilzomib",
      "drugBrandList": [
        {
          "id": 29,
          "brandName": "Kyprolis",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 135,
      "genericName": "Carboplatin",
      "drugBrandList": [
        {
          "id": 102,
          "brandName": "Paraplatin",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 92,
      "genericName": "Idarubicin",
      "drugBrandList": [
        {
          "id": 74,
          "brandName": "Idamycin",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 141,
      "genericName": "Ramucirumab",
      "drugBrandList": []
    },
    {
      "id": 58,
      "genericName": "Ado-trastuzumab emtansine",
      "drugBrandList": [
        {
          "id": 46,
          "brandName": "Kadcyla",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 62,
      "genericName": "Temozolomide",
      "drugBrandList": [
        {
          "id": 51,
          "brandName": "Temodar",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 111,
      "genericName": "Goserelin",
      "drugBrandList": [
        {
          "id": 85,
          "brandName": "Zoladex",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 142,
      "genericName": "Neratinib",
      "drugBrandList": [
        {
          "id": 106,
          "brandName": "Nerlynx",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 6,
      "genericName": "Trastuzumab",
      "drugBrandList": [
        {
          "id": 4,
          "brandName": "Herceptin",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 17,
      "genericName": "Letrozole",
      "drugBrandList": [
        {
          "id": 12,
          "brandName": "Femara",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 15,
      "genericName": "Nilotinib",
      "drugBrandList": [
        {
          "id": 11,
          "brandName": "Tasigna",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 9,
      "genericName": "Mesna",
      "drugBrandList": [
        {
          "id": 47,
          "brandName": "Mesnex",
          "manufacturer": ""
        },
        {
          "id": 6,
          "brandName": "Mesnex, various",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 68,
      "genericName": "Gemcitabine",
      "drugBrandList": [
        {
          "id": 96,
          "brandName": "Gemzar",
          "manufacturer": ""
        },
        {
          "id": 55,
          "brandName": "Gemzar, various",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 145,
      "genericName": "Lonsurf",
      "drugBrandList": []
    },
    {
      "id": 146,
      "genericName": "Ipilimumab",
      "drugBrandList": [
        {
          "id": 107,
          "brandName": "Yervoy Nivolumab",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 60,
      "genericName": "nab-paclitaxel",
      "drugBrandList": [
        {
          "id": 49,
          "brandName": "Abraxane",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 147,
      "genericName": "Bosulif",
      "drugBrandList": []
    },
    {
      "id": 163,
      "genericName": "Hydrocortisone",
      "drugBrandList": []
    },
    {
      "id": 124,
      "genericName": "Chlorambucil",
      "drugBrandList": [
        {
          "id": 105,
          "brandName": "Leukeran",
          "manufacturer": ""
        },
        {
          "id": 92,
          "brandName": "Various",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 64,
      "genericName": "Calquence",
      "drugBrandList": []
    },
    {
      "id": 36,
      "genericName": "Cytarabine",
      "drugBrandList": [
        {
          "id": 27,
          "brandName": "Ara-C",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 106,
      "genericName": "Bendamustine",
      "drugBrandList": [
        {
          "id": 83,
          "brandName": "Treanda",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 149,
      "genericName": "Avelumab (Bavencio) ",
      "drugBrandList": []
    },
    {
      "id": 122,
      "genericName": "Melphalan",
      "drugBrandList": [
        {
          "id": 90,
          "brandName": "Alkeran",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 67,
      "genericName": "Temodar",
      "drugBrandList": []
    },
    {
      "id": 52,
      "genericName": "Epirubicin",
      "drugBrandList": [
        {
          "id": 41,
          "brandName": "Ellence, various",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 88,
      "genericName": "Fluorouracil",
      "drugBrandList": [
        {
          "id": 71,
          "brandName": "5-FU",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 152,
      "genericName": "Gilotrif",
      "drugBrandList": []
    },
    {
      "id": 153,
      "genericName": "Cyramza",
      "drugBrandList": []
    },
    {
      "id": 69,
      "genericName": "Etoposide",
      "drugBrandList": [
        {
          "id": 56,
          "brandName": "VP-16",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 70,
      "genericName": "Niraparib",
      "drugBrandList": [
        {
          "id": 57,
          "brandName": "Zejula",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 105,
      "genericName": "Topotecan",
      "drugBrandList": [
        {
          "id": 82,
          "brandName": "Hycamtin",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 158,
      "genericName": "Talazoparib",
      "drugBrandList": [
        {
          "id": 114,
          "brandName": "Talzenna",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 14,
      "genericName": "Dactinomycin",
      "drugBrandList": [
        {
          "id": 10,
          "brandName": "Actinomycin",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 155,
      "genericName": "Vincristine",
      "drugBrandList": [
        {
          "id": 112,
          "brandName": "Oncovin, VCR",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 160,
      "genericName": "Irinotecan",
      "drugBrandList": [
        {
          "id": 116,
          "brandName": "Camptosar",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 33,
      "genericName": "Lenalidamide",
      "drugBrandList": []
    },
    {
      "id": 80,
      "genericName": "Fludarabine",
      "drugBrandList": [
        {
          "id": 65,
          "brandName": "Fludara",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 144,
      "genericName": "Gemcitabine (Gemzar), CIsplatin (Platinum)",
      "drugBrandList": []
    },
    {
      "id": 73,
      "genericName": "Gemcitabine (Gemzar), Paclitaxel (Taxol)",
      "drugBrandList": []
    },
    {
      "id": 75,
      "genericName": "Elotuzumab",
      "drugBrandList": [
        {
          "id": 61,
          "brandName": "Empliciti",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 76,
      "genericName": "Erdafitinib (Balversa)",
      "drugBrandList": []
    },
    {
      "id": 148,
      "genericName": "Vinorelbine",
      "drugBrandList": [
        {
          "id": 108,
          "brandName": "Navelbine",
          "manufacturer": ""
        }
      ]
    },
    {
      "id": 164,
      "genericName": "Yervoy",
      "drugBrandList": []
    },
    {
      "id": 77,
      "genericName": "Atezolizumab",
      "drugBrandList": [
        {
          "id": 62,
          "brandName": "Tecentriq",
          "manufacturer": ""
        }
      ]
    }
  ]
}
